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Abstract 
Background 
Prostate cancer has a highly variable clinical course, which cannot be fully explained by 
clinicopathological variables. New biomarkers are needed to better inform treatment 
decisions at diagnosis to prevent the overtreatment of indolent disease, whilst allowing   
more aggressive disease to be appropriately treated with interventional and adjunctive 
treatments. 
Methods 
This discovery study used TaqMan arrays to measure the expression of a panel of 
91 putative markers of prostate cancer progression in archival biopsy samples from 
67 prostate cancer patients treated with radical prostatectomy and/or radiotherapy. 
The gene expression data were correlated with clinical outcome and binary logistic 
regression analysis was used to identify predictive models of 5-year biochemical/clinical 
recurrence. 
Results 
Multivariate logistic regression models were focused to a final set of 28 two-gene and 
9 three-gene models of recurrence which showed the highest overall performance in 
terms of calibration (Likelihood Ratio Test statistic (χ2)) and discriminatory accuracy 
(Area Under the Curve), whilst retaining parsimony (smallest number of predictor 
variables).  
The best performing models according to χ2 were AMACR.EFNA5.SDHA (χ2(3) = 22.483, 
p<0.0001) and AMACR.HPRT1.SDHA (χ2(3) = 22.265, p<0.0001). In addition to 
demonstrating a highly significant improvement in fit to the data in comparison to the 
null model, these models had high discriminatory accuracy (Area Under the Curve of 
0.812 and 0.829 respectively). By selecting an optimal threshold for categorisation of 
the patients into the recurrent or non-recurrent group, AMACR.EFNA5.SDHA could 
correctly categorise 76.1% of patients with a sensitivity and specificity of 81% and 73.9% 
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respectively. AMACR.HPRT1.SDHA could correctly categorise 85.1% of patients with 
a sensitivity and specificity of 81% and 87% respectively. 
Conclusion 
The study identified a selection of two- and three-gene models with potential to predict 
5-year recurrence in this set of prostate cancer patients. These models may provide 
novel prognostic information beyond standard prognostic variables at the time of 
treatment selection but would need to be externally validated in another set of prostate 
cancer patients to confirm their generalizability as prostate cancer biomarkers. The 
findings contributed to knowledge regarding disease progression in prostate cancer. 
Several genes of interest were identified, some of which have previously been described 
in relation to prostate cancer progression and others that showed a novel association. 
A large proportion of the identified genes were key genes in metabolic pathways, 
underlining the importance of metabolic reprogramming in prostate cancer progression. 
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 Introduction 
1.1 Prostate cancer epidemiology 
In the UK, prostate cancer is the most common cancer and the second leading cause of 
cancer-related death in men. The most recently published statistics from the year 2015 
show that 47,151 men were diagnosed with prostate cancer within that year alone and 
11,631 men died from the disease (1)(Figure 1.1). 
 
Figure 1.1 The 20 most common cancers, UK, 2015, Cancer Research UK (2)  
 
Prostate cancer development is influenced by both genetic and lifestyle/environmental 
factors, with age, family history and ethnicity being the most significant risk factors (3). 
The greatest risk factor is undoubtedly age, with over 75% of cases diagnosed in men 
aged 60 and above (4). The number of prostate cancers diagnosed within each age range 
and the age-specific incidence rates are shown in Figure 1.2. 
The prostate cancer incidence rates have increased considerably over the last few 
decades in many countries, including the UK, with incidental detection of asymptomatic 
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disease through serum prostate-specific antigen (PSA) testing and transurethral 
resection of the prostate (TURP) making a significant contribution to this rise (5). Survival 
for men with prostate cancer has also increased during this time, with the latest 
statistics showing 5- and 10-year survival rates of 85% and 84% respectively, compared 
with 37% and 25% in the early 1970s (6). 
 
Figure 1.2 Average number of new prostate cancer cases per year and age-specific incidence rates, 
males, UK, 2013-2015 (7) 
 
However, although improvements in treatment have contributed to the better survival 
rates, the widespread use of PSA testing has led to the detection of greater numbers of 
early stage prostate cancers, which would artifically raise survival rates (8). This is 
reflected by a prostate cancer mortality rate that has remained relatively stable over the 
last few decades (9).  
Excluding age, a family history of prostate cancer appears to be the strongest risk factor 
for the disease. The relative risk of prostate cancer is increased two to three fold in 
individuals who have a first degree relative with prostate cancer and increased further 
if multiple relatives are affected or if the affected relative was diagnosed before the age 
of 65 (10). 
Prostate cancer incidence rates show a large degree of variation worldwide with the 
highest rates in northern and western Europe, Australia/New Zealand and North 
America, and the lowest rates in Asian countries (11). This is largely due to the high 
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prevalence of PSA testing and biopsies in developed countries, although genetic and 
environmental risk factors such as diet may also play a role (Figure 1.3).  
 
Figure 1.3 Estimated prostate cancer incidence worldwide (estimated age-standardized rates per 
100,000)(12) 
 
Prostate cancer mortality rates are higher in less developed countries. However, the 
variation in worldwide mortality rates is lower than the variation in incidence rates, as 
PSA testing has a larger influence on incidence than mortality (12).  
There are undoubtedly inherent genetic differences involved in disease risk, as 
evidenced by the variation in prostate cancer incidence between different ethnic groups 
within the same country (13). Black men of both African and Caribbean descent have 
a risk of prostate cancer that is approximately three fold greater than their white 
counterparts of a similar age (14). Importantly, black men tend to show faster disease 
progression, and have significantly higher prostate cancer-specific mortality rates in 
comparison to white men (15, 16).  
Although no definite modifiable risk factors have been identified for prostate cancer yet, 
there is some evidence that dietary factors may influence both the development of 
prostate cancer and its progression (17, 18). For example, a high intake of dairy products 
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and well-cooked red meat may be a risk factor (17, 19) and lycopene (an antioxidant 
found in tomatoes) may act as a preventative factor (20). 
1.2 The prostate 
The prostate is an accessory gland of the male reproductive system situated below the 
bladder and in front of the rectum and completely encircling the urethra at its origin 
(Figure 1.4). Prostatic fluid secreted by the prostate’s glandular tissue plays an important 
role in sperm function, including its motility (21). At ejaculation, strong muscular 
contractions of the prostate propel the prostatic fluid in to the urethra, where it mixes 
with sperm and seminal fluid to form semen. The prostate also has roles relating to the 
control of urine flow and to the metabolism of the hormone testosterone.  
 
 
The prostate is well innervated and surrounded by a fibrocollagenous capsule. It is 
comprised of four main zones: the peripheral, central and transition zone containing 
approximately 70%, 25% and 5% of the glandular tissue respectively, and the anterior 
fibromuscular zone which contains no glandular tissue (23)(Figure 1.5). 
The glandular zones contain tubuloacinar glands, which consist of numerous secretory 
units called acini, connected to a complex network of branching ducts that open onto 
Figure 1.4 The location of the prostate gland (22) 
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the urethra. These glands are supported by well vascularised, loose connective tissue 
and embedded in a supporting fibromuscular stroma (Figure 1.5). 
 
 
 
The acini of the prostate glands are lined with simple or pseudostratified epithelium, 
which is thrown into folds projecting into the large irregular lumen. This epithelium 
consists of a luminal layer of secretory cells, below which is a basal layer of non-secretory 
cells. Neuroendocrine (NE) cells are sparsely distributed throughout the prostatic 
epithelium (Figure 1.6 and Figure 1.7).  
Figure 1.5 The zones of the prostate (24, 25) 
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Figure 1.6 High power microscopic image of normal prostate gland acini (26) 
 
 
Figure 1.7 Schematic representation of the normal prostate epithelium (27) 
 
The luminal cells are terminally differentiated cells, which generate the secretory 
products of the prostate, including PSA and prostatic acid phosphatase (PAP). As the 
luminal layer is dependent on androgens for its survival, the luminal secretory cells show 
an abundance of androgen receptors (AR)(28). 
The basal cells are relatively undifferentiated cells (29). These cells lack secretory activity 
and express only low levels of AR as the basal layer is not dependent on androgens for 
its survival (30). However, the basal layer contains an important subset of androgen-
responsive stem cells (31), which give rise to the more rapidly dividing population of 
transit amplifying cells, an expanding hierarchy of cells with different stages of 
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differentiation which eventually commit to terminal differentiation (32). This is an 
androgen-dependent process that allows the secretory layer of the prostate to be 
maintained (33). 
The processes of cell growth, proliferation and differentiation in the prostate gland are 
tightly regulated to maintain homeostasis of the epithelial layer and are dependent on 
a delicate balance between androgens, oestrogens and stromal growth factors with 
stromal-epithelial interactions playing an important role (34, 35). 
The NE cells are dendritic intraepithelial cells, which produce a range of neurosecretory 
products, such as hormones and growth factors (36). NE cells lack the AR and play a role 
in the regulation of epithelial cell growth and differentiation, through androgen-
independent mechanisms (37). 
Androgens and the prostate 
Androgens regulate important processes involved in the growth and function of the 
prostate (38). Testosterone and its metabolite 5α-dihydrotestosterone (DHT) exert their 
cellular effects in the prostate through binding to the AR, an intracellular steroid 
hormone receptor, which acts as a ligand-activated transcription factor. The cytoplasmic 
AR undergoes a change in conformation with ligand binding, which results in its 
translocation to the nucleus. In the nucleus, the AR binds to androgen response 
elements (AREs) in the promoter regions of target genes to regulate their transcription. 
These androgen responsive genes play vital roles in prostate cell proliferation, 
differentiation and survival (39). Androgen signalling through the stromal AR is 
important for maintaining homeostasis of the epithelial layer and androgen signalling 
through the epithelial AR promotes the secretory function of the prostate through the 
expression of genes which encode secretory proteins including PSA, PAP and kallikrein-
2 (KLK2)(40, 41).  
  
8 
 
1.3 Prostate pathology 
  Benign prostatic hyperplasia 
Benign prostatic hyperplasia (BPH) is a non-malignant growth of the prostate gland, 
arising from the uncontrolled proliferation of prostatic stromal and epithelial cells in the 
transition zone of the prostate. This may cause pressure to be exerted on the urethra 
resulting in lower urinary tract symptoms (LUTS)(42). In comparison to prostate cancer, 
which involves the proliferation of cells with marked molecular abnormalities, BPH is an 
overgrowth of normal prostatic cells. Both conditions are dependent on androgens for 
their growth and development, and show a marked increase in prevalence with age (40, 
43). However, BPH is more prevalent than prostate cancer and occurs almost exclusively 
in the transition zone of the prostate, which is rarely the site of the index tumour in 
prostate cancer (44). The presence of BPH does not substantially increase the risk of 
prostate cancer (45), although the two conditions may coexist. 
  High-grade prostatic intraepithelial neoplasia 
High-grade prostatic intraepithelial neoplasia (HGPIN) is characterised by an enhanced 
cellular proliferation within the prostatic ducts and acini, and shares structural 
similarities to prostate cancer, such as a loss of basal cells and nuclear and nucleolar 
enlargement (46). Unlike prostate cancer, the basal cell layer in HGPIN remains intact. 
HGPIN is considered a precursor of prostate cancer and is most prevalent in the 
peripheral zone of the prostate, similar to prostate cancer (47). HGPIN is frequently 
found concomitant with prostate cancer in regions adjacent to cancer (47). The finding 
of HGPIN at prostate biopsy, particularly in multiple cores, is significantly associated with 
an increased risk of prostate cancer at follow-up biopsy (48). Underlining the role of 
HGPIN as a precursor to prostate cancer are the shared biological and molecular 
features between the two conditions, with HGPIN reflecting alterations which are 
intermediate in the transition from normal to malignant prostatic epithelium (49).    
9 
 
  Prostate cancer  
The vast majority of prostate cancers are acinar adenocarcinomas, arising in the 
epithelial cells lining the acini of the prostate glands. Prostate cancer usually arises in 
the peripheral zone of the prostate, with only 10-20% of prostate cancers originating in 
the transition zone (50) and <10% in the central zone (51).  
Due to improvements in detection, over 80% of prostate cancers in the UK are diagnosed 
as localised or locally advanced disease, with the majority of these being localised (52). 
Prostate cancer is frequently asymptomatic as it tends to occur in the peripheral zone, 
which is farthest away from the urethra. If symptoms do occur they are usually LUTS 
including obstructive and voiding symptoms (53).  
Due the frequent late presentation of symptoms in prostate cancer, some patients 
present with metastatic disease, where cancer has spread to the regional lymph nodes 
or to other parts of the body. The most frequent sites of distant metastases in prostate 
cancer besides the non-regional lymph nodes are the bones, followed by the liver and 
lungs (54). In comparison to a nearly 100% disease-specific survival for localised prostate 
cancer, less than a third of men presenting with metastatic disease survive beyond five 
years (55).  
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1.4 Prostate cancer treatments 
Watchful waiting/active surveillance 
Watchful waiting involves the monitoring of a prostate cancer patient with regular PSA 
tests but no active treatment (although symptomatic treatment is given if necessary). 
This strategy is used for men who are more likely to die from other causes than prostate 
cancer due to their advanced age, co-morbidities or due to having low risk disease. This 
approach saves patients from suffering treatment-related impairment of quality of life 
as a result of undergoing invasive treatments, which are unlikely to benefit them. 
Active surveillance aims to avoid or postpone definitive treatment in men with localised, 
low risk disease and takes a more active approach to monitoring, involving regular PSA 
tests, digital rectal examinations (DRE) and repeat biopsies, with early curative 
intervention given if needed. 
Radical prostatectomy 
Radical prostatectomy (RP) is the mainstay of treatment for men with localised disease 
and a life expectancy of >10 years, who have a high chance of dying from prostate cancer 
without radical treatment. RP involves the removal of the prostate along with the 
seminal vesicles and some surrounding tissue. Men with locally advanced disease can 
be treated with surgery but require adjunctive therapies such as radiotherapy or 
hormone therapy (56). RP is associated with a risk of acute complications including 
cardiovascular complications and wound infection/bleeding (57). The incidence of long-
term complications from the procedure is high, with a prevalence of erectile dysfunction 
and incontinence of approximately 80% and 20% respectively (57).  
Radiotherapy 
Radiotherapy may be used to treat localised or locally advanced disease and may be 
administered as external beam radiotherapy (EBRT) or brachytherapy, either with or 
without hormone therapy. EBRT involves high dose irradiation of the prostate from 
outside the body. Brachytherapy is a more focused approach, which irradiates the 
cancer from within the prostate. EBRT is used as an adjunctive therapy in RP patients to 
improve outcome, particularly in men with adverse pathologic findings such as pT3 
stage, extraprostatic extension or seminal vesicle invasion. Additionally, it is used to 
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treat local disease recurrence in men with biochemical recurrence (BCR) after surgery 
and has a role in the palliative treatment of advanced disease, where it can be used to 
shrink bone metastases and alleviate pain. Radiotherapy, particularly EBRT, is associated 
with both transient and long-term complications such as incontinence, rectal urgency 
and erectile dysfunction (58). 
Androgen deprivation therapy (hormone therapy) 
Both normal and malignant prostate epithelial cells are dependent on androgen 
signalling for their survival and growth (59). In prostate cancer, androgen deprivation 
therapy (ADT) can be used to deprive the androgen-sensitive prostate cancer cells of 
androgens. A good initial response to ADT is seen in most patients with androgen-
dependent disease resulting in tumour regression due to the cessation of proliferation 
and instigation of apoptosis (60). ADT is usually administered via luteinizing hormone-
releasing hormone (LHRH) agonists or antagonists, which halt the production of 
androgens by the testes. Alternatively, antiandrogens which prevent the binding of 
androgens to the AR may be used. ADT is associated with significant morbidity including 
hot flashes, loss of bone mineral density and the development of metabolic syndrome 
(61-63). 
Although ADT may be used as a primary therapy, it is more commonly used as an 
adjunctive treatment with surgery or radiotherapy for the treatment of 
intermediate/high risk localised disease, locally advanced disease and lymph node 
positive disease (64-66).  
ADT may be used for disease control and symptomatic relief in metastatic prostate 
cancer (67). The clinical response to ADT is rarely sustained and tumour growth 
inevitably recurs due the development of metastatic castration-resistant prostate 
cancer (mCRPC)(68), which has a poor prognosis (survival is usually less than two years) 
(69). 
Treatments for mCRPC  
Treatments that may provide symptom relief and improve survival in men with mCRPC 
include abiraterone acetate, which selectively inhibits a critical enzyme in the androgen 
biosynthesis pathway (70) or systemic treatments such as docetaxel, a cytotoxic 
chemotherapeutic agent (71). 
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1.5  Prostate cancer diagnosis and the PSA test 
The serum PSA test and the DRE are the most frequently used initial tests for prostate 
cancer. An indication for a prostate needle biopsy would be an elevated serum PSA 
measurement and/or abnormal DRE. 
PSA is a kallikrein-like serine protease encoded by the androgen-responsive gene 
kallikrein related peptidase 3 (KLK3) and secreted almost exclusively by the epithelial 
cells of the prostate gland. The serum PSA level is elevated in prostate cancer due to 
disruption of the prostate architecture, which allows PSA to pass more easily into the 
circulation. The risk of finding prostate cancer increases with more elevated PSA 
concentrations (72), with the likelihood of finding advanced disease increasing with 
higher PSA concentrations (73). The traditional serum PSA cutoff is 4.0ng/ml (74); 
however this cutoff value may be adjusted according to age and other factors such as 
ethnicity (75). 
Several limitations are associated with the use of the PSA test for the detection of 
prostate cancer. Despite being highly tissue-specific, the PSA test is not cancer-specific 
and elevations are also found in benign conditions of the prostate, including BPH and 
prostatitis (76). As a result, a large proportion of men with PSA values ≥4.0 ng/ml are 
not found to have prostate cancer on biopsy, and have been unnecessarily exposed to 
the risks and side effects of this procedure (77). Although the positive predictive value 
for a PSA 10-20ng/ml is relatively high (~74%), it is only ~50% for a PSA 4-10ng/ml where 
there is significant overlap between the PSA ranges of BPH and prostate cancer (78). The 
serum PSA test also has some limitations with regard to sensitivity as prostate cancer, 
including high-grade disease, may be found in men with a serum PSA within the normal 
range (79). 
The PSA test plays a central role in the serial monitoring of prostate cancer patients after 
RP or radiotherapy. After RP, the serum PSA should drop to an almost undetectable level 
due to the complete removal of the prostate tissue. BCR after RP is usually defined by 
a serum PSA value of >0.2ng/ml or a slight variation on this definition (80). BCR is 
a surrogate endpoint and time to systemic progression and death may take a protracted 
course (81). The timing of BCR is important for assessing the future risk of progression. 
13 
 
For instance, a short time interval between the end of surgery/radiotherapy and BCR or 
a short PSA doubling time is highly predictive of earlier clinical progression and prostate 
cancer-specific death (82, 83).  
 Transrectal ultrasound (TRUS)-guided prostate biopsy 
Transrectal ultrasound (TRUS)-guided biopsy is used for the definitive diagnosis of 
prostate cancer and for prognostic purposes. Under the guidance of an ultrasound 
probe, a fine needle is passed into the prostate to collect several thin cores of tissue for 
histological examination by a pathologist. If cancer is present, the percentage cancer 
involvement in each core and the amount of positive cores are used to assess tumour 
volume. The biopsy samples are histopathologically graded using the Gleason grading 
system (84). 
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1.6  Prostate cancer prognosis 
Stage, Gleason grade and the serum PSA level are the most important prognostic tools, 
which are used in combination to guide the clinical management of prostate cancer. 
 Staging  
The most common system of staging is the Tumour-Node-Metastasis (TNM) system (85), 
which describes the extent of the primary tumour (T category) and whether the cancer 
has spread to the regional lymph nodes (N category) or metastasized to other parts of 
the body (M category). The clinical stage is an estimate of the extent of disease prior to 
treatment, based purely on the results of the physical examination (DRE), biopsy and 
imaging studies (e.g. bone scans, computerized tomography (CT) and magnetic 
resonance imaging (MRI)). The pathologic stage can only be measured in surgically 
treated patients as it incorporates both the clinical staging results and the pathology 
results from the tissue removed at surgery. Pathologic staging is more accurate than 
clinical staging, as it provides a more direct assessment of the nature and extent of 
disease. The main categories of the TNM staging system are described in Figure 1.8. 
Most of the categories in Figure 1.8 have futher subcategories (a, b, c) to allow more 
specific descriptions. 
 
Figure 1.8 The TNM staging system (85) 
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Prostate cancer can then be broadly categorised as localised, locally advanced and 
advanced, based on the TNM staging as follows: 
Localised   T1, N0, M0 
    T2, N0, M0 
    
Locally advanced  T3, N0, M0 
    T4, N0, M0 
    any T, N1, M0 
  
Advanced   any T, any N, M1 
 The Gleason grading system  
Biopsy and RP samples are graded by the Gleason grading system, which classifies 
a tissue based on its degree of differentiation (86)(Figure 1.9). This system consists of 
grades 1-5; with the tissue becoming less differentiated with increasing grade as its 
resemblance to the normal glandular architecture of the prostate lessens. However, 
grades 1 and 2 are not generally used for biopsy samples. The Gleason score (GS) is the 
sum of the primary grade (the most frequent pattern) followed by the secondary grade 
(second most frequent), e.g. 3+4 = 7. 
 
Figure 1.9  Gleason grading system according to the International Society of Urological Pathology (87) 
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 Pretreatment serum PSA 
The pretreatment serum PSA test is also used for prognostic purposes as it is positively 
associated with adverse clinicopathological parameters such as extracapsular extension 
and seminal vesicle invasion (88). Furthermore, studies have found preoperative PSA to 
be an independent predictor of biochemical recurrence-free survival and prostate 
cancer-specific survival after RP (82, 88). 
 Risk stratification 
As a result of improved detection methods, the incidence of men diagnosed with non-
metastatic prostate cancer has increased, particularly the proportion of men with 
localised disease, which has a heterogeneous outcome (52). The majority of these 
prostate cancers have a slow disease progression, which is unlikely to cause symptoms 
or become lethal for up to 15 years, even if untreated (89). Often due to the advanced 
age of most prostate cancer patients, these men will die of competing causes before 
treatment is ever necessary (57). However, locally advanced disease and a minority of 
localised prostate cancers have a much higher risk of metastasis and death within this 
time (90). For these prostate cancers and/or men with a high life expectancy, 
interventional treatments such as surgery and radiotherapy are potentially curative 
options, which may increase disease-specific survival (91). 
It is of paramount importance to determine the level of risk for each patient at the time 
of diagnosis in terms of the potential for the cancer to spread, to avoid overtreatment 
of clinically insignificant disease, whilst ensuring that no curative opportunities are 
missed to prevent disease progression in patients with more aggressive disease.  
Risk stratification is the foundation for clinical decision-making and treatment selection 
in men with non-metastatic prostate cancer and uses the three most important 
prognostic indicators available at diagnosis: the pretreatment PSA, clinical tumour stage 
and biopsy GS. The most widely used method of risk statification is the D’Amico system, 
which classifies patients into low, intermediate and high risk categories for disease 
progression after definitive treatment (RP or EBRT) and may be used to guide treatment 
decisions (92, 93)(Table 1.1). 
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Table 1.1 D’Amico risk classifications 
Risk Score 
Low risk T1-2a and GS ≤6 and PSA <10  
Intermediate risk T2b and/or GS 7 and/or PSA 10-20 
High risk ≥T2c and/or GS 8-10 and/or PSA >20  
 
Although D’Amico’s risk categories are useful for guiding treatment decisions, there 
exists a significant heterogeneity of prognoses within each risk category, particularly 
within the intermediate risk group which is the largest group of prostate cancer patients 
(94).  
Nomograms, which use point scales of clinicopathological variables to calculate the 
continuous probability of a particular outcome provide a more accurate and 
individualised method of prediction than risk categories. A widely used preoperative 
nomogram for the prediction of 5 or 10 year probability of prostate cancer recurrence 
after surgery is Stephenson’s nomogram (95), which is based on the variables 
preoperative PSA, clinical stage, biopsy GS, and also includes the results of systematic 
biopsies and adjusts for the year of surgery to account for stage migration. 
A newer predictive tool called the Cancer of the Prostate Risk Assessment (CAPRA) score 
combines the accuracy of the best nomograms, with the usability of the D’Amico 
classification system (96). The CAPRA score can be used to predict outcome after RP and 
other treatments including radiotherapy, primary ADT and watchful waiting/active 
surveillance (97, 98). The variables incorporated in the CAPRA score are: age, 
preoperative PSA, biopsy GS, clinical tumour stage and the percentage of positive cores 
on biopsy. The CAPRA score demonstrates a relatively high discriminatory accuracy for 
the prediction of BCR after RP (c-index of 0.66-0.81)(99).  
 Limitations of clinical prognostic tools    
Even the best performing predictive tools have significant limitations and there still 
exists a significant heterogeneity of outcome between prostate cancer patients with 
similar clinicopathological variables. Prognostic tools such as nomograms are developed 
using retrospective studies of particular populations of prostate cancer patients. 
Therefore, they may not be universally applicable to prostate cancer patients with 
different clinical demographics and geographic location (100). 
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Secondly and most importantly, all the aforementioned predictive tools are restricted 
by the inherent limitations of their component parts: the GS, staging and the serum PSA. 
In particular, preoperative prediction tools which can be used at the time of treatment 
selection, tend to be poorer predictors of outcome than the postoperative tools, which 
incorporate pathologic findings (101). The lower discriminatory value of the 
pretreatment tools results from under/overgrading of the biopsy sample in comparison 
to the pathologic sample and/or inaccuracies in predicting the extent of disease using 
clinical rather than pathologic staging.  
Limitations in the biopsy GS result from both sampling error and the subjective nature 
of the Gleason grading system. The biopsy procedure samples a very small amount of 
the total prostate tissue. As the majority of prostate cancers are multifocal exhibiting 
grade heterogeneity (102), the biopsy may under-represent areas of high grade disease 
that are significant prognostically or oversample clinically insignificant areas. This results 
in frequent discordance between the biopsy and pathologic GS, with biopsy 
undergrading found in over 20% of cases and overgrading in approximately 10% (103). 
Gleason grading is also limited by its subjective nature and is prone to intra- and inter-
pathologist variation of interpretation (104). 
Clinical staging at the time of treatment selection is highly subjective and assessment of 
the extent of disease and prediction of outcome may be inaccurate (105) due to 
limitations in the available detection techniques such as TRUS, MRI and CT scans (106). 
A problem of clinical understaging has been reported as most prevalent (105). 
Additionally, the pretreatment PSA has limitations as a prognostic tool. In particular, the 
predictive value of PSA is low for patients with a serum PSA below 10ng/ml, which has 
accounted for an increasing number of prostate cancer patients in the past few decades 
(107). The majority of these patients do not require active treatment due to a prolonged 
natural disease course, but a small number of prostate cancers progress despite a low 
or undetectable serum PSA level. In fact, in prostate cancer patients with high GS (8-10), 
low serum PSA levels (<4.0 ng/ml) are associated with a particularly aggressive form of 
the disease (108). 
Limitations in the tools used for risk classification make clincial decision-making difficult. 
Overgrading/staging has led to the overtreatment of clinically insignificant disease with 
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interventional treatments such as RP and radiotherapy, which are associated with high 
morbidity and financial cost (109). Undergrading/staging has led to some missed 
opportunites to provide curative treatment for men with aggressive disease and the 
failure to identify patients who could benefit from adjunctive treatments alongside 
RP/radiotherapy to improve their chances of survival (110). 
 Biomarker research and molecular technologies 
The requirement to delineate prostate cancer patients according to their risk of disease 
progression to better inform treatment decisions has resulted in the search for 
prognostic biomarkers. A more individualised approach to risk stratification is especially 
important in prostate cancer due to the heterogeneity of its clinical behaviour, wide 
range of treatment options and the high risk of impairment to quality of life associated 
with its treatments (58).  
Biomarker research has focused on biomarkers that can distinguish between prostate 
cancer patients who can confidently be assigned to conservative management (active 
surveillance) and those who would benefit from interventional treatments such as 
RP and radiotherapy. A particular challenge is whether to treat patients within the 
intermediate risk group (according to currently used risk classifications) with active 
surveillance or definitive treatment (111). Secondly, the 10-year BCR rate after RP and 
definitive radiotherapy is 20-40% and 30-50% respectively (112, 113). There is therefore 
a need to more accurately identify patients who are at a high risk of recurrence after 
surgery or radiotherapy and who would benefit from adjunctive therapies to improve 
their outlook, e.g. radiotherapy and/or ADT with RP. 
Molecular technologies have been critical to understanding the complex molecular 
alterations that initiate and drive the progression of prostate cancer. As these 
alterations may underpin the wide array of clinical phenotypes and behaviour in 
prostate cancer even amongst patients with similar clinicopathological features, these 
tools have been used in the search for prognostic prostate cancer biomarkers. Although 
non-invasive biomarkers (e.g. serum or urine) would be ideal, tissue samples may offer 
the most amenable sample source for biomarker research. Ideally, these markers should 
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be able to be measured in biopsy samples, as this is often the only tissue sample 
available at the time of treatment selection. 
A myriad of different deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and protein 
markers have been explored in prostate cancer. Despite many of these biomarkers 
showing significant potential to be useful for risk prediction in prostate cancer, none 
have so far been routinely incorporated into clinical practice. For a biomarker to be 
adopted into clinical practice, it would have to demonstrate an ability to improve upon 
the currently used clinical prognostic tools, either in addition to these tools or alone 
(114). However, the exploration of these biomarkers has led to an increased knowledge 
regarding the molecular alterations that are associated with prostate cancer 
progression. Many of the molecular alterations that have been identified as being 
associated with disease progression in prostate cancer have a known role in the 
acquisition of individual or multiple hallmark traits of cancer (115). In the next section, 
the hallmark traits of cancer and the molecular changes associated with their attainment 
are described, with an emphasis on the alterations found in prostate cancer progression.  
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 The hallmark traits of cancer  
Cancer is driven by genetic alterations in somatic cells which dysregulate cellular 
pathways, primarily through the activation of oncogenes and the disruption of tumour 
suppressor genes. These changes allow cancer cells to acquire the hallmark traits of 
cancer as described by Hanahan and Weinberg (116)(Figure 1.10). 
 
Figure 1.10 The hallmark traits of cancer (adapted from (116)) 
 
These hallmark traits provide the cell with growth and survival advantages over its 
neighbouring cells. A process similar to Darwinian selection occurs whereby variant cells, 
which have acquired changes that aid in the acquisition of the traits, are selected and 
undergo clonal expansion (117). As further genetic alterations are accumulated and 
selected, the cells gradually acquire all the hallmark traits. The accumulation of genetic 
alterations continues throughout disease progression (118). 
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Self-sufficiency in growth signals 
For normal cells to begin actively proliferating from a quiescent state, they are 
dependent on extracellular growth signals, which control entry into and progression 
through growth and division cycles (118). In contrast, cancer cells are not dependent on 
exogenous growth stimulation, leading to unregulated, chronic proliferation, which 
interferes with the normal homeostasis of cell number, tissue structure and function 
(116). Cancer cells attain this characteristic through a variety of mechanisms, which 
cause dysregulation of important intracellular growth signalling pathways, such as the 
mitogen-activated protein kinase (MAPK) cascade and the phosphoinositide 3-kinase 
(PI3K) pathway (118).  
Firstly, there may be upregulation of growth factor ligands, which initiate these signal 
transduction pathways (119). Cancer cells may send signals to surrounding normal cells 
to increase the release of external growth factors (120). Alternatively, cancer cells may 
produce their own growth factors, to which they respond by a process of autocrine 
proliferative stimulation, thereby reducing their reliance on external growth factors 
(121, 122). 
Cancer cells may gain autonomy over growth signalling through the overexpression or 
mutation of tyrosine kinase growth factor receptors, leading to a heightened response 
to normal levels of ligand or ligand-independent signalling. The epidermal growth factor 
receptors, epidermal growth factor receptor (EGFR)(123) and receptor tyrosine-protein 
kinase erbB-2 (ERBB2)(124) are overexpressed in a proportion of prostate cancers, with 
expression positively correlated with disease progression (123, 125), particularly with 
the transition to androgen-independence (126, 127). 
Furthermore, growth signalling pathways may be activated by alterations to 
downstream intracellular signal transducers or the transcription factor targets 
themselves, leading to an increased expression of proliferation-associated genes (128). 
For instance, an important transcription factor of the MAPK pathway called the Myc 
proto-oncogene protein (MYC) is frequently overexpressed in prostate cancer, with copy 
number gains of its gene (MYC) increasing in frequency with disease progression (129, 
130). The frequency of MYC amplification is significantly increased in androgen-
independent prostate cancer (131). 
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Insensitivity to antigrowth signals 
Normal cells receive multiple anti-proliferative signals, which act predominantly through 
the cell cycle to block proliferation and maintain quiescence. Cancer cells have adopted 
various strategies to evade these signals through the activation of components that 
drive cell cycle progression and inactivation of those that restrain its progression. 
A central point of action in antigrowth signalling is the G1/S checkpoint of the cell cycle, 
which allows the cell to monitor its environment and halt transition into the S phase if 
something is awry (132). A key component of the G1 checkpoint is the retinoblastoma-
associated protein (RB1) which prevents progression through this checkpoint in its 
hypophosphorylated state by sequestering the transcription factors necessary for the 
G1/S transition (133). Dysregulation of the retinoblastoma pathway, which results in 
progression through this checkpoint and unchecked proliferation, is a universal finding 
in cancer (118). Alterations may include overexpression of cyclins and cyclin-dependent 
kinases (134, 135) which act to phosphorylate RB1, as well as the loss of cyclin-
dependent kinase inhibitors which keep RB1 in its hypophosphorylated form by 
inhibiting cyclin/cyclin-dependent kinase complexes (136). Alternatively, upstream 
signals of the pathway may be affected such as the antiproliferative signalling molecule, 
transforming growth factor beta-1 (TGFB1)(137). 
In prostate cancer, the expression of cyclin-dependent kinase inhibitors such as cyclin-
dependent kinase inhibitor 1B (CDKN1B) may be reduced (138). Dysregulation of TGF-
beta-1 signalling is a feature of prostate tumourigenesis, where the growth inhibitory 
effects of TGFB1 are counteracted, leading it to paradoxically stimulate tumour 
progression (139). Elevated levels of plasma and tissue TGFB1 have been correlated with 
features of aggressive disease in some studies (140, 141). 
Additionally, alterations of the tumor protein p53 gene (TP53) leading to reduced 
protein function are found in a proportion of prostate cancers and are associated with 
adverse outcome (142). TP53 is a transcription factor involved in a cell’s response to 
internal stress such as DNA damage and oncogene activation, through activation of 
genes involved in cell cycle arrest and apoptosis (143). TP53 acts as a regulator of the 
G1/S checkpoint and other important transition points including the G2/M checkpoint 
(144)(Figure 1.11). 
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Another tumour suppressor gene called the phosphatase and tensin homolog (PTEN) is 
frequently lost in prostate cancer (145). PTEN encodes an important negative regulator 
of the PI3K pathway, which mediates cellular growth, proliferation and survival (146). 
Through its inhibitory action on the PI3K pathway, the PTEN protein has a regulatory 
role in all phases of the cell cycle including the G1/S and G2/M transitions (Figure 1.11). 
Its loss will therefore allow unimpeded progression through the cell cycle at these 
checkpoints (147). 
 
Figure 1.11 The phases of the cell cycle showing two of the major checkpoints (G1/S, G2/M) and the 
molecules which regulate them 
 
Evading apoptosis 
Expansion of the tumour cell population is not only determined by the rate of cell 
proliferation but also the rate of cell death, particularly from apoptosis. Apoptosis is 
a highly ordered process, which is induced in situations such as DNA damage, oncogene 
activation and hypoxia. It involves two major classes of molecules: cell-surface receptors 
called sensors which monitor both the intracellular and extracellular environment, and 
effectors which initiate the apoptotic machinery (118). Apoptosis is prevented by the 
binding of survival factors such as insulin-like growth factor I and II (IGF1/2) to their 
specific receptors, whereas death signals such as Fas ligand binding to the Fas receptor 
will initiate the process (118). Of central importance to the apoptotic cascade is the 
balance of different members of the Bcl-2 family which consists of pro-apoptotic 
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proteins, e.g. apoptosis regulator BAX (BAX) and Bcl-2 homologous antagonist/killer 
(BAK1), and anti-apoptotic proteins such as apoptosis regulator Bcl-2 (BCL2) and Bcl-2-
like protein 2 (BCL2L2)(148). Although the apoptotic program is initially instigated by 
oncogene expression to eliminate mutant cells, cancer cells must become resistant to 
apoptosis to allow a tumour to progress. Inhibition of apoptosis plays a critical role in 
cancer progression by increasing the survival of tumour cells, which results in an overall 
net tumour growth and promotes genomic instability (149). Importantly, evasion of 
apoptosis is necessary for the survival of disseminated cancer cells during metastasis 
and plays a role in drug resistance (150, 151). 
Mechanisms that may contribute to the evasion of apoptosis in prostate cancer and 
have been correlated with its progression include: increased IGF survival signalling (152), 
downregulation of components of death signalling pathways such as the Fas pathway 
(153) and upregulation of the important anti-apoptotic proteins BCL2 (154) and 
baculoviral IAP repeat-containing protein 5 (BIRC5)(155). Upregulation of BCL2 is 
particularly important for the transition to androgen-independence that may occur after 
treatment with androgen ablation therapy (156). 
Limitless replicative potential 
Non-cancerous cells undergo a finite number of divisions before they enter senescence. 
The cell-autonomous program which prevents limitless replication must be overcome 
by cancer cells, if a tumour is to expand to a size which compromises health (118). This 
process was illustrated by Hayflick et al. (157), who showed that normal fibroblasts in 
culture exhibited a finite replicative potential before they became senescent. In 
comparison, cells that had their RB1 and TP53 tumour suppressor proteins rendered 
non-functional multiplied to further generations until a second state called crisis was 
reached. The crisis state was characterised mainly by cell death and karyotypic disarray, 
but with an occasional mutant cell arising with the potential to continue multiplying 
indefinitely. This process was termed immortalization and gave an insight into how 
cancer cells that have accumulated the necessary attributes for tumour formation are 
selected for in vivo and can break the mortality barrier (158). 
Of great importance to the mortality barrier are telomeres, multiple repeats of a short 
DNA sequence, which protect the ends of chromosomes from degradation and fusion 
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with other chromosomes. With each cell division, a portion of the telomere is lost due 
to the inability of DNA polymerases to entirely replicate the 3’ ends of DNA during the 
S phase of the cell cycle (159). Progressive telomeric loss eventually triggers damage 
response pathways, causing the cell to either enter senescence or die through entry into 
the crisis state. Cancer cells have ingenious mechanisms to maintain telomere stability, 
allowing them to bypass the mortality barrier, including the reactivation of telomerase 
(the enzyme responsible for adding DNA sequences to the ends of telomeres)(160, 161) 
and a process called alternative lengthening of telomeres, which uses recombination-
based interchromosomal exchanges of sequence information to maintain telomeres 
(162). 
Telomere shortening appears to be an early stage alteration in prostate cancer (163), 
rendering chromosomes more vulnerable to fusion, breakage and rearrangement, 
thereby promoting carcinogenesis through chromosomal instability. In contrast, 
increased telomerase activity has been shown to correlate with disease progression in 
prostate cancer (164). In particular, the gene TERT which encodes the catalytic subunit 
of the telomerase enzyme complex called telomerase reverse transcriptase has been 
investigated as a non-invasive marker of aggressive disease (165). 
Sustained angiogenesis 
A tumour cannot progress beyond 1-2mm in size, invade surrounding tissue or 
disseminate without the formation of its own vascular network through a process called 
angiogenesis (166). Angiogenesis is the development of new blood vessels from pre-
existing vasculature and is an essential requirement of carcinogenesis to sustain the 
growth of the expanding mass, through the provision of nutrients and oxygen and the 
removal of waste. The angiogenic switch is activated at an early stage of carcinogenesis 
by an upregulation of angiogenic activators including growth factors, integrins and 
enzymes; and a downregulation of angiogenesis inhibitors (118). In response to 
proangiogenic signals, the usually quiescent vascular endothelial cells start to divide and 
migrate into surrounding tissue forming a vascular sprout. This is followed by the 
organisation of endothelial cells into hollow tubes that gradually evolve into a network 
of blood vessels (167)(Figure 1.12). 
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Figure 1.12 Steps involved in angiogenesis (168) 
 
In prostate cancer several angiogenic activators have been found to be significantly 
upregulated, including a potent proangiogenic growth factor called vascular endothelial 
growth factor A (VEGFA)(169), which plays a critical role in angiogenesis through its 
effect on endothelial cell function. A positive correlation of both VEGFA and its receptors 
with disease progression have been demonstrated (170, 171). Additionally, some 
studies show upregulation of the enzyme prostaglandin G/H synthase 2 (PTGS2)(172), 
a central mediator of angiogenesis, as well as induction of matrix metalloproteinases 
(MMPs)(173, 174) in prostate cancer. MMPs are proteolytic enzymes which enable the 
extracellular matrix (ECM) to be degraded and remodelled, thereby allowing endothelial 
cells to migrate and invade surrounding tissue. The expression of PTGS2, 72 kDa type IV 
collagenase (MMP2) and matrix metalloproteinase-9 (MMP9) have been positively 
correlated with adverse clinicopathological parameters and poor outcome in prostate 
cancer (172, 175, 176). Conversely, endogenous angiogenesis inhibitors, such as 
thrombospondin-1 (THBS1), may be downregulated in prostate cancer (177). 
Reprogramming of energy metabolism 
Rapidly proliferating cells require reprogramming of their energy metabolism to allow 
the bioenergetic demands of their altered cellular activity to be met. They require 
energy in the form of adenosine triphosphate (ATP) and a raft of macromolecules such 
as nucleotides, proteins and fatty acids for the assembly of new cells (178). Hence, 
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dysregulation is seen in the proteins and enzymes of key metabolic pathways during 
carcinogenesis (179). A characteristic change in energy metabolism, exhibited in many 
types of cancer cells, is the Warburg effect whereby cancer cells shift their energy 
metabolism of glucose to glycolysis even when sufficient oxygen is available, rather than 
through the tricarboxylic acid (TCA) cycle and the electron transfer chain (180). This is 
called aerobic glycolysis and appears initially to be counterproductive as it provides 
a much lower yield of ATP than can be achieved through aerobic respiration. However, 
alongside an increased flux of glucose, the Warburg effect in cancer cells allows an 
amplified rate of ATP generation. Additionally, it allows glycolytic intermediates to be 
channelled into various biosynthetic pathways to support proliferation, e.g. 
nonessential amino acids, nicotinamide adenine dinucleotide phosphate (NADPH), 
glycerol and citrate for lipids, and ribose sugars for nucleotides (181). To increase 
glucose flux, cancer cells may increase both the uptake and utilization of glucose, for 
instance through an upregulation of glucose transporters (182). However, metabolic 
reprogramming exhibits high variability between different cancers and it is now 
generally accepted that tumour cells rely on a combination of both aerobic glycolysis 
and oxidative metabolism to supply their energy and macromolecular needs (183).  
In prostate cancer, oxidative metabolism remains important for carcinogenesis and the 
Warburg effect tends to be a feature of more advanced disease only (184). Importantly, 
in comparison to other cells in the body, normal peripheral zone cells of the prostate 
have a distinctive metabolic profile, allowing them to accumulate high levels of citrate, 
PSA and polyamines, which are secreted into the prostatic fluid (185). The extremely 
high levels of citrate are due to direct inhibition of m-aconitase, a mitochondrial enzyme 
that catalyses the first step of citrate oxidation in the TCA cycle, as a result of high 
intracellular levels of zinc (186). Without citrate oxidation, the usual continuation of the 
TCA cycle (which is seen in other organs) is effectively halted, resulting in a much lower 
production of ATP (186). Conversely, energy production in malignant prostate cells 
becomes more efficient as the ability to accumulate zinc is diminished, leading to 
reactivation of m-aconitase and the ability to oxidise large quantities of citrate through 
the TCA cycle (187). These changes are illustrated schematically in Figure 1.13. 
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Figure 1.13 Metabolism in the healthy prostate and at different stages of prostate cancer: a) Normal 
prostate b) Early prostate cancer c) Late prostate cancer (adapted from (188)) 
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Metabolic profiling studies have highlighted important metabolic pathways in prostate 
cancer as well as identifying prognostic metabolic profiles and individual biomarkers 
(189). Metabolic changes that have been documented in prostate cancer and may be 
associated with its progression include: overexpression of fatty acid synthase (FASN) 
(190), a key enzyme in de novo fatty acid synthesis, which may reflect an increased need 
for lipid biosynthesis in rapidly proliferating cells for membrane formation and 
intracellular signalling; increased alpha-methyl-CoA racemase (AMACR), an enzyme 
which is involved in the beta oxidation of branched chain fatty acids and fatty acid 
derivatives (191); an increased production of the metabolite sarcosine 
(192)(a byproduct of methionine metabolism which is a central pathway in the 
methylation of DNA, RNA and proteins); and an increased 
(choline+creatine+polyamines)/citrate ratio (193). 
Tissue invasion and metastasis 
Once the growth of a primary malignant tumour is progressive and it has its own vascular 
network, cancer cells from the tumour may invade surrounding tissue. This may be 
followed by metastasis, where cancer cells spread through the blood and lymphatic 
vessels to distant sites in the body. For micrometastases to colonize, they must develop 
their own vascular network, evade the host immune response and respond to organ-
specific factors that promote their growth (194). Cancer cells at the distant site can then 
invade the host stroma and enter blood vessels to start the process of producing 
additional metastases (194). Metastases represent a lethal threat to the host, being 
responsible for 90% of cancer deaths from solid tumours (195). The multi-stage process 
of metastasis is depicted in Figure 1.14.  
 
31 
 
 
Figure 1.14 Schematic representation of the multiple stages of metastasis (196) 
 
Invasion and metastasis utilise similar mechanistic strategies, including the release of 
extracellular proteolytic enzymes such as MMPs, serine proteases and cysteine 
proteases from cancer cells and conscripted stromal cells, which effectively degrade and 
remodel the tumour microenvironment to facilitate the passage of cancer cells through 
the epithelium, blood vessels and stroma (118). Every step involved in metastasis is 
dependent on changes in the coupling of tumour cells to both adjacent cells and the 
ECM. Therefore, changes in the expression and distribution of integrins (which mediate 
cell to ECM adhesion) and changes to cell adhesion molecules (CAMs) such as cadherins 
and immunoglobulins are also fundamental to allow tumour cells to migrate and invade, 
and to allow growth at a distant site (197). 
In prostate cancer, serine proteases have been found to be upregulated. Studies have 
demonstrated increased expression of urokinase-type plasminogen activator (PLAU) 
(198) and upregulation of the gene HPN which codes for serine protease hepsin (199). 
PLAU catalyses the conversion of plasminogen to plasmin upon binding to its receptor 
called urokinase plasminogen activator surface receptor (PLAUR), promoting the 
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degradation of the basement membrane and ECM by the activation of a cascade of 
proteolytic enzymes (200).      
Cadherin-1 (CDH1) expression has been found to be significantly downregulated in 
prostate cancer, with reduced expression correlated with poor prognosis (201). CDH1 is 
an important cell adhesion molecule of the cadherin family which plays a pivotal role in 
the maintenance of cell architecture. Changes in the expression of CAMs of the 
immunoglobulin supergene family, such as the CD166 antigen (ALCAM), have been 
linked to prostate cancer progression (202). 
Epithelial-mesenchymal transition 
The epithelial-mesenchymal transition (EMT) is a developmental regulatory program, 
which is activated during the progression of epithelial cancers as it enables cancer cells 
to acquire a migratory phenotype through the loss of epithelial characteristics and the 
development of mesenchymal properties (203). Interactions of the cancerous cells with 
the surrounding stromal cells are important for the induction of EMT, as reflected by the 
identification of EMT processes concentrated at the invasive front of a primary tumour 
(204). 
Several characteristics of EMT are correlated with disease progression in prostate cancer 
and may hold prognostic significance, including increased vimentin expression (205) and 
cadherin switching (206). Cadherin switching refers to the loss of CDH1 and an increased 
expression of another type of cadherin called cadherin-2 (CDH2) as the normal epithelial 
architecture is lost and there is a transition to a mesenchymal, more invasive and 
metastatic phenotype (207). 
Genomic instability 
The development of the aforementioned cancer traits is dependent on a succession of 
clonal expansions, each of which offers the cancer cells a selective growth advantage. 
Due to the highly vigilant genome maintenance systems that detect and resolve errors 
in the DNA, the spontaneous mutation rate of normal somatic cells is extremely low 
(118). The number of genetic alterations found in tumours is vastly higher than can be 
explained by this low spontaneous mutation rate (208). This disparity can be explained 
by genome instability, an increase in the rate at which genetic alterations are 
accumulated, which aids clonal evolution and thereby encourages the acquisition of 
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additional cancer traits (209). Genome instability can be categorised as nucleotide 
instability, microsatellite instability which causes gain or loss of short nucleotide repeats, 
and chromosome instability resulting in alterations of chromosome number or structure 
(209). The molecular causes of genome instability in sporadic cancers are poorly defined, 
in comparison to hereditary cancer, where genomic instability is linked with specific 
mutations in DNA repair genes (210). 
Chromosomal instability is the most prevalent form of genome instability in sporadic, 
solid cancers and results from alterations in chromosomal instability genes, such as the 
genes involved in chromosome segregation and the mitotic spindle checkpoint (211, 
212). Chromosomal instability leads to aneuploidy, the gain or loss of whole or 
segmental chromosomes (e.g. through amplifications, deletions or translocations)(209). 
Aneuploidy is associated with loss of heterozygosity (LOH), a central mechanism by 
which tumour suppressor genes are inactivated (213). Microsatellite instability is also 
seen in some sporadic cancers and is caused by epigenetic inactivation or mutations of 
mismatch repair genes (214).   
In prostate cancer there is an increased frequency of both gains and losses of 
chromosomal DNA with disease progression (215), and some alterations may be 
predictive of poor outcome such as amplification at 8q24, a region which contains the 
oncogene MYC (MYC proto-oncogene, bHLH transcription factor)(129). Probably the 
most frequent chromosomal rearrangement in prostate cancer is the TMPRSS2:ERG 
gene fusion between the androgen-regulated gene transmembrane serine protease 2 
(TMPRSS2) and ETS transcription factor ERG (ERG)(216). 
Evasion of the immune system and tumour-promoting inflammation 
Evasion of immune destruction is an essential hallmark of cancer as described below. 
Paradoxically, the inflammatory response may also be tumour promoting and can aid 
the acquisition of the hallmark capabilities by contributing certain molecules to the 
tumour microenvironment (217). 
Tumour-promoting inflammation  
Chronic inflammation is a significant risk factor for the development of cancer (218). In 
the normal acute inflammatory response to infection or injury, regenerative 
proliferation and inflammation subside once the causative agent is removed and repair 
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is complete. In contrast, the persistence of initiating agents or a failure of the normal 
mechanisms that resolve inflammation may lead to a state of chronic inflammation 
(219). If cells have suffered mutagenic changes, chronic inflammation supports their 
continued proliferation due to the array of growth and survival factors provided by the 
inflammatory cells, thereby promoting carcinogenesis (219).  
After cancer initiation, the tumour microenvironment will be infiltrated by an array of 
immune cells including tumour-associated macrophages, mast cells and neutrophils 
(220), which promote malignant progression through the production of cytotoxic 
mediators such as growth factors, proangiogenic factors and ECM degrading enzymes 
(221). Additionally, immune cells generate reactive oxygen and nitrogen species, 
inducing oxidative genomic damage and post-translational modifications, which may 
dysregulate central pathways involved in cell cycle progression or DNA repair (222). 
Several studies have shown an increased risk of prostate cancer in men with a history of 
prostatitis (inflammation of the prostate)(223), which may be caused by infectious 
agents or oestrogens (224, 225). The link between chronic inflammation and the 
development of prostate cancer has led to the characterisation of a potential precursor 
of prostate cancer called proliferative inflammatory atrophy (PIA), which describes 
atrophic lesions of the prostate associated with chronic inflammation and proliferation 
in response to epithelial injury (226). PIA may be a precursor of HGPIN and prostate 
cancer in some cases (227). There is an identifiable progressive pathway of genetic 
alterations between PIA, HGPIN and prostate cancer including the reduced expression 
of tumour suppressor genes such as NK3 homeobox 1 (NKX3-1)(228) and an increased 
expression of the anti-apoptotic BCL2 (229). 
Hypermethylation of the glutathione S-transferase pi 1 (GTSP1) gene may be critical for 
the transition of PIA into HGPIN and prostate cancer (230). The glutathione 
S-transferases are a family of enzymes which protect the genome from oxidative stress 
inflicted by inflammatory processes, by catalysing the detoxification of reactive 
electrophiles. Promoter hypermethylation of GSTP1, which leads to its inactivation, is 
probably the most frequent genomic alteration in HGPIN and prostate cancer and leaves 
cells vulnerable to oxidative genome damage caused by inflammation (231). 
Hypermethylated GSTP1 has shown some promise as a non-invasive 
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diagnostic/prognostic prostate cancer marker, as it can be measured in samples such as 
serum and urine (232, 233). 
Stromal interactions 
The interactions between a tumour and its microenvironment are vital for cancer 
growth and progression. The tumour recruits and/or activates various stromal cells to 
the local microenvironment to form the tumour stroma which contains cancer 
associated fibroblasts (CAFs) and cells of the tumour associated vasculature and 
inflammatory cells (234). In comparison to normal stromal cells, the tumour stromal 
cells induce or upregulate various molecules which contribute to the proliferative and 
invasive phenotype of the cancer cells, including growth factors, angiogenic factors and 
proteolytic enzymes. Furthermore, the tumour stroma contains immune cells which 
allow the tumour to evade the host immune system (234). Complex reciprocal signalling 
back and forth between the tumour and stromal cells allows them to coevolve together, 
which contributes to cancer progression. This process is repeated at distant sites of 
colonisation, if metastasis occurs (235). 
In prostate cancer, the reactive stroma is enriched with myofibroblasts and CAFs and 
shows a significant reduction in differentiated smooth muscle cells (236). Characteristic 
changes to the ECM composition include an increased expression of hyaluronan (237) 
and a reduced expression of desmin (238). Additionally, there is an increased expression 
of growth factors such as fibroblast growth factor 2 (FGF2)(239) and matrix remodelling 
enzymes (240).  
Some components of the reactive stroma show prognostic significance in prostate 
cancer. For instance, expression of stromal hyaluronan (237) and tumour epithelial 
hyaluronidase-1 (HYAL1)(which degrades hyaluronan)(241) are positively correlated 
with disease progression. Hyaluronan may aid tumour progression through its 
stimulatory effect on cell proliferation (237) and role in tumour cell motility (242). 
Hyaluronidases such as HYAL1 are important for processing hyaluronan into fragments 
with potent angiogenic properties, thereby promoting neovascularisation (243).      
Evading immune destruction 
For tumours to progress they must evade the body’s immune system, either by avoiding 
immune system detection or by disabling or eliminating immune cells (244). Tumour 
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cells can avoid detection by shedding surface antigens or by the dysregulation of 
important components required for effective antigen presentation (245, 246). As 
a result, tumours exhibit a poor ability to stimulate T cells or to act as targets for tumour-
specific T cells. Immunosuppression in cancer may directly target the T cell response, 
e.g. through the downregulation of co-stimulatory molecules on the tumour cell surface 
(247), which prevents the co-stimulatory signals to the T cells that are necessary for their 
activation. There may also be upregulation of the co-inhibitory molecules that oppose 
T cell activation (248). Tumour and tumour stromal cells also produce a host of 
immunosuppressive factors, including cytokines and enzymes which inhibit immune cell 
activity (249). Finally, the formation of tumours encourages the recruitment and 
expansion of suppressor immune cell populations to the area such as regulatory T cells 
(250) and myeloid-derived suppressor cells (251), which secrete immunosuppressive 
modulators that suppress the effector function of T cells (252). 
Immunosuppressive factors present in the microenvironment of prostate tumours 
include: signal transducers and activators of transcription (STATs)(253) and 
immunosuppressive cytokines (254). An expansion in the number of regulatory T cells 
such as FOXP3+ cells is also a feature of the tumour microenvironment in prostate 
cancer (255), with higher numbers of these cells representing a poor prognostic factor 
(256). Additionally, the coinhibitory ligand CD276 antigen (CD276) is upregulated in 
prostate cancer tissue (257), with increased expression associated with adverse clinical 
outcome (258). 
 Prostate cancer prognostic biomarkers 
Many of the genes/proteins found to be dysregulated in prostate cancer have been 
investigated as potential prognostic biomarkers. A small selection of potential 
prognostic biomarkers, which have been widely investigated in prostate cancer, are 
critically evaluated in Appendix 1. The biomarkers included in Appendix 1 have been 
classified according to their putative roles in cancer (Table 1.2).  
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Table 1.2 Examples of potential biomarkers of prostate cancer progression   
Self-sufficiency in growth signals MKI67 proliferation marker protein Ki-67 
 EZH2/EZH2 enhancer of zeste 2 polycomb repressive 
complex 2 subunit 
 MYC MYC proto-oncogene, bHLH transcription 
factor  
Insensitivity to antigrowth signals PTEN/PTEN phosphatase and tensin homolog 
 CCP score 31-gene signature of cell cycle progression 
genes 
Evading apoptosis BCL2 apoptosis regulator Bcl-2 
 IGFBP3 insulin-like growth factor-binding protein 3 
Sustained angiogenesis MVD microvessel density 
 PTGS2 prostaglandin G/H synthase 2 
Tissue invasion and metastasis PLAU/PLAUR urokinase-type plasminogen activator,  
urokinase plasminogen activator surface  
receptor 
 CDH1 cadherin-1 
 Four-kallikrein panel  
 p2PSA [-2]proPSA and derivatives 
Genomic instability TMPRSS2:ERG gene fusion  
Stromal interactions stromal HA/HYAL1 stromal hyaluronan/hyaluronidase-1 
 serum BAP/uNTX serum bone-specific alkaline 
phosphatase/urinary N-telopeptide 
 
 Gene expression panels 
Due to the complex molecular alterations that are characteristic of prostate cancer 
progression, it would be unrealistic to expect a single biomarker to fulfil the role of risk 
prediction and small panels of markers may more accurately reflect the clinical 
phenotype of prostate cancer. 
Gene expression studies using complementary DNA (cDNA)/oligonucleotide microarray 
technology are important in the discovery phase of prognostic biomarkers in prostate 
cancer. However, such studies produce huge volumes of data that are difficult to resolve 
further. Additionally, microarray studies have a requirement for high quality RNA and so 
generally use fresh frozen tissue (259). This presents a problem as fresh frozen tissue is 
limited in both its availability and its associated clinical follow-up data, with which to 
correlate the gene expression data. In comparison, formalin-fixed paraffin-embedded 
(FFPE) samples are more readily available and possess well-documented follow-up data. 
However, due to a lower quality and quantity of RNA extracted from FFPE samples, 
a more sensitive technique such as real-time quantitative polymerase chain reaction 
(qPCR) analysis is required (260). Therefore, genes of interest that have been identified 
in microarray studies are frequently validated in FFPE samples using real-time qPCR 
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(261). However, real-time qPCR is too labour-intensive and expensive to realistically 
validate the expression of more than 10-20 genes. 
Despite these problems, some studies have identified gene expression profiles that can 
predict Gleason grade (262) and more relevant clinical endpoints such as BCR, systemic 
progression and prostate cancer-specific death (263-265). Some of these studies found 
the identified molecular signatures to be superior to GS for the prediction of clinical 
outcome (263).  
Although some of the results are promising, few of the identified gene panels have been 
thoroughly validated in independent studies. Additionally, the molecular signatures 
between studies have rarely overlapped (266). As a result, there are just a handful of 
gene panels that have been incorporated into commercially available tests and none 
have been routinely used in clinical practice.  
The Prolaris and the Oncotype Dx are both biopsy tests used for risk stratification in men 
with newly diagnosed low/intermediate risk prostate cancer (267). Biopsy tests have 
high clinical applicability as they have the potential to be used at the time of diagnosis 
for the stratification of patients for either active surveillance or therapeutic 
interventions. These tests have been found to add meaningful prognostic information 
when used alongside standard clinicopathological variables at the time of treatment 
selection (268). 
Prolaris® test 
The Prolaris® test (Myriad Genetics, Salt Lake City, UT, USA) is a 46 gene expression panel 
including 31 cell cycle progression (CCP) genes and 15 housekeeping genes, which is 
expressed as the CCP score. The CCP score has been found to be an independent 
predictor of BCR after RP and EBRT, and prostate cancer-specific mortality in 
conservatively managed patients (263, 269, 270). Prolaris testing may allow risk 
stratification beyond standard clinicopathological variables (263). 
The Prolaris test can also be used with radical prostatectomy samples to select patients 
with a high risk of BCR who may benefit from adjunctive therapy (271). 
39 
 
Oncotype DX® test 
The Oncotype DX® test (Genomic Health Inc, Redwood City, CA, USA) is a 17 gene 
expression panel including 12 cancer-related genes representing four biological 
pathways (stromal response, androgen signalling, proliferation, cellular organization) 
and 5 reference genes, which are combined to form the Genomic Prostate Score (GPS). 
The GPS has been found to be an independent predictor of unfavourable pathology 
found at RP (primary Gleason grade 4 or any grade 5 and/or non-organ confined 
disease). The addition of the GPS to a pretreatment clinical model such as the CAPRA 
provides a more accurate prediction of the presence/absence of unfavourable 
pathology compared with clinical  information alone (272, 273).  
These tests are not in widespread use as they require further validation through 
prospective studies to identify the long-term impact of changes in clinical management 
based on test results (e.g. shifting patients from interventional to non-interventional 
treatment)(274). These tests are very expensive and the financial and practical 
implications of using them need to be investigated. 
Additionally, although the aforementioned biopsy tests have shown predictive ability for 
men with low/intermediate risk disease (as defined by standard clinicopathological 
parameters), these tests are not suitable for men with high risk disease (268). 
 This study 
Therefore this study focused on the identification of progression-related gene markers 
in prostate cancer biopsy samples that would be relevant to patients with a wide range 
of conventional risk parameters. Identified genes were investigated as to whether they 
had potential to be used alone or in combination to provide novel prognostic 
information about prostate cancer patients and ultimately prove useful to inform 
treatment decisions. 
The TaqMan array study and its data analysis are described in detail in Chapter 2. The 
findings are described in relation to a pilot study by Larkin et al., from which the idea for 
this study originated (275). 
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 TaqMan array study 
2.1 Introduction 
 Background 
The clinical behaviour of prostate cancer is highly variable and despite much research, 
the cause of this variability remains poorly understood. Many prostate cancers have 
a long natural history with a low risk of systemic progression or death from the disease 
during the first 15 years. The deaths that occur within this time are usually the result of 
competing causes. Conversely, some patients exhibit a more aggressive form of the 
disease, which metastasizes quickly and proves lethal within a short time frame (276). 
A major challenge that exists in the clinical management of prostate cancer is the 
differentiation of patients with aggressive disease from those with a slow-growing form 
of the disease. Clinicians rely heavily on the use of Gleason grading of biopsy samples 
and clinical staging for treatment decision-making. These tools are limited in their ability 
to accurately predict tumour behaviour, as a result of biopsy sampling error and 
inaccurate clinical staging due to the multifocal and heterogeneous nature of prostate 
cancer, and the limitations of the Gleason grading system (103-105). As a consequence, 
there remains a significant problem of overtreatment in men with relatively indolent 
disease, exposing these men to the unnecessary risks and side effects of treatment, in 
an attempt to avoid undertreating the minority of prostate cancer patients with 
aggressive disease (109). 
Due to the limitations of clinical prognostic tools, the variability in disease behaviour and 
the risk of treatment-related impairment on quality of life, a more individualised 
approach to risk assessment in prostate cancer is necessary. Prognostic molecular assays 
offer the potential to provide a more individualised method to inform treatment 
decisions, such as whether to start treatment immediately or to manage conservatively, 
and whether adjunctive therapy is necessary. 
The aim of this research was to identify molecular markers of prostate cancer 
progression and to investigate whether any of these markers could be used individually 
or in combination to predict the risk of disease recurrence after RP or radiotherapy. This 
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could potentially provide novel prognostic information to better inform treatment 
decisions in newly-diagnosed prostate cancer patients.  
TaqMan array technology was chosen as it offered a medium throughput method which 
retained the sensitivity of standard real-time qPCR but allowed the analysis of multiple 
genes at once (277). This provided a much less time-consuming and labour-intensive 
method to collect expression data for a large number of genes (96 genes) in multiple 
samples. This technology was sensitive enough to allow the use of RNA extracted from 
FFPE biopsy samples (277). The use of FFPE samples allowed the gene expression data 
to be correlated with patient outcome over a long follow-up period. Gene expression 
data were correlated with clinical outcome (biochemical/clinical recurrence) and binary 
logistic regression (LR) analysis was used to identify gene models with the potential to 
categorise patients according to 5-year disease recurrence after treatment. 
 Previous pilot study 
The study extended a previous ‘proof of concept’ study by Larkin et al., which analysed 
the expression of 91 putative prostate cancer progression genes in 29 radical 
prostatectomy samples using a similar TaqMan array to our study (275). Using 
LR analysis, they identified several genes that in certain combinations, could relatively 
accurately predict GS ≥7 or biochemical/clinical recurrence in their dataset. The gene 
models were ranked according to their overall percent accuracy (percentage of the total 
number of samples that were correctly predicted).  
In their study the single gene models of HSPB1 and INMT could predict GS ≥7 vs <7 with 
an overall percent accuracy of 82.8% and 79.3% respectively. The models ABL1, ANPEP, 
CD9, EFNA1, GPM6A, ITGB4 and NELL2 could predict GS with an accuracy of 75.9%. PSCA 
could predict GS with an accuracy of 72.4%.    
The multivariate gene models co-utilising the markers ANPEP/PSCA, ABL1/ANPEP and 
ANPEP/GPM6A correctly predicted 86.2%, 82.8% and 82.8% of cases according to the 
GS respectively. 
ANPEP, INMT and TRIP13 as single gene models could correctly categorise 
recurrent/non-recurrent disease in 79.3%, 75.9% and 69% of patients. TRIP13 
42 
 
expression, in combination with the preoperative PSA level and GS, had the highest 
overall percent accuracy for the prediction of recurrence (85.7%)(275). 
 The current study - new research 
The present study (BB study) sought to validate and extend the findings of the previous 
study (SL study) using a similar method of RNA extraction, cDNA synthesis and real-time 
qPCR analysis. However, a much larger set of prostate cancer samples (67 successfully 
analysed samples) was used to enhance the reliability of the findings. A limitation of the 
previous study, besides the small sample size, was the inclusion of RP samples only 
(275). This represented a possible bias towards disease with a lower risk of recurrence, 
as RP tends to be performed in organ-confined disease of low/intermediate GS (278). 
This limitation was overcome in the present study by expanding the range of recurrence 
risks through the inclusion of biopsy samples from both radiotherapy (RT) patients and 
RP patients. Importantly, the use of predominantly biopsy samples (where available) 
sought to increase the clinical utility of the study. Biopsies are often the only samples 
available at the time of treatment decision-making, so a biopsy-based prognostic 
biomarker would offer the potential to provide novel objective information to aid the 
clinician at the time of treatment selection. The differences in the sample set between 
the SL and the BB study are described in Table 2.1. 
Table 2.1 Comparison of samples included in the SL and BB study 
Study Primary treatment Sample type 
RP RT RP TURP Biopsy 
SL study 29 0 29 0 0 
BB study 33 34 12 3 52 
 
The BB study also included several important developments to both the practical and 
data analysis methods in comparison to the SL study (which was only a pilot study) to 
improve the validity of the findings. In particular, the use of a more statistically valid 
method for ranking the predictive models was included in the BB study. These changes 
are explained in detail in the method development Sections 2.3.3 and 2.3.4. 
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 Aims 
• To successfully measure the expression of a panel of putative prostate cancer 
progression genes in archival prostate biopsy samples from men with varying 
grades and stages of prostate cancer treated with RP and/or RT.  
• To correlate the gene expression data with clinical outcome and identify any 
genes with potential as markers of biochemical/clinical recurrence.  
• To thoroughly investigate whether any of the genes can be utilized, either 
individually or in combination, as logistic regression models for the prediction 
of biochemical/clinical recurrence within 5 years from treatment.  
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2.2 Materials and methods 
 Introduction/practical considerations 
 Choice of practical methodology 
Due to resource limitations for storing frozen tissue and the requirement to preserve 
tissue architecture for diagnosis, tissue samples in pathology departments are routinely 
formalin-fixed and paraffin-embedded before storage. In addition to their abundance, 
such archival samples possess well-documented patient data. They are ideal for 
retrospective molecular studies, which correlate gene expression data with clinical 
outcome. Therefore, archival prostate cancer samples offered a rich resource of samples 
for this study.  
Studies have found that gene expression profiles using FFPE tissue show a high relative 
concordance with frozen tissue (279). However, the quality and yield of RNA extracted 
from FFPE tissue is typically lower than from frozen tissue (260). Due to the formalin 
fixation, nucleic acid is trapped and modified by the formation of protein-nucleic acid 
crosslinks, leading to a low yield of RNA, which is typically highly fragmented and 
chemically modified (279, 280). RNA degradation continues with the time that the 
samples are kept in storage at room temperature (279). 
Due to these factors, gene expression quantification from FFPE samples can only be 
achieved using a highly sensitive technique such as fluorescence-based real-time qPCR 
analysis and the detection rate is lower (higher cycle threshold (Ct) values) in 
comparison to frozen tissue (281). 
Several important measures were implemented in this study to overcome the 
compromised quantity and quality of RNA and to increase the chance of successful real-
time qPCR. These measures are described as follows:  
RNA extraction 
The RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion, Austin, TX, USA) was used to 
extract the RNA from the FFPE samples. This kit was ideal for the recovery of fragmented 
RNA as it is designed to extract the maximal amount of RNA of all sizes using rapid glass-
fibre filter technology. Importantly, this kit includes a protease digestion and heating 
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step to release RNA covalently bound to protein and reverse some of the chemical 
modifications. The Ambion RecoverAll kit performs highly in terms of the quantity and 
quality of RNA that can be extracted from FFPE samples, maximising the amount of 
amplifiable RNA available (282). 
Reverse transcription and TaqMan array analysis 
It was also important to optimise the reverse transcription step as degraded and 
chemically modified RNA can impair the efficiency of this step. Random primers were 
used as they tend to generate the highest yield of cDNA (283). These prime at multiple 
points throughout the messenger RNA (mRNA) transcript rather than at the polyA tail 
only, as is the case with oligo-dT primers. They are therefore ideally suited to the RNA 
extracted from FFPE tissue, which is typically degraded and prone to loss of the polyA 
tails due to the modification of bases by formalin (280). 
The TaqMan® array (Applied Biosystems, Carlsbad, CA, USA) was chosen for the study 
as it offered a medium-throughput method for fluorescence-based real-time qPCR 
analysis (277). TaqMan arrays offer a sensitive and reproducible method to study gene 
expression (277) and have been used for the validation of prognostic gene biomarkers 
in various cancers including prostate cancer (284). This technology requires a low cDNA 
input and so was ideal for the limited quantities of cDNA obtained from the FFPE tissue 
in this study, particularly from the minimally-sized biopsy samples (284). 
For the real-time qPCR, short amplicons were chosen as they produce lower Ct values 
(improved sensitivity) than longer amplicons for the amplification of short cDNA 
templates (from degraded RNA)(285). The use of the internal reference gene 
hydroxymethylbilane synthase (HMBS) was fundamental to normalise the gene 
expression data as it corrected for differences in the total RNA quantity and quality 
between samples. 
 Design of the new TaqMan array 
For this study the TaqMan arrays were customised with 96 gene targets, which allowed 
up to 4 samples to be run per card (two ports per sample). Further background 
information on TaqMan arrays can be found in Appendix 3. 
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The design of the array was based on the array used in the pilot study (SL study)(275), 
which had been customised with 91 putative prostate cancer progression markers 
(Figure 2.1). The majority of the prostate cancer-related genes in the SL study had been 
identified as important prostate carcinogenesis genes in a study by Narayanan and 
Keedwell (286), which analysed published microarray data using artificial neural 
networks. Other genes had been identified through an extensive literature search or as 
a result of previous work in the department (287, 288).  
The ABI manufacturing control 18S ribosomal RNA (18S) was also included on the array 
in addition to four other housekeeping genes that had been documented as showing 
stable expression in prostate cancer tissues between different stages and grades (289): 
hydroxymethylbilane synthase (HMBS), TATA-box binding protein (TBP), hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) and succinate dehydrogenase complex 
flavoprotein subunit A (SDHA).  
The new array (BB array)(Figure 2.2) included the same genes (including housekeeping 
genes) as the SL array except for the following changes:  
Ten genes were removed, that had been found to show p-values of >0.5 in the 
independent samples t-tests (for the comparison of the GS ≥7 and <7 group and/or 
recurrent and non-recurrent group) in the SL study (275). As a p-value of >0.5 suggested 
that these genes were unlikely to be useful in LR models, they were excluded from the 
array to provide space for other genes of interest. The excluded genes were CDH2, 
CTNNA1, HSPA5, KCNN4, MMP9, RBM12, SFPQ, TGM2, HSP90B1 and WIF1.  
The genes ERBB2, C3, HPX, MKI67, MT1X, MUC1, PLAU, PTEN and TF were selected for 
the BB array as replacements for these genes. On theoretical grounds, ERBB2, MK167 
MUC1, PLAU and PTEN were highlighted as putative prostate cancer progression 
markers following a review of current literature. 
For instance, MUC1 encodes a transmembrane glycoprotein, which has been strongly 
associated with clinicopathological parameters of aggressive disease and poor prognosis 
in several types of cancer including prostate cancer (290-292). As MUC1 is an anti-
adhesion molecule, it has been proposed that it may enhance the invasive and 
metastatic potential of cancer cells (292), for example by reducing cadherin-1 and 
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integrin-mediated cell adhesion (293, 294). In prostate cancer, studies have found MUC1 
mRNA and protein overexpression to correlate with aggressive clinicopathological 
features and poor prognosis (290, 291). 
The remainder of the novel genes on the new array (C3, HPX, MT1X and TF) were 
highlighted as genes of interest based on previous work in our department. For example, 
hemopexin (HPX) was identified as a putative marker of high grade prostate cancer 
(GS ≥7) in a serum proteome study (295). A further tissue microarray study showed 
significant differences in hemopexin expression across benign, low grade (<7), high 
grade (≥7) and metastatic tissue (295). Hemopexin is a serum glycoprotein which 
transports heme from the bloodstream to the liver for metabolism and iron recovery 
(296). Despite the fact that the role of hemopexin in cancer is not fully elucidated, 
numerous proteomic profiling studies using serum/plasma samples or other body fluids 
have identified hemopexin as being significantly up- or downregulated in various types 
of cancer including prostate cancer (297, 298). 
The full names of each gene incorporated on the SL and BB array can be found in 
Appendix 2, where they have been grouped according to their putative roles in cancer 
initiation/progression.  
The proportion of the total number of genes on the BB array within each category are 
illustrated in Figure 2.3. 
 
48 
 
 
 
Figure 2.1 Genes included on the SL array and their putative roles in cancer initiation/progression 
Samples
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDH2* CDKN1C CHM CRHR1 CTNNA1* A
CYP11A1 DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 B
HSPA5* HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB6 KCNN4* KLHL5 M M P2 M M P9* M NX1 M YC* NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC PLCL2 PLLP C
POP5 PRIM 2 PSCA PTGFR PVALB PVT1 RAP1GAP RBM 12* RHBDL1 SDHA SERPINB5 SFPQ* SLC44A2 PRELID3A TBP TBRG4 TERT TGFB2 TGM 2* HSP90B1* TRAFD1 TRIP13 VASH1 WIF1* D
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDH2 * CDKN1C CHM CRHR1 CTNNA1 * E
CYP11A1 DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 F
HSPA5 * HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB6 KCNN4 * KLHL5 M M P2 M M P9 * M NX1 M YC * NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC PLCL2 PLLP G
POP5 PRIM 2 PSCA PTGFR PVALB PVT1 RAP1GAP RBM 12 * RHBDL1 SDHA SERPINB5 SFPQ * SLC44A2 PRELID3A TBP TBRG4 TERT TGFB2 TGM 2 * TRA1 * TRAFD1 TRIP13 VASH1 WIF1 * H
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDH2 * CDKN1C CHM CRHR1 CTNNA1 * I
CYP11A1 DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 J
HSPA5 * HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB6 KCNN4 * KLHL5 M M P2 M M P9 * M NX1 M YC * NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC PLCL2 PLLP K
POP5 PRIM 2 PSCA PTGFR PVALB PVT1 RAP1GAP RBM 12 * RHBDL1 SDHA SERPINB5 SFPQ * SLC44A2 PRELID3A TBP TBRG4 TERT TGFB2 TGM 2 * TRA1 * TRAFD1 TRIP13 VASH1 WIF1 * L
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDH2 * CDKN1C CHM CRHR1 CTNNA1 * M
CYP11A1 DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 N
HSPA5 * HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB6 KCNN4 * KLHL5 M M P2 M M P9 * M NX1 M YC * NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC PLCL2 PLLP O
POP5 PRIM 2 PSCA PTGFR PVALB PVT1 RAP1GAP RBM 12 * RHBDL1 SDHA SERPINB5 SFPQ * SLC44A2 PRELID3A TBP TBRG4 TERT TGFB2 TGM 2 * TRA1 * TRAFD1 TRIP13 VASH1 WIF1 * P
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Figure 2.2 Genes included on the BB array and their putative roles in cancer initiation/progression 
Samples
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL C3* CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDKN1C CHM CRHR1 CYP11A1 A
DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERBB2* ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 B
HPX* HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB4 ITGB6 ITGB6 KLHL5 M KI67* M M P2 M NX1 M T1X* M UC1* NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC C
PLAU* PLCL2 PLLP POP5 PRIM 2 PSCA PTEN* PTGFR PVALB PVT1 RAP1GAP RHBDL1 SDHA SERPINB5 SLC44A2 PRELID3A TBP TBRG4 TERT TF* TGFB2 TRAFD1 TRIP13 VASH1 D
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL C3 CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDKN1C CHM CRHR1 CYP11A1 E
DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERBB2 ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 F
HPX HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB4 ITGB6 ITGB6 KLHL5 M KI67 M M P2 M NX1 M T1X M UC1 NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC G
PLAU PLCL2 PLLP POP5 PRIM 2 PSCA PTEN PTGFR PVALB PVT1 RAP1GAP RHBDL1 SDHA SERPINB5 SLC44A2 PRELID3A TBP TBRG4 TERT TF TGFB2 TRAFD1 TRIP13 VASH1 H
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL C3 CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDKN1C CHM CRHR1 CYP11A1 I
DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERBB2 ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 J
HPX HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB4 ITGB6 ITGB6 KLHL5 M KI67 M M P2 M NX1 M T1X M UC1 NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC K
PLAU PLCL2 PLLP POP5 PRIM 2 PSCA PTEN PTGFR PVALB PVT1 RAP1GAP RHBDL1 SDHA SERPINB5 SLC44A2 PRELID3A TBP TBRG4 TERT TF TGFB2 TRAFD1 TRIP13 VASH1 L
ABL1 ALCAM ALPG AM ACR ANPEP ANXA2 APOBEC3G ASB2 ATP10B BRCA2 18S ATP5M PL C3 CANX CD109 CD4 CD44 CD9 CDC42EP3 CDH1 CDKN1C CHM CRHR1 CYP11A1 M
DPT EDNRA EEF1A1 EFNA1 EFNA2 EFNA3 EFNA4 EFNA5 ERBB2 ERG EZH2 F11R FABP5 FADS1 GPM 6A GPR12 GPR19 GSTM 3 GSTM 5 GUCY1A1 HM BS HOXC6 HPN HPRT1 N
HPX HSPB1 INM T IRF7 ITGA2 ITGA3 ITGA5 ITGB1 ITGB4 ITGB4 ITGB6 ITGB6 KLHL5 M KI67 M M P2 M NX1 M T1X M UC1 NDUFAF1 NELL2 PNP NUP50 PCDH18 PGC O
PLAU PLCL2 PLLP POP5 PRIM 2 PSCA PTEN PTGFR PVALB PVT1 RAP1GAP RHBDL1 SDHA SERPINB5 SLC44A2 PRELID3A TBP TBRG4 TERT TF TGFB2 TRAFD1 TRIP13 VASH1 P
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Figure 2.3 Genes on the BB array, categorised according to their roles in cancer initiation/progression 
 
 Choice of data analysis 
In this study, two different relative quantification methods were used to convert 
TaqMan array data (Ct values) to normalised gene expression ratios: the 2-∆Ct method 
and the Pfaffl method (275). The 2-∆Ct method is relative quantification in its simplest 
form and is described alongside a description of real-time qPCR data analysis in 
Appendix 3. 
The Pfaffl method calculates a target gene expression ratio as a fold increase relative to 
a control sample and is normalised to the expression of a reference gene (299). This 
method accounts for the fact that the target and reference genes may not exhibit the 
same amplification efficiencies. The equation for the Pfaffl method is as follows: 
𝑅𝑎𝑡𝑖𝑜 =  
𝐸𝑡𝑎𝑟𝑔𝑒𝑡
∆𝐶𝑡,𝑡𝑎𝑟𝑔𝑒𝑡(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑡𝑒𝑠𝑡)
𝐸𝑟𝑒𝑓
∆𝐶𝑡,𝑟𝑒𝑓(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑡𝑒𝑠𝑡)
 
Etarget  and Eref are the real-time PCR amplification efficiencies of the target and reference gene transcripts.  
∆Cttarget is the Ct of the target gene in the control sample minus the Ct of the target gene in the test sample. 
ΔCtref is the Ct of the reference gene in the control sample minus the Ct of the reference gene in the test 
sample. 
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The housekeeping gene HMBS was used as the reference gene for normalisation as it 
has been found to demonstrate extremely low variation between grades and stages of 
prostate cancer (289, 300). The use of HMBS as a suitable reference gene for this study 
was confirmed by demonstrating its stability between samples (ΔCt method), and its low 
variability between the GS ≥7 and <7 group and between the recurrent and non-
recurrent group (Appendix 4). 
Binary logistic regression (LR) was selected as an appropriate statistical method for 
creation of the predictve models, as the outcome (dependent) variable consisted of only 
two categories (recurrent and non-recurrent). LR was used to model the probability of 
the outcome (being in either the recurrent or non-recurrent group) based on the 
expression of particular genes (independent/predictor variables). 
In comparison to linear regression, LR does not require a linear relationship between the 
independent variables and the dependent variable. This is fundamental, as the use of 
a categorical dependent variable violates the assumption of linearity found in ordinary 
regression. LR uses a log transformation of the outcome (dependent variable) to allow 
the non-linear relationship between the independent variables and dependent variable 
to be modelled in a linear manner. This was ideal as it allowed an understanding of the 
effect of several predictor variables (genes) on the single dichotomous dependent 
variable (i.e. how expression of a set of genes affects membership in the recurrent or 
non-recurrent categories). Importantly, LR controls for any confounding between 
predictor variables, which would not be possible if the predictor variables were analysed 
separately (301). Furthermore, LR does not require that the independent variables or 
dependent variable be normally distributed or have equal variance between groups.  
A more detailed description of LR analysis and Receiver Operating Characteristic (ROC) 
curves, which were used to test the discriminatory accuracy of the identified predictive 
models, can be found in Appendix 5. This includes a detailed description of the 
important parameters found in the LR output from SPSS (statistical package used in this 
study). 
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 Sample size and power calculations 
It was essential to ensure that the study included enough data to reliably estimate the 
parameters for the logistic regression equation in a multivariate analysis, to reduce the 
risk of creating unreliable models artificially produced by the data. Sample size 
calculation for LR, which ensures an acceptable level of statistical power, tends to be 
based on the rule of thumb of 10 events per variable (EPV) where the events describe 
the number of samples in the minority group (302). However, more recent studies have 
challenged this rule and suggest that the use of 5-9 EPV is sufficient (303).  
Due to limitations in the number of samples that could be accessed and processed, the 
sample size of this study was small. Additionally, despite processing 105 prostate cancer 
samples, the final number of samples successfully analysed was only 67. (The reasons 
behind the exclusion of 38 samples is explained in detail in Section 2.3.2). However, as 
the number of events (number of patients in the recurrent group) was 21, up to 
3 predictor variables could be used (7 EPV). Therefore, single, two-gene and three-gene 
LR models could be analysed for the categorisation of patients according to recurrence. 
The EPV for the single, two- and three-gene models are illustrated in Table 2.2. 
Table 2.2 The events per variable for the single, two-gene and three-gene models 
Number of positive 
events 
Number of variables 
in model 
Events per variable 
(EPV) 
21 1 21 
21 2 11 
21 3 7 
 
A secondary LR analysis was considered for the comparison of late recurrence (between 
year 5 and 10) and early recurrence (between year 0 and 5). However, complete 10-year 
outcome data was only available for some of the patients. Importantly, only 6 of these 
patients could be classified as suffering late recurrence. The low number of events 
precluded the use of late/early recurrence as the dependent variable in multivariate 
LR analysis.  
Prostate cancer-specific death was also considered as an endpoint for LR analysis. Due 
to the usually protracted disease progression in prostate cancer, there were few 
prostate cancer-specific deaths within follow up. More specifically, no prostate cancer-
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specific deaths occurred within 5 years and only 4 within 10 years. The use of prostate 
cancer-specific death as an endpoint would have required a much longer follow-up 
period and a far greater sample size than was possible for this study.  
 Ethical permissions 
The study used archival prostate cancer tissue samples that had been formalin-fixed and 
paraffin-embedded for routine clinical analysis and storage within the Department of 
Pathology, Queen Alexandra Hospital (QAH), Portsmouth. At the time of the 
experimental work, ethical consent for the use of the samples in research was already 
in place as part of the protocols associated with the Portsmouth Molecular Pathology 
Tissue Bank (07/MRE08/2). The tissue bank was headed by Professor Ian Cree, the 
director of the Translational Oncology Research Centre (TORC), QAH, where the 
practical work was completed in its entirety. Due to ethical permissions lapsing in 2012 
with the closure of the tissue bank, new ethical permissions were gained in 2016 so that 
updated patient outcome data could be accessed for the final data analysis and write-
up (see Section 2.3.4.3 for further details). 
 Practical methods 
 Sample sourcing and clinical information 
FFPE sample blocks from patients with varying grades and stages of prostate cancer 
were collected from storage with their corresponding haematoxylin and eosin labelled 
slides. The samples consisted of predominantly biopsies but RP and TURP samples were 
used if a biopsy was not available. 
Patient data including pathology results, dates/types of treatment and outcome data 
(including both biochemical and clinical parameters) were sourced by accessing the 
databases at the QAH, including the Apex Pathology System and the Graphnet system 
(Electronic Patient Records). Where insufficient data was found by these methods, 
patients’ notes were investigated by a research nurse, clinical trials assistant or 
pathologist. 
Patients were categorised as having recurrent disease based on information pertaining 
to biochemical recurrence and/or clinical recurrence (such as the presence of novel 
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metastases). The presence of BCR in patients who had undergone RP was defined by 
a serum PSA of ≥0.2ng/ml followed by a subsequent confirmatory PSA of >0.2ng/ml, as 
suggested by the American Urological Association (80). For patients who had received 
RT, BCR was defined by a PSA level greater than or equal to the post-treatment nadir 
plus 2ng/ml, according to the American Society for Therapeutic Radiology and Oncology 
(304). 
 Identification and extraction of areas of interest 
A histopathologist examined the haematoxylin and eosin labelled slides from sections 
of the sample blocks. Cancerous areas containing the purest tumour, i.e. those with the 
smallest amount of stroma and inflammation were marked and graded (according to the 
Gleason system). To ensure reproducibility, the same histopathologist was responsible 
for marking all the slides. 
Two 0.6mm tissue cores (if possible) were punched from the areas of highest Gleason 
grade on the corresponding sample block using a manual tissue arrayer (Beecher 
Instruments, Inc., Sun Prairie, WI, USA) and the tissue punches placed in a 1.5ml 
microcentrifuge tube. Care was taken to avoid cross-contamination between samples 
by rubbing gloved hands with 70% industrial methylated spirit and cleaning arrayer 
punches with DNA Zap™ (Applied Biosystems, Carlsbad, CA, USA; AM9890) between 
samples. 
 RNA extraction 
RNA was extracted from the tissue punches using the RecoverAll™ Total Nucleic Acid 
Isolation Kit (Ambion, Austin, TX, USA; AM1975) with a modified protocol as follows: 
Deparaffinization 
Tubes containing the tissue punches were prewarmed in a heat block at 70⁰C for 15-20 
mins followed by the addition of 1ml of 100% xylene to each tube (prewarmed to 50⁰C 
for 15-20 mins). Samples were incubated at 50⁰C for 3 mins to melt the paraffin followed 
by centrifugation at 13,000g for 2 mins. Xylene was carefully removed and discarded 
using a fine-tipped Pasteur pastette, with care taken to avoid disruption to the tissue 
pellet. The pellet was washed twice to remove residual xylene, with each wash using 
1ml of 100% ethanol that was subsequently removed with a pastette after 
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centrifugation as before. After the second wash, the pellet was air dried at room 
temperature (10-15 mins) with care taken to avoid overdrying the pellet. 
Protease digestion 
200µl of digestion buffer followed by 4µl of protease solution (both supplied with the 
kit) were added to each sample. After the tissue pellet was brought down into the 
solution by pulse centrifugation, the sample was incubated in a heat block at 50⁰C for 
15 mins followed by 15 mins at 80⁰C to break protein cross-links and reverse chemical 
modifications of the RNA. 
After the protease digestion, 240µl of isolation additive was added. The lysate was either 
processed immediately or stored at -20⁰C awaiting the nucleic acid isolation step. 
Nucleic acid isolation 
550µl of 100% ethanol was added to the lysate and 700µl of ethanol/lysate mixture was 
loaded onto the filter cartridge, which was held in the collection tube. After 
centrifugation at 10,000g for 60s and once the flow-through had been discarded, the 
remaining lysate/ethanol sample was loaded onto the filter and the process repeated. 
700µl of wash 1 was then added to the filter cartridge and the tubes centrifuged at 
10,000g for 30s with the flow-through discarded. This was followed by the addition of 
500µl of wash 2/3 and an identical centrifugation at 10,000g for 30s. A further 
centrifugation of the filter cartridge tube assembly for 30s removed the residual wash 
from the filter cartridge. 
To remove contaminating DNA from the sample, 60µl of a DNase solution (6µl 10x 
buffer, 4µl DNase (included in kit) and 50µl nuclease-free water (Promega, Madison, WI, 
USA; P1193)) was carefully applied to the centre of each filter cartridge. After incubation 
at room temperature for 30 mins, the samples were washed with 700µl of wash 1 as 
before except that after the wash was added, the tubes were left at room temperature 
for 60s before centrifugation. This was followed by two identical washes with wash 2/3 
as previously described. The tube assembly was spun for a further 60s to remove the 
residual wash 2/3. Finally, the filter cartridge was transferred to a new collection tube. 
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Elution of RNA 
For elution of the RNA, 110µl of nuclease-free water (prewarmed to 95⁰C)(Promega) 
was carefully added to the centre of each filter cartridge. After incubation at room 
temperature for 60s, the samples were centrifuged at 10,000g for 60s. The eluate was 
carefully reapplied to the filter cartridge and the process repeated. The filter cartridge 
was discarded and the eluate containing the RNA was measured for quantity and purity 
using a NanoDrop® ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, 
USA) as described below. 
In instances where RNA was not immediately converted to cDNA, RNA samples were 
stored at -80⁰C to prevent RNA degradation. 
 Assessment of RNA concentration and purity 
The concentration and purity of the RNA samples were measured using a Nanodrop® 
ND-1000 spectrophotometer (Thermo Scientific) according to the manufacturer’s 
instructions. 1.3µl of the sample was applied to the sample retention system after 
zeroing the instrument using nuclease-free water (Promega).  
 Reverse transcription of RNA to cDNA 
RNA was converted to cDNA using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems; 4368814). Master mixes were prepared to a 2X concentration 
using stock reagents supplied with the kit and nuclease-free water (Promega) to make 
a final volume of 75µl and 15µl per sample for the reverse transcription positive (Table 
2.3) and reverse transcription negative (Table 2.4) master mix respectively.  
Appropriate volumes of each master mix were aliquoted for each sample and an equal 
quantity of diluted sample RNA was added to each master mix to make a 1X final 
concentration. The reverse transcription negative master mix was used to check for 
genomic DNA contamination in the RNA sample and did not contain any reverse 
transcriptase enzyme. 
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Table 2.3 Reagent volumes required for reverse transcription positive reaction 
 
Table 2.4 Reagent volumes required for reverse transcription negative reaction 
Reagent Volume (µl) 
Promega nuclease-free water 7.8 
10X reverse transcription buffer 3 
25X dNTPs 1.2 
10X random primers 3 
Multiscribe™ reverse transcriptase (50U/µl) 0 
Total per 2X Master Mix reaction 15 
Add diluted sample 15 
 
After mixing carefully, the tubes were placed in a cooling block until they were loaded 
onto a peqSTAR 96 Universal thermocycler machine (PEQLAB Ltd., Erlangen, Germany). 
The thermocycler conditions for the reverse transcription reaction consisted of: step 1 
(10 mins at 25⁰C) and step 2 (120 mins at 37⁰C). The cDNA was stored at -20⁰C until use. 
 Preamplification of cDNA 
cDNA was preamplified prior to its use on the BB array. Each gene that was present on 
the array (apart from 18S) underwent the preamplification procedure. Therefore, 
TaqMan® Gene Expression Assays (Applied Biosystems; 4331182) were required for 
95 genes. 
Pooling Taqman assays 
Equal volumes of each 20X TaqMan® Gene Expression Assay (Applied Biosystems) were 
pooled. The pooled assays were then diluted with 1X Tris-EDTA (TE) buffer (Promega; 
V6231) for a 0.2X final concentration per assay. The gene expression assay mix was 
stored at -20⁰C until use. 
Preamplification PCR 
Preamplification reactions were prepared for each sample. Each reaction contained 25µl 
of TaqMan® PreAmp Master Mix (2X)(Applied Biosystems; 4391128), 12.5µl of pooled 
assay mix (0.2X, each assay) and 12.5µl of sample cDNA.  
Reagent Volume (µl) 
Promega nuclease-free water 31.5 
10X reverse transcription buffer 15 
25X deoxyribonucleotide triphosphates (dNTPs) 6 
10X random primers 15 
Multiscribe™ reverse transcriptase (50U/µl) 7.5 
Total per 2X Master Mix reaction 75 
Add diluted sample 75 
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Preamplification reactions were run on the peqSTAR 96 Universal thermocycler machine 
(PEQLAB Ltd.) with the following cycling conditions: 95⁰C 10 mins, (14 cycles of: 95⁰C 
15s, 60⁰C 4 mins). Preamplification products were either kept on ice for immediate use 
or stored at -20⁰C until use. 
 Running the TaqMan array card 
Design of the TaqMan® array 
The BB Taqman array cards (Applied Biosystems; 4342259) were customised with 
96 TaqMan® Gene Expression Assays (Figure 2.2). Assay numbers are listed in Appendix 
2. 
Preparation of the TaqMan® array 
The 7900HT Fast Real-Time PCR machine (Applied Biosystems) was switched on at least 
30 mins prior to use, to enable the laser to warm up. During this time, the array cards 
were brought to room temperature. 
100µl of diluted preamplified cDNA was added to 100µl of Taqman® Universal PCR 
Master Mix (X2)(Applied Biosystems; 4304437). The solution was added to two ports of 
the array by pipetting 100µl into each port. The sample was introduced via the larger of 
the two sample holes of the port, with care taken to avoid introducing air bubbles. The 
plate was centrifuged twice using a Sorvall® Legend T centrifuge (Thermo Scientific) at 
331g for 1 min each time. The plate was sealed with an array sealer (Applied Biosystems) 
and the loading port strip cut off.  
The plates were run with identical cycling parameters each time which were: 50⁰C 
2 mins, 94.5⁰C 10 mins, (40 cycles of: 97⁰C 30s, 59.7⁰C 1 min) according to the 
manufacturer’s instructions. 
N.B. The 48 gene arrays used for testing the control DNA and for use in the method 
development are shown in Appendix 6. These plates were run with 8 samples per card 
as each port led to all 48 genes. 
 Preparation and testing of control cDNA 
Control cDNA for use in the standard curve and replicate experiments consisted of 
pooled cDNA procured from FFPE tissue samples of a variety of different cancers 
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including prostate cancer, using a similar extraction and reverse transcription procedure 
as described above. However, 8-10 tissue sections from the control samples were used 
rather than tissue punches to maximise the cDNA yield. An equal volume of each cDNA 
sample was used to produce the pooled cDNA. 
Control cDNA underwent batch testing which consisted of three runs using a 48 gene 
array (Appendix 6). The first two arrays were run by different operators on different days 
using 300ng/µl of control cDNA (diluted with nuclease-free water) in five ports with 
a no-template control (nuclease-free water) in the final three ports. Batch testing was 
required to ensure that the control cDNA contained sufficient and uniform quantities of 
the genes on the array and to ensure high reproducibility between control replicates. 
A final array was run in a similar format but using reverse transcription negative control 
cDNA to ensure there was no genomic DNA contamination (N.B. the control cDNA was 
not preamplified at this point). 
 Standard curve and replicate plates 
Sample and control cDNA were diluted in 1X TE buffer (Promega) before use in the 
prostate TaqMan array card (BB array). 
A standard curve plate was run before the sample plates and consisted of 1:20, 1:100 
and 1:200 dilutions of preamplified control cDNA. A replicate plate was run before and 
after the sample plates, which consisted of a 1:20 dilution of preamplified control cDNA 
run in triplicate.  
The sample plates were run using a 1:20 dilution of preamplified sample cDNA with 
a total of four samples run per card. The raw data for each plate (Ct values) were saved 
as an SDS file.    
 Data analysis methods 
The amplification plots for each gene were initially viewed in SDS software (version 
2.4.1; Applied Biosystems). As the optimal baseline and threshold values varied 
significantly between the genes, these values were set individually for each gene with 
the settings held constant for every plate (see Section 2.3.4.4). 
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 Setting the baseline and threshold values 
SDS files from the replicate and sample plates were initially converted from AQ to RQ 
data files using the SDS software, so they could be imported into ExpressionSuite 
software (version 1.1; Thermo Fisher Scientific), which allowed multi-plate analysis of 
the amplification plots for each gene. Multi-plate analysis was necessary to optimise the 
baseline and threshold settings for each gene, thereby ensuring accurate Ct values. 
The baseline was determined by viewing the data for each gene in the linear scale 
amplification plot and if the amplification curves were not flat at zero, adjusting the 
baseline (from the default setting of 3-15 cycles) so that the baseline stop value was 
approximately 1-2 cycles before the earliest amplification (Figure 2.4). 
The threshold value for each gene was also manually set (using the logarithmic (log) 
scale amplification plot) at a value significantly above the baseline but within the 
exponential phase of the amplification plot (Figure 2.5). The precision of the assay was 
also demonstrated to be high at the threshold value, as evidenced by the merging 
together of the replicate amplification curves (Figure 2.6). 
The data for the standard curve were analysed using the chosen baseline and threshold 
values for each gene in the SDS software as an AQ file.  
Replicate and sample plates were analysed with these baseline and threshold values but 
using the ExpressionSuite software, as the chosen settings only needed to be imported 
once for all plates. 
After the software analysed the data from each plate with the chosen settings, the 
Ct values were exported and analysed in Excel before statistical analysis with SPSS 
(version 24; IBM, Portsmouth, UK).  
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Figure 2.4 Amplification plots for the housekeeping gene HMBS (linear view): a) before baseline setting 
(Rn vs cycle number) b) after correctly setting baseline at 3-19 cycles (ΔRn vs cycle number) 
 
 
 
Figure 2.5 Amplification plots for HMBS (log view) showing threshold value at 0.426 
62 
 
Figure 2.6 Amplification plots for HMBS (log view) showing high precision of replicates 
 
 Standard curve and replicate plate analysis 
Before Ct values could be used for quantification, it was essential to confirm that the 
qPCR assay was optimised using information from the standard curve and replicate 
plates. 
Initially, the standard curve data for each gene was plotted as the Ct value vs the log of 
each standard dilution (Figure 2.7). As the standard dilutions were expressed as dilution 
factors (1:20, 1:100 and 1:200) rather than concentrations, they were given proportional 
values (50, 10 and 5) to enable a plot to be generated. 
 
 
Standard curve data was collated in Excel and included the parameters calculated 
automatically by the SDS software: the coefficient of determination (R2), the slope and 
the y intercept. The R2 was used to measure the fit of the data to the regression line (as 
Figure 2.7 Standard curve plot for HMBS 
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a measure of linearity). The slope of the regression line was used to assess the 
percentage amplification efficiency (%E) of each gene using the following formula:  
𝐴𝑚𝑝𝑙𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐸) = 10−1/𝑠𝑙𝑜𝑝𝑒 
%𝐸 = (𝐸 − 1) 𝑥 100%. 
The precision and reproducibility of the assay were determined from the results of the 
replicate plates by measuring intra-assay (within array) and inter-assay (between arrays) 
variation. As Ct values cannot be used directly to calculate variation (as log units), it was 
necessary to initially convert Ct values for the replicates to actual quantities using the 
equation of the linear regression line from the standard curve. 
Calculation of actual quantities using the linear regression equation (y = mx + c) 
y = Ct value 
m = slope 
x = quantity 
c = y intercept 
 
𝐶𝑡 =  𝑠𝑙𝑜𝑝𝑒 (𝑙𝑜𝑔 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦) + 𝑦 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 
𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 =  10
(
𝐶𝑡−𝑦 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡
𝑠𝑙𝑜𝑝𝑒
)
 
The calculation of actual quantities allowed intra- and inter-assay variation to be 
assessed for all the reference genes, as there was no requirement to normalise to 
a reference gene. It is important to remember that, as dilution factors were used rather 
than concentrations for the standard curve, these values were proportional quantities 
rather than absolute quantities.  
To assess intra-assay variation for each gene, the mean and standard deviation between 
the triplicate samples within each plate were calculated. The percentage coefficient of 
variation (%CV) was then determined using the following formula: 
%𝐶𝑉 = (𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛/𝑚𝑒𝑎𝑛) ∗ 100 
Likewise, inter-assay variation was determined as the %CV between the two replicate 
plates. 
64 
 
 Relative quantification of sample data 
Before data quantification of the samples, any undetermined genes were given a Ct 
value of 40 to make statistical analysis easier. Next, any cDNA samples which showed 
low expression of the housekeeping gene HMBS (Ct ≥35) were excluded from further 
analysis as the samples were not deemed to be of sufficient cDNA quality (305). 
Ct values were converted to normalised gene expression ratios by two different relative 
quantification methods: the Pfaffl method (299) and the 2-∆Ct method, using HMBS as 
the reference gene. The Pfaffl equation (Section 2.2.1.3) used amplification efficiencies 
of the target and reference genes which were taken from the standard curve 
experiments. The Ct values of the target and reference genes for the control sample 
were obtained from the replicate plates (the mean of the 6 replicates). 
Both datasets were natural logarithm (ln) transformed to normalise the data. Statistical 
analysis was performed using SPSS (version 24; IBM, Portsmouth, UK). 
Before analysis in SPSS, patients were assigned a binary score according to 5-year 
disease recurrence (biochemical and/or clinical). Those who did not experience 
recurrence were assigned to group “0” and those who experienced recurrence were 
assigned to group “1”. This time period was measured from the date of RP (in surgically 
managed patients) or the start of RT treatment (if no surgery given). 
 SPSS analysis - Independent samples t-tests 
Initially, independent samples t-tests were performed on both Pfaffl and 2-ΔCt datasets 
to determine any differences in the mean expression of each gene between the 
recurrent and non-recurrent group. 
Only genes with a p-value <0.5 in both datasets were analysed further. Only the Pfaffl 
dataset was used for the subsequent LR analysis for reasons explained in Section 2.3.4.6. 
Both the GS and the pretreatment PSA value were also checked for any differences 
between the recurrent and non-recurrent group and taken forward into LR analysis if 
a p-value of <0.5 was found. The pretreatment PSA was analysed with an independent 
samples t-test as above, but the GS was analysed with a Mann-Whitney U test as it was 
ordinal data. 
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 SPSS analysis - Correlation analysis 
Prior to LR analysis, it was necessary to assess any correlation between the genes using 
a Pearson correlation analysis (also using SPSS). Genes which correlated with each other 
(p<0.05) were not put together in LR models. This step was taken to avoid the problem 
of multicollinearity, the presence of two or more independent variables (predictors) 
which are not just correlated with the dependent variable but are also closely correlated 
to each other. Multicollinearity can confound the results of LR by causing unreliable 
estimates of the regression coefficients, which may lead to incorrect assumptions about 
the relationship between predictors and the dependent variable (306). 
 SPSS analysis - Binary logistic regression analysis 
Binary LR was performed univariately for the genes selected from the independent 
samples t-tests. These genes were combined in two and three gene combinations, using 
only non-correlating genes together in each model. The number of possible gene 
combinations for the models was prohibitively large for manual ‘point and click’ 
processing in SPSS. An automated approach was developed using a Visual Basic for 
Applications (VBA) script in Excel (written by Mr Andrew Bickers) to produce SPSS syntax 
scripts that would perform all the univariate and multivariate LRs that were required 
without user intervention. The script also formatted the outputs to produce only tables 
containing the required parameters. These outputs were combined in Excel to produce 
a single spreadsheet containing the necessary information, with one row representing 
each gene combination. The spreadsheet could be used to rank the gene models 
according to any of the parameters. This provided a simple method to rank the large 
numbers of gene models by the chosen parameter of overall performance, the 
Likelihood Ratio Test statistic (ΔG2/χ2). In the method development, it also provided 
a method by which the gene models could be ordered by the overall percent accuracy 
(the previously used ranking parameter in the SL study and for the first submission of 
the BB study). The validity of using the overall percent accuracy for ranking was 
questioned during the method development and the comparison of the data ranked by 
each method allowed a critical comparison between the two ranking methods. The 
rationale behind the decision to use χ2 for ranking the models rather than the overall 
percent accuracy is described in detail in the method development Section 2.3.4.8. 
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 Ranking the logistic regression models 
Ranking by the Likelihood Ratio Test statistic (ΔG2) 
For the final analysis, the single, two-gene and three-gene LR models were ranked in 
decreasing order of the value for the Likelihood Ratio Test statistic (ΔG2). This value was 
calculated automatically by SPSS to compare each model with the null model (constant 
only model without predictor variable(s)). 
The ΔG2 is calculated using the Likelihood Ratio Test (LRT). This statistic was chosen as 
a measure of overall performance of each model as it is considered the most accurate 
goodness-of-fit test in LR analysis, particularly in small datasets (307). The goodness-of-
fit is an essential characteristic of the overall performance of a predictive model and 
describes how well the model fits the observed data, i.e. the deviance between the 
observed and predicted outcomes. A smaller deviance indicates a better fit to the 
observed data. In this study, it described how well the model predicted the observed 
outcomes for the patients (categorised correctly into the recurrent or non-recurrent 
group). 
Likelihood Ratio Test in SPSS 
The LRT is used to compare the goodness-of-fit of two models, a restricted model (with 
fewer predictors) and a final model (more predictors), where the models are 
hierarchically nested, i.e. the final model differs from the restricted model by the 
addition of one or more predictors. 
SPSS uses the LRT to compare the performance of each model in relation to the null 
model (constant only model without predictor variable(s)). The LRT statistic (ΔG2) is 
automatically calculated by the software and describes the improvement in fit under the 
final model (with predictor variable(s)) in comparison to the fit under the null model. 
ΔG2 is denoted χ2 in SPSS as it follows a chi-squared distribution. 
SPSS calculates χ2 after it has selected the parameter estimates (coefficients) for the final 
model, which achieve the greatest likelihood of the observed outcome (see Appendix 5 
for a fuller description of LR analysis). It separately fits the null model and the final model 
to the data and calculates the -2*ln likelihood (-2LL) for each. This value is used rather 
than the likelihood to make calculation easier. The -2LL describes the deviance between 
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the observed and the predicted outcomes, with smaller values reflecting a better fit. 
SPSS aims to achieve the lowest possible value for the -2LL. χ2 is calculated as the 
difference between the -2LL of the null model and the -2LL of the final model as shown 
below: 
𝛥𝐺2 =   𝜒2
𝑑𝑓
= −2 ∗ ln
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑓𝑜𝑟 𝑛𝑢𝑙𝑙 𝑚𝑜𝑑𝑒𝑙
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑓𝑜𝑟 𝑓𝑖𝑛𝑎𝑙 𝑚𝑜𝑑𝑒𝑙
  
                  =  (−2𝐿𝐿 𝑛𝑢𝑙𝑙 𝑚𝑜𝑑𝑒𝑙)  − (−2𝐿𝐿 𝑓𝑖𝑛𝑎𝑙 𝑚𝑜𝑑𝑒𝑙) 
df is the degrees of freedom (the number of predictor variables added to the final model) 
A higher value of χ2 reflects a larger difference between the -2LL of the null model and 
the final model, therefore indicating a better fitting model. 
SPSS also calculated a p-value for χ2, which was essential to identify whether the 
improvement in fit obtained by adding the variable(s) to the null model was statistically 
significant. χ2 follows a chi-squared distribution, with the degrees of freedom (df) equal 
to the difference in the number of predictor variables between the null and the final 
model. A larger value for χ2 results in a smaller p-value, which provides evidence that 
the final model is a significant improvement over the null model. 
The results section includes only models for which the p-value for χ2 was significant to 
the conventional confidence level of 95% (p<0.05). Additionally, only the two-gene 
models are included, for which the χ2 exceeded the highest value obtained for the single 
gene models; and only the three-gene models for which the χ2 exceeded the highest 
value obtained for the two-gene models. 
Ranking by the overall percent accuracy (used in the pilot study and method 
development) 
During the method development, before χ2 had been selected as an appropriate 
measure of overall performance, the predictive models were ranked in descending order 
of the overall percent accuracy as this had been the method used in the SL study. During 
the method development, it was decided to use the χ2 in preference to the overall 
percent accuracy (2.3.4.8). To validate our decision to use χ2, the ranking of the best 
performing models by χ2 was compared with the ranking by overall percent accuracy 
(2.3.4.8 and 2.3.10). 
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Overall percent accuracy in SPSS  
The overall percent accuracy is calculated automatically by SPSS and is the percentage 
of cases that are correctly classified. The overall percent accuracy is calculated as: 
[(true positive+true negatives)/total] * 100 
SPSS calculated the overall percent accuracy by initially calculating the predicted 
probability of being in the recurrent group for each patient by incorporating the 
appropriate gene expression values into the LR equation (SPSS previously selected the 
parameter estimates for the equation). The patients were classified into either the 
recurrent or non-recurrent group based on their predicted probability. SPSS uses 
a default threshold of 0.5. Therefore, patients with a predicted probability ≥0.5 were 
classified as recurrent and those with a predicted probability of <0.5 were classified as 
non-recurrent. SPSS then compared the predicted categories with the observed 
categories and calculated the number of patients correctly classified into both the 
recurrent and non-recurrent groups. The overall percent accuracy was then calculated 
as the total number of correctly classified patients out of the total number of patients. 
Several additional parameters from the LR output, that will be referred to later, include 
the significance of the Wald statistic, the Nagelkerke R2 and the odds ratio. 
The Wald statistic is another measure of goodness-of-fit that was included in the SPSS 
output. The Wald chi-square test describes the significance of each predictor variable in 
an LR model by testing the null hypothesis that the regression coefficient for the variable 
is zero. The significance for the Wald statistic could therefore be used to assess the 
contribution that each gene made to the model (p<0.05 would indicate a significant 
contribution to a 95% confidence level).  
The odds ratio is the exponentiated regression coefficient for the predictor variable. 
Although the regression coefficient is used in the LR equation, it is difficult to interpret 
as it is measured in natural logarithmic units. In comparison, the odds ratio is easier to 
interpret. Here the odds ratio described the number by which the raw odds in favour of 
the patient being in the recurrent group were multiplied for a one-unit increase in 
expression of the gene (predictor variable). 
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The Nagelkerke R2 is also described. This is a pseudo R2 statistic, as LR does not have an 
equivalent to the R2 found in Ordinary Least Squares regression. Although the 
Nagelkerke R2 has limitations and should not be considered a measure of the goodness 
of fit, it does offer a relative measure of the proportion of variation in outcome that is 
explained by a model (307). 
 Using the LRT to assess the effect of additional predictor 
variables 
The second use of the LRT in this study was to compare the fit of each two-gene model 
with its nested single gene models and each three-gene model with its nested two-gene 
models. This was necessary to assess whether the addition of another variable 
significantly improved upon each single and two-gene model and consequently if the 
addition of the variable was justified. As the -2LL had been calculated for each model 
automatically by SPSS, the LRT statistic (χ2) comparing the restricted model (fewer 
predictor variables) with the final model could be calculated manually by subtracting the 
-2LL of the final model from the -2LL of the restricted model. As the LRT statistic follows 
a chi-squared distribution, the significance (of the improvement in fit) could be 
calculated using an online chi square probability calculator using the value for χ2 and the 
degrees of freedom (N.B. the degrees of freedom here is the number of predictor 
variables added to the restricted model to make the final model).  
𝛥𝐺2 =   𝜒2
𝑑𝑓
= −2 ∗ ln
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑓𝑜𝑟 𝑠𝑚𝑎𝑙𝑙𝑒𝑟 𝑚𝑜𝑑𝑒𝑙
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑓𝑜𝑟 𝑙𝑎𝑟𝑔𝑒𝑟 𝑚𝑜𝑑𝑒𝑙
  
                  =  (−2𝐿𝐿 𝑠𝑚𝑎𝑙𝑙𝑒𝑟 𝑚𝑜𝑑𝑒𝑙)  −  (−2𝐿𝐿 𝑙𝑎𝑟𝑔𝑒𝑟 𝑚𝑜𝑑𝑒𝑙) 
df is the number of predictor variables added to the smaller model to make the larger model 
 
For instance, the two-gene model AMACR.EFNA5 was compared with both single gene 
models AMACR and EFNA5. Likewise, the three-gene model AMACR.EFNA5.SDHA was 
compared to AMACR.EFNA5, AMACR.SDHA and EFNA5.SDHA. 
The LRT statistic was also used in a similar manner to test the effect of adding the GS to 
each of the single and two-gene models. Here, the χ2 was calculated as the (-2LL of 
gene(s) only model) - (-2LL of the genes(s) and GS model). 
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 SPSS - Receiver Operating Characteristic curves 
The discriminatory ability of the gene models to categorise patients according to 
recurrence was tested using Receiver Operating Characteristic (ROC) curves.  
ROC curves (Figure 2.8) were plotted in SPSS using the predicted probabilities for the 
samples, which were calculated during the LR analysis by the software using the 
LR equation.  
 
Figure 2.8 ROC curve plotted in SPSS 
 
The SPSS output produced a list of coordinates of the curve, from which an optimal cut-
off point (c*) of predicted probability was determined for each gene model by 
maximising the value of the Youden Index (J)(308) described by the equation below, 
where c is the cut-off point. 
 𝑌𝑜𝑢𝑑𝑒𝑛 𝑖𝑛𝑑𝑒𝑥 (𝐽) =  𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 (𝑐) + 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 (𝑐) − 1 
 Genes in the top performing gene models 
To identify the most frequently found genes in the best performing predictive models 
(those with the highest χ2 values), the percentage prevalence of each gene was 
calculated in the highest 19.4%, 9.3%, and 2.8% of the two-gene models and the highest 
12.7%, 6.1% and 2% of the three-gene models. To compare our method of ranking (χ2) 
with the method used in the pilot study (overall percent accuracy), the percentage 
prevalence of each gene was also calculated for similarly sized divisions in the top two- 
and three-gene models according to the overall percent accuracy. These divisions were 
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selected as appropriate to take into account the quantisation of the overall percent 
accuracy data, where multiple gene models presented with the same value, and was the 
reason that more rounded percentages were not used (explained further in the method 
development Section 2.3.4.8). 
The calculations for the prevalence of each gene in each fraction were performed by 
counting the total number of times each gene appeared. The percentage prevalence was 
calculated by dividing this number by the total number of genes included in all the 
models in the fraction and multiplying by 100.  
The percentage prevalence of each gene in the three fractions was plotted separately 
for the highest models according to χ2 and according to overall percent accuracy. The 
genes were listed from left to right in order of decreasing significance for the Wald 
statistic (increasing p-value) found in the univariate LR analysis. 
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2.3 Results 
 Introduction 
The results section includes: 
• Information about the patients included in the study. 
• A method development section - developments since the pilot study. 
• The results of the independent samples t-tests, logistic regression analysis and 
ROC analysis - identification of predictive models of recurrence. 
• Description of the prevalence of each gene in the best performing predictive 
models of recurrence - a novel manner for identifying the most important 
predictors. 
• Comparison of the results of this study with the results of the pilot study. 
 Samples 
105 samples were processed through to the relative quantification stage. However, 
38 samples were removed for the reasons listed below, leaving 67 samples taken into 
statistical analysis.  
• patient treated with hormones only (7 samples) 
• patient conservatively managed (3 samples) 
• patient had metastatic disease at diagnosis (6 samples) 
• insufficient follow-up data (8 samples) 
• patient died of other causes within the 5 years (2 samples - these patients died 
of lymphoma and abdominal aortic aneurysm) 
• low HMBS expression (Ct value ≥35)(12 samples) 
 
Of the 67 patients included in the final analysis, 21 were categorised as recurrent and 
46 as non-recurrent. There were 40 patients classified as GS ≥7 and 27 classified as 
GS <7. 
Clinicopathological information for each of the final 67 patients can be found in 
Appendix 7. 
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 Method development of practical methods 
 Introduction 
A preamplification procedure was included in the final methods to enrich the sample 
cDNA before its use in the TaqMan array. This was necessary, as during the investigative 
period, a problem had been found regarding the amount of amplifiable cDNA. This 
problem and the steps taken to resolve it are described in more detail below. 
 Enrichment of cDNA for successful real-time qPCR 
The first BB array plate which was run, was a standard curve plate consisting of 150ng/µl, 
300ng/µl, and 600ng/µl concentrations of non-preamplified (NPA) control cDNA. This 
plate showed Ct values of <35 for the majority of genes, but even at the highest 
concentration, over 15% of the genes on the array had Ct values which were either 
undetected (≥40) or higher than would be considered optimal for accurate gene 
expression determination (≥35)(305). 
In comparison, when the first sample cDNA was run on the next BB array at 300ng/µl, 
over 70% of the genes on the array were either undetermined or showed Ct values of 
≥35.  
To ensure that the problem was not specific to the first 4 samples, another set of 
samples were run on a 48 gene TaqMan array, which contained a selection of cancer-
related genes (Appendix 6). This array was readily available in the department and was 
used in preference to the BB array due to the limited numbers of the latter. The Ct values 
remained high (≥35) at a cDNA concentration of both 300ng/µl and 600ng/µl.  
In contrast to these findings, preliminary measurements of the RNA and cDNA samples 
by UV-spectroscopy appeared to show adequate concentrations for downstream real-
time qPCR analysis (Table 2.5). The RNA samples showed less than ideal purity as 
demonstrated by a value of ~1.5 for the ratio of the absorbance at 260nm and 280nm 
(A260/280)(pure RNA should be ~2.0). However, the A260/280 ratio tends to be lower 
for RNA extracted from FFPE tissue than from fresh frozen tissue (309). 
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Table 2.5 RNA/cDNA concentration and purity of samples 1-11 as measured by UV-spectroscopy 
Sample RNA cDNA 
 
A260/280 
 
Conc (ng/µl) 
 
A260/280 
 
Conc (ng/µl) 
1 1.4 26.7 1.8 2234.7 
2 1.3 50.1 1.8 2275.7 
3 1.4 39.5 1.8 2241.4 
4 1.4 50.1 1.8 2279.1 
5 1.5 35.6 1.8 2146.9 
6 1.5 30.5 1.8 2036.4 
7 1.5 30.6 1.8 2066.7 
8 1.4 57.6 1.8 2158.6 
9 1.5 50.2 1.8 2151.2 
10 1.6 36.9 1.8 2004.2 
11 1.6 44.6 1.8 2092.9 
 
The high Ct values suggested the presence of low target cDNA quantity and/or quality 
despite a reasonable input of cDNA based on the spectrophotometric measurement. 
This overestimation of the cDNA concentration by the spectrophotometer would likely 
have resulted from the contribution of other components of the reverse transcription 
mix to the absorbance readings at 260nm, e.g. dNTPs and remaining RNA. Therefore, 
UV-spectroscopy was not a suitable method to measure the cDNA concentration.  
Spectrophotometric measurement of the RNA samples before reverse transcription 
showed a relatively low yield of RNA (27-58ng/µl). The low yield was expected, as RNA 
yield tends to be significantly lower from FFPE tissue than fresh tissue as protein-nucleic 
acid crosslinking makes RNA extraction more difficult. Furthermore, the low RNA yield 
in this study may have been compounded by the limited amount of tissue per sample 
(two 0.6mm tissue punches), as well as difficulties in procuring these tissue punches due 
to the minimal size of the biopsy samples. 
However, this yield should have been enough to allow successful real-time qPCR 
analysis. Therefore, the high Ct values suggested a problem with the quality of the RNA. 
Crucially, spectrophotometric assessment of RNA does not measure integrity, an 
important parameter of the RNA quality that affects subsequent molecular analysis. The 
integrity of RNA extracted from FFPE tissue is invariably compromised as a result of the 
fixation and embedding processes and is typically highly fragmented and chemically 
modified (279, 280). These samples were also several years old and storage at room 
temperature tends to cause further degradation of RNA (310). Despite steps to 
overcome these issues, as described in Section 2.2.1.1, an issue of insufficient 
75 
 
amplifiable cDNA remained. The poor quality of the RNA may have limited the efficiency 
of the reverse transcription reaction leading to a much lower cDNA yield than would be 
expected for the RNA input amount.  
The Ct values were much higher than those found in the pilot study (which did not 
require a preamplification)(275). Despite these differences, the concentrations of RNA 
as measured spectrophotometrically were within a similar range between the two 
studies. The pilot study used only RP samples, whereas our study had used 
predominantly biopsy samples. The different size of the samples, which can affect how 
the tissue reacts to processing and storage, may have been responsible for the 
differences in the RNA quality between the studies (281). Additionally, surgical and 
biopsy samples are procured and processed differently, so there would likely be many 
variables between the sample types that could affect RNA quality.  
The purity of the RNA, as measured by the A260/A280 ratio, was slightly lower than the 
generally acceptable value for RNA of ≥1.8. This is a common finding when using FFPE 
samples (311). A low A260/A280 ratio may be caused by the presence of proteins or 
other contaminants which absorb at 280nm and may suggest some residual formalin or 
protein crosslinks from the fixation process (312). 
To increase the amount of amplifiable target cDNA for use in the array, a preliminary 
preamplification step using the TaqMan® PreAmp Master Mix Kit (Applied Biosystems) 
was included to amplify the 95 target genes (every gene on the TaqMan array apart from 
18S). This kit was chosen as it had the capacity to amplify the specific cDNA gene targets 
on the array multifold with high reproducibility, without significantly modifying the 
original gene expression profile (313, 314).   
As found by other studies, the inclusion of a preamplification step shifted the Ct values 
to much lower values thereby increasing the sensitivity of the real-time qPCR analysis 
and expanding the number of genes that could be analysed (315). 
As both the NPA and preamplified (PA) cDNA for samples 1-4 were analysed with the 
BB array, this allowed a direct comparison of the Ct values before and after 
preamplification. Table 2.6 shows the number of analysable genes (Ct<35) in the NPA 
and PA cDNA for these samples. It clearly shows the low number of analysable genes in 
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the NPA samples. After preamplification, the number of analysable genes was 
significantly increased. 
Table 2.6 The number of analysable genes (Ct<35) in the NPA and PA samples 
  Number of genes Ct<35 
Sample RNA conc NPA PA 
1 26.7 25 81 
2 50.1 5 57 
3 39.5 25 64 
4 50.1 23 81 
 
Table 2.7 shows the decrement in Ct value (ΔCt = CtNPA-CtPA) due to the preamplification 
for each housekeeping gene. The ΔCt values for the entire set of genes can be found in 
Appendix 8. 
Table 2.7 Difference in Ct value between the NPA and PA samples for the housekeeping genes 
Sample  HMBS HPRT1 SDHA TBP 
1 NPA 37.94 40 35.51 40 
 PA 26.38 30.28 26.62 28.23 
 ΔCt 11.55 9.72 8.89 11.77 
      
2 NPA 40 40 40 40 
 PA 33.08 40 30.45 33.65 
 ΔCt 6.92 0 9.55 6.35 
      
3 NPA 40 40 34.40 40 
 PA 29.02 40 27.92 31.35 
 ΔCt 10.98 0 6.48 8.65 
      
4 NPA 34.23 40 35.42 40 
 PA 26.84 33.86 27.14 33.68 
 ΔCt 7.39 6.15 8.28 6.32 
      
 Mean ΔCt 9.21 3.97 8.30 8.27 
 
Due to the problems encountered with spectrophotometric measurement, after the 
preamplification, the cDNA samples were added to the array according to their dilution 
factor rather than any specific concentration. 
 Method development of data analysis 
 Introduction 
There were many important developments to the data analysis methods incorporated 
since the pilot study (and since the initial submission of the thesis). These were essential 
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to enhance the validity of the findings and were done in accordance with the 
recommendations made by the external examiner. These developments are described 
in the following sections and include: 
• Correlation of gene expression data with recurrence rather than GS (Section 
2.3.4.2). 
• Use of a longer follow-up period requiring updated patient outcome data 
(Section 2.3.4.2 and 2.3.4.3).  
• Setting baseline and threshold values individually for each gene to ensure 
optimal results (Section 2.3.4.4). 
• Relaxation of the criteria for entry of genes into the logistic regression analysis 
(Section 2.3.4.5). 
• Use of the Pfaffl dataset only for logistic regression analysis (Section 2.3.4.6). 
• Use of an automated approach for the logistic regression analysis (Section 
2.3.4.7) 
• Exploration and use of an alternative method for ranking the logistic regression 
models (Section 2.3.4.8).  
 Clinical endpoints and updated outcome data 
Using recurrence as the clinical endpoint 
In the pilot study, LR models were identified that could predict RP patients into groups 
according to GS (≥7 vs <7). A further LR analysis was performed using recurrence as the 
dependent variable, as a more meaningful clinical endpoint. However, the findings of 
the recurrence analysis in the pilot study were limited by the incomplete follow-up data 
available for the patients.  
The initial analysis of our dataset (first submission) also included a preliminary 
LR analysis using GS ≥7 and <7 groups. A secondary analysis was included using 
recurrence as the dependent variable but the length of follow-up data available for the 
patients was only short at that time. 
The previous use of GS as a surrogate for aggressive and indolent prostate cancer is 
flawed as GS shows limited correlation with actual patient outcome (see points below). 
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Therefore, the final analysis focused on the identification of predictive models of disease 
recurrence only. 
• GS does not entirely explain the risk of disease progression in prostate cancer. 
Although GS 8-10 is associated with a high risk of disease progression and 
death from prostate cancer (316), some patients within this group have a 
favourable outcome (317). Additionally, some patients with GS 6 have an 
unfavourable outcome (318). 
 
• In particular, patients with GS 7 are a prognostically heterogeneous group 
(319). A large proportion of patients in this study fell within this group (>40%). 
Therefore, patients with both favourable and unfavourable outcomes would be 
included in the so-called “aggressive” group (GS ≥7). This was confirmed by the 
mixture of both recurrent and non-recurrent patients with GS 7 in this dataset. 
 
• Some patients only had a biopsy GS available for categorisation (those treated 
with RT only). Biopsies are prone to inaccuracies of grading for the reasons 
described earlier, with undergrading of biopsies the most frequently 
encountered problem (320). Therefore, some of the patients who had a GS of 6 
on biopsy and therefore classified in the low GS group (<7), may have actually 
had a higher GS if the entire prostate had been analysed, and would be more 
correctly classified as GS ≥7 (321). 
Extending follow-up 
To enhance the clinical relevance of any significant findings from the study, it was 
necessary to analyse the gene expression data using a longer follow-up period. This 
necessitated that various parameters of disease outcome for the patients, including 
biochemical and clinical parameters, be updated to cover the years that had elapsed 
since this clinical information was last accessed (approximately 2012).  
By extending the clinical information available, the statistical analysis could be 
performed using 5-year disease recurrence/non-recurrence as the dependent variable. 
Predictive models of disease recurrence within 5 years of RP/RT would be clinically 
relevant as most recurrences in prostate cancer occur within 5 years from treatment 
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(322). Additionally, earlier disease recurrence may signal more aggressive disease with 
a significantly increased risk of disease-specific mortality (323). 
Previously (at first submission of the thesis) only 3 years outcome data were available 
for the patients. Similarly, the pilot study had limited outcome data available at that 
time. In fact, the pilot study did not use a constant follow-up time for the statistical 
analysis with the length of follow-up varying between patients from 2 to 5 years.   
Updating the outcome data before our final analysis meant that some patients whose 
data had previously been excluded as incomplete, could now be included. This time, the 
data acquisition included the use of the database Graphnet (Electronic Patient Records) 
as an additional source of clinical information alongside the other previously used 
sources (the pathology records and patient notes). This may have increased the amount 
of clinical information available. 
 New ethical permissions 
An issue arose regarding access to the new patient data, as the ethical permissions that 
had originally allowed the use of the samples in the study (and therefore access to 
patient data) had lapsed. At the time of the experimental work in the TORC, QAH (2009-
2012), Medical Research and Ethics Committee (MREC) approval was in place for the use 
of the samples in research through their inclusion in the Portsmouth Molecular 
Pathology Tissue Bank (07/MRE08/2). This approval expired in 2012 with the closure of 
the Tissue Bank after the departure of Professor Ian Cree, the director of TORC. 
Therefore in 2016, it was necessary to submit a new application for Health Research 
Authority (HRA) approval before any additional patient data could be accessed. 
Additionally, an internal review with the Science Faculty Ethics Committee (SFEC) at the 
University of Portsmouth (UoP) was required.  
Both applications were successful, with receipt of an approval letter from the HRA and 
a letter of Favourable Ethical Opinion from the SFEC. As there was no joint research 
agreement in place between the Portsmouth Hospitals Trust (PHT) and the UoP, a new 
data transfer agreement was drawn up and signed by both parties. 
Data collection proceeded after a letter of Confirmation of Capacity and Capability from 
the PHT had been received (Ref PHT/2016/100). 
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The PHT assigned a local collaborator (Dr Sharon Glaysher) at the hospital to oversee 
the collection of the patient data, which were accessed using hospital databases and 
patients’ notes by Dr Glaysher and members of staff in the Oncology and Urology teams. 
The data were anonymized prior to my receiving it, as I no longer held an honorary 
contract at the PHT.  
A graphical depiction of the steps to gain access to the necessary patient data is shown 
in Figure 2.9. 
 
Figure 2.9 Steps to gain new ethical approval to access patient data 
 
 Optimal setting of the baseline and threshold values 
In the initial data analysis (first submission) the baseline was set at 3-15 cycles (default 
range) and the threshold value at 0.5, which were the settings used in the pilot study. 
The same settings were used for every target sequence on the array. It became evident 
that these settings were not optimal for every gene on the array due to the variability in 
expression levels between genes. For instance, the baseline stop value of 15 was set too 
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low for less abundant genes and too high for more abundant genes (Figure 2.10). If the 
baseline is set too low, then there will be insufficient amount of background subtracted. 
If the baseline is set too high, it would eliminate cycles in which the amplification starts 
to rise above the background. Either scenario may lead to inaccurate determination of 
Ct values. 
Furthermore, the threshold value of 0.5 was not suitable for every gene. The threshold 
value should be set at a value above the background fluorescence and within the 
exponential growth portion of the amplification curve for accurate quantification of 
starting template amount. The value of 0.5 was found to be too high for many of the 
less abundant genes, where it was situated in the plateau phase rather than in the 
exponential portion of the amplification plot (Figure 2.11). The measurement of 
Ct values in the plateau phase leads to inaccurate quantification as there is no longer 
doubling of the amplification product with each cycle, so the fluorescent signal cannot 
be used to accurately determine the amount of template. 
Therefore, for the final analysis, the baseline and threshold were set individually for each 
gene for optimal settings. The baseline was set so that the stop value was approximately 
1-2 cycles before the earliest amplification ensuring that background noise was 
eliminated. The threshold value for each gene was set at a value within the exponential 
phase of the amplification plot. 
To allow the appropriate settings to be found for each gene, it was necessary to view 
the amplification plots from all the sample plates together. ExpressionSuite software 
(version 1.1; Thermo Fisher Scientific) was ideal for this purpose. Once the optimal 
settings for each gene had been selected, they could be imported once into 
ExpressionSuite and then used for the analysis of the data from every plate, as it was 
essential to keep the settings constant between the samples. 
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Figure 2.10 Inappropriate setting of the baseline 
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 Independent samples t-tests - relaxing criterion for entry into 
multivariate logistic regression analysis 
In the initial submission of the BB study, only genes found to have a p-value of <0.05 in 
the independent samples t-test were used as predictors in the multivariate LR models. 
This stringent criterion had also been used in the pilot study. For the final analysis, the 
cut-off value for inclusion of the genes into the multivariate LR analysis was relaxed to 
include every gene with a p-value of <0.5. After relaxing this threshold, the number of 
genes that could be included in the models increased from 3 in the pilot study to 39 in 
the final analysis. 
The relaxation of the entry criterion for the selection of variables was necessary, as the 
use of the conventional significance cut-off (p<0.05) may fail to identify variables that 
could have important predictive value in regression models (324). It is possible for 
variables in combination to be highly predictive of outcome, despite each variable 
showing only a weak association with outcome. Several authors suggest selecting all 
variables with a significance for the Wald statistic of p<0.25 in the univariate LR analysis 
(325, 326).  
A cut-off of p<0.5 was used in this study to ensure that no potentially important genes 
were excluded, as the sample set was small and p-values may fail to reach significance 
in small sample sizes, despite a large magnitude of effect (327). Further increasing the 
threshold was deemed necessary as the selection was based on the p-value from the 
Figure 2.11 The threshold is set too high 
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t-test rather than on the p-value of the Wald statistic from the univariate analysis (as 
described in these other studies) and these two tests describe the relationship between 
the predictor variables and outcome in different ways. Therefore, a relaxed criterion of 
p<0.5 was considered most appropriate. 
 Pfaffl dataset 
For the final analysis, only the Pfaffl dataset was used in the LR analysis rather than both 
datasets (Pfaffl and 2-ΔCt) as had been used previously. The Pfaffl method provided 
a more reliable method of relative quantification than the 2-ΔCt method, as it controls for 
differences between the amplification efficiencies of the target and reference genes 
(299). From the results of the standard curve experiments, it was evident that there 
were differences between the amplification efficiencies of most of the genes and the 
reference gene HMBS. Therefore, this method was deemed more suitable. Additionally, 
it would have been too time-consuming to analyse both datasets in the multivariate 
LR analysis as the amount of data had increased substantially due to the relaxation of 
the inclusion criterion for entry of predictor variables.  
 Automated approach to logistic regression analysis 
Relaxing the threshold for inclusion of genes resulted in a significant increase in the 
number of possible gene combinations to be processed. It would have been prohibitively 
time-consuming to process the large number of two- and three-gene combinations 
manually in SPSS (Table 2.8). Therefore, an automated process was developed for the 
project. 
Table 2.8 Number of gene combinations for logistic regression analysis 
Number of genes Number of combinations 
Single 39 
Two-gene combinations 387 
Three-gene combinations 1482 
 
The SPSS package has several methods of automation including the use of macros and 
scripts in various programming languages. Automation in SPSS allows the same or similar 
commands to be issued repeatedly and for input sources and output formats to be 
defined. 
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The most common method of automation is SPSS Scripting, which is based on SaxBasic 
language. SPSS macros are created from the SPSS command syntax language. Scripting 
can also be undertaken in Python. Scripts in the SPSS command syntax language and 
Python can be combined to run together. 
In order to produce scripts to perform LR on the lists of gene combinations, a VBA script 
was used in Microsoft Excel. This script was written by Mr Andrew Bickers. Each gene 
combination, for which a LR was required, occupied a row in a spread sheet (Figure 
2.12). The VBA script, invoked by a button in the spread sheet, looped through the rows 
generating an SPSS syntax phrase for each gene combination in an ASCII text file that 
commanded SPSS to perform a LR on those gene combinations. The gene names 
corresponded to the column titles in an SPSS input file (Figure 2.13). 
 
Figure 2.12 VBA script in Excel spreadsheet containing list of two-gene combinations 
 
 
Figure 2.13 Example snippet of SPSS input file for logistic regression analysis 
 
The VBA script (Figure 2.14) also used some embedded Python commands to format the 
output.  
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The final syntax text file was named as *.sps and could be read directly into SPSS as 
a syntax file (Figure 2.15). The syntax contained formatting commands to output the 
relevant tables and specify output locations as well as the parameters required to 
perform LRs. 
 
Figure 2.14 VBA script 
 
 
Figure 2.15 Final syntax file 
 
The output files generated by executing this syntax contained the relevant tables (Table 
2.9) from the LR output. These outputs were exported and combined in Excel to produce 
a single spreadsheet containing all the required information with one row representing 
each gene combination (Figure 2.16). These final spread sheets were produced for 
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single, two- and three-gene combinations. The LR outputs in this format provided all the 
necessary information in one spreadsheet, which simplified analysis and allowed ranking 
of the gene models by any parameter. 
Table 2.9 List of tables exported from logistic regression output 
Name of table Information included 
Classification table (final model) Percent predicted correctly - overall, non-recurrence, recurrence 
Hosmer and Lemeshow test Chi-square, sig. 
Omnibus tests of model coefficients Chi-square, sig. 
Model summary -2 ln likelihood, Cox & Snell R square, Nagelkerke R square 
Variables in the equation Gene names, sig. 
 
 
 
Figure 2.16 Snippet of final spreadsheet containing information from the logistic regression outputs 
 
 Insights about ranking the logistic regression models 
The pilot study (and the first submission) had ranked the LR models according to their 
overall percent accuracy as this is a highly intuitive method of describing performance 
of a predictive model. Although this method of ranking was initially used to rank the 
models in the final analysis, the appropriateness of this method for assessing overall 
model performance was questioned based on the following findings: 
Limitations of the overall percent accuracy 
Ranking the models by overall percent accuracy led to a quantisation effect of the data, 
which made ranking difficult. The overall percent accuracies fell into discrete values with 
multiple models having the same value. This “quantisation” of the data resulted from 
the fact that the overall percent accuracy is calculated by the software as the number of 
patients correctly categorised. Therefore, differences in the overall percent accuracy are 
caused by either an increase or decrease in the number of patients correctly categorised, 
resulting in the percentage value increasing or decreasing by a specific amount. This 
effect was compounded by the small sample size in this study, which meant that a 1.49% 
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change in overall percent accuracy was observed for every additional patient correctly 
or incorrectly predicted [(1/67) * 100]. 
It was also evident that despite a good overall percent accuracy for some models, they 
showed imbalanced values for the sensitivity (the proportion of recurrent patients 
correctly classified as recurrent) and the specificity (the proportion of non-recurrent 
patients correctly classified as non-recurrent), with a distinctly higher value for the 
specificity than the sensitivity for all the models. These values are given in the logistic 
regression output but are not adequately described by the overall percent accuracy, 
which does not give information about the number of correct and incorrect 
classifications of each class (328). 
Additionally, the overall percent accuracy is not a reliable measure of performance in 
imbalanced datasets (the number of samples in the “1” group is markedly higher than 
the “0” group) and leads to misleading accuracies as the minority class contributes less 
to the overall accuracy. As algorithms are essentially accuracy driven, they tend to 
predict all samples into the majority class, which may lead to an overestimation of the 
overall percent accuracy (329). This dataset was moderately imbalanced, with 21 
patients in the recurrent group (“1”) and 46 in the non-recurrent group (“0”).  
This can be exacerbated by the fact that SPSS uses a threshold of 0.5 to decide between 
classes. In imbalanced datasets, where the predicted probabilities of the minority class 
tend to be underestimated, this threshold is not appropriate and may lead to unreliable 
accuracies and an imbalance of sensitivity and specificity, as seen in our models (330). 
(The identification of an optimal threshold to maximise sensitivity and specificity is 
explained in more detail in the results Sections 2.3.7.4, 2.3.8.5 and 2.3.8.8). 
The overall percent accuracy is also misleading, if not given in the context of the null 
model. In this dataset, the value for the null model was high at 68.7%. This reflected the 
large proportion of non-recurrent cases, as the null model simply classified every sample 
as non-recurrent. The percent accuracy does not accurately describe the gene models 
in relation to the null model; i.e. the improvement in performance that can be achieved 
by the addition of the gene(s) to the null model. Therefore, models appearing to have 
a good performance based on their overall percent accuracy may not be as promising if 
the percent accuracy for the null model is high.  
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It was apparent that some of the highest-ranking models according to overall percent 
accuracy contained variables with a low significance (high p-value) for the Wald statistic. 
Conversely, many of the lower-ranking gene models contained variables with lower 
p-values for the Wald significance. From this, it could be deduced that some of the best 
performing models according to percent accuracy contained variables that were not 
making any significant contribution to the model and others containing only highly 
significant variables were ranked much lower. For example, the two-gene model 
AMACR.ANPEP was ranked at number 5. The Wald significance for the two variables 
AMACR and ANPEP were 0.014 and 0.440 respectively showing that ANPEP made no 
significant contribution to the model. Conversely, AMACR.SDHA was ranked at number 
43. Both AMACR and SDHA had highly significant values for the Wald statistic of 0.003 
and 0.009 respectively. A similar pattern emerged for the three-gene models. For 
example, the three-gene model ABL1.GUCY1A1.PLLP was ranked number 5 according to 
the overall percent accuracy. The Wald significance for the three variables ABL1, 
GUCY1A1 and PLLP were 0.022, 0.041 and 0.279 respectively. This demonstrated that 
the variable PLLP did not significantly contribute to the model. Conversely, the gene 
model AMACR.HPRT1.SDHA was ranked at number 54. Each of the three variables 
AMACR, HPRT1 and SDHA were highly significant at 0.005, 0.049 and 0.008. 
A further observation that cast doubt on the use of the overall percent accuracy for 
ranking the models was found in the results of a preliminary analysis, which had been 
used to visualise the most important genes in the large number of processed models. 
Distribution of genes in the best performing gene models according to overall 
percent accuracy  
A graphical representation of the prevalence of each of the 39 genes in the best 
performing predictive models (according to the overall percent accuracy) was produced. 
Although a plot of prevalence in the top 10% of the models would have been ideal, due 
to the overall percent values falling into discrete values, the top 9.3% and 12.7% of the 
two-gene and three-gene models respectively were selected to ensure that all models 
with values within this range were included. 
The percentage prevalence of each gene within these upper fractions was calculated as 
described in Section 2.2.5.10. These values were then separately plotted on a bar chart 
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in order of increasing p-value obtained from the independent samples t-test (Figure 2.17 
and Figure 2.18). 
It was evident from the plots that the gene AMACR, with a prevalence of 26.4% and 
20.2% in the two- and three-gene models respectively, was the most prevalent gene in 
the top models according to overall percent accuracy. The prevalence of AMACR was 
approximately 3-4 times that found for any other gene. As would be expected, AMACR 
had a highly significant p-value in the independent samples t-test of 0.018. However, 
the genes HPRT1 and SDHA, which had the most highly significant p-values in the t-test, 
had a prevalence of only 5.6% each in the two-gene models and 6.4% and 1.8% 
respectively in the three-gene models. A number of genes which had much higher 
p-values were found to be as prevalent or more prevalent than HPRT1 and SDHA, namely 
PVT1 with a p-value of 0.073 had a prevalence of 6.6% in the three-gene models; 
GUCY1A1 with a p-value of 0.149 had a prevalence of 5.6% and 6% in the two- and three-
gene models respectively and EFNA5 with a p-value of 0.151 had a prevalence of 6.9% 
in the two-gene models. The relatively high prevalence of some genes with even higher 
p-values was also noticed, e.g. NELL2 and PLLP with p-values of 0.292 and 0.303 
respectively. NELL2 had a prevalence of 4.2% in the two-gene models and PLLP had 
a prevalence of 4.3% in the three-gene models. 
The discrepancies between the p-values for the t-test and the prevalence of the genes 
in the models with the highest overall percent accuracy contributed to concerns 
regarding the validity of using the overall percent accuracy to rank the models.  
Summary of limitations of the overall percent accuracy 
To summarise, the overall percent accuracy was not considered appropriate as 
a measure of overall performance in this study due to its unreliability in imbalanced 
datasets, its use of a default threshold of 0.5 and its inability to describe both sensitivity 
and specificity. This decision was backed up by several authors who advised that it is 
unsuitable as a measure of overall performance of LR models due to the described 
reasons (328, 330). The overall percent accuracy was also problematic for ranking due 
to the described problem of quantisation of the data, which prevented individual 
ranking of the models within each discrete value.
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 Figure 2.17 Percentage prevalence of each gene in the highest 9.3% of the two-gene models according to overall percent accuracy 
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Figure 2.18 Percentage prevalence of each gene in the highest 12.7% of the three-gene models according to overall percent accuracy 
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Ranking by the Likelihood Ratio Test statistic 
The described limitations of using overall percent accuracy precluded its use as 
a measure of overall model performance in this study. Instead, it was decided to use the 
χ2 for ranking purposes as the LRT test is the most useful parameter of goodness-of-fit 
in an LR model (307)(described in Section 2.2.5.7). 
Ranking the gene models in descending order of χ2 was ideal as this value was calculated 
automatically in SPSS to compare the null model and the final model. Therefore, this 
parameter gave the performance of the model in the context of the null model, so these 
values could be directly compared between models and used for ranking purposes. 
Furthermore, as the χ2 was different for every model, the models could be ranked more 
specifically than was possible with the overall percent accuracy.  
As the LRT can also be used to compare any two nested models, it could also be used for 
the comparison of each two-gene model with its nested single gene models and each 
three-gene model with its nested two-gene models. This was essential to identify if the 
more complex model offered any significant improvement over the restricted model. 
Only models which offered a significant improvement over their nested models would 
be considered useful models. This could also be ascertained by investigating whether 
the added predictor variable had high significance for the Wald statistic. However, as 
the LRT is considered more reliable than the Wald test, the LRT was preferred for this 
purpose (307). 
To validate the decision to use the χ2, another plot was produced which compared the 
highest performing models ranked by χ2 with those ranked by the overall percent 
accuracy. The percentage prevalence of each gene in the highest 9.3% and 12.7% of the 
two- and three-gene models ranked by χ2 was calculated and the prevalence according 
to each ranking method was plotted on one graph (Figure 2.19 and Figure 2.20). 
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Figure 2.19 Percentage prevalence of each gene in the highest 9.3% of the two-gene models according to χ2 and overall percent accuracy 
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Figure 2.20 Percentage prevalence of each gene in the highest 12.7% of the three-gene models according to χ2 and overall percent accuracy 
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The plots according to χ2 showed that AMACR was the most prevalent gene at 25% and 
23.2% for the two- and three-gene models respectively. The prevalence of AMACR was 
2-3 times the prevalence for any other gene. However, although HPRT1 and SDHA were 
lower than AMACR, their prevalence values were higher than those found in the gene 
models with the highest overall percent accuracy. Generally, the prevalence of the genes 
in the top models ranked by χ2 was higher for the genes with low p-values (<0.05) and 
lower for the genes with high p-values (>0.05). This was reflected graphically by a more 
gradual decline in the prevalence as the p-value increased than was observed for the 
overall percent accuracy. The percentage of genes with p-values <0.05 and >0.05 in the 
top models according to each ranking method is shown in Table 2.10. It shows the higher 
percentage of genes with p-values <0.05 in the top models ranked by χ2 in comparison 
to those ranked by overall percent accuracy. For example, the percentage of genes with 
p-values <0.05 is 62.5% in the top two-gene models according to χ2 compared with 
45.8% in the top two-gene models according to overall percent accuracy.  
Table 2.10 The percentage of genes with p-values <0.05 and >0.05 in the top gene models ranked by χ2 
and overall percent accuracy 
p-value In top 9.3% In top 12.7% 
Two-gene % Three-gene χ2 Two-gene % Three-gene χ2 
% genes < p=0.05 45.8 62.5 39.4 46.5 
% genes > p=0.05 54.2 37.5 60.6 53.5 
  
A plot has also been included which depicts the genes from left to right according to the 
increasing p-value for the Wald significance (univariate LR) rather than the p-value for 
the t-test (Figure 2.21). 
It was evident from this plot, that the prevalence and the Wald significance were 
correlated as a gradual decline in the prevalence was noted as the significance for the 
Wald statistic reduced (p-value increased). This suggested that the p-value for the Wald 
significance may be a more suitable measure for selecting genes for inclusion into 
multivariate LR analysis as described by others (325, 326).
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Figure 2.21 Percentage prevalence of each gene in the highest 9.3% of the two-gene models in order of Wald significance from univariate logistic regression 
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This plot shows that the genes with lower p-values for the Wald significance had 
consistently higher prevalence in the top models according to χ2, with a gradual decline 
in prevalence as the p-value increased. In contrast, the peaks for the overall percent 
accuracy do not follow this pattern, with a relatively high prevalence observed for genes 
with high p-values, e.g. a prevalence of 4.2% for NELL2 (p-value of 0.289). 
Some interesting observations were also made when viewing the entire set of two- and 
three-gene models ranked by the different methods. The ranking of the models by χ2 
resulted in a very different order to the gene models in comparison to the order 
obtained using the overall percent accuracy. Ranking according to χ2 resulted in gene 
models at the top of list having consistently lower p-values for the Wald statistic (p<0.05) 
than was found in the gene models with the highest overall percent accuracy.  
For example, the three-gene model AMACR.HPRT1.SDHA which had been ranked at 
number 54 according to the overall percent accuracy was ranked at number 2 according 
to the χ2. Each of the three variables were highly significant at 0.005, 0.049 and 0.008 
respectively.  ABL1.GUCY1A1.PLLP, which had been ranked at number 5 according to the 
overall percent accuracy, was ranked at number 421 according to χ2. This gene model 
contained the variable PLLP which had a low significance of 0.279.  
The relationship between χ2 and the Wald statistic was not surprising as these two tests 
are asymptotically equivalent (331). However, the Wald test is used to test the 
significance of each individual coefficient in the model whereas χ2 compares the overall 
model with the null model. The χ2 was chosen to rank the models as it gave a measure 
of the whole model and was considered superior to the Wald statistic as a measure of 
overall performance (307). 
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  Optimisation of the assay 
Optimisation of the assay was demonstrated using important parameters obtained from 
the standard curve for each gene. The standard curve of every gene included on the 
array was assessed except for the genes ALPG, CD4 and GPM6A, which were excluded 
as they showed undetermined Ct values for every dilution of the control cDNA.  
There are too many standard curve plots to include in the results, so the plots of the 
5 housekeeping genes (18S, HMBS, HPRT1, SDHA and TBP) are presented and described 
here (Figure 2.22). 
Figure 2.22 Standard curves for housekeeping genes 
 
The %E and the R2 values are presented in Table 2.11. The acceptable range of %E in 
real-time qPCR is 90-110%. The housekeeping gene HMBS showed a value of 103%, 
which was close to an ideal value of 100% signifying near perfect doubling of the 
amplification product with each cycle. The %E of HPRT1 and TBP were also within the 
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optimal range at 94% but the amplification efficiencies of 18S and SDHA were slightly 
lower than optimal at 86% and 82% respectively. The R2 values for 18S, HMBS, HPRT1 
and TBP demonstrated high linearity (>0.990). The R2 value for SDHA was marginally 
below optimal at 0.978. 
Table 2.11 Amplification efficiencies and R2 values for the housekeeping genes 
Gene %E R2 
18S 86.1 0.991 
HMBS 102.8 1.000 
HPRT1 93.5 0.995 
SDHA 81.8 0.978 
TBP 94.3 0.994 
 
The %E and R2 values for the entire set of genes on the array can be found in the 
electronic Appendix 8. The %E tended to be within the optimal range or only slightly 
outside these boundaries for the majority of the genes. There were only a few genes for 
which the %E was significantly lower than optimal (APOPBEC3G, CRHR1, HPX, ITGA2, 
MMP2, MNX1, PSCA, PRELID3A and TERT) and only one gene, where the %E was 
significantly higher than optimal (EEF1A1). Every gene on the array had an optimal 
R2 value of >0.980 except for CRHR1, EDNRA, EFNA3, GSTM5, PCDH18 and TERT. 
Another important characteristic of an optimised assay is high reproducibility as 
demonstrated by low intra- and inter-assay variation. The intra- and inter-assay 
variation (as measured by the %CV) for each housekeeping gene is shown in Table 2.12. 
The intra-assay variation was ideally low for 18S, HMBS and TBP (<10%). The intra-assay 
variation was higher for HPRT1 and SDHA. The inter-assay variation was ~15% for all 
5 housekeeping genes. The values for the entire set of genes are shown in Appendix 8.  
Table 2.12 Intra- and inter-assay variation for the housekeeping genes 
Gene 
%CV 
replicate plate 1 
(intra-assay) 
%CV 
replicate plate 2 
(intra-assay) 
%CV between 
plate 1 and 2 
(inter-assay) 
18S 3.5 9.2 15.9 
HMBS 2.5 7.1 12.5 
HPRT1 6.0 37.8 15.6 
SDHA 25.4 33.5 15.0 
TBP 9.9 8.5 12.1 
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 Independent samples t-tests 
The independent samples t-tests for comparison of gene expression between the 
recurrent and non-recurrent group identified 39 genes with a p-value <0.5 in both 
datasets. The 39 genes are shown in Table 2.13 and Table 2.14 for the Pfaffl and 2-ΔCt 
datasets respectively. For each gene, the table includes the significance of the t-test 
(p-value), the mean expression in the recurrent and non-recurrent group and the fold 
difference between the groups. 
From the 39 genes, 23 showed increased expression and 16 showed decreased 
expression in the recurrent versus non-recurrent group (in both datasets).  
Only 5 genes were significantly differentially expressed between the groups in both 
datasets to the conventional significance level of 95% (p<0.05). These genes were 
AMACR, HPRT1, PLAU, PTEN and SDHA.  
In both datasets, the genes AMACR, HPRT1 and PTEN showed significantly decreased 
expression in the recurrent versus non-recurrent group. The expression of PLAU and 
SDHA were significantly increased in the recurrent vs non-recurrent group. 
A further 6 genes were significant to a confidence level of 90% (p<0.1): ABL1, ANXA2, 
ATP10B, CDH1, PGC and PVT1. 
The GS was also included in the LR analysis as it had a p-value <0.5 in the Mann-Whitney 
U test. The preoperative PSA was not included (p>0.5). 
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Table 2.13 Genes with p<0.5 in the independent samples t-tests for the comparison of the recurrent and 
non-recurrent group (Pfaffl dataset) 
Gene sig. 
Mean ↑/↓  
with recurrence Fold difference Non-recurrence Recurrence 
ABL1 0.045 -0.251 0.006 ↑ 42.83 
AMACR 0.018 2.786 1.714 ↓ 1.63 
ANPEP 0.205 -1.149 -0.444 ↑ 2.59 
ANXA2 0.072 -2.234 -1.808 ↑ 1.24 
ATP10B 0.054 -8.812 -7.531 ↑ 1.17 
ATP5MPL 0.295 -0.360 -0.213 ↑ 1.69 
C3 0.202 -2.195 -1.854 ↑ 1.18 
CD109 0.125 -1.753 -1.465 ↑ 1.20 
CDH1 0.052 0.126 0.396 ↑ 3.14 
CHM 0.331 -0.697 -0.527 ↑ 1.32 
DPT 0.098 -1.891 -1.302 ↑ 1.45 
EFNA1 0.155 -0.453 -0.246 ↑ 1.84 
EFNA5 0.151 -0.548 -1.137 ↓ 2.07 
EZH2 0.451 -1.476 -1.708 ↓ 1.16 
F11R 0.235 -0.769 -0.623 ↑ 1.23 
FABP5 0.274 -1.164 -0.941 ↑ 1.24 
GSTM3 0.146 -0.434 -0.150 ↑ 2.89 
GSTM5 0.438 -0.483 -0.911 ↓ 1.89 
GUCY1A1 0.149 0.662 0.403 ↓ 1.64 
HPRT1 0.008 -0.372 -1.272 ↓ 3.42 
IRF7 0.356 -1.472 -1.795 ↓ 1.22 
ITGA2 0.244 -0.589 -0.350 ↑ 1.68 
ITGB1 0.115 -0.460 -0.216 ↑ 2.13 
ITGB6b 0.433 -2.701 -3.107 ↓ 1.15 
NDUFAF1 0.154 -0.185 -0.698 ↓ 3.77 
NELL2 0.292 -0.328 0.040 ↑ 9.2 
PNP 0.322 -1.401 -1.714 ↓ 1.22 
PCDH18 0.197 -0.076 -0.494 ↓ 6.5 
PGC 0.070 -4.145 -5.170 ↓ 1.25 
PLAU 0.020 -2.807 -2.297 ↑ 1.22 
PLLP 0.303 -1.142 -1.731 ↓ 1.52 
POP5 0.088 -0.087 0.126 ↑ 2.45 
PTEN 0.038 0.141 -0.788 ↓ 6.59 
PTGFR 0.422 -1.732 -2.136 ↓ 1.23 
PVT1 0.073 -0.102 0.236 ↑ 3.31 
SDHA 0.013 -0.262 0.055 ↑ 5.76 
SERPINB5 0.360 -3.942 -4.651 ↓ 1.18 
TBRG4 0.362 -0.786 -0.685 ↑ 1.15 
TRAFD1 0.149 0.089 0.406 ↑ 4.56 
      
GS 0.372   ↑  
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Table 2.14 Genes with p<0.5 in the independent samples t-tests for the comparison of the recurrent and 
non-recurrent group (2-ΔCt dataset) 
Gene sig. 
Mean ↑/↓  
with recurrence Fold difference Non-recurrence Recurrence 
ABL1 0.073 1.151 1.369 ↑ 1.19 
AMACR 0.023 2.546 1.588 ↓ 1.6 
ANPEP 0.214 0.736 1.433 ↑ 1.95 
ANXA2 0.069 2.920 3.339 ↑ 1.14 
ATP10B 0.049 -8.262 -7.049 ↑ 1.17 
ATP5MPL 0.439 1.660 1.777 ↑ 1.07 
C3 0.264 1.697 2.015 ↑ 1.19 
CD109 0.099 -1.145 -0.851 ↑ 1.35 
CDH1 0.049 3.472 3.741 ↑ 1.08 
CHM 0.402 -0.808 -0.659 ↑ 1.23 
DPT 0.120 0.237 0.818 ↑ 3.45 
EFNA1 0.165 1.308 1.508 ↑ 1.15 
EFNA5 0.143 -2.037 -2.676 ↓ 1.31 
EZH2 0.411 -1.917 -2.188 ↓ 1.14 
F11R 0.224 1.992 2.138 ↑ 1.07 
FABP5 0.270 0.293 0.512 ↑ 1.75 
GSTM3 0.262 -0.311 -0.072 ↑ 4.32 
GSTM5 0.389 -3.383 -3.917 ↓ 1.16 
GUCY1A1 0.056 1.532 1.152 ↓ 1.33 
HPRT1 0.025 -1.595 -2.578 ↓ 1.62 
IRF7 0.342 -1.857 -2.196 ↓ 1.18 
ITGA2 0.391 0.202 0.368 ↑ 1.82 
ITGB1 0.219 2.891 3.089 ↑ 1.07 
ITGB6b 0.398 -4.176 -4.645 ↓ 1.11 
NDUFAF1 0.183 -3.290 -3.961 ↓ 1.2 
NELL2 0.344 -2.096 -1.749 ↑ 1.2 
PNP 0.297 -0.260 -0.606 ↓ 2.33 
PCDH18 0.206 -0.607 -0.997 ↓ 1.64 
PGC 0.062 -4.912 -6.032 ↓ 1.23 
PLAU 0.023 0.069 0.568 ↑ 8.23 
PLLP 0.250 -2.651 -3.419 ↓ 1.29 
POP5 0.114 -0.244 -0.047 ↑ 5.19 
PTEN 0.030 -3.756 -4.827 ↓ 1.29 
PTGFR 0.393 -2.727 -3.170 ↓ 1.16 
PVT1 0.096 -2.330 -2.010 ↑ 1.16 
SDHA 0.046 0.898 1.166 ↑ 1.3 
SERPINB5 0.368 -3.504 -4.170 ↓ 1.19 
TBRG4 0.297 -0.083 0.030 ↑ 3.77 
TRAFD1 0.204 0.346 0.635 ↑ 1.84 
      
GS 0.372   ↑  
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 Univariate logistic regression analysis  
 Single gene models ranked by χ2 
The selected output parameters from the univariate LR analysis of the 39 genes are 
listed in Table 2.15. A model containing only GS is also included in the table. 
The single gene models were ranked in descending order of the LRT statistic (χ2), which 
described the improvement in fit achieved through the addition of each gene to the null 
model. The degrees of freedom (df) and the significance of χ2 are shown to the right of 
each χ2 value. 
The models with the highest value for χ2 were AMACR (χ2(1) = 7.8, p<0.01) and HPRT1 
(χ2(1) = 6.7, p<0.01). The higher the value for χ2, the higher the significance (lower 
p-value) and the greater the improvement in fit under the final model than the null 
model. To reiterate, χ2 was calculated as the (-2LL of the null model) - (-2LL of the final 
model). Therefore, as the -2LL of the null model remained constant, a higher value for 
χ2 reflected a lower -2LL of the final model (the model fitted the data better). 
The addition of either AMACR or HPRT1 offered a significant improvement over the null 
model to a 99% confidence level (p<0.01). SDHA, PLAU, PTEN, ABL1 and CDH1 
significantly improved the fit of the null model to a 95% confidence level (p<0.05). 
A further number of genes improved the fit of the model to a 90% confidence level 
(p<0.1): ATP10B, PVT1, ANXA2, PGC, EFNA5, TRAFD1, POP5, DPT and GUCY1A1. The 
remainder of the genes had p-values >0.1, suggesting that these single gene models 
were not significantly better for predicting the data than the null model. However, this 
did not prevent the genes being included in the multivariate analysis as they had 
potential to be useful in combination, particularly those with p-values <0.25.  
The GS as a single predictor was ranked near the bottom of the list (p-value of >0.3) 
showing that it offered no significant improvement over the null model for the 
prediction of recurrence. 
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Table 2.15 Output parameters from the logistic regression analysis of the single gene models (listed in descending order of χ2)  
Gene(s) 
-2LL χ2 df sig. 
Nagelkerke 
 R2 
Wald significance Percent Accuracy (%) 
1 2 3 1 2 3 Recurrent 
Non- 
recurrent Overall 
Null Model   83.324          68.7 
AMACR   75.564 7.760 1 0.0053 0.154 0.009   33.3 95.7 76.1 
HPRT1   76.595 6.728 1 0.0095 0.134 0.022   14.3 95.7 70.1 
SDHA   77.088 6.236 1 0.0125 0.125 0.020   23.8 95.7 73.1 
PLAU   77.835 5.489 1 0.0191 0.111 0.026   19.0 93.5 70.1 
PTEN   79.164 4.159 1 0.0414 0.085 0.048   19.0 95.7 71.6 
ABL1   79.322 4.002 1 0.0455 0.081 0.053   19.0 93.5 70.1 
CDH1   79.372 3.952 1 0.0468 0.080 0.060   14.3 97.8 71.6 
ATP10B   79.611 3.712 1 0.0540 0.076 0.058   14.3 91.3 67.2 
PVT1   79.880 3.444 1 0.0635 0.070 0.083   9.5 97.8 70.1 
ANXA2   79.973 3.351 1 0.0672 0.069 0.076   0.0 95.7 65.7 
PGC   80.025 3.298 1 0.0693 0.068 0.074   9.5 97.8 70.1 
EFNA5   80.235 3.089 1 0.0788 0.063 0.090   14.3 100.0 73.1 
TRAFD1   80.313 3.011 1 0.0827 0.062 0.125   9.5 97.8 70.1 
POP5   80.374 2.950 1 0.0859 0.061 0.098   4.8 100.0 70.1 
DPT   80.481 2.843 1 0.0918 0.058 0.102   4.8 97.8 68.7 
GUCY1A1   80.505 2.819 1 0.0931 0.058 0.102   4.8 100.0 70.1 
PCDH18   80.625 2.699 1 0.1004 0.055 0.116   9.5 97.8 70.1 
ITGB1   80.809 2.515 1 0.1128 0.052 0.118   9.5 97.8 70.1 
CD109   80.833 2.491 1 0.1145 0.051 0.128   9.5 100.0 71.6 
GSTM3   81.128 2.196 1 0.1384 0.045 0.147   0.0 100.0 68.7 
ITGA2   81.263 2.061 1 0.1511 0.043 0.160   4.8 100.0 70.1 
EFNA1   81.293 2.030 1 0.1542 0.042 0.160   9.5 97.8 70.1 
NDUFAF1   81.367 1.957 1 0.1618 0.040 0.167   14.3 97.8 71.6 
PNP   81.448 1.876 1 0.1708 0.039 0.223   4.8 100.0 70.1 
ANPEP   81.647 1.677 1 0.1954 0.035 0.204   0.0 100.0 68.7 
C3   81.647 1.677 1 0.1953 0.035 0.202   0.0 97.8 67.2 
PLLP   81.710 1.614 1 0.2040 0.033 0.205   14.3 97.8 71.6 
F11R   81.868 1.456 1 0.2276 0.030 0.234   4.8 100.0 70.1 
FABP5   82.095 1.229 1 0.2676 0.026 0.271   0.0 100.0 68.7 
NELL2   82.157 1.166 1 0.2801 0.024 0.289   0.0 100.0 68.7 
ATP5MPL   82.173 1.151 1 0.2833 0.024 0.292   0.0 100.0 68.7 
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SERPINB5   82.246 1.078 1 0.2992 0.022 0.299   0.0 100.0 68.7 
CHM   82.311 1.013 1 0.3143 0.021 0.329   4.8 100.0 70.1 
EZH2   82.460 0.864 1 0.3526 0.018 0.358   4.8 100.0 70.1 
TBRG4   82.460 0.864 1 0.3525 0.018 0.357   0.0 100.0 68.7 
IRF7   82.488 0.835 1 0.3607 0.017 0.359   4.8 97.8 68.7 
PTGFR   82.674 0.649 1 0.4203 0.014 0.419   0.0 100.0 68.7 
ITGB6b   82.703 0.621 1 0.4306 0.013 0.428   0.0 100.0 68.7 
GSTM5   82.719 0.605 1 0.4367 0.013 0.434   0.0 100.0 68.7 
              
GS   82.357 0.966 1 0.3256 0.020 0.330   0.0 100.0 68.7 
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The table also gives a value for the significance of the Wald statistic, which shows the 
contribution that each variable (coefficient) makes to the model. The significance values 
for the Wald test were in a similar range to those found for the χ2. This was expected as 
these tests are asymptotically equivalent as they are both likelihood-based tests.  
The values obtained for the pseudo R2 statistic called the Nagelkerke R2 also decreased 
in parallel with the χ2. The model containing AMACR had the highest value for the 
Nagelkerke R2 of 0.154, showing that approximately 15% of the variation in recurrence 
could be described by this model. In comparison, the model GSTM5 had a Nagelkerke R2 
of only 0.013, showing that only 1% of the variation in recurrence was described by this 
model (i.e. GSTM5 as a single gene model was virtually worthless for predicting 
recurrence).  
The overall percent accuracy is included in the table for comparison with the χ2. The 
percentage of recurrent and non-recurrent cases that were predicted correctly are also 
included from the SPSS classification table (sensitivity and specificity). 
An overall percent accuracy for the single gene model AMACR showed it could predict 
76% of the patients correctly. However, despite 96% of patients with non-recurrent 
disease being correctly predicted, only 33% of those with recurrent disease were 
correctly predicted (high specificity and low sensitivity). The limitations of using percent 
accuracy to assess the performance of a predictive model are explained in detail in the 
method development in Section 2.3.4.8. 
Importantly, the LR output also contained the variables for the logistic regression 
equation including the regression coefficient for each variable and the regression 
constant. These variables were needed to allow computation of the predicted 
probability of each patient being in the recurrent group, which was essential before 
classification into either the recurrent or non-recurrent group could take place. The 
regression coefficient describes the increase (or decrease) in the ln odds (logit) of 
a patient being in the recurrent group for a one-unit increase in expression of the gene 
(predictor variable). Although necessary for the LR equation, this value is extremely 
difficult to interpret. In comparison, the odds ratio (exponent of the coefficient) is easier 
to interpret and describes the increase/decrease in raw odds of the patient being in the 
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recurrent group for a one-unit increase in gene expression. The odds ratio therefore 
provided a useful description of the effect on outcome for each gene in the model. These 
regression coefficients and odds ratios for the single gene models are shown in Table 
2.16. 
Table 2.16 Variables in the equation for the single gene models 
Model Predictor β coefficient Standard Error Odds Ratio (95%CI) Wald sig. 
1 AMACR -0.517 0.196 0.596 (0.406-0.877) 0.009 
2 HPRT1 -0.550 0.241 0.577 (0.360-0.925) 0.022 
3 SDHA 1.423 0.610 4.148 (1.254-13.716) 0.020 
4 PLAU 0.769 0.345 2.158 (1.097-4.243) 0.026 
5 PTEN -0.313 0.158 0.732 (0.537-0.997) 0.048 
6 ABL1 1.095 0.567 2.988 (0.984-9.077) 0.053 
7 CDH1 1.054 0.560 2.869 (0.957-8.606) 0.060 
8 ATP10B 0.202 0.107 1.224 (0.993-1.509) 0.058 
9 PVT1 0.743 0.428 2.102 (0.909-4.863) 0.083 
10 ANXA2 0.557 0.314 1.745 (0.943-3.228) 0.076 
11 PGC -0.225 0.126 0.799 (0.624-1.022) 0.074 
12 EFNA5 -0.368 0.218 0.692 (0.452-1.060) 0.090 
13 TRAFD1 0.800 0.521 2.227 (0.802-6.183) 0.125 
14 POP5 0.978 0.590 2.659 (0.836-8.451) 0.098 
15 DPT 0.342 0.209 1.408 (0.934-2.122) 0.102 
16 GUCY1A1 -0.767 0.468 0.464 (0.185-1.163) 0.102 
17 PCDH18 -0.454 0.289 0.635 (0.361-1.118) 0.116 
18 ITGB1 0.717 0.458 2.048 (0.834-5.029) 0.118 
19 CD109 0.617 0.405 1.853 (0.838-4.097) 0.128 
20 GSTM3 0.544 0.375 1.723 (0.826-3.593) 0.147 
21 ITGA2 0.604 0.430 1.830 (0.787-4.253) 0.160 
22 EFNA1 0.682 0.486 1.978 (0.764-5.125) 0.160 
23 NDUFAF1 -0.263 0.190 0.769 (0.530-1.116) 0.167 
24 PNP -0.438 0.359 0.645 (0.319-1.306) 0.223 
25 ANPEP 0.167 0.131 1.182 (0.913-1.529) 0.204 
26 C3 0.344 0.270 1.411 (0.832-2.394) 0.202 
27 PLLP -0.188 0.148 0.829 (0.620-1.108) 0.205 
28 F11R 0.693 0.582 2.000 (0.639-6.258) 0.234 
29 FABP5 0.384 0.349 1.468 (0.741-2.910) 0.271 
30 NELL2 0.223 0.211 1.250 (0.827-1.889) 0.289 
31 ATP5MPL 0.550 0.522 1.734 (0.623-4.827) 0.292 
32 SERPINB5 -0.105 0.101 0.901 (0.739-1.097) 0.299 
33 CHM 0.422 0.433 1.525 (0.653-3.561) 0.329 
34 EZH2 -0.259 0.282 0.772 (0.444-1.340) 0.358 
35 TBRG4 0.598 0.650 1.819 (0.509-6.496) 0.357 
36 IRF7 -0.177 0.194 0.837 (0.573-1.224) 0.359 
37 PTGFR -0.110 0.137 0.895 (0.685-1.170) 0.419 
38 ITGB6b -0.105 0.133 0.900 (0.694-1.168) 0.428 
39 GSTM5 -0.097 0.124 0.908 (0.712-1.157) 0.434 
       
GS 0.246 0.253 1.279 (0.779-2.098) 0.330 
 
From Table 2.16 it is evident that the odds of the patient being in the recurrent group 
were decreased as the expression of AMACR increased by one unit (as reflected by the 
negative sign of the coefficient and an odds ratio of less than one). The odds ratio of 
0.596 shows that the odds of the patient being in the recurrent group approximately 
halved as AMACR expression increased. Therefore, the patient was more likely to be in 
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the recurrent group with a lower expression of AMACR. In comparison, the odds ratio 
for SDHA is 4.148, reflecting that the odds of the patient being in the recurrent group 
were multiplied by approximately 4 for every one-unit increase in SDHA expression. 
Conversely, at the end of the list, GSTM5 has an odds ratio of 0.908. This value is close 
to 1, suggesting that the odds of the patient being in the recurrent group were not 
affected by the expression of GSTM5. 
 Single gene models ranked by overall percent accuracy 
The single gene models ordered by the overall percent accuracy are shown in Table 2.17 
for comparison with the order of the models ranked by χ2.  
The order of the gene models was substantially different to the order according to χ2. 
To illustrate the difference between the two ranking methods, the rank of each model 
using each method is shown in the far left-hand columns. The difference in the rank 
between the two ranking methods is also included (rank change). 
It was evident that ranking according to overall percent accuracy pushed some genes 
such as HPRT1 and PLAU, which were at the top of the list according to the χ2, further 
down the list. Other genes near the bottom of the list according to χ2, such as CD109, 
NDUFAF1 and PLLP, were moved to near the top of the list according to overall percent 
accuracy. Additionally, ranking by the percent accuracy resulted in the presence of genes 
with high p-values for the Wald significance in the top portion of the list, e.g. CHM and 
EZH2, and likewise those with relatively low p-values at the bottom of the list, e.g. 
ANXA2 and ATP10B.  
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Table 2.17 Single gene models ranked in descending order of the overall percent accuracy 
Rank 
change 
Rank 
(-2LL) 
 Rank 
(%) 
Gene(s) Percent Accuracy (%)  
χ2 df sig. 
Nagelkerke 
R2 
Wald significance 
1 2 3 Recurrent 
Non- 
Recurrent Overall 1 2 3 
   Null Model     68.7        
0 1 1 AMACR   33.3 95.7 76.1 7.760 1 0.0053 0.154 0.009   
10 12 2 EFNA5   14.3 100.0 73.1 3.089 1 0.0788 0.063 0.090   
0 3 3 SDHA   23.8 95.7 73.1 6.236 1 0.0125 0.125 0.020   
15 19 4 CD109   9.5 100.0 71.6 2.491 1 0.1145 0.051 0.128   
2 7 5 CDH1   14.3 97.8 71.6 3.952 1 0.0468 0.080 0.060   
17 23 6 NDUFAF1   14.3 97.8 71.6 1.957 1 0.1618 0.040 0.167   
20 27 7 PLLP   14.3 97.8 71.6 1.614 1 0.2040 0.033 0.205   
3 5 8 PTEN   19.0 95.7 71.6 4.159 1 0.0414 0.085 0.048   
3 6 9 ABL1   19.0 93.5 70.1 4.002 1 0.0455 0.081 0.053   
23 33 10 CHM   4.8 100.0 70.1 1.013 1 0.3143 0.021 0.329   
11 22 11 EFNA1   9.5 97.8 70.1 2.030 1 0.1542 0.042 0.160   
22 34 12 EZH2   4.8 100.0 70.1 0.864 1 0.3526 0.018 0.358   
15 28 13 F11R   4.8 100.0 70.1 1.456 1 0.2276 0.030 0.234   
2 16 14 GUCY1A1   4.8 100.0 70.1 2.819 1 0.0931 0.058 0.102   
13 2 15 HPRT1   14.3 95.7 70.1 6.728 1 0.0095 0.134 0.022   
5 21 16 ITGA2   4.8 100.0 70.1 2.061 1 0.1511 0.043 0.160   
1 18 17 ITGB1   9.5 97.8 70.1 2.515 1 0.1128 0.052 0.118   
6 24 18 PNP   4.8 100.0 70.1 1.876 1 0.1708 0.039 0.223   
2 17 19 PCDH18   9.5 97.8 70.1 2.699 1 0.1004 0.055 0.116   
9 11 20 PGC   9.5 97.8 70.1 3.298 1 0.0693 0.068 0.074   
17 4 21 PLAU   19.0 93.5 70.1 5.489 1 0.0191 0.111 0.026   
8 14 22 POP5   4.8 100.0 70.1 2.950 1 0.0859 0.061 0.098   
14 9 23 PVT1   9.5 97.8 70.1 3.444 1 0.0635 0.070 0.083   
11 13 24 TRAFD1   9.5 97.8 70.1 3.011 1 0.0827 0.062 0.125   
0 25 25 ANPEP   0.0 100.0 68.7 1.677 1 0.1954 0.035 0.204   
5 31 26 ATP5MPL   0.0 100.0 68.7 1.151 1 0.2833 0.024 0.292   
12 15 27 DPT   4.8 97.8 68.7 2.843 1 0.0918 0.058 0.102   
1 29 28 FABP5   0.0 100.0 68.7 1.229 1 0.2676 0.026 0.271   
9 20 29 GSTM3   0.0 100.0 68.7 2.196 1 0.1384 0.045 0.147   
9 39 30 GSTM5   0.0 100.0 68.7 0.605 1 0.4367 0.013 0.434   
5 36 31 IRF7   4.8 97.8 68.7 0.835 1 0.3607 0.017 0.359   
6 38 32 ITGB6b   0.0 100.0 68.7 0.621 1 0.4306 0.013 0.428   
3 30 33 NELL2   0.0 100.0 68.7 1.166 1 0.2801 0.024 0.289   
3 37 34 PTGFR   0.0 100.0 68.7 0.649 1 0.4203 0.014 0.419   
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3 32 35 SERPINB5   0.0 100.0 68.7 1.078 1 0.2992 0.022 0.299   
1 35 36 TBRG4   0.0 100.0 68.7 0.864 1 0.3525 0.018 0.357   
29 8 37 ATP10B   14.3 91.3 67.2 3.712 1 0.0540 0.076 0.058   
12 26 38 C3   0.0 97.8 67.2 1.677 1 0.1953 0.035 0.202   
29 10 39 ANXA2   0.0 95.7 65.7 3.351 1 0.0672 0.069 0.076   
                
   GS   0.0 100.0 68.7 0.966 1 0.3256 0.020 0.330   
112 
 
 Gleason score added as a predictor variable to single gene 
models 
Although GS as a single variable model provided no significant improvement over the 
null model, it could potentially have been useful in combination with other variables. 
The LRT was used to ascertain if the addition of the GS to the single gene models led to 
a significant improvement in their overall fit. Therefore, χ2 in this circumstance, 
described the difference between the -2LL of the gene only model and the -2LL of the 
final model (including both the gene and the GS). These χ2 values are listed in Table 2.18. 
Table 2.18 The χ2 values showing the effect of adding Gleason score to each single gene model 
Gene(s) χ2 df sig. 
1 2 3 diff from gene 1   
AMACR  GS 1.525 1 0.217 
HPRT1  GS 0.808 1 0.369 
SDHA  GS 1.006 1 0.316 
PLAU  GS 0.791 1 0.374 
PTEN  GS 0.451 1 0.502 
ABL1  GS 1.545 1 0.214 
CDH1  GS 1.332 1 0.248 
ATP10B  GS 0.418 1 0.518 
PVT1  GS 0.608 1 0.436 
ANXA2  GS 1.837 1 0.175 
PGC  GS 0.939 1 0.333 
EFNA5  GS 0.360 1 0.549 
TRAFD1  GS 0.772 1 0.380 
POP5  GS 1.655 1 0.198 
DPT  GS 1.794 1 0.180 
GUCY1A1  GS 1.081 1 0.299 
PCDH18  GS 0.648 1 0.421 
ITGB1  GS 1.284 1 0.257 
CD109  GS 1.648 1 0.199 
GSTM3  GS 1.542 1 0.214 
ITGA2  GS 1.114 1 0.291 
EFNA1  GS 1.219 1 0.270 
NDUFAF1  GS 0.756 1 0.385 
PNP  GS 1.002 1 0.317 
ANPEP  GS 1.373 1 0.241 
C3  GS 1.047 1 0.306 
PLLP  GS 0.782 1 0.377 
FABP5  GS 0.838 1 0.360 
NELL2  GS 1.238 1 0.266 
ATP5MPL  GS 1.359 1 0.244 
SERPINB5  GS 1.109 1 0.292 
CHM  GS 1.456 1 0.228 
EZH2  GS 1.512 1 0.219 
TBRG4  GS 1.288 1 0.256 
IRF7  GS 0.907 1 0.341 
PTGFR  GS 0.924 1 0.336 
 
The addition of GS led to a slight reduction in the -2LL for the final model (shown by 
a positive value for χ2) as would be expected with the addition of another predictor 
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variable to the model. However, the value for χ2 was not significant for any of the 
models, which demonstrated that the addition of GS made no significant improvement 
to any of the single gene models. 
 ROC curves of the single gene models 
ROC curves were plotted for the single gene models as a measure of discriminatory 
accuracy and to identify the most appropriate threshold value for prediction of the 
patients in either the recurrent or non-recurrent group. The ROC plots are shown for the 
genes AMACR, HPRT1, SDHA, PLAU and PTEN, which were the top single gene models 
(according to the χ2)(Figure 2.23). The area under the curve (AUC) values from the plots 
are shown in Table 2.19 in descending order of the χ2. 
 
Figure 2.23 ROC curves for the best single gene models 
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Table 2.19 AUC values for the single gene models 
Genes ranked by 
χ2 AUC 
AUC 
Rank 
AMACR 0.677 2 
HPRT1 0.731 1 
SDHA 0.663 6 
PLAU 0.664 5 
PTEN 0.671 3 
ABL1 0.659 7 
CDH1 0.628 12 
ATP10B 0.639 9 
PVT1 0.599 19 
ANXA2 0.657 8 
PGC 0.667 4 
EFNA5 0.585 25 
TRAFD1 0.586 24 
POP5 0.598 21 
DPT 0.635 10 
GUCY1A1 0.616 14 
PCDH18 0.549 35 
ITGB1 0.608 15 
CD109 0.622 13 
GSTM3 0.630 11 
ITGA2 0.588 23 
EFNA1 0.601 17 
NDUFAF1 0.568 32 
PNP 0.580 28 
ANPEP 0.602 16 
C3 0.601 18 
PLLP 0.516 37 
F11R 0.578 29 
FABP5 0.582 27 
NELL2 0.594 22 
ATP5MPL 0.569 31 
SERPINB5 0.528 36 
CHM 0.571 30 
EZH2 0.510 38 
TBRG4 0.585 26 
IRF7 0.467 39 
PTGFR 0.599 20 
ITGB6b 0.563 33 
GSTM5 0.552 34 
   
GS 0.565  
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The single gene model with the highest AUC was HPRT1 at 0.731. AMACR, SDHA, PLAU, 
PTEN, ABL1, ANXA2 and PGC had lower AUC values, within a narrow range of 0.657-
0.677. It was evident that a significant proportion of the single gene models had AUC 
values that were only slightly above 0.5, suggesting that their predictive accuracy was 
only slightly better than a random classification. The single gene models containing EZH2 
and IRF7 had AUC values of 0.510 and 0.467 respectively, showing that these genes had 
no predictive value as single gene models. The ranking of the AUC values did not 
completely correlate with the ranking by the χ2, although a similar trend was observed 
with the AUC decreasing alongside the χ2. 
The threshold at which the Youden index (J) was highest, which can be used as an 
optimal cut-off point for classification, is shown for the top 5 single gene models 
(according to χ2)(Table 2.20). It is important to note that this value simply provided the 
value at which the combination of sensitivity and specificity was highest and did not 
always provide the most balanced combination of these parameters. If an alternative 
threshold would offer a more balanced combination of sensitivity and specificity, this is 
provided below the threshold at which J is highest. 
Table 2.20 Optimal thresholds for the top single gene models 
Single gene model Cut-off value Sensitivity Specificity 
AMACR 0.335 0.571 0.783 
AMACR 0.286 0.619 0.674 
HPRT1 0.236 1.000 0.391 
HPRT1 0.315 0.524 0.804 
SDHA 0.275 0.762 0.587 
PLAU 0.309 0.571 0.674 
PTEN 0.284 0.667 0.674 
 
For the single gene model AMACR, at a threshold of 0.335 (at which J is highest), 
a sensitivity of 57% and a specificity of 78% could be attained. However, a slightly more 
balanced combination of these parameters could be found using an alternative 
threshold of 0.286, providing a 62% sensitivity and 67% specificity. 
Similarly, for HPRT1 at a threshold of 0.236 (at which J is highest), the sensitivity and 
specificity were 100% and 39% respectively. By selecting a different threshold of 0.315, 
a more balanced combination of sensitivity and specificity of 52% and 80% respectively 
could be achieved.   
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 Multivariate logistic regression analysis 
 Correlation analysis 
The final number of two- and three-gene combinations analysed in the multivariate 
LR were 387 and 1,482 respectively. As there were many correlating genes which could 
not be put together, these numbers were a significant reduction from the total number 
of possible gene combinations from the 39 genes. If there had been no correlating 
genes, the number of novel two- and three-gene combinations would have been 741 
and 9,139 respectively. The results of the correlation analysis can be found in the 
electronic Appendix 8. 
Due to the large number of models that were analysed, the complete results for the 
multivariate LR analysis are provided in the electronic Appendix 8. From these results, 
a total of 139 two-gene models and 771 three-gene models demonstrated a significant 
improvement over the null model (p<0.05 for the χ2). 
However, unless a two-gene model offers a lower -2LL than could be achieved with 
a single gene model; or unless a three-gene model offers a lower -2LL than could be 
achieved by a two-gene model, the use of the model with more predictor variables 
would not usually be justified.  
Therefore, only the two-gene models which improved upon the best single gene model 
are included in this section. Similarly, only the three-gene models which improved upon 
the best two-gene model are included. These two- and three-gene models were the top 
79 and 22 respectively (according to χ2). 
 Two-gene models ranked by χ2   
The important parameters from the LR output of the top 79 two-gene models are shown 
in Table 2.21.
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Table 2.21 Output parameters from the logistic regression analysis of the top two-gene models (listed in descending order of χ2)  
Gene(s) 
-2LL χ2 df sig. 
Nagelkerke 
R2 
Wald Significance Percent Accuracy (%) 
1 2 3 1 2 3 Recurrent 
Non- 
recurrent  Overall 
Null Model   83.324          68.7 
AMACR SDHA  66.602 16.722 2 0.0002 0.310 0.003 0.009  38.1 91.3 74.6 
HPRT1 PLAU  68.547 14.777 2 0.0006 0.278 0.015 0.011  42.9 93.5 77.6 
AMACR HPRT1  70.141 13.183 2 0.0014 0.251 0.015 0.038  42.9 95.7 79.1 
HPRT1 SDHA  70.351 12.973 2 0.0015 0.247 0.031 0.021  28.6 97.8 76.1 
ANXA2 HPRT1  70.355 12.969 2 0.0015 0.247 0.019 0.009  33.3 87.0 70.1 
AMACR ATP10B  70.377 12.947 2 0.0015 0.247 0.005 0.029  33.3 89.1 71.6 
AMACR DPT  71.229 12.094 2 0.0024 0.232 0.005 0.047  42.9 89.1 74.6 
AMACR TRAFD1  71.233 12.091 2 0.0024 0.232 0.005 0.089  47.6 95.7 80.6 
ABL1 AMACR  71.301 12.023 2 0.0025 0.231 0.047 0.008  42.9 95.7 79.1 
AMACR PVT1  71.883 11.440 2 0.0033 0.221 0.008 0.080  42.9 93.5 77.6 
AMACR EFNA5  71.932 11.392 2 0.0034 0.220 0.007 0.069  42.9 91.3 76.1 
AMACR GSTM3  71.975 11.349 2 0.0034 0.219 0.005 0.065  38.1 93.5 76.1 
AMACR POP5  71.983 11.341 2 0.0034 0.219 0.007 0.075  33.3 95.7 76.1 
AMACR CDH1  72.210 11.114 2 0.0039 0.215 0.011 0.084  33.3 91.3 73.1 
HPRT1 POP5  72.215 11.109 2 0.0039 0.215 0.020 0.055  23.8 95.7 73.1 
EFNA5 SDHA  72.360 10.964 2 0.0042 0.212 0.051 0.012  33.3 95.7 76.1 
AMACR ITGB1  72.395 10.929 2 0.0042 0.211 0.007 0.081  33.3 91.3 73.1 
CD109 HPRT1  72.397 10.927 2 0.0042 0.211 0.055 0.014  23.8 95.7 73.1 
AMACR FABP5  72.646 10.678 2 0.0048 0.207 0.005 0.096  38.1 93.5 76.1 
PTEN SDHA  72.679 10.645 2 0.0049 0.206 0.039 0.018  33.3 89.1 71.6 
AMACR SERPINB5  72.746 10.577 2 0.0050 0.205 0.005 0.101  33.3 89.1 71.6 
AMACR PTEN  72.801 10.523 2 0.0052 0.204 0.016 0.108  28.6 91.3 71.6 
PCDH18 SDHA  72.864 10.460 2 0.0054 0.203 0.060 0.016  23.8 95.7 73.1 
PCDH18 PLAU  72.945 10.379 2 0.0056 0.202 0.043 0.013  28.6 95.7 74.6 
PGC SDHA  72.954 10.370 2 0.0056 0.201 0.047 0.013  23.8 89.1 68.7 
ATP10B HPRT1  73.021 10.302 2 0.0058 0.200 0.062 0.026  23.8 93.5 71.6 
PLAU PTEN  73.084 10.240 2 0.0060 0.199 0.021 0.034  38.1 89.1 73.1 
PGC PLAU  73.106 10.218 2 0.0060 0.199 0.035 0.014  28.6 93.5 73.1 
C3 HPRT1  73.166 10.158 2 0.0062 0.198 0.075 0.017  23.8 93.5 71.6 
AMACR ANXA2  73.194 10.130 2 0.0063 0.197 0.014 0.131  42.9 93.5 77.6 
F11R HPRT1  73.227 10.097 2 0.0064 0.197 0.081 0.012  28.6 95.7 74.6 
AMACR PNP  73.275 10.049 2 0.0066 0.196 0.007 0.178  28.6 93.5 73.1 
NDUFAF1 PLAU  73.420 9.904 2 0.0071 0.193 0.041 0.010  33.3 91.3 73.1 
AMACR ATP5MPL  73.462 9.862 2 0.0072 0.192 0.006 0.162  42.9 93.5 77.6 
GUCY1A1 HPRT1  73.563 9.761 2 0.0076 0.190 0.092 0.017  33.3 93.5 74.6 
ABL1 PTEN  73.643 9.681 2 0.0079 0.189 0.024 0.022  28.6 91.3 71.6 
AMACR PLLP  73.764 9.560 2 0.0084 0.187 0.008 0.186  38.1 91.3 74.6 
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AMACR C3  73.787 9.537 2 0.0085 0.186 0.008 0.188  42.9 91.3 76.1 
AMACR CD109  73.810 9.513 2 0.0086 0.186 0.012 0.199  38.1 93.5 76.1 
HPRT1 TRAFD1  73.829 9.495 2 0.0087 0.186 0.034 0.172  23.8 97.8 74.6 
ATP5MPL HPRT1  73.939 9.385 2 0.0092 0.184 0.120 0.018  23.8 95.7 73.1 
DPT HPRT1  73.947 9.377 2 0.0092 0.184 0.114 0.031  28.6 95.7 74.6 
AMACR TBRG4  73.948 9.375 2 0.0092 0.183 0.006 0.213  38.1 93.5 76.1 
GSTM3 HPRT1  73.991 9.332 2 0.0094 0.183 0.118 0.023  23.8 95.7 73.1 
PLAU PLLP  74.082 9.242 2 0.0098 0.181 0.011 0.058  33.3 91.3 73.1 
CHM HPRT1  74.105 9.219 2 0.0100 0.181 0.153 0.016  19.0 95.7 71.6 
HPRT1 PGC  74.169 9.155 2 0.0103 0.179 0.030 0.124  28.6 93.5 73.1 
HPRT1 NELL2  74.301 9.023 2 0.0110 0.177 0.017 0.141  33.3 95.7 76.1 
AMACR ITGA2  74.307 9.017 2 0.0110 0.177 0.012 0.272  38.1 91.3 74.6 
AMACR PCDH18  74.311 9.013 2 0.0110 0.177 0.016 0.281  38.1 93.5 76.1 
ABL1 GUCY1A1  74.312 9.012 2 0.0110 0.177 0.022 0.034  38.1 95.7 77.6 
CDH1 PGC  74.317 9.007 2 0.0111 0.177 0.026 0.031  23.8 93.5 71.6 
ABL1 HPRT1  74.342 8.982 2 0.0112 0.176 0.145 0.046  23.8 97.8 74.6 
AMACR EFNA1  74.364 8.960 2 0.0113 0.176 0.012 0.282  42.9 93.5 77.6 
GUCY1A1 TRAFD1  74.380 8.943 2 0.0114 0.176 0.024 0.032  23.8 95.7 73.1 
AMACR NELL2  74.412 8.911 2 0.0116 0.175 0.008 0.295  42.9 93.5 77.6 
POP5 PTEN  74.491 8.833 2 0.0121 0.174 0.047 0.021  28.6 91.3 71.6 
EFNA1 HPRT1  74.539 8.785 2 0.0124 0.173 0.164 0.022  23.8 95.7 73.1 
CDH1 HPRT1  74.549 8.775 2 0.0124 0.172 0.171 0.051  14.3 93.5 68.7 
CDH1 GUCY1A1  74.603 8.721 2 0.0128 0.171 0.027 0.039  23.8 93.5 71.6 
PNP SDHA  74.624 8.700 2 0.0129 0.171 0.212 0.016  28.6 97.8 76.1 
AMACR ITGB6b  74.627 8.697 2 0.0129 0.171 0.007 0.331  33.3 91.3 73.1 
AMACR NDUFAF1  74.743 8.581 2 0.0137 0.169 0.014 0.370  23.8 89.1 68.7 
AMACR CHM  74.746 8.578 2 0.0137 0.169 0.009 0.384  38.1 93.5 76.1 
AMACR F11R  74.751 8.573 2 0.0138 0.169 0.012 0.371  38.1 93.5 76.1 
GUCY1A1 PLAU  74.765 8.559 2 0.0139 0.169 0.088 0.025  33.3 95.7 76.1 
HPRT1 PVT1  74.878 8.446 2 0.0147 0.166 0.045 0.210  28.6 95.7 74.6 
HPRT1 ITGB1  74.883 8.441 2 0.0147 0.166 0.034 0.196  23.8 95.7 73.1 
AMACR ANPEP  74.958 8.366 2 0.0153 0.165 0.014 0.440  42.9 93.5 77.6 
ATP10B PTEN  75.015 8.309 2 0.0157 0.164 0.047 0.036  38.1 87.0 71.6 
PLAU SERPINB5  75.050 8.274 2 0.0160 0.163 0.013 0.098  23.8 93.5 71.6 
AMACR GSTM5  75.092 8.232 2 0.0163 0.162 0.009 0.490  28.6 93.5 73.1 
AMACR IRF7  75.093 8.231 2 0.0163 0.162 0.010 0.491  33.3 91.3 73.1 
CD109 PTEN  75.204 8.120 2 0.0172 0.160 0.059 0.025  23.8 93.5 71.6 
FABP5 HPRT1  75.222 8.102 2 0.0174 0.160 0.246 0.026  19.0 95.7 71.6 
GSTM5 SDHA  75.227 8.097 2 0.0175 0.160 0.172 0.011  28.6 93.5 73.1 
PLAU PVT1  75.397 7.927 2 0.0190 0.157 0.043 0.137  28.6 93.5 73.1 
GUCY1A1 PVT1  75.472 7.852 2 0.0197 0.155 0.044 0.047  28.6 97.8 76.1 
ABL1 PGC  75.475 7.849 2 0.0198 0.155 0.041 0.054  33.3 95.7 76.1 
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The χ2 values for the listed two-gene models were all significant (p<0.05) showing that 
these gene models fitted the data significantly better than the null model. The χ2 values 
were higher than those obtained for any of the single gene models (due to the lower -2LL 
in the two-gene models versus the single gene models). These findings were expected 
as only the models that provided a significant improvement over the null model and 
provided a better fit than any of the single gene models were listed.  
The top two-gene models were AMACR.SDHA (χ2(2) = 16.7, p<0.0005) and HPRT1.PLAU 
(χ2(2) = 14.8, p<0.001). These two-gene models offered much higher values for χ2 (and 
higher significance) than the values found for either of the single gene models nested 
within them. For instance, AMACR.SDHA fitted the data better than either AMACR 
(χ2(1) = 7.8, p<0.01) or SDHA (χ2(1) = 6.2, p<0.05).  
The Nagelkerke R2 values for the two-gene models were also substantially higher than 
those found for the single gene models. For example, the Nagelkerke R2 for 
AMACR.SDHA was 0.31, which suggests that this two-gene model accounted for 31% of 
the variation in recurrence. In contrast, only 15% and 13% of the variation in recurrence 
was accounted for by the single gene models of AMACR and SDHA respectively. 
The values for the Wald significance showed whether each gene made a significant 
contribution to the model. For most of the two-gene models presented here, each gene 
made a significant contribution to the model (p<0.05). However, there were some gene 
models (particularly those further down the list), where one of the predictors did not 
make a significant contribution to the model, e.g. ITGA2 in AMACR.ITGA2 (p-value 
>0.25). 
The variables in the LR equations are given for the top 20 two-gene models (Table 2.22). 
These include the regression coefficients and odds ratios as had been done previously 
for the single gene models. However, as there is more than one predictor variable in 
each model, an adjusted odds ratio is given, which is the increase/decrease in the odds 
for a one-unit increase in expression of the variable when controlling for all other 
variables in the model. 
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Table 2.22 Variables in the equation for the two-gene models 
Model Predictor β coefficient Standard 
Error 
Odds ratio (95%CI) p-value 
1 AMACR -0.653 0.220 0.521 (0.338-0.802) 0.003  
SDHA 1.899 0.726 6.680 (1.610-27.715) 0.009 
2 HPRT1 -0.758 0.311 0.469 (0.255-0.863) 0.015  
PLAU 1.080 0.422 2.944 (1.286-6.737) 0.011 
3 AMACR -0.489 0.202 0.613 (0.413-0.911) 0.015  
HPRT1 -0.506 0.244 0.603 (0.374-0.973) 0.038 
4 HPRT1 -0.608 0.282 0.545 (0.313-0.947) 0.031  
SDHA 1.488 0.642 4.426 (1.257-15.589) 0.021 
5 ANXA2 0.843 0.360 2.322 (1.148-4.699) 0.019  
HPRT1 -0.698 0.266 0.498 (0.295-0.838) 0.009 
6 AMACR -0.591 0.210 0.554 (0.367-0.836) 0.005  
ATP10B 0.261 0.119 1.298 (1.027-1.639) 0.029 
7 AMACR -0.592 0.210 0.553 (0.367-0.835) 0.005  
DPT 0.455 0.229 1.576 (1.005-2.470) 0.047 
8 AMACR -0.573 0.202 0.564 (0.379-0.838) 0.005  
TRAFD1 0.999 0.588 2.717 (0.858-8.601) 0.089 
9 ABL1 1.205 0.608 3.338 (1.014-10.988) 0.047  
AMACR -0.543 0.205 0.581 (0.389-0.868) 0.008 
10 AMACR -0.526 0.197 0.591 (0.402-0.869) 0.008  
PVT1 0.811 0.463 2.251 (0.908-5.577) 0.080 
11 AMACR -0.546 0.201 0.579 (0.391-0.859) 0.007  
EFNA5 -0.420 0.232 0.657 (0.417-1.034) 0.069 
12 AMACR -0.591 0.211 0.554 (0.366-0.838) 0.005  
GSTM3 0.727 0.395 2.069 (0.955-4.484) 0.065 
13 AMACR -0.551 0.203 0.577 (0.387-0.859) 0.007  
POP5 1.144 0.642 3.140 (0.893-11.042) 0.075 
14 AMACR -0.507 0.200 0.603 (0.407-0.891) 0.011  
CDH1 1.008 0.583 2.741 (0.874-8.603) 0.084 
15 HPRT1 -0.662 0.284 0.516 (0.296-0.900) 0.020  
POP5 1.368 0.713 3.927 (0.971-15.882) 0.055 
16 EFNA5 -0.501 0.257 0.606 (0.367-1.002) 0.051  
SDHA 1.716 0.682 5.564 (1.461-21.189) 0.012 
17 AMACR -0.552 0.204 0.576 (0.386-0.858) 0.007  
ITGB1 0.845 0.485 2.327 (0.900-6.017) 0.081 
18 CD109 0.872 0.454 2.391 (0.982-5.823) 0.055  
HPRT1 -0.660 0.270 0.517 (0.304-0.877) 0.014 
19 AMACR -0.599 0.212 0.549 (0.363-0.832) 0.005  
FABP5 0.645 0.387 1.906 (0.893-4.072) 0.096 
20 PTEN -0.337 0.164 0.714 (0.518-0.984) 0.039  
SDHA 1.485 0.629 4.413 (1.287-15.138) 0.018 
 
For the highest ranking two-gene model AMACR.SDHA, the adjusted odds ratio is 0.521 
for AMACR and 6.680 for SDHA. Therefore, the patient was approximately half as likely 
to be in the recurrent group for a one-unit increase in AMACR and approximately 7 times 
as likely to be in the recurrent group for a one-unit increase in SDHA.  
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 Two-gene models by overall percent accuracy 
The top two-gene models ordered by overall percent accuracy are shown in Table 2.23. 
The ranking of the two-gene models by overall percent accuracy was very different to 
the ranking by χ2. Some of the gene models with the highest χ2 had been pushed down 
the list. AMACR.SDHA was the highest two-gene model according to χ2 but was ranked 
at 43 according to the overall percent accuracy. Importantly, this gene model showed 
high significance for the Wald statistic for both AMACR and SDHA (p<0.01), indicating 
that both predictors were significant. Conversely, ABL1.PTGFR was ranked at 149 
according to χ2, providing a non-significant improvement over the null model, but was 
ranked at 13 according to the overall percent accuracy. This gene model contained only 
one significant predictor variable (ABL1)(p<0.05). The other predictor variable PTGFR 
(p>0.15) made no significant contribution to the model. The number of models which 
contained a non-significant predictor variable was higher in the overall percent accuracy 
list in comparison to the χ2 list. 
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Table 2.23 Two-gene models ranked in descending order of the overall percent accuracy 
Rank 
change 
Rank 
(-2LL) 
 Rank 
(%) 
Gene(s) Percent Accuracy (%)  
χ2 df sig. 
Nagelkerke 
R2 
Wald Significance 
1 2 3 Recurrent 
Non- 
Recurrent Overall 1 2 3 
   Null Model     68.7        
7 8 1 AMACR TRAFD1  47.6 95.7 80.6 12.091 2 0.0024 0.232 0.005 0.089  
7 9 2 ABL1 AMACR  42.9 95.7 79.1 12.023 2 0.0025 0.231 0.047 0.008  
0 3 3 AMACR HPRT1  42.9 95.7 79.1 13.183 2 0.0014 0.251 0.015 0.038  
47 51 4 ABL1 GUCY1A1  38.1 95.7 77.6 9.012 2 0.0110 0.177 0.022 0.034  
64 69 5 AMACR ANPEP  42.9 93.5 77.6 8.366 2 0.0153 0.165 0.014 0.440  
24 30 6 AMACR ANXA2  42.9 93.5 77.6 10.130 2 0.0063 0.197 0.014 0.131  
27 34 7 AMACR ATP5MPL  42.9 93.5 77.6 9.862 2 0.0072 0.192 0.006 0.162  
46 54 8 AMACR EFNA1  42.9 93.5 77.6 8.960 2 0.0113 0.176 0.012 0.282  
47 56 9 AMACR NELL2  42.9 93.5 77.6 8.911 2 0.0116 0.175 0.008 0.295  
0 10 10 AMACR PVT1  42.9 93.5 77.6 11.440 2 0.0033 0.221 0.008 0.080  
9 2 11 HPRT1 PLAU  42.9 93.5 77.6 14.777 2 0.0006 0.278 0.015 0.011  
67 79 12 ABL1 PGC  33.3 95.7 76.1 7.849 2 0.0198 0.155 0.041 0.054  
136 149 13 ABL1 PTGFR  28.6 97.8 76.1 5.763 2 0.0560 0.116 0.032 0.186  
24 38 14 AMACR C3  42.9 91.3 76.1 9.537 2 0.0085 0.186 0.008 0.188  
24 39 15 AMACR CD109  38.1 93.5 76.1 9.513 2 0.0086 0.186 0.012 0.199  
48 64 16 AMACR CHM  38.1 93.5 76.1 8.578 2 0.0137 0.169 0.009 0.384  
6 11 17 AMACR EFNA5  42.9 91.3 76.1 11.392 2 0.0034 0.220 0.007 0.069  
47 65 18 AMACR F11R  38.1 93.5 76.1 8.573 2 0.0138 0.169 0.012 0.371  
0 19 19 AMACR FABP5  38.1 93.5 76.1 10.678 2 0.0048 0.207 0.005 0.096  
8 12 20 AMACR GSTM3  38.1 93.5 76.1 11.349 2 0.0034 0.219 0.005 0.065  
29 50 21 AMACR PCDH18  38.1 93.5 76.1 9.013 2 0.0110 0.177 0.016 0.281  
9 13 22 AMACR POP5  33.3 95.7 76.1 11.341 2 0.0034 0.219 0.007 0.075  
20 43 23 AMACR TBRG4  38.1 93.5 76.1 9.375 2 0.0092 0.183 0.006 0.213  
157 181 24 C3 GUCY1A1  28.6 97.8 76.1 5.199 2 0.0743 0.105 0.131 0.069  
107 132 25 DPT EFNA5  23.8 100.0 76.1 6.155 2 0.0461 0.123 0.092 0.090  
107 133 26 EFNA5 GSTM3  23.8 100.0 76.1 6.149 2 0.0462 0.123 0.070 0.094  
74 101 27 EFNA5 POP5  23.8 100.0 76.1 7.213 2 0.0272 0.143 0.053 0.061  
12 16 28 EFNA5 SDHA  33.3 95.7 76.1 10.964 2 0.0042 0.212 0.051 0.012  
37 66 29 GUCY1A1 PLAU  33.3 95.7 76.1 8.559 2 0.0139 0.169 0.088 0.025  
48 78 30 GUCY1A1 PVT1  28.6 97.8 76.1 7.852 2 0.0197 0.155 0.044 0.047  
17 48 31 HPRT1 NELL2  33.3 95.7 76.1 9.023 2 0.0110 0.177 0.017 0.141  
28 4 32 HPRT1 SDHA  28.6 97.8 76.1 12.973 2 0.0015 0.247 0.031 0.021  
73 106 33 IRF7 SDHA  33.3 95.7 76.1 7.131 2 0.0283 0.142 0.350 0.020  
300 334 34 NELL2 PLLP  23.8 100.0 76.1 2.752 2 0.2526 0.057 0.294 0.213  
26 61 35 PNP SDHA  28.6 97.8 76.1 8.700 2 0.0129 0.171 0.212 0.016  
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148 184 36 PGC PLLP  28.6 97.8 76.1 5.157 2 0.0759 0.104 0.065 0.174  
50 87 37 ABL1 EFNA5  23.8 97.8 74.6 7.577 2 0.0226 0.150 0.050 0.077  
15 53 38 ABL1 HPRT1  23.8 97.8 74.6 8.982 2 0.0112 0.176 0.145 0.046  
122 161 39 ABL1 PLLP  28.6 95.7 74.6 5.570 2 0.0617 0.112 0.054 0.211  
33 7 40 AMACR DPT  42.9 89.1 74.6 12.094 2 0.0024 0.232 0.005 0.047  
8 49 41 AMACR ITGA2  38.1 91.3 74.6 9.017 2 0.0110 0.177 0.012 0.272  
5 37 42 AMACR PLLP  38.1 91.3 74.6 9.560 2 0.0084 0.187 0.008 0.186  
42 1 43 AMACR SDHA  38.1 91.3 74.6 16.722 2 0.0002 0.310 0.003 0.009  
151 195 44 ANPEP EFNA5  19.0 100.0 74.6 5.005 2 0.0819 0.101 0.175 0.086  
137 182 45 ANXA2 EZH2  28.6 95.7 74.6 5.183 2 0.0749 0.105 0.046 0.189  
74 120 46 ANXA2 GUCY1A1  28.6 95.7 74.6 6.479 2 0.0392 0.130 0.065 0.085  
91 138 47 ATP10B PNP  28.6 95.7 74.6 6.021 2 0.0493 0.121 0.046 0.210  
144 192 48 ATP10B PTGFR  23.8 97.8 74.6 5.057 2 0.0798 0.102 0.040 0.248  
68 117 49 ATP10B PVT1  28.6 95.7 74.6 6.704 2 0.0350 0.134 0.075 0.099  
63 113 50 CDH1 EFNA5  23.8 97.8 74.6 6.874 2 0.0322 0.137 0.070 0.109  
79 130 51 CDH1 PNP  19.0 100.0 74.6 6.196 2 0.0451 0.124 0.051 0.208  
34 86 52 CDH1 PTEN  28.6 95.7 74.6 7.584 2 0.0226 0.150 0.079 0.062  
74 127 53 DPT GUCY1A1  28.6 95.7 74.6 6.328 2 0.0423 0.127 0.071 0.073  
12 42 54 DPT HPRT1  28.6 95.7 74.6 9.377 2 0.0092 0.184 0.114 0.031  
92 147 55 EFNA5 ITGA2  19.0 100.0 74.6 5.783 2 0.0555 0.116 0.076 0.120  
120 176 56 EFNA5 NELL2  19.0 100.0 74.6 5.398 2 0.0673 0.109 0.056 0.142  
211 268 57 EFNA5 PLLP  28.6 95.7 74.6 3.987 2 0.1362 0.081 0.129 0.342  
146 204 58 EFNA5 TBRG4  23.8 97.8 74.6 4.854 2 0.0883 0.098 0.054 0.197  
39 98 59 EZH2 PLAU  33.3 93.5 74.6 7.252 2 0.0266 0.144 0.195 0.019  
32 92 60 EZH2 SDHA  28.6 95.7 74.6 7.401 2 0.0247 0.147 0.301 0.018  
156 217 61 F11R GUCY1A1  23.8 97.8 74.6 4.667 2 0.0969 0.095 0.182 0.082  
31 31 62 F11R HPRT1  28.6 95.7 74.6 10.097 2 0.0064 0.197 0.081 0.012  
223 286 63 F11R PLLP  23.8 97.8 74.6 3.614 2 0.1641 0.074 0.166 0.146  
82 146 64 GSTM3 GUCY1A1  28.6 95.7 74.6 5.786 2 0.0554 0.116 0.094 0.068  
30 35 65 GUCY1A1 HPRT1  33.3 93.5 74.6 9.761 2 0.0076 0.190 0.092 0.017  
142 208 66 GUCY1A1 PNP  19.0 100.0 74.6 4.808 2 0.0903 0.097 0.095 0.207  
30 97 67 GUCY1A1 POP5  23.8 97.8 74.6 7.260 2 0.0265 0.144 0.049 0.051  
1 67 68 HPRT1 PVT1  28.6 95.7 74.6 8.446 2 0.0147 0.166 0.045 0.210  
29 40 69 HPRT1 TRAFD1  23.8 97.8 74.6 9.495 2 0.0087 0.186 0.034 0.172  
148 218 70 ITGA2 PLLP  23.8 97.8 74.6 4.635 2 0.0985 0.094 0.097 0.109  
47 24 71 PCDH18 PLAU  28.6 95.7 74.6 10.379 2 0.0056 0.202 0.043 0.013  
50 122 72 PGC PTEN  33.3 93.5 74.6 6.451 2 0.0397 0.129 0.133 0.082  
106 179 73 PLLP POP5  23.8 97.8 74.6 5.219 2 0.0736 0.105 0.136 0.072  
172 246 74 PLLP TRAFD1  23.8 97.8 74.6 4.355 2 0.1133 0.088 0.250 0.141  
175 250 75 POP5 PTGFR  19.0 100.0 74.6 4.281 2 0.1176 0.087 0.071 0.246  
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 Addition of Gleason score to the two-gene models 
The effect of adding the GS to each two-gene model is shown in Table 2.24 (here 
χ2 describes the difference in -2LL between the two-gene model and the final model 
including two genes and the GS).  
Table 2.24 The χ2 values showing the effect of adding Gleason score to each two-gene model 
Gene(s) χ2 
df sig. 1 2 3 diff from gene 1+2 
AMACR SDHA GS 1.703 1 0.192 
HPRT1 PLAU GS 0.621 1 0.431 
AMACR HPRT1 GS 1.282 1 0.258 
HPRT1 SDHA GS 0.737 1 0.391 
ANXA2 HPRT1 GS 2.098 1 0.148 
AMACR ATP10B GS 0.915 1 0.339 
AMACR DPT GS 2.806 1 0.094 
AMACR TRAFD1 GS 1.191 1 0.275 
ABL1 AMACR GS 2.258 1 0.133 
AMACR PVT1 GS 1.098 1 0.295 
AMACR EFNA5 GS 0.667 1 0.414 
AMACR GSTM3 GS 2.230 1 0.135 
AMACR POP5 GS 2.293 1 0.130 
AMACR CDH1 GS 1.773 1 0.183 
HPRT1 POP5 GS 1.383 1 0.240 
EFNA5 SDHA GS 0.247 1 0.619 
AMACR ITGB1 GS 2.061 1 0.151 
CD109 HPRT1 GS 1.417 1 0.234 
AMACR FABP5 GS 1.275 1 0.259 
PTEN SDHA GS 0.401 1 0.527 
AMACR SERPINB5 GS 1.940 1 0.164 
AMACR PTEN GS 0.942 1 0.332 
PCDH18 SDHA GS 0.291 1 0.590 
PCDH18 PLAU GS 0.144 1 0.704 
PGC SDHA GS 0.823 1 0.364 
ATP10B HPRT1 GS 0.302 1 0.583 
PLAU PTEN GS 0.325 1 0.569 
PGC PLAU GS 0.693 1 0.405 
C3 HPRT1 GS 0.737 1 0.391 
AMACR ANXA2 GS 2.300 1 0.129 
AMACR PNP GS 1.625 1 0.202 
NDUFAF1 PLAU GS 0.505 1 0.477 
AMACR ATP5MPL GS 2.153 1 0.142 
GUCY1A1 HPRT1 GS 0.898 1 0.343 
ABL1 PTEN GS 0.796 1 0.372 
AMACR PLLP GS 1.328 1 0.249 
AMACR C3 GS 1.695 1 0.193 
AMACR CD109 GS 2.275 1 0.132 
HPRT1 TRAFD1 GS 0.465 1 0.495 
ATP5MPL HPRT1 GS 1.429 1 0.232 
DPT HPRT1 GS 1.625 1 0.202 
AMACR TBRG4 GS 2.102 1 0.147 
GSTM3 HPRT1 GS 1.714 1 0.191 
PLAU PLLP GS 0.551 1 0.458 
CHM HPRT1 GS 1.283 1 0.257 
HPRT1 PGC GS 0.852 1 0.356 
HPRT1 NELL2 GS 1.116 1 0.291 
AMACR ITGA2 GS 1.646 1 0.200 
AMACR PCDH18 GS 1.232 1 0.267 
ABL1 GUCY1A1 GS 1.903 1 0.168 
CDH1 PGC GS 1.399 1 0.237 
ABL1 HPRT1 GS 1.036 1 0.309 
AMACR EFNA1 GS 1.804 1 0.179 
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GUCY1A1 TRAFD1 GS 0.822 1 0.365 
AMACR NELL2 GS 1.803 1 0.179 
POP5 PTEN GS 0.963 1 0.326 
EFNA1 HPRT1 GS 0.944 1 0.331 
CDH1 HPRT1 GS 1.151 1 0.283 
CDH1 GUCY1A1 GS 1.622 1 0.203 
PNP SDHA GS 1.025 1 0.311 
AMACR NDUFAF1 GS 1.330 1 0.249 
AMACR CHM GS 2.187 1 0.139 
GUCY1A1 PLAU GS 0.834 1 0.361 
HPRT1 PVT1 GS 0.539 1 0.463 
HPRT1 ITGB1 GS 0.989 1 0.320 
AMACR ANPEP GS 1.799 1 0.180 
ATP10B PTEN GS 0.090 1 0.764 
PLAU SERPINB5 GS 0.985 1 0.321 
AMACR IRF7 GS 1.483 1 0.223 
CD109 PTEN GS 0.994 1 0.319 
FABP5 HPRT1 GS 0.739 1 0.390 
PLAU PVT1 GS 0.537 1 0.464 
GUCY1A1 PVT1 GS 0.575 1 0.448 
ABL1 PGC GS 1.425 1 0.233 
 
The low significance for the χ2 values showed that the addition of GS as a predictor 
variable provided no significant improvement to the fit of the two-gene models. 
 ROC curves of the two-gene models 
The ROC curves for the top 5 two-gene models (according to χ2) are shown in Figure 
2.24, with the full list of AUC values in Table 2.25. 
 
Figure 2.24 ROC curves for the best two-gene models 
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Table 2.25 AUC values for the two-gene models 
AUC 
Rank Gene models ordered by χ2 AUC 
AMACR SDHA 0.784 5 
HPRT1 PLAU 0.808 1 
AMACR HPRT1 0.769 7 
HPRT1 SDHA 0.757 12 
ANXA2 HPRT1 0.788 3 
AMACR ATP10B 0.744 20 
AMACR DPT 0.755 13 
AMACR TRAFD1 0.738 25 
ABL1 AMACR 0.744 21 
AMACR PVT1 0.706 50 
AMACR EFNA5 0.723 35 
AMACR GSTM3 0.747 18 
AMACR POP5 0.709 45 
AMACR CDH1 0.727 32 
HPRT1 POP5 0.764 8 
EFNA5 SDHA 0.700 56 
AMACR ITGB1 0.726 33 
CD109 HPRT1 0.764 9 
AMACR FABP5 0.722 37 
PTEN SDHA 0.706 51 
AMACR SERPINB5 0.732 28 
AMACR PTEN 0.713 43 
PCDH18 SDHA 0.748 17 
PCDH18 PLAU 0.704 53 
PGC SDHA 0.749 15 
ATP10B HPRT1 0.749 16 
PLAU PTEN 0.735 26 
PGC PLAU 0.726 34 
C3 HPRT1 0.793 2 
AMACR ANXA2 0.695 63 
F11R HPRT1 0.778 6 
AMACR PNP 0.707 49 
NDUFAF1 PLAU 0.718 38 
AMACR ATP5MPL 0.692 67 
GUCY1A1 HPRT1 0.710 44 
ABL1 PTEN 0.732 29 
AMACR PLLP 0.705 52 
AMACR C3 0.708 46 
AMACR CD109 0.699 57 
HPRT1 TRAFD1 0.741 23 
ATP5MPL HPRT1 0.755 14 
DPT HPRT1 0.745 19 
AMACR TBRG4 0.697 60 
GSTM3 HPRT1 0.730 31 
PLAU PLLP 0.708 47 
CHM HPRT1 0.788 4 
HPRT1 PGC 0.741 24 
HPRT1 NELL2 0.734 27 
AMACR ITGA2 0.704 54 
AMACR PCDH18 0.674 75 
ABL1 GUCY1A1 0.716 41 
CDH1 PGC 0.723 36 
ABL1 HPRT1 0.744 22 
AMACR EFNA1 0.660 79 
GUCY1A1 TRAFD1 0.704 55 
AMACR NELL2 0.692 68 
POP5 PTEN 0.697 61 
EFNA1 HPRT1 0.731 30 
CDH1 HPRT1 0.761 10 
CDH1 GUCY1A1 0.685 71 
PNP SDHA 0.671 78 
AMACR ITGB6b 0.695 64 
AMACR NDUFAF1 0.697 62 
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AMACR CHM 0.674 76 
AMACR F11R 0.674 77 
GUCY1A1 PLAU 0.685 72 
HPRT1 PVT1 0.716 42 
HPRT1 ITGB1 0.759 11 
AMACR ANPEP 0.699 58 
ATP10B PTEN 0.717 40 
PLAU SERPINB5 0.689 69 
AMACR GSTM5 0.699 59 
AMACR IRF7 0.693 66 
CD109 PTEN 0.708 48 
FABP5 HPRT1 0.718 39 
GSTM5 SDHA 0.682 74 
PLAU PVT1 0.695 65 
GUCY1A1 PVT1 0.683 73 
ABL1 PGC 0.688 70 
 
The ROC plots for the two-gene models showed a greater coverage of the left-hand 
portion of the plot than was found for the single gene models as reflected by higher AUC 
values (higher discriminatory accuracy). More than 70% of the two-gene models had 
AUC values >0.7. The top 5 models according to the χ2 had AUC values of 
AMACR.SDHA(0.784), HPRT1.PLAU(0.808), AMACR.HPRT1(0.769), HPRT1.SDHA(0.757) 
and ANXA2.HPRT1(0.788). 
The threshold at which J is highest is shown for the top 5 two-gene models (Table 2.26). 
For HPRT1.PLAU, an alternative threshold is given below the value for the highest J, as 
this threshold provided a better balance of sensitivity and specificity. At the threshold 
of 0.245 (at which J is highest), HPRT1.PLAU showed a sensitivity and specificity of 91% 
and 63% respectively. However, a better balance of sensitivity and specificity of 71% and 
76% respectively could be achieved using a threshold of 0.335. 
Table 2.26 Optimal thresholds for the top two-gene models 
Two-gene model Cut-off value Sensitivity Specificity 
AMACR SDHA 0.316 0.714 0.783 
HPRT1 PLAU 0.245 0.905 0.630 
HPRT1 PLAU 0.335 0.714 0.761 
AMACR HPRT1 0.371 0.619 0.848 
HPRT1 SDHA 0.402 0.524 0.935 
ANXA2 HPRT1 0.284 0.810 0.739 
 
 Three-gene models ranked by χ2 
The parameters from the LR output for the three gene-models (ranked by χ2) are shown 
in Table 2.27.  
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Table 2.27 Output parameters from the logistic regression analysis of the top three-gene models (listed in descending order of χ2)  
Gene(s) 
-2LL χ2 df sig. 
Nagelkerke 
R2 
Wald Significance Percent Accuracy (%) 
1 2 3 1 2 3 Recurrent 
Non-
recurrent Overall 
Null Model   83.324          68.7 
AMACR EFNA5 SDHA 60.841 22.483 3 0.0001 0.401 0.002 0.039 0.004 61.9 89.1 80.6 
AMACR HPRT1 SDHA 61.059 22.265 3 0.0001 0.397 0.005 0.049 0.008 52.4 91.3 79.1 
AMACR PNP SDHA 63.162 20.162 3 0.0002 0.365 0.002 0.156 0.007 42.9 91.3 76.1 
AMACR PCDH18 SDHA 63.182 20.142 3 0.0002 0.365 0.004 0.080 0.005 57.1 93.5 82.1 
AMACR SDHA SERPINB5 63.381 19.943 3 0.0002 0.362 0.002 0.007 0.082 57.1 89.1 79.1 
AMACR PTEN SDHA 63.461 19.863 3 0.0002 0.361 0.005 0.084 0.008 47.6 93.5 79.1 
AMACR GSTM5 SDHA 64.196 19.128 3 0.0003 0.349 0.002 0.121 0.004 52.4 89.1 77.6 
AMACR PLLP SDHA 64.806 18.518 3 0.0003 0.339 0.003 0.186 0.009 47.6 91.3 77.6 
HPRT1 PGC PLAU 65.015 18.309 3 0.0004 0.336 0.019 0.066 0.007 42.9 89.1 74.6 
AMACR HPRT1 POP5 65.046 18.278 3 0.0004 0.335 0.012 0.028 0.039 52.4 93.5 80.6 
GUCY1A1 HPRT1 PLAU 65.137 18.187 3 0.0004 0.334 0.077 0.010 0.010 38.1 95.7 77.6 
AMACR ATP10B HPRT1 65.174 18.150 3 0.0004 0.333 0.009 0.032 0.045 47.6 93.5 79.1 
HPRT1 PLAU PTGFR 65.208 18.116 3 0.0004 0.333 0.008 0.005 0.069 47.6 93.5 79.1 
AMACR ITGB6b SDHA 65.257 18.067 3 0.0004 0.332 0.002 0.246 0.008 47.6 89.1 76.1 
AMACR ANXA2 HPRT1 65.350 17.974 3 0.0004 0.331 0.031 0.037 0.016 47.6 93.5 79.1 
AMACR HPRT1 TRAFD1 65.761 17.563 3 0.0005 0.324 0.007 0.052 0.114 57.1 95.7 83.6 
AMACR ATP10B EFNA5 65.903 17.420 3 0.0006 0.322 0.003 0.020 0.051 47.6 91.3 77.6 
AMACR IRF7 SDHA 66.150 17.174 3 0.0007 0.318 0.004 0.505 0.009 47.6 91.3 77.6 
AMACR DPT HPRT1 66.265 17.059 3 0.0007 0.316 0.009 0.061 0.059 42.9 91.3 76.1 
AMACR GSTM3 HPRT1 66.300 17.024 3 0.0007 0.315 0.009 0.059 0.043 38.1 91.3 74.6 
AMACR ATP5MPL HPRT1 66.356 16.968 3 0.0007 0.314 0.009 0.069 0.027 47.6 91.3 77.6 
AMACR DPT PVT1 66.359 16.965 3 0.0007 0.314 0.004 0.027 0.048 47.6 89.1 76.1 
129 
 
These 22 models had been selected for inclusion into the results section as these were 
the only three-gene models which provided a significant improvement (lower -2LL) over 
the best performing two-gene model AMACR.SDHA. The χ2 values for the listed three-
gene models were higher than the values obtained for any of the listed two-gene 
models.  
The models with the best overall fit were AMACR.EFNA5.SDHA (χ2(3) = 22.5, p<0.0001) 
and AMACR.HPRT1.SDHA (χ2(3) = 22.3, p<0.0001). Both predictive models contained 
only predictor variables which each made a significant contribution to the predictive 
model as shown by the significance of the Wald statistic (p<0.05). 
The Naglekerke R2 of AMACR.EFNA5.SDHA and AMACR.HPRT1.SDHA were 0.401 and 
0.397 respectively, suggesting that approximately 40% of the variability in recurrence 
could be explained by either of these models. This was higher than the values for the 
two-gene models nested within these models. For instance, the Nagelkerke R2 was only 
0.310, 0.220 and 0.212 for AMACR.SDHA, AMACR.EFNA5 and EFNA5.SDHA respectively.  
Approximately a third of the three-gene models contained genes, which each made 
a significant contribution to the model (p<0.05 for the Wald significance). The remainder 
of the models contained one gene that did not make a significant contribution to the 
model, e.g. AMACR.IRF7.SDHA contained the variable IRF7 (Wald significance of p>0.5) 
which failed to make any significant contribution to the performance of the simpler 
model AMACR.SDHA. Although the significance for the Wald statistic gives a good 
estimation of the contribution of each gene to the model, the LRT is a more accurate 
measure of performance in logistic regression. Therefore, in Section 2.3.9 the LRT was 
used to assess the contribution of each variable in the two- and three-gene models by 
comparing the overall fit between the restricted model (model without the additional 
variable) and the complex model (model with the additional variable). 
The variables in the LR equations for the three-gene models are listed in Table 2.28. 
For the highest model AMACR.EFNA5.SDHA, the odds ratios were 0.497, 0.546 and 9.772 
for the variables AMACR, EFNA5 and SDHA. Therefore, the odds of a patient being in the 
recurrent group were multiplied by approximately 10 for a one-unit increase in SDHA 
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expression. Conversely, the odds of the patient being in the recurrent group were 
approximately halved for a one-unit increase in AMACR or EFNA5 expression.    
 Three-gene models by overall percent accuracy 
The three-gene models ranked by overall percent accuracy are listed in Table 2.29. 
The order of the three-gene models according to the overall percent accuracy was very 
different to the order by χ2 as was found for the two-gene models. For instance, the 
model AMACR.GUCY1A1.PLLP was ranked at number 5 according to overall percent 
accuracy but was ranked at number 421 according to the χ2. This model contained the 
variable PLLP, which had a high p-value for the Wald significance (p>0.25). Conversely 
the second highest three-gene model according to χ2 (AMACR.HPRT1.SDHA) was ranked 
at number 54 according to the overall percent accuracy. This gene model contained only 
highly significant variables (p<0.05). 
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Table 2.28 Variables in the equation for the three-gene models 
Model Predictor β coefficient Standard Error Odds ratio (95%CI) p-value 
1 AMACR -0.699 0.224 0.497 (0.320-0.771) 0.002  
EFNA5 -0.606 0.294 0.546 (0.307-0.971) 0.039  
SDHA 2.279 0.793 9.772 (2.064-46.262) 0.004 
2 AMACR -0.630 0.223 0.532 (0.344-0.825) 0.005  
HPRT1 -0.578 0.293 0.561 (0.316-0.996) 0.049  
SDHA 2.014 0.754 7.493 (1.708-32.876) 0.008 
3 AMACR -0.698 0.225 0.497 (0.320-0.774) 0.002  
PNP -0.792 0.558 0.453 (0.152-1.352) 0.156  
SDHA 2.135 0.793 8.457 (1.787-40.022) 0.007 
4 AMACR -0.646 0.226 0.524 (0.337-0.816) 0.004  
PCDH18 -0.776 0.443 0.460 (0.193-1.097) 0.080  
SDHA 2.566 0.921 13.019 (2.139-79.237) 0.005 
5 AMACR -0.767 0.242 0.464 (0.289-0.746) 0.002  
SDHA 1.943 0.721 6.982 (1.698-28.709) 0.007  
SERPINB5 -0.205 0.118 0.814 (0.646-1.027) 0.082 
6 AMACR -0.631 0.226 0.532 (0.342-0.828) 0.005  
PTEN -0.314 0.181 0.731 (0.512-1.043) 0.084  
SDHA 1.993 0.750 7.334 (1.687-31.881) 0.008 
7 AMACR -0.683 0.226 0.505 (0.324-0.786) 0.002  
GSTM5 -0.217 0.140 0.805 (0.612-1.059) 0.121  
SDHA 2.219 0.780 9.201 (1.996-42.422) 0.004 
8 AMACR -0.675 0.225 0.509 (0.327-0.792) 0.003  
PLLP -0.241 0.182 0.786 (0.551-1.123) 0.186  
SDHA 1.970 0.752 7.169 (1.642-31.297) 0.009 
9 HPRT1 -0.683 0.291 0.505 (0.285-0.894) 0.019  
PGC -0.266 0.145 0.766 (0.577-1.018) 0.066  
PLAU 1.208 0.451 3.347 (1.382-8.102) 0.007 
10 AMACR -0.528 0.209 0.590 (0.392-0.889) 0.012  
HPRT1 -0.630 0.287 0.533 (0.303-0.935) 0.028  
POP5 1.571 0.761 4.813 (1.083-21.389) 0.039 
11 GUCY1A1 -0.924 0.522 0.397 (0.143-1.105) 0.077  
HPRT1 -0.767 0.299 0.464 (0.258-0.835) 0.010  
PLAU 1.160 0.451 3.190 (1.317-7.728) 0.010 
12 AMACR -0.561 0.214 0.571 (0.375-0.868) 0.009  
ATP10B 0.263 0.123 1.301 (1.023-1.654) 0.032  
HPRT1 -0.510 0.254 0.601 (0.365-0.989) 0.045 
13 HPRT1 -0.865 0.328 0.421 (0.221-0.800) 0.008  
PLAU 1.375 0.494 3.957 (1.502-10.422) 0.005  
PTGFR -0.291 0.160 0.747 (0.546-1.023) 0.069 
14 AMACR -0.677 0.224 0.508 (0.328-0.788) 0.002  
ITGB6b -0.175 0.151 0.839 (0.624-1.129) 0.246  
SDHA 1.964 0.738 7.126 (1.677-30.285) 0.008 
15 AMACR -0.454 0.211 0.635 (0.420-0.960) 0.031  
ANXA2 0.759 0.364 2.135 (1.046-4.361) 0.037  
HPRT1 -0.644 0.266 0.525 (0.312-0.886) 0.016 
16 AMACR -0.562 0.210 0.570 (0.378-0.860) 0.007  
HPRT1 -0.608 0.313 0.545 (0.295-1.005) 0.052  
TRAFD1 0.828 0.523 2.288 (0.821-6.376) 0.114 
17 AMACR -0.636 0.218 0.529 (0.346-0.811) 0.003  
ATP10B 0.298 0.128 1.347 (1.048-1.730) 0.020  
EFNA5 -0.486 0.249 0.615 (0.378-1.001) 0.051 
18 AMACR -0.644 0.221 0.525 (0.341-0.809) 0.004  
IRF7 -0.140 0.210 0.869 (0.575-1.313) 0.505  
SDHA 1.922 0.734 6.838 (1.621-28.847) 0.009 
19 AMACR -0.553 0.212 0.575 (0.380-0.871) 0.009  
DPT 0.441 0.235 1.555 (0.980-2.466) 0.061  
HPRT1 -0.523 0.277 0.593 (0.344-1.020) 0.059 
20 AMACR -0.558 0.214 0.572 (0.376-0.871) 0.009  
GSTM3 0.796 0.422 2.218 (0.970 5.072) 0.059  
HPRT1 -0.558 0.276 0.572 (0.333-0.982) 0.043 
21 AMACR -0.544 0.210 0.581 (0.385-0.876) 0.009  
ATP5MPL 1.170 0.643 3.221 (0.913-11.360) 0.069  
HPRT1 -0.629 0.284 0.533 (0.306-0.930) 0.027 
22 AMACR -0.608 0.210 0.545 (0.361-0.822) 0.004  
DPT 0.537 0.243 1.710 (1.061-2.756) 0.027  
PVT1 0.995 0.503 2.706 (1.009-7.256) 0.048 
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Table 2.29 Three-gene models ranked in descending order of the overall percent accuracy 
              
Rank 
change 
Rank 
(-2LL) 
 Rank 
(%) 
Gene(s) Percent Accuracy (%)  
χ2 df sig. 
Nagelkerke  
R2 
Wald Significance 
1 2 3 Recurrent 
Non- 
Recurrent Overall 1 2 3 
   Null Model             
25 26 1 AMACR C3 HPRT1 95.7 57.1 83.6 16.527 3 0.0009 0.307 0.016 0.077 0.025 
14 16 2 AMACR HPRT1 TRAFD1 95.7 57.1 83.6 17.563 3 0.0005 0.324 0.007 0.052 0.114 
118 121 3 AMACR PCDH18 POP5 97.8 52.4 83.6 13.506 3 0.0037 0.257 0.011 0.167 0.055 
94 98 4 ABL1 AMACR PLLP 95.7 52.4 82.1 13.845 3 0.0031 0.262 0.046 0.007 0.183 
416 421 5 ABL1 GUCY1A1 PLLP 95.7 52.4 82.1 10.200 3 0.0169 0.198 0.022 0.041 0.279 
31 37 6 ABL1 GUCY1A1 PTEN 95.7 52.4 82.1 15.924 3 0.0012 0.297 0.008 0.021 0.013 
17 24 7 AMACR EFNA5 POP5 93.5 57.1 82.1 16.565 3 0.0009 0.308 0.004 0.037 0.038 
47 55 8 AMACR HPRT1 PVT1 95.7 52.4 82.1 15.180 3 0.0017 0.285 0.013 0.077 0.185 
5 4 9 AMACR PCDH18 SDHA 93.5 57.1 82.1 20.142 3 0.0002 0.365 0.004 0.080 0.005 
84 94 10 AMACR PVT1 TRAFD1 95.7 52.4 82.1 13.890 3 0.0031 0.263 0.005 0.206 0.207 
73 84 11 ABL1 AMACR PCDH18 95.7 47.6 80.6 14.122 3 0.0027 0.267 0.037 0.016 0.179 
101 113 12 ABL1 GUCY1A1 HPRT1 97.8 42.9 80.6 13.621 3 0.0035 0.258 0.066 0.042 0.052 
207 220 13 AMACR ANPEP TRAFD1 95.7 47.6 80.6 12.121 3 0.0070 0.233 0.006 0.861 0.115 
36 50 14 AMACR CHM HPRT1 93.5 52.4 80.6 15.441 3 0.0015 0.289 0.017 0.176 0.024 
54 69 15 AMACR EFNA1 HPRT1 93.5 52.4 80.6 14.468 3 0.0023 0.273 0.022 0.270 0.035 
42 58 16 AMACR EFNA5 PVT1 91.3 57.1 80.6 15.015 3 0.0018 0.282 0.006 0.075 0.084 
16 1 17 AMACR EFNA5 SDHA 89.1 61.9 80.6 22.483 3 0.0001 0.401 0.002 0.039 0.004 
12 30 18 AMACR EFNA5 TRAFD1 91.3 57.1 80.6 16.265 3 0.0010 0.303 0.003 0.062 0.093 
333 352 19 AMACR F11R PLLP 93.5 52.4 80.6 10.787 3 0.0129 0.209 0.011 0.274 0.144 
22 42 20 AMACR GSTM3 PVT1 93.5 52.4 80.6 15.793 3 0.0013 0.295 0.004 0.045 0.057 
124 145 21 AMACR GSTM5 TRAFD1 93.5 52.4 80.6 13.132 3 0.0044 0.250 0.005 0.307 0.085 
12 10 22 AMACR HPRT1 POP5 93.5 52.4 80.6 18.278 3 0.0004 0.335 0.012 0.028 0.039 
193 216 23 AMACR IRF7 TRAFD1 95.7 47.6 80.6 12.201 3 0.0067 0.234 0.005 0.739 0.108 
91 115 24 AMACR PNP PVT1 93.5 52.4 80.6 13.584 3 0.0035 0.258 0.006 0.206 0.085 
153 178 25 AMACR PLLP PVT1 95.7 47.6 80.6 12.650 3 0.0055 0.242 0.007 0.273 0.107 
90 116 26 CD109 HPRT1 PGC 95.7 47.6 80.6 13.580 3 0.0035 0.258 0.049 0.019 0.109 
47 74 27 EFNA5 PTEN SDHA 95.7 47.6 80.6 14.271 3 0.0026 0.270 0.078 0.071 0.012 
313 341 28 GSTM3 GUCY1A1 PTEN 97.8 42.9 80.6 10.888 3 0.0123 0.211 0.071 0.053 0.031 
504 533 29 NELL2 PGC PTEN 97.8 42.9 80.6 9.334 3 0.0252 0.183 0.105 0.067 0.066 
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 ROC curves of the three-gene models 
The ROC curves for the top 5 three-gene models (excluding those with non-significant 
variables, see Section 2.3.9) are shown in Figure 2.25 and the AUC values for the three-
gene models are shown in Table 2.30. 
 
Figure 2.25 ROC curves for the best three-gene models 
Table 2.30 AUC values for the three-gene models 
Gene models ordered by χ2  AUC 
AUC 
Rank 
AMACR EFNA5 SDHA 0.812 7 
AMACR HPRT1 SDHA 0.829 1 
AMACR PNP SDHA 0.802 16 
AMACR PCDH18 SDHA 0.804 12 
AMACR SDHA SERPINB5 0.816 5 
AMACR PTEN SDHA 0.803 14 
AMACR GSTM5 SDHA 0.788 20 
AMACR PLLP SDHA 0.792 17 
HPRT1 PGC PLAU 0.819 3 
AMACR HPRT1 POP5 0.808 10 
GUCY1A1 HPRT1 PLAU 0.813 6 
AMACR ATP10B HPRT1 0.807 11 
HPRT1 PLAU PTGFR 0.821 2 
AMACR ITGB6b SDHA 0.803 15 
AMACR ANXA2 HPRT1 0.818 4 
AMACR HPRT1 TRAFD1 0.811 8 
AMACR ATP10B EFNA5 0.775 21 
AMACR IRF7 SDHA 0.791 18 
AMACR DPT HPRT1 0.810 9 
AMACR GSTM3 HPRT1 0.804 13 
AMACR ATP5MPL HPRT1 0.791 19 
AMACR DPT PVT1 0.772 22 
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The ROC plots for the three-gene models covered a greater portion of the left-hand 
corner of the plot than the two-gene models, which was reflected in AUC values of 
>0.770 for every model, with over 70% of the three-gene models showing AUC values 
>0.8. The gene model AMACR.HPRT1.SDHA showed the highest value of 0.829.  
The optimal cut-off values for the top 5 three-gene models are shown in Table 2.31.  
Table 2.31 Optimal thresholds for the top three-gene models 
Three-Gene model Cut-off value Sensitivity Specificity 
AMACR EFNA5 SDHA 0.219 0.810 0.739 
AMACR HPRT1 SDHA 0.312 0.810 0.870 
AMACR HPRT1 POP5 0.340 0.714 0.870 
AMACR ATP10B HPRT1 0.353 0.619 0.848 
AMACR ATP10B HPRT1 0.308 0.714 0.739 
AMACR ANXA2 HPRT1 0.288 0.810 0.804 
 
The top three-gene models provided relatively high values for both sensitivity and 
specificity. For example, using a threshold of 0.312, a sensitivity and specificity of 81% 
and 87% respectively could be achieved using the gene model AMACR.HPRT1.SDHA.   
 Comparison of single, two-gene and three-gene models 
The primary use of the LRT statistic (χ2) was to compare the overall fit of each model 
with the null model. These values were used as a method to rank the single, two- and 
three-gene models. As the LRT can be used to compare any two nested models, a 
secondary use in this study was to compare the fit of each two-gene model with each of 
its nested single gene models; and to compare the three-gene models with their nested 
two-gene models. This was essential to evaluate the significance of the improvement in 
fit attained by the addition of another gene to a model. This could provide evidence as 
to whether its addition, which makes a relatively more complex model, can be justified.  
The χ2 values presented in Table 2.32 show the difference in the overall fit of each two-
gene model with the fit of each of its nested single gene models. This value was 
calculated as the -2LL (single gene model) minus the -2LL (two-gene model).  
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Table 2.32  χ2 values between the two-gene models and their nested single gene models 
Gene(s) χ2 χ2 
1 2 3 
diff. from 
gene 1 df sig. 
diff. from 
gene 2 df sig. 
AMACR SDHA  8.962 1 0.003 10.486 1 0.001 
HPRT1 PLAU  8.048 1 0.005 9.288 1 0.002 
AMACR HPRT1  5.423 1 0.020 6.454 1 0.011 
HPRT1 SDHA  6.244 1 0.013 6.737 1 0.009 
ANXA2 HPRT1  9.618 1 0.002 6.240 1 0.013 
AMACR ATP10B  5.187 1 0.023 9.234 1 0.002 
AMACR DPT  4.335 1 0.037 9.252 1 0.002 
AMACR TRAFD1  4.331 1 0.037 9.080 1 0.003 
ABL1 AMACR  8.021 1 0.005 4.263 1 0.039 
AMACR PVT1  3.681 1 0.055 7.997 1 0.005 
AMACR EFNA5  3.632 1 0.057 8.303 1 0.004 
AMACR GSTM3  3.589 1 0.058 9.153 1 0.003 
AMACR POP5  3.581 1 0.058 8.391 1 0.004 
AMACR CDH1  3.354 1 0.067 7.162 1 0.008 
HPRT1 POP5  4.380 1 0.036 8.159 1 0.004 
EFNA5 SDHA  7.875 1 0.005 4.728 1 0.030 
AMACR ITGB1  3.169 1 0.075 8.414 1 0.004 
CD109 HPRT1  8.436 1 0.004 4.198 1 0.041 
AMACR FABP5  2.918 1 0.088 9.449 1 0.002 
PTEN SDHA  6.485 1 0.011 4.409 1 0.036 
AMACR SERPINB5  2.818 1 0.093 9.500 1 0.002 
AMACR PTEN  2.763 1 0.097 6.363 1 0.012 
PCDH18 SDHA  7.761 1 0.005 4.224 1 0.040 
PCDH18 PLAU  7.680 1 0.006 4.890 1 0.027 
PGC SDHA  7.071 1 0.008 4.134 1 0.042 
ATP10B HPRT1  6.590 1 0.010 3.574 1 0.059 
PLAU PTEN  4.751 1 0.029 6.080 1 0.014 
PGC PLAU  6.919 1 0.009 4.729 1 0.030 
C3 HPRT1  8.481 1 0.004 3.429 1 0.064 
AMACR ANXA2  2.370 1 0.124 6.779 1 0.009 
F11R HPRT1  8.641 1 0.003 3.368 1 0.067 
AMACR PNP  2.289 1 0.130 8.173 1 0.004 
NDUFAF1 PLAU  7.947 1 0.005 4.415 1 0.036 
AMACR ATP5MPL  2.102 1 0.147 8.711 1 0.003 
GUCY1A1 HPRT1  6.942 1 0.008 3.032 1 0.082 
ABL1 PTEN  5.679 1 0.017 5.521 1 0.019 
AMACR PLLP  1.800 1 0.180 7.946 1 0.005 
AMACR C3  1.777 1 0.183 7.860 1 0.005 
AMACR CD109  1.754 1 0.185 7.023 1 0.008 
HPRT1 TRAFD1  2.766 1 0.096 6.484 1 0.011 
ATP5MPL HPRT1  8.234 1 0.004 2.656 1 0.103 
DPT HPRT1  6.534 1 0.011 2.648 1 0.104 
AMACR TBRG4  1.616 1 0.204 8.512 1 0.004 
GSTM3 HPRT1  7.137 1 0.008 2.604 1 0.107 
PLAU PLLP  3.753 1 0.053 7.628 1 0.006 
CHM HPRT1  8.206 1 0.004 2.490 1 0.115 
HPRT1 PGC  2.426 1 0.119 5.856 1 0.016 
HPRT1 NELL2  2.294 1 0.130 7.856 1 0.005 
AMACR ITGA2  1.257 1 0.262 6.956 1 0.008 
AMACR PCDH18  1.253 1 0.263 6.314 1 0.012 
ABL1 GUCY1A1  5.010 1 0.025 6.193 1 0.013 
CDH1 PGC  5.055 1 0.025 5.708 1 0.017 
ABL1 HPRT1  4.980 1 0.026 2.253 1 0.133 
AMACR EFNA1  1.200 1 0.273 6.929 1 0.009 
GUCY1A1 TRAFD1  6.125 1 0.013 5.933 1 0.015 
AMACR NELL2  1.152 1 0.283 7.745 1 0.005 
POP5 PTEN  5.883 1 0.015 4.673 1 0.031 
EFNA1 HPRT1  6.754 1 0.009 2.056 1 0.152 
CDH1 HPRT1  4.823 1 0.028 2.046 1 0.153 
CDH1 GUCY1A1  4.769 1 0.029 5.902 1 0.015 
PNP SDHA  6.824 1 0.009 2.464 1 0.117 
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AMACR ITGB6b  0.937 1 0.333 8.076 1 0.005 
AMACR NDUFAF1  0.821 1 0.365 6.624 1 0.010 
AMACR CHM  0.818 1 0.366 7.565 1 0.006 
AMACR F11R  0.813 1 0.367 7.117 1 0.008 
GUCY1A1 PLAU  5.740 1 0.017 3.070 1 0.080 
HPRT1 PVT1  1.717 1 0.190 5.002 1 0.025 
HPRT1 ITGB1  1.712 1 0.191 5.926 1 0.015 
AMACR ANPEP  0.606 1 0.436 6.689 1 0.010 
ATP10B PTEN  4.596 1 0.032 4.149 1 0.042 
PLAU SERPINB5  2.785 1 0.095 7.196 1 0.007 
AMACR GSTM5  0.472 1 0.492 7.627 1 0.006 
AMACR IRF7  0.471 1 0.493 7.395 1 0.007 
CD109 PTEN  5.629 1 0.018 3.960 1 0.047 
FABP5 HPRT1  6.873 1 0.009 1.373 1 0.241 
GSTM5 SDHA  7.492 1 0.006 1.861 1 0.173 
PLAU PVT1  2.438 1 0.118 4.483 1 0.034 
GUCY1A1 PVT1  5.033 1 0.025 4.408 1 0.036 
ABL1 PGC  3.847 1 0.050 4.550 1 0.033 
 
These χ2 values were positive for all the gene models demonstrating that the overall fit 
of the two-gene models was an improvement over their individual single gene models 
(reduction in -2LL with the addition of another gene). Each row in the table shows 
a different two-gene model; the column “difference from gene 1” shows the χ2 between 
a single gene model containing only the first gene and the two-gene model. The column 
“difference from gene 2” shows the χ2 between the single gene model containing only 
the second gene and the two-gene model. The df is 1 as one predictor variable (gene) 
was added to each single gene model. The significance for each χ2 value is included. 
The table is better described with an example such as AMACR.SDHA. The χ2 between 
AMACR and AMACR.SDHA was 8.962 with a high significance (p<0.005). This explained 
that a significant improvement to the fit of the single gene model AMACR was achieved 
by adding SDHA to form the two-gene model AMACR.SDHA. The χ2 between SDHA and 
AMACR.SDHA was slightly higher at 10.486 (p<0.005) verifying that the addition of 
AMACR to the single gene model SDHA led to a significant improvement in its fit. The 
effect of adding AMACR to SDHA was slightly higher than that achieved by adding SDHA 
to AMACR (as AMACR had a lower -2LL than SDHA as a single gene model). 
For the top 9 genes on the list of two-gene models, it was evident that the addition of 
each of the genes in the model led to a significant improvement on either of the single 
gene models. Therefore, these two-gene models are useful in combination. Further 
down the list there are two-gene models for which one of the genes is clearly not 
contributing to the model, e.g. AMACR.TBRG4. The addition of TBRG4 to AMACR 
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resulted in a χ2 of 1.616, which was not significant (p-value of 0.204). However, the 
addition of AMACR to TBRG4 was significant (p<0.005). This was not surprising due to 
the low -2LL of AMACR as a single gene model. As the fit under AMACR.TBRG4 was no 
better than under AMACR alone, the addition of TBRG4 would be worthless. 
The χ2 between each three-gene model and its nested two-gene models are presented 
in Table 2.33. For example, for AMACR.EFNA5.SDHA, the column “difference from gene 
2+3”, shows the difference in -2LL between EFNA5.SDHA and AMACR.EFNA5.SDHA; the 
column “difference from gene 1 + 3” shows the difference in -2LL between 
AMACR.SDHA and AMACR.EFNA5.SDHA and the column “difference from gene 1+2” 
shows the difference in -2LL between AMACR.EFNA5 and AMACR.EFNA5.SDHA. 
Table 2.33 χ2 values between the three-gene models and their nested two-gene models 
Gene(s) χ2 χ2 χ2 
1 2 3 
diff. from 
gene 2+3 df sig. 
diff. from 
gene 1+3 df sig. 
diff. from 
gene 1+2 df sig.  
AMACR EFNA5 SDHA 11.519 1 0.001 5.761 1 0.016 11.091 1 0.001 
AMACR HPRT1 SDHA 9.292 1 0.002 5.543 1 0.019 9.082 1 0.003 
AMACR PNP SDHA 11.462 1 0.001 3.44 1 0.064 10.113 1 0.002 
AMACR PCDH18 SDHA 9.682 1 0.002 3.42 1 0.064 11.129 1 0.001 
AMACR SDHA SERPINB5 12.735 1 0.000 9.365 1 0.002 3.221 1 0.073 
AMACR PTEN SDHA 9.218 1 0.002 3.141 1 0.076 9.34 1 0.002 
AMACR GSTM5 SDHA 11.031 1 0.001 2.406 1 0.121 10.896 1 0.001 
AMACR PLLP SDHA 10.805 1 0.001 1.796 1 0.180 8.958 1 0.003 
HPRT1 PGC PLAU 8.091 1 0.005 3.532 1 0.060 9.154 1 0.003 
AMACR HPRT1 POP5 7.169 1 0.007 6.937 1 0.008 5.095 1 0.024 
GUCY1A1 HPRT1 PLAU 3.410 1 0.065 9.628 1 0.002 8.426 1 0.004 
AMACR ATP10B HPRT1 7.847 1 0.005 4.967 1 0.026 5.203 1 0.023 
HPRT1 PLAU PTGFR 10.874 1 0.001 10.435 1 0.001 3.339 1 0.068 
AMACR ITGB6b SDHA 10.897 1 0.001 1.345 1 0.246 9.37 1 0.002 
AMACR ANXA2 HPRT1 5.005 1 0.025 4.791 1 0.029 7.844 1 0.005 
AMACR HPRT1 TRAFD1 8.068 1 0.005 5.472 1 0.019 4.38 1 0.036 
AMACR ATP10B EFNA5 10.045 1 0.002 6.029 1 0.014 4.474 1 0.034 
AMACR IRF7 SDHA 10.043 1 0.002 0.452 1 0.501 8.943 1 0.003 
AMACR DPT HPRT1 7.682 1 0.006 3.876 1 0.049 4.964 1 0.026 
AMACR GSTM3 HPRT1 7.691 1 0.006 3.841 1 0.050 5.675 1 0.017 
AMACR ATP5MPL HPRT1 7.583 1 0.006 3.785 1 0.052 7.106 1 0.008 
AMACR DPT PVT1 9.728 1 0.002 5.524 1 0.019 4.87 1 0.027 
 
The data in Table 2.33 show that the highest three-gene models AMACR.EFNA5.SDHA 
and AMACR.HPRT1.SDHA contain good combinations of genes. The addition of AMACR 
to EFNA5.SDHA resulted in a χ2 of 11.519 (p<0.001), the addition of EFNA5 to AMACR. 
SDHA resulted in a χ2 of 5.761 (p<0.05) and the addition of SDHA to AMACR.EFNA5 
resulted in a χ2 of 11.091 (p<0.001). However, realistically it is important to know the 
improvement that can be achieved from the best of the nested two-gene models. Here, 
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AMACR.SDHA had the lowest -2LL of the nested models, so the improvement attained 
by adding EFNA5 was more modest with a χ2 = 5.761 (p<0.05). However, the 
improvement was significant so the addition of EFNA5 to AMACR.SDHA may be justified. 
For some of the other three-gene models, although there was a reduction in the -2LL in 
the three-gene model in comparison to the nested two-gene model (positive value for 
χ2), the improvement in fit was not significant. For example, the addition of IRF7 to 
AMACR.SDHA provided virtually no improvement (p>0.5), therefore AMACR.IRF7.SDHA 
would not be considered an improvement over AMACR.SDHA.  
After eliminating any two- and three-gene models that contained one or more non-
significant predictors (p>0.05) according to this method, 28 two gene-models and 
9 three-gene models remained (Table 2.34 and Table 2.35). These models are the only 
two- and three-gene models listed which offer a significant improvement over their 
nested single and two-gene models respectively.  
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Table 2.34 Two-gene models with significant predictor variables 
Gene(s) 
-2LL χ2 df sig. 
Nagelkerke 
R2 
Wald Significance Percent Accuracy (%) 
1 2 3 1 2 3 Recurrent 
Non- 
recurrent Overall 
Null Model   83.324          68.7 
AMACR SDHA  66.602 16.722 2 0.0002 0.310 0.003 0.009  38.1 91.3 74.6 
HPRT1 PLAU  68.547 14.777 2 0.0006 0.278 0.015 0.011  42.9 93.5 77.6 
AMACR HPRT1  70.141 13.183 2 0.0014 0.251 0.015 0.038  42.9 95.7 79.1 
HPRT1 SDHA  70.351 12.973 2 0.0015 0.247 0.031 0.021  28.6 97.8 76.1 
ANXA2 HPRT1  70.355 12.969 2 0.0015 0.247 0.019 0.009  33.3 87.0 70.1 
AMACR ATP10B  70.377 12.947 2 0.0015 0.247 0.005 0.029  33.3 89.1 71.6 
AMACR DPT  71.229 12.094 2 0.0024 0.232 0.005 0.047  42.9 89.1 74.6 
AMACR TRAFD1  71.233 12.091 2 0.0024 0.232 0.005 0.089  47.6 95.7 80.6 
ABL1 AMACR  71.301 12.023 2 0.0025 0.231 0.047 0.008  42.9 95.7 79.1 
HPRT1 POP5  72.215 11.109 2 0.0039 0.215 0.020 0.055  23.8 95.7 73.1 
EFNA5 SDHA  72.360 10.964 2 0.0042 0.212 0.051 0.012  33.3 95.7 76.1 
CD109 HPRT1  72.397 10.927 2 0.0042 0.211 0.055 0.014  23.8 95.7 73.1 
PTEN SDHA  72.679 10.645 2 0.0049 0.206 0.039 0.018  33.3 89.1 71.6 
PCDH18 SDHA  72.864 10.460 2 0.0054 0.203 0.060 0.016  23.8 95.7 73.1 
PCDH18 PLAU  72.945 10.379 2 0.0056 0.202 0.043 0.013  28.6 95.7 74.6 
PGC SDHA  72.954 10.370 2 0.0056 0.201 0.047 0.013  23.8 89.1 68.7 
PLAU PTEN  73.084 10.240 2 0.0060 0.199 0.021 0.034  38.1 89.1 73.1 
PGC PLAU  73.106 10.218 2 0.0060 0.199 0.035 0.014  28.6 93.5 73.1 
NDUFAF1 PLAU  73.420 9.904 2 0.0071 0.193 0.041 0.010  33.3 91.3 73.1 
ABL1 PTEN  73.643 9.681 2 0.0079 0.189 0.024 0.022  28.6 91.3 71.6 
ABL1 GUCY1A1  74.312 9.012 2 0.0110 0.177 0.022 0.034  38.1 95.7 77.6 
CDH1 PGC  74.317 9.007 2 0.0111 0.177 0.026 0.031  23.8 93.5 71.6 
GUCY1A1 TRAFD1  74.380 8.943 2 0.0114 0.176 0.024 0.032  23.8 95.7 73.1 
POP5 PTEN  74.491 8.833 2 0.0121 0.174 0.047 0.021  28.6 91.3 71.6 
CDH1 GUCY1A1  74.603 8.721 2 0.0128 0.171 0.027 0.039  23.8 93.5 71.6 
ATP10B PTEN  75.015 8.309 2 0.0157 0.164 0.047 0.036  38.1 87.0 71.6 
CD109 PTEN  75.204 8.120 2 0.0172 0.160 0.059 0.025  23.8 93.5 71.6 
GUCY1A1 PVT1  75.472 7.852 2 0.0197 0.155 0.044 0.047  28.6 97.8 76.1 
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Table 2.35 Three-gene models with significant predictor variables 
Gene(s) 
-2LL χ2 df sig. 
Nagelkerke 
R2 
Wald Significance Percent Accuracy (%) 
1 2 3 1 2 3 Recurrent 
Non- 
recurrent Overall 
AMACR EFNA5 SDHA 60.841 22.483 3 0.0001 0.401 0.002 0.039 0.004 61.9 89.1 80.6 
AMACR HPRT1 SDHA 61.059 22.265 3 0.0001 0.397 0.005 0.049 0.008 52.4 91.3 79.1 
AMACR HPRT1 POP5 65.046 18.278 3 0.0004 0.335 0.012 0.028 0.039 52.4 93.5 80.6 
AMACR ATP10B HPRT1 65.174 18.150 3 0.0004 0.333 0.009 0.032 0.045 47.6 93.5 79.1 
AMACR ANXA2 HPRT1 65.350 17.974 3 0.0004 0.331 0.031 0.037 0.016 47.6 93.5 79.1 
AMACR HPRT1 TRAFD1 65.761 17.563 3 0.0005 0.324 0.007 0.052 0.114 57.1 95.7 83.6 
AMACR ATP10B EFNA5 65.903 17.420 3 0.0006 0.322 0.003 0.020 0.051 47.6 91.3 77.6 
AMACR DPT HPRT1 66.265 17.059 3 0.0007 0.316 0.009 0.061 0.059 42.9 91.3 76.1 
AMACR DPT PVT1 66.359 16.965 3 0.0007 0.314 0.004 0.027 0.048 47.6 89.1 76.1 
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The different steps involved in the data analysis are summarised in Figure 2.26, which 
illustrates how the predictive models were selected, and then gradually pared down to 
those with the best overall performance in terms of the χ2 whilst retaining parsimony. 
 
Figure 2.26 Flow diagram to show predictive modelling process 
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 Distribution of genes in the top gene models  
By graphically representing the prevalence of each gene in the highest-ranking models 
(by χ2), genes of interest were identified which may be potential progression markers of 
prostate cancer with use as predictors in LR models of recurrence. It should be reiterated 
that the prevalence plots included all gene models in the selected fractions. The 
prevalence plots were produced before any models containing non-significant variables 
were removed.  
The plots give an insight into the distribution of the genes in the models with the highest 
values for χ2 and illustrate how the prevalence changes as the selected divisions are 
narrowed towards the highest percentiles (~top 2%). The prevalence of the highest 
models according to overall percent accuracy were plotted in the same manner for 
comparison and to illustrate the differences in the best performing models between the 
two ranking methods. The four plots are included to allow comparisons between the 
ranking methods and between the two- and three-gene models. The genes are listed in 
order of increasing p-value for the Wald significance from the univariate LR analysis. The 
plots could potentially identify genes, even those with higher than conventional p-values 
for the Wald significance, that may be useful in combination with other genes, as 
evidenced by a significant presence in the best performing models. 
Figure 2.27 and Figure 2.28 show the distribution of genes in the top two-gene models 
ranked by χ2 and overall percent accuracy. Figure 2.29 and Figure 2.30 show the 
distribution of genes in the top three-gene models ranked by χ2 and overall percent 
accuracy.  
The plots show the percentage prevalence of each gene in the highest 19.4% (Fraction 
1), 9.3% (Fraction 2) and 2.8% (Fraction 3) of the two-gene models (Figure 2.27 and  
Figure 2.28) and the highest 12.7% (Fraction 1), 6.1% (Fraction 2) and 2.0% (Fraction 3) 
of the three-gene models (Figure 2.29 and Figure 2.30). 
The percentage prevalence of each gene is illustrated by blue, orange and grey bars for 
Fraction 1, 2 and 3 respectively. A marker has been included to identify the genes with 
p-values <0.05.  
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The plots illustrate the high prevalence of AMACR (which had the lowest p-value for the 
Wald statistic of 0.009) in comparison to any other genes for both the two- and three-
gene models ranked by both methods. 
The prevalence is lower for HPRT1 and SDHA which also had a Wald significance of 
p<0.025. The prevalence of these two genes is greater in the χ2 plot in comparison to 
the overall percent accuracy plot. For example, HPRT1 is approximately twice as 
prevalent in the top fraction (Fraction 3) in the χ2 compared to the overall percent 
accuracy plot. The most prevalent genes in the top models according to χ2 are generally 
those with p-values <0.05. The prevalence tends to reduce after this point, with low 
prevalence associated with genes with p-values >0.05. In comparison, the prevalence of 
many of the genes with p-values >0.05 is relatively high in the top models according to 
overall percent accuracy. The prevalence of some of these genes is as high as the genes 
with highly significant p-values (<0.05). This pattern is accentuated in the three-gene 
models ranked by overall percent accuracy. It is also important to note the increased 
prevalence of some of the genes with p-values >0.05 in the three-gene models 
compared with the two-gene models ranked by χ2. The prevalence tends to remain 
relatively high for genes with p-values up to 0.15 (up to GSTM3), a finding which is not 
evident in the two-gene models. 
It is also clear from the χ2 plots that the genes with the highest significance for the Wald 
statistic (p<0.05), which are those with the highest overall prevalence, show the greatest 
prevalence in the upper fraction (top ~2%).
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Figure 2.27 Distribution of the genes in the highest two-gene models according to χ2 
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Figure 2.28 Distribution of the genes in the highest two-gene models according to overall percent accuracy 
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Figure 2.29 Distribution of the genes in the highest three-gene models according to χ2 
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Figure 2.30 Distribution of the genes in the highest three-gene models according to overall percent accuracy 
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 Comparison to the pilot study 
 Independent samples t-tests for the prediction of GS groups 
As predictive models of disease outcome are more clinically relevant than predictive 
models of high GS (≥7), the current study (BB study) focused on the identification of 
predictive models of recurrence. 
A logistic regression analysis using recurrence as the dependent variable had also been 
included in the pilot study, but the limited follow-up data available at that time 
decreased the validity of the identified models of recurrence. Therefore, the pilot study 
had focused on the identification of models, which could categorise prostate cancer 
patients according to GS (≥7 vs <7). 
The BB study focused on identifying predictive models of recurrence. However, for 
comparison with the SL study, independent samples t-tests were also performed on the 
datasets to compare gene expression between GS ≥7 and <7. 
The list of genes showing differential expression between the groups to a conventional 
level of significance (p<0.05)(both Pfaffl and 2-ΔCt datasets) are shown for each study 
(Table 2.36). 
Table 2.36 Differentially expressed genes (p<0.05) between GS ≥7 and <7 in the SL and BB study 
SL Study BB Study 
Gene Pfaffl  Delta Ct   Gene Pfaffl  Delta Ct   
ABL1 0.037 * 0.028 * ↓ BRCA2 0.021 * 0.024 * ↓ 
ANPEP 0.005 ** 0.011 * ↓ EFNA2 0.019 * 0.019 * ↑ 
CD9 0.028 * 0.018 * ↓ GPR19 0.024 * 0.024 * ↑ 
EFNA1 0.006 ** 0.004 ** ↓ INMT 0.041 * 0.037 * ↓ 
GPM6A 0.015 * 0.043 * ↓ RHBDL1 0.019 * 0.019 * ↑ 
HSPB1 0.025 * 0.037 * ↓ VASH1 0.009 ** 0.011 * ↑ 
INMT 0.015 * 0.031 * ↓       
ITGB4 0.021 * 0.017 * ↓       
NELL2 0.018 * 0.015 * ↓       
PSCA 0.024 * 0.044 * ↓       
            
PSA 0.346     PSA 0.744     
* p<0.05,** p<0.01 
↑/↓ illustrates increased/decreased expression in the GS ≥7 group 
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In the SL study, 10 genes were identified as being significantly differentially expressed 
between GS ≥7 and <7 (in both datasets). EFNA1 was significant to a 99% confidence 
level (p<0.01) and ABL1, ANPEP, CD9, GPM6A, HSPB1, INMT, ITGB4, NELL2 and PSCA 
were significant to a 95% confidence level (p<0.05). All these genes were found to show 
significantly lower expression in GS ≥7 versus <7. 
The BB study found 6 genes to be differentially expressed between the groups to 
a conventional significance level (p<0.05). These genes were BRCA2, EFNA2, GPR19, 
INMT, RHBDL1 and VASH1. The genes BRCA2 and INMT showed significantly lower 
expression in GS ≥7 vs <7. EFNA2, GPR19, RHBDL1 and VASH1 showed significantly 
higher expression in GS ≥7 vs <7.  
The only gene found to be significantly differentially expressed according to GS (p<0.05) 
in both studies was INMT, which showed reduced expression in the GS ≥7 group (in both 
studies).  
From the genes that were significantly differentially expressed in the SL study, only 
NELL2, PSCA, ANPEP and CD9 showed p-values <0.5 in the BB study (ANPEP and CD9 had 
values <0.25). The remainder of the significant genes in the SL study (ABL1, EFNA1, 
HSPB1, ITGB4) had p-values of >0.5 in the BB study and GPM6A was one of the excluded 
genes (not expressed). 
The genes ANPEP, CD9, and NELL2 showed a lower expression in the high GS group in 
both studies. PSCA showed higher expression in the high GS group in the BB study but 
lower expression in this group in the SL study. 
Apart from INMT, the genes which were differentially expressed in the BB study (p<0.05) 
(BRCA2, EFNA2, GPR19 and RHBDL1 and VASH1) were of no significance in the SL study 
(p>0.5). The genes BRCA2, EFNA2 and GPR19 had not been expressed (therefore 
excluded) and the genes RHBDL1 and VASH1 had p-values >0.5 in the SL study. 
Altogether, a total of 25 genes showed p-values <0.5 in both studies in the independent 
samples t-tests comparing GS groups (Table 2.37). 
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Table 2.37 Genes with p-values <0.5 in both studies for the independent samples t-tests (GS ≥7 vs <7) 
Gene 
SL Study BB Study 
Pfaffl  Delta Ct   Pfaffl  Delta Ct   
ANPEP 0.005 ** 0.011 * ↓ 0.240  0.237  ↓ 
APOBEC3G 0.249  0.253  ↓ 0.309  0.338  ↑ 
ASB2 0.061  0.161  ↓ 0.081  0.081  ↓ 
CANX 0.109  0.357  ↓ 0.429  0.430  ↓ 
CD44 0.131  0.316  ↓ 0.111  0.113  ↓ 
CD9 0.028 * 0.018 * ↓ 0.152  0.133  ↓ 
CDC42EP3 0.059  0.055  ↓ 0.206  0.153  ↓ 
CDKN1C 0.009 ** 0.086  ↓ 0.299  0.304  ↓ 
CHM 0.113  0.383  ↓ 0.226  0.223  ↓ 
EZH2 0.106  0.376  ↓ 0.111  0.119  ↑ 
F11R 0.170  0.239  ↓ 0.063  0.063  ↓ 
FABP5 0.132  0.360  ↓ 0.433  0.433  ↑ 
GSTM3 0.056  0.040 * ↓ 0.146  0.136  ↓ 
HOXC6 0.131  0.177  ↑ 0.093  0.092  ↑ 
INMT 0.015 * 0.031 * ↓ 0.041 * 0.037 * ↓ 
ITGA2 0.133  0.217  ↓ 0.357  0.267  ↓ 
ITGA3 0.178  0.231  ↓ 0.249  0.264  ↓ 
ITGA5 0.150  0.441  ↓ 0.308  0.309  ↓ 
NELL2 0.018 * 0.015 * ↓ 0.250  0.248  ↓ 
NUP50 0.276  0.342  ↓ 0.387  0.386  ↑ 
PCDH18 0.491  0.444  ↓ 0.324  0.320  ↓ 
PSCA 0.024 * 0.044 * ↓ 0.452  0.456  ↑ 
RAP1GAP 0.234  0.490  ↓ 0.105  0.107  ↓ 
TBRG4 0.054  0.278  ↓ 0.155  0.166  ↓ 
TRAFD1 0.072  0.070  ↓ 0.207  0.186  ↑ 
* p<0.05,** p<0.01 
↑/↓ illustrates increased/decreased expression in the GS ≥7 group 
          
 
In the SL study, all the genes showed lower expression in the GS ≥7 group compared 
with the <7 group except HOXC6, which showed higher expression. HOXC6 also showed 
higher expression in the GS ≥7 group in the BB study. In the BB study, most of the genes 
showed lower expression in the GS ≥7 group as had been found in the SL study, except 
APOBEC3G, EZH2, FABP5, NUP50, PSCA and TRAFD1 which showed higher expression in 
the GS ≥7 group (different direction to the SL study). 
The following section compares the results between the two studies of the independent 
sample t-tests used for the comparison of gene expression between the recurrent and 
non-recurrent group. 
 Independent samples t-tests comparing the recurrent and non-
recurrent group 
The results of the t-tests comparing the recurrent and non-recurrent group are 
presented for both studies (Table 2.38).  
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Table 2.38 Independent samples t-tests comparing gene expression between the recurrent and non-
recurrent group in the SL and BB study 
SL Study   BB Study   
Gene Pfaffl  Delta Ct   Gene Pfaffl   Delta Ct   
@18S 0.223  0.325  ↓ @18S 0.528  0.384   
ABL1 0.301  0.373  ↓ ABL1 0.045 * 0.073  ↑ 
ALCAM 0.333  0.637   ALCAM 0.829  0.990   
ALPG N  N   ALPG N  N   
AMACR 0.770  0.334   AMACR 0.018 * 0.023 * ↓ 
ANPEP 0.030 * 0.041 * ↓ ANPEP 0.205  0.214  ↑ 
ANXA2 0.987  0.569   ANXA2 0.072  0.069  ↑ 
APOBEC3G 0.147  0.149  ↓ APOBEC3G 0.881  0.773   
ASB2 0.255  0.421  ↓ ASB2 0.894  0.894   
ATP5MPL 0.849  0.659   ATP5MPL 0.295  0.439  ↑ 
ATP10B N  N   ATP10B 0.054  0.049 * ↑ 
BRCA2 N  N   BRCA2 0.417  0.516   
C3 
 
    C3 0.202  0.264  ↑ 
CANX 0.531  0.954   CANX 0.571  0.523   
CD109 0.343  0.398  ↓ CD109 0.125  0.099  ↑ 
CD4 0.146  0.230  ↓ CD4 N  N   
CD44 0.100  0.089  ↓ CD44 0.992  0.757   
CD9 0.141  0.121  ↓ CD9 0.736  0.938   
CDC42EP3 0.115  0.067  ↓ CDC42EP3 0.751  0.956   
CDH1 0.496  0.394  ↑ CDH1 0.052  0.049 * ↑ 
CDH2 0.759  0.260   CDH2      
CDKN1C 0.094  0.287  ↓ CDKN1C 0.713  0.762   
CHM 0.373  0.755   CHM 0.331  0.402  ↑ 
CRHR1 0.840  0.659   CRHR1 0.416  0.617   
CTNNA1 0.569  0.995   CTNNA1      
CYP11A1 N  N   CYP11A1 0.846  0.841   
DPT 0.215  0.241  ↓ DPT 0.098  0.120  ↑ 
EDNRA 0.281  0.523   EDNRA 0.789  0.768   
EEF1A1 0.211  0.315  ↓ EEF1A1 0.193  0.855   
EFNA1 0.242  0.429  ↓ EFNA1 0.155  0.165  ↑ 
EFNA2 N  N   EFNA2 0.948  0.870   
EFNA3 N  N   EFNA3 0.783  0.680   
EFNA4 N  N   EFNA4 0.958  0.800   
EFNA5 0.409  0.804   EFNA5 0.151  0.143  ↓ 
ERBB2 
 
    ERBB2 0.465  0.526   
ERG 0.346  0.214  ↑ ERG 0.699  0.741   
EZH2 0.881  0.670   EZH2 0.451  0.411  ↓ 
F11R 0.931  0.671   F11R 0.235  0.224  ↑ 
FABP5 0.343  0.595   FABP5 0.274  0.270  ↑ 
FADS1 0.406  0.882   FADS1 0.571  0.453   
GPM6A 0.171  0.281  ↓ GPM6A N  N   
GPR12 N  N   GPR12 0.902  0.783   
GPR19 N  N   GPR19 0.923  0.897   
GSTM3 0.159  0.114  ↓ GSTM3 0.146  0.262  ↑ 
GSTM5 N  N   GSTM5 0.438  0.389  ↓ 
GUCY1A1 0.434  0.909   GUCY1A1 0.149  0.056  ↓ 
HOXC6 0.344  0.416  ↑ HOXC6 0.739  0.720   
HPN 0.665  0.683   HPN 0.636  0.985   
HPRT1 0.791  0.647   HPRT1 0.008 ** 0.025 * ↓ 
HPX 
 
    HPX 0.874  0.632   
HSPA5 0.672  0.671   HSPA5      
HSPB1 0.048  0.050  ↓ HSPB1 0.541  0.558   
INMT 0.006 ** 0.010 * ↓ INMT 0.416  0.507   
IRF7 0.371  0.744   IRF7 0.356  0.342  ↓ 
ITGA2 0.354  0.611   ITGA2 0.244  0.391  ↑ 
ITGA3 0.391  0.449  ↓ ITGA3 0.880  0.732   
ITGA5 0.461  0.807   ITGA5 0.445  0.525   
ITGB1 0.448  0.745   ITGB1 0.115  0.219  ↑ 
ITGB4 0.190  0.369  ↓ ITGB4b 0.413  0.513   
ITGB6 0.314  0.586   ITGB6b 0.433  0.398  ↓ 
KCNN4 0.574  0.609   KCNN4      
KLHL5 0.383  0.565   KLHL5 0.702  0.625   
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MKI67 
 
    MKI67 0.728  0.829   
PVALB 0.161  0.172  ↓ PVALB 0.857  0.849   
MMP2 0.186  0.303  ↓ MMP2 0.798  0.634   
MMP9 0.831  0.116   MMP9      
MNX1 N  N   MNX1 0.517  0.758   
MT1X 
 
    MT1X 0.940  0.828   
MUC1 
 
    MUC1 0.702  0.879   
MYC 0.126  0.271  ↓ MYC      
NDUFAF1 0.371  0.577   NDUFAF1 0.154  0.183  ↓ 
NELL2 0.096  0.080  ↓ NELL2 0.292  0.344  ↑ 
PNP 0.413  0.340  ↑ PNP 0.322  0.297  ↓ 
NUP50 0.729  0.817   NUP50 0.668  0.681   
PCDH18 0.706  0.667   PCDH18 0.197  0.206  ↓ 
PGC 0.713  0.587   PGC 0.070  0.062  ↓ 
PLAU 
 
    PLAU 0.020 * 0.023 * ↑ 
PLCL2 0.963  0.827   PLCL2 0.874  0.967   
PLLP 0.246  0.350  ↓ PLLP 0.303  0.250  ↓ 
POP5 0.604  0.940   POP5 0.088  0.114  ↑ 
PRIM2A 0.249  0.100  ↓ PRIM2 0.624  0.782   
PSCA 0.232  0.327  ↓ PSCA 0.879  0.952   
PTEN 
 
    PTEN 0.038 * 0.030 * ↓ 
PTGFR 0.845  0.163   PTGFR 0.422  0.393  ↓ 
PVT1 0.725  0.956   PVT1 0.073  0.096  ↑ 
RAP1GAP 0.469  0.769   RAP1GAP 0.508  0.490   
RBM12 0.502  0.760   RBM12      
RHBDL1 0.900  0.467   RHBDL1 0.480  0.529   
SDHA 0.206  0.309  ↓ SDHA 0.013 * 0.046 * ↑ 
SFPQ 0.219  0.273  ↓ SFPQ      
SERPINB5 N  N   SERPINB5 0.360  0.368  ↓ 
SLC44A2 0.777  0.712   SLC44A2 0.513  0.534   
PRELID3A N  N   PRELID3A 0.792  0.976   
TBP 0.476  0.962   TBP 0.812  0.962   
TBRG4 0.539  0.756   TBRG4 0.362  0.297  ↑ 
TERT N  N   TERT 0.854  0.824   
TF 
 
    TF 0.476  0.553   
TGFB2 N  N   TGFB2 0.534  0.408   
TGM2 0.342  0.410  ↓ TGM2      
HSP90B1 0.701  0.509   HSP90B1      
TRAFD1 0.508  0.939   TRAFD1 0.149  0.204  ↑ 
TRIP13 0.030 * 0.031 * ↑ TRIP13 0.615  0.592   
VASH1 0.881  0.650   VASH1 0.691  0.570   
WIF1 0.738  0.779   WIF1      
  
 
           
GS 0.051     GS 0.372     
PSA 0.195     PSA 0.842     
* p<0.05,** p<0.01   
↑/↓ illustrates increased/decreased expression in the recurrent group   
N = no expression   
 
The only genes found to be significantly differentially expressed (p<0.05) in the SL study 
between the recurrent versus non-recurrent group were ANPEP, INMT and TRIP13. The 
expression of ANPEP and INMT were significantly lower, and the expression of TRIP13 
was significantly higher in the recurrent versus non-recurrent group. 
In the BB study, a different set of genes were found to be differentially expressed 
between the recurrent and non-recurrent group to a conventional significance level 
(p<0.05): AMACR, HPRT1, PLAU, PTEN and SDHA. The expression of AMACR, HPRT1 and 
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PTEN were lower in the recurrent versus non-recurrent group. The expression of PLAU 
and SDHA was higher in the recurrent versus non-recurrent group. 
There were no genes found to be significantly differentially expressed between the 
recurrent and non-recurrent group (p<0.05) in both studies.  
The genes INMT and TRIP13, which were found to be highly significant in the previous 
study, had p-values >0.5 in the BB study. ANPEP showed a p-value of <0.5 in both studies, 
but in comparison to the SL study (where ANPEP expression was reduced in the 
recurrent group), its expression was increased in the recurrent group in the BB study. 
The genes AMACR and HPRT1, which were found to be significantly differentially 
expressed according to recurrence in the BB study, were of no significance in the 
SL study (p>0.5). SDHA was the only significant gene in our study which had a p-value 
<0.5 in the previous study. However, SDHA displayed decreased expression in the 
SL study but increased expression in the BB study in the recurrent group. The final two 
highly significant genes in our study were PLAU and PTEN, which had been specific to 
the BB study only. 
If the SL study had used our relaxed threshold of p<0.5 for inclusion of variables into the 
multivariate LR analysis, they would have taken forward 34 genes rather than 3. The 
BB study used 39 genes for the multivariate LR analysis. 
A total of 11 genes were found to show p-values <0.5 in both studies for the comparison 
of recurrent and non-recurrent groups (Table 2.39). 
Table 2.39 Genes with p-values <0.5 in both studies in the independent samples t-tests (recurrent vs 
non-recurrent) 
Gene 
SL Study BB Study 
Pfaffl  Delta Ct   Pfaffl  Delta Ct   
ABL1 0.301  0.373  ↓ 0.045 * 0.073  ↑ 
ANPEP 0.030 * 0.041 * ↓ 0.205  0.214  ↑ 
CD109 0.343  0.398  ↓ 0.125  0.099  ↑ 
CDH1 0.496  0.394  ↑ 0.052  0.049 * ↑ 
DPT 0.215  0.241  ↓ 0.098  0.120  ↑ 
EFNA1 0.242  0.429  ↓ 0.155  0.165  ↑ 
GSTM3 0.159  0.114  ↓ 0.146  0.262  ↑ 
NELL2 0.096  0.080  ↓ 0.292  0.344  ↑ 
PNP 0.413  0.340  ↑ 0.322  0.297  ↓ 
PLLP 0.246  0.350  ↓ 0.303  0.250  ↓ 
SDHA 0.206  0.309  ↓ 0.013 * 0.046 * ↑ 
* p<0.05,** p<0.01 
↑/↓ illustrates increased/decreased expression in the recurrent group  
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For most of these genes, the gene expression difference between the recurrent and non-
recurrent group was in a different direction between the two studies. The only gene for 
which the direction of change between the recurrent and non-recurrent group 
concurred between the studies was CDH1 (higher in recurrent). The BB study had 
a larger number of genes demonstrating increased expression in the recurrent group in 
comparison to the SL study. 
It is important to note that the significance obtained for the GS and preoperative PSA 
were much higher in the SL study (lower p-values). Only the GS was included as 
a predictor variable for the multivariate analysis in the BB study (p<0.5), whereas both 
GS and PSA had been included in the SL study. 
 Predictive models of recurrence in SL study 
Due to their strict entry criterion, the SL study took forward only three genes (ANPEP, 
INMT and TRIP13) into LR analysis for recurrence. 
The output parameters from the univariate LR of these genes are shown for both the 
Pfaffl (Table 2.40) and 2-ΔCt (Table 2.41) datasets as LR was performed on both datasets 
in the SL study.  
The models are listed in decreasing order of the χ2 (although they were not ordered by 
this parameter in the SL study).  
For both datasets in the SL study, the χ2 values for the single gene models ANPEP and 
TRIP13 were significant to a 95% confidence level (p<0.05). The χ2 value for the single 
gene model INMT was significant to a 99% confidence level (p<0.01). Therefore, all three 
genes showed a significant improvement over the null model for the prediction of 
recurrence. INMT was the model with the best overall fit of the three genes in both 
datasets. 
A single variable model including only the GS was significantly better than the null model 
(p<0.05). A model including only PSA was not significantly better than the null model 
(p-value >0.15).  
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In comparison to the SL study, the variables INMT, TRIP13 and PSA were not included in 
our LR analysis of recurrence due to their low significance in the t-tests (p>0.5).  
ANPEP and GS were included (p<0.5), although the p-values obtained for these variables 
in the t-tests were much higher than the values found in the SL study. In comparison to 
the SL study, which found the single gene model ANPEP to significantly improve upon 
the null model, the BB study did not find ANPEP to significantly improve upon the null 
model for the prediction of recurrence (χ2(1) = 1.7, p-value 0.2). Furthermore, ANPEP 
did not feature in the top 10% of two-gene models and only very rarely in the top 10% 
of three-gene models in the BB study. 
Additionally, in the BB study, the GS provided no benefit as either a single predictor 
model or when added to any single-gene or two-gene models. 
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Table 2.40 Single gene models for the prediction of recurrence in the SL study (Pfaffl dataset)  
Gene(s) 
-2LL 
Null 
model -2LL χ2 df sig. 
Nagelkerke 
R2 
Wald 
sig.   Percent Accuracy (%) AUC 
1 2 3       1 2 3 Recurrent 
Non- 
recurrent Overall  
INMT   35.924 28.381 7.542 1 0.006 0.322 0.035   33.3 95.0 75.9 0.772 
TRIP13   35.924 30.632 5.292 1 0.021 0.235 0.050   33.3 85.0 69.0 0.767 
ANPEP   35.924 30.851 5.073 1 0.024 0.226 0.048   44.4 95.0 79.3 0.783 
GS   35.924 31.701 4.223 1 0.040 0.191 0.080   11.1 95.0 69.0 0.703 
PSA   33.503 31.766 1.738 1 0.187 0.086 0.201   12.5 95.0 71.4 0.647 
 
Table 2.41 Single gene models for the prediction of recurrence in the SL study (2-ΔCt dataset) 
Gene(s) 
-2LL 
Null 
model -2LL χ2 df sig. 
Nagelkerke  
R2 
Wald 
sig.     Percent Accuracy (%) AUC 
1 2 3       1 2 3 Recurrent 
Non- 
recurrent Overall  
INMT   35.924 29.156 6.768 1 0.009 0.293 0.050   22.2 95.0 72.4 0.75 
TRIP13   35.924 30.665 5.259 1 0.022 0.234 0.050   22.2 90.0 69.0 0.75 
ANPEP   35.924 31.509 4.415 1 0.036 0.199 0.057   22.2 90.0 69.0 0.772 
GS   35.924 31.701 4.223 1 0.04 0.191 0.080   11.1 95.0 69.0 0.703 
PSA   33.503 31.766 1.738 1 0.187 0.086 0.201   12.5 95.0 71.4 0.647 
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The results from the multivariate LR analysis of the SL study are shown in Table 2.42 and 
Table 2.43. The two-variable models which offered a significant improvement over the 
null model (χ2, p<0.05) were INMT.GS, TRIP13.GS and TRIP13.PSA in the Pfaffl dataset 
and INMT.TRIP13, INMT.GS and TRIP13.GS in the 2-ΔCt dataset. The model TRIP13.GS was 
the best performing two-variable model in both datasets: χ2(2) = 10.7, p<0.01 (Pfaffl 
dataset) and χ2(2) = 10.5, p<0.01 (2-ΔCt dataset), with high discriminatory accuracy as 
demonstrated by AUC values of 0.833 and 0.861 respectively. 
However, the only two-variable model which offered a significant improvement over its 
nested single gene model was TRIP13.GS in both datasets. This was calculated as 
previously described (-2LL single gene model) - (-2LL two-variable model)(data included 
in Appendix 8).  
The three-variable models, which offered a significant improvement over the null model 
(χ2, p<0.05) were TRIP13.GS.PSA in the Pfaffl dataset and INMT.TRIP13.GS and 
TRIP13.GS.PSA in the 2-ΔCt dataset. TRIP13.GS.PSA offered a significant improvement 
over the two-variable model TRIP13.GS in the Pfaffl dataset only (χ2 = 3.99, p<0.05). 
The values obtained for the χ2 (between the null and final model) in the BB study reached 
higher values for the top two- and three-gene models than those in the SL study. 
Additionally, there was a more significant improvement in the three-variable models in 
comparison to the two-variable models in our study. Despite lower χ2 values for the best 
models in the SL study than the BB study, the overall percent accuracy and AUC values 
of the best models in the two studies were in a similar range. 
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Table 2.42 Multivariate logistic regression analysis for the prediction of recurrence in the SL study (Pfaffl dataset) 
 
Table 2.43 Multivariate logistic regression analysis for the prediction of recurrence in the SL study (2-ΔCt dataset) 
Gene(s) 
-2LL Null 
model -2LL χ2 df sig. 
Nagelkerke 
 R2 
Wald Significance 
  
  
Percent Accuracy (%) 
  
  
AUC 1 2 3 1 2 3 Recurrent 
Non- 
recurrent Overall 
INMT TRIP13 GS 35.924 23.799 12.124 3 0.007 0.481 0.272 0.096 0.123 55.6 90 79.3 0.867 
TRIP13 GS  35.924 25.389 10.535 2 0.005 0.429 0.044 0.039  77.8 85.0 82.8 0.861 
TRIP13 GS PSA 33.503 23.129 10.374 3 0.016 0.444 0.055 0.047 0.319 62.5 90.0 82.1 0.863 
INMT TRIP13  35.924 26.527 9.396 2 0.009 0.390 0.110 0.142  44.4 90.0 75.9 0.828 
INMT GS  35.924 27.609 8.315 2 0.016 0.351 0.103 0.253  33.3 90.0 72.4 0.817 
TRIP13 PSA  33.503 27.838 5.665 2 0.059 0.263 0.078 0.269  50 95.0 82.1 0.763 
INMT PSA  33.503 28.965 4.538 2 0.103 0.214 0.135 0.835  12.5 95.0 71.4 0.731 
ANPEP PSA  33.503 29.966 3.537 2 0.171 0.17 0.203 0.435  25.0 90.0 71.4 0.756 
Gene(s) 
-2LL Null 
model -2LL χ2 df sig. 
Nagelkerke 
 R2 
Wald Significance 
  
  
Percent Accuracy (%) 
  
  
AUC 1 2 3 1 2 3 Recurrent 
Non- 
recurrent Overall 
TRIP13 GS PSA 33.503 21.241 12.262 3 0.007 0.508 0.036 0.043 0.2 87.5 85.0 85.7 0.888 
TRIP13 GS  35.924 25.231 10.693 2 0.005 0.434 0.04 0.036  55.6 80.0 72.4 0.833 
INMT GS  35.924 26.696 9.228 2 0.01 0.384 0.07 0.231  44.4 90.0 75.9 0.822 
TRIP13 PSA  33.503 26.56 6.943 2 0.031 0.315 0.054 0.192  50 85.0 75.0 0.819 
ANPEP PSA  33.503 28.893 4.61 2 0.1 0.218 0.122 0.384  12.5 90.0 67.9 0.806 
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2.4 Discussion 
 Gleason score analysis   
In the independent samples t-tests, there was no overlap between the significantly 
differentially expressed genes according to recurrence and the significantly differentially 
expressed genes according to GS (≥7 vs <7)(p<0.05). Furthermore, many of the genes 
with p-values <0.5 in both analyses showed an expression change between the recurrent 
and non-recurrent group that was in a different direction to the change between the GS 
≥7 and <7 group. 
It was also evident that the GS had no use as a predictor variable of recurrence in this 
dataset in either the univariate or multivariate LR analysis. There was only a marginal 
difference in the mean GS between the recurrent and non-recurrent group (6.90 and 
6.63 respectively, p-value of 0.372 in Mann-Whitney U test). These findings were caused 
mainly by the large proportion of GS 7 patients in this dataset (>40%). Patients with GS 7 
tumours have a heterogeneous clinical outcome (319), as demonstrated here by the 
finding of 18 non-recurrent and 9 recurrent patients within this group. 
Additionally, the GS may not have been accurately assigned for all patients, especially 
those for whom only a biopsy GS was available (those treated with RT only). Biopsy 
grading has well-documented limitations and is prone to over- and undergrading (320).  
It is interesting to note that the GS in the SL study differed to an almost conventional 
significance level between the recurrent and non-recurrent group (p-value 0.051)(275). 
GS was also found to be an important predictor variable in their multivariate LR analysis. 
The GS may have been more reliably assigned in the SL study as only RP patients were 
included, so only pathologic GS was used for categorisation rather than biopsy GS. 
The lack of correlation between the GS and recurrence in the BB study would have 
negated the prognostic relevance of any identified differentially expressed genes 
between GS ≥7 and <7. Therefore the GS could not be reliably used as a surrogate for 
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aggressive disease. This validated the choice to use recurrence as the clinical endpoint 
in the final study. 
Contrary to these findings, the GS has been used in the discovery process of some gene 
expression studies to identify putative genes of prostate cancer progression, which were 
then further analysed using outcome data (261, 262). However, these studies compared 
GS ≥8 (or Gleason grade 4/5) and GS ≤6 (or Gleason grade 3) and excluded GS 7 in the 
discovery phase as these more highly segregated groups have a closer association with 
outcome (262, 332). Other studies found no overlap between genes which were 
predictive of GS and those that were predictive of recurrence, suggesting that the gene 
expression changes associated with dedifferentiation may be different to those 
associated with outcome (290, 333).  
 Comparison of recurrence analysis between the BB and 
SL study   
There were few similarities between the SL study and the BB study regarding the genes 
found to be differentially expressed between the recurrent and non-recurrent group. 
The significant genes (p<0.05) were different between the two studies and AMACR, 
which in the BB study was found to be significantly differentially expressed according to 
recurrence (p-value 0.018) and the most prevalent gene in the best performing 
LR models, had a p-value of >0.5 in the t-tests of the SL study. HPRT1, the most 
significantly differentially expressed gene in the BB study (p-value 0.008) had a p-value 
of >0.5 in the SL study. SDHA was found to be significantly increased in the recurrent 
group in the BB study (p-value 0.013), whereas it was reduced in the recurrent group in 
the SL study (although not significantly). Similarly, ANPEP was significantly reduced in 
the recurrent group in the SL study but increased in this study (although not 
significantly).  
There were only 11 genes with p-values <0.5 in both studies and crucially, all these 
11 genes except CDH1, demonstrated a different direction of gene expression in the two 
studies between the recurrent and non-recurrent group. CDH1 was the only gene with 
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a p-value of <0.5 in both studies, which showed the same pattern of expression between 
the two studies (increased expression in the recurrent group). 
Two of the genes that were found be significant in the BB study were PLAU and PTEN. 
These genes were novel to the BB array and had been selected based on their 
association with prostate cancer progression in other studies (see Appendix 1). These 
genes were found to be important predictor variables in the LR models, which validated 
the decision to incorporate these genes on the BB array. 
The fact that the two studies identified different genes as showing differential 
expression in recurrent disease is not an uncommon finding in gene expression studies 
(334). Although a similar assay platform was used, there were many key differences in 
methodology between the SL and BB study, which resulted from the extensive method 
development that was carried out in the latter study including the essential optimization 
of the baseline and threshold settings. Importantly, the BB study used a larger set of 
samples which were predominantly biopsies, whereas the SL study used only 
RP samples. The gene expression data in the BB study was analysed with a longer follow-
up period than the SL study and the outcome data was more complete.  
It is not possible to directly compare the results of the two studies due to these 
differences. Furthermore, the more relaxed threshold in the BB study for inclusion of 
predictor variables into multivariate LR models resulted in the analysis of 2,019 models 
in comparison to only 13 in the SL study.  
The SL study tested only one two-gene model (INMT.TRIP13)(2-ΔCt dataset only). In 
comparison, the BB study tested 39 single-, 387 two-gene and 1482 three-gene models. 
The remainder of the models in their study had included GS and/or PSA alongside 
a single gene rather than combinations of genes. 
To reiterate, the SL study used overall percent accuracy as the primary measure of 
overall model performance. In comparison, the BB study used χ2 for the reasons 
described in Section 2.3.4.8. Both studies included ROC analysis as an important 
measure of discriminatory accuracy.  
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It must be stressed that the SL study was only a pilot study and the BB study comprised 
three times as many patients to enhance the validity of the findings. Importantly, the 
pilot study had only 9 positive events (9 recurrent patients) compared with 21 in the 
BB study. For LR to be statistically valid and to avoid the identification of spurious models 
through overfitting, the use of at least 5-9 EPV is advised (303). The validity of the two- 
and three-variable models in the SL study, which had an EPV of only 4.5 and 
3 respectively, were therefore compromised. Despite the study finding some potentially 
useful two- and three-variable predictive models of recurrence (TRIP13.GS.PSA and 
TRIP13.GS), the results of the single variable models in their study would be considered 
the most reliable.  
The single gene model INMT was the highest performing single gene model in the 
SL study for the prediction of recurrence (according to χ2). In comparison, the BB study 
found AMACR to be the highest performing model of recurrence. The values for the 
χ2 and its significance were similar between INMT in the SL study and AMACR in the 
BB study. The AUC value for INMT in their study was higher at 0.772 than AMACR in the 
BB study (0.677). However, the two- and three-gene models in the BB study (which 
contained a suitable number of variables for the sample size) provided significantly 
higher values for both the χ2 and AUC than was found for the single gene models in 
either study. 
 BB study - recurrence analysis 
The BB study found 7 single gene models (AMACR, HPRT1, SDHA, PLAU, PTEN, ABL1, 
CDH1) that offered a significant improvement over the null model for the prediction of 
recurrence in this dataset (χ2, p<0.05). However, the amount of variation in recurrence 
which was explained by AMACR and HPRT1 (the genes with the highest χ2 value) was 
low at ~15% and 13% respectively, as described by the Nagelkerke R2. The discriminatory 
accuracy (as shown by the AUC values) was good for HPRT1, at 0.731. The remaining 
6 genes (even AMACR) had AUC values between 0.628-0.677, demonstrating that the 
discriminatory accuracy was not ideal. Therefore, the ability of the genes individually in 
LR models to discriminate between recurrent and non-recurrent patients was limited. 
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There were 28 two-gene models which offered a significant improvement over their 
nested single gene models (as assessed by the secondary use of χ2), and an improvement 
over the best single gene model (lower -2LL). The two-gene models at the bottom of the 
list were not ideal as they offered only a marginally lower -2LL value than the lowest 
value obtained for the single gene models (AMACR). Therefore, they did not offer any 
significant benefit over the parsimonious single gene model AMACR. The best 
performing two-gene models of AMACR.SDHA and HPRT1.PLAU showed χ2 values that 
were approximately twice the value obtained for AMACR as a single gene model. The 
better fit of these two-gene models to the data was also reflected by much higher 
significance values for the χ2. These two-gene models explained a much larger amount 
of the variation in recurrence (31% and 28% respectively). The AUC values were 0.784 
and 0.808 for AMACR.SDHA and HPRT1.PLAU respectively, suggesting good 
discriminatory accuracy. By selecting the optimal threshold for categorisation of 
patients, a good balance of sensitivity and specificity could be achieved for the predictive 
models. For HPRT1.PLAU the threshold at which the value for the Youden’s index was 
highest provided a high sensitivity of 91% and a lower specificity of 63%. A better 
balance of sensitivity and specificity of 71% and 76% was achieved by selecting an 
alternative threshold. The sensitivity and specificity of AMACR.SDHA was 71% and 78% 
respectively.  
There were 9 three-gene models that offered both an improvement over their nested 
two-gene models and over the best two-gene model. The best performing models 
AMACR.EFNA5.SDHA and AMACR.HPRT1.SDHA could explain ~40% of the variation in 
recurrence and these two models had AUC values of 0.812 and 0.829 respectively, 
showing excellent discriminatory accuracy. The sensitivity and specificity at the optimal 
threshold was 81% and 74% for AMACR.EFNA5.SDHA respectively, and 81% and 87% for 
AMACR.HPRT1.SDHA. The remainder of the three-gene models provided only limited 
improvement (marginally lower -2LL) over the best performing two-gene model of 
AMACR.SDHA. Therefore, the use of AMACR.EFNA5.SDHA and AMACR.HPRT1.SDHA may 
be justified, but the use of the remainder of the three-gene models may not.  
It was not possible to add any further predictor variables to the three-gene models as it 
was imperative to keep the number of variables to a minimum due to the small sample 
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size (302). Ideally, a larger sample size would have been used, but there were limitations 
regarding the number of samples that could be accessed, so the study had to adapt the 
number of variables included in the models according to the final sample size. The use 
of a model that is too complex for the dataset increases the risk of overfitting, which is 
when the model becomes tailored to the features of the specific sample that it is tested 
on, including its noise and anomalies. This leads to misleading values for the parameters 
in the LR output. An overfitted model would be highly unlikely to fit another random 
sample and so would have no value as a predictive model for future use (335). 
Additionally, exceeding the appropriate number of predictor variables will prevent the 
LR analysis from adequately controlling for confounding variables (301). Confounding 
variables are extraneous variables which influence both the independent and 
dependent variables and may lead to a spurious association between them. 
 Calibration and discrimination - evaluating the performance 
of the predictive models 
It is important to mention that the χ2 and the AUC values were used to measure different 
characteristics of the overall performance of the predictive models. The χ2 measures 
goodness-of-fit and is used to measure the calibration of a model, i.e. the agreement 
between the predicted and observed outcomes. The AUC is a measure of discrimination, 
i.e. how well the model distinguishes between recurrent and non-recurrent patients 
(336). Generally, as the χ2 values decreased so did the AUC values; i.e. the models with 
the highest calibration were usually the models with the highest discriminatory 
accuracy, although they did not correlate exactly. For example, the single gene model 
HPRT1 had a higher AUC value than AMACR, despite AMACR having the highest χ2. 
Although it is important to assess both calibration and discrimination when evaluating 
the overall performance of a predictive model, the χ2 in this study provided the most 
suitable parameter by which to rank the vast numbers of candidate two- and three-gene 
models. The AUC values were not suitable for ranking purposes as these values fall 
within a narrow range from 0.5-1. The larger range of χ2 values and the attributes of 
using this parameter to evaluate the overall performance of the models (explained in 
the method development Section 2.3.4.8) made it ideal for ranking purposes. 
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Furthermore, the secondary use of the χ2, describing the improvement in fit provided by 
the addition of another predictor to a single or two-gene model, enabled a useful 
method by which to assess the importance of each predictor variable in each model. 
 Gene prevalence plots 
The plots of gene prevalence in the top performing models were useful to illustrate how 
the highest predictive models varied, depending on whether χ2 or the overall percent 
accuracy was used for ranking. This is explained in detail in the method development 
Section 2.3.4.8 and contributed to the decision to use χ2 as the ranking method.  
The prevalence plots allowed an assessment of the prevalence of each gene in the best 
performing two- and three-gene models according to χ2. It is important to remember 
that a limitation of using such a method is the fact that the prevalence plots included 
every tested model in the top fractions. Therefore, models containing non-significant 
predictor variables were also included, which could potentially have led to an 
overrepresentation of some genes without significant predictive value. This was more 
evident for the three-gene models as some of these models contained a non-significant 
variable but, due to the high significance of the remaining variables, their ranking was 
high.  
Despite these limitations, the plots provided a useful description of the genes that were 
found most frequently in the best performing two- and three-gene models and were 
important predictor variables in this study. It was evident that the prevalence of AMACR 
far exceeded any of the other genes in the top models. This was important and 
highlighted AMACR as an important putative progression marker in prostate cancer. 
Although the genes with p-values <0.05 were more likely to present in the best 
performing models, the plots also demonstrated that it was important to use a more 
relaxed p-value threshold for inclusion of predictors into multivariate LR (as genes with 
p-values >0.05 also presented).  
The genes in this study had been selected for LR analysis based on the p-value of the 
t-test rather than the Wald test (from the univariate LR analysis). In the method 
development, the prevalence was plotted in increasing order of the p-value for the t-test 
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initially. Subsequently, the prevalence was plotted in increasing order of the p-value for 
the Wald test. The prevalence correlated better with the significance of the Wald test 
than the t-test, providing a clearer picture of potential p-value thresholds that could be 
selected for inclusion of genes into multivariate analysis. In future, the p-value for the 
Wald test may be a more appropriate method by which to select predictor variables for 
the multivariate analysis, as has been suggested by others (325, 326). These studies used 
a threshold of 0.25, which would have been suitable in this study, as no genes were 
found in the final lists of models which had p-values >0.25. Table 2.44 shows the genes 
included in the final 28 two-gene and 9 three-gene models, which were the best 
performing models containing only significant predictor variables. The p-values for both 
the t-test and the Wald test are included. 
Table 2.44 Genes found in the best performing two- and three-gene models 
Gene t-test  
p-value 
Wald test 
 p-value 
Two-gene 
models 
Three-gene 
models 
AMACR 0.018 0.0085 6 9 
HPRT1 0.008 0.0225 6 6 
SDHA 0.013 0.0197 6 2 
PLAU 0.02 0.0258 5 0 
PTEN 0.038 0.0479 6 0 
ABL1 0.045 0.0535 3 0 
CDH1 0.052 0.0600 2 0 
ATP10B 0.054 0.0580 2 2 
PVT1 0.073 0.0825 1 1 
ANXA2 0.072 0.0762 1 1 
PGC 0.070 0.0741 3 0 
EFNA5 0.151 0.0904 1 2 
TRAFD1 0.149 0.1245 2 1 
POP5 0.088 0.0975 2 1 
DPT 0.098 0.1022 1 2 
GUCY1A1 0.149 0.1015 4 0 
PCDH18 0.197 0.1157 2 0 
CD109 0.125 0.1277 2 0 
NDUFAF1 0.154 0.1669 1 0 
 
The following section provides a brief description of the potential significance of the 
genes found in the best performing predictive models. 
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 Genes included in the highest multivariate logistic regression 
models according to χ2  
 Genes with high prevalence in the models 
AMACR   
AMACR (alpha-methyl-CoA racemase) was the most prevalent gene in the best 
performing two- and three-gene models according to χ2 by several fold. AMACR was 
a predictor in each of the highest ranking three-gene models and demonstrated 
a significant reduction in expression in the recurrent compared with the non-recurrent 
samples (p<0.05). AMACR encodes a peroxisomal and mitochondrial enzyme involved in 
the beta-oxidation of branched chain fatty acids and bile acid intermediates (337) and is 
well-documented in prostate cancer where it is overexpressed at both the 
transcriptional and protein level (191, 199). Immunohistochemistry of AMACR is 
currently utilised as a diagnostic tissue marker of the disease in biopsy samples (338).  
Regarding its prognostic potential, the results are conflicting. In agreement with our 
findings, some studies have found reduced AMACR expression (mRNA/protein) to be 
correlated with disease progression in prostate cancer. Low mRNA/protein expression 
of AMACR has been found to be correlated with adverse clinicopathological parameters, 
including elevated clinical stage (339, 340), and several studies have shown 
a significantly lower expression in metastatic compared to localized disease (341, 342). 
Few studies have correlated AMACR expression with outcome, although Rubin et al. 
found low AMACR protein expression to be an independent predictor of BCR in a cohort 
of RP patients (343). They also found low AMACR expression to be predictive of disease-
specific death in conservatively managed prostate cancer patients (343). Other studies 
have either found no significant association between AMACR expression and outcome 
(339) or the opposite finding of an association between high expression and poor 
prognosis (344, 345).  
Increased AMACR expression may be important for energy provision in prostate cancer 
cells, through its role in the beta-oxidation of fatty acids, a catabolic pathway which 
generates energy in the form of ATP (346). De novo fatty acid synthesis is also 
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consistently upregulated in prostate cancer through the overexpression of fatty acid 
synthase, particularly with disease progression (347, 348). The significance of 
a downregulation in AMACR with disease progression as found in our study and others 
is not yet known. It may reflect a complex shifting balance between lipid synthesis and 
oxidation to ensure that both lipids and energy are supplied to the prostate cancer cells 
for growth and survival (346). 
HPRT1 
HPRT1 (hypoxanthine phosphoribosyltransferase 1) was the most significantly 
differentially expressed gene between the groups, showing significantly lower 
expression in the recurrent versus non-recurrent group (p<0.01).  
HPRT1 had originally been included on the array as a housekeeping gene. Its use as 
a reference gene in this study was precluded by its high variability between the samples, 
including between the recurrent and non-recurrent group (Appendix 4). The finding that 
HPRT1 expression varied significantly between the non-recurrent and recurrent group 
was novel and highlighted the fact that so-called housekeeping genes can vary 
considerably under different circumstances and need to be selected carefully. Contrary 
to our findings, some studies have demonstrated the suitability of HPRT1 as a reference 
gene in prostate cancer as they demonstrated its low variability between samples, 
particularly between different grades and stages of disease (289). As a result of HPRT1 
being considered a housekeeping gene, there are few studies that have investigated its 
expression as a target gene in prostate cancer.  
HPRT1 encodes a central enzyme in the purine salvage pathway, which synthesizes 
purine nucleotides from intermediates produced in the degradative pathway for RNA 
and DNA (349). It is important to note that purines can be synthesized by either the de 
novo pathway or the salvage pathway (350). The de novo synthesis of nucleotides is 
known to be significantly upregulated in neoplastic cells to support DNA replication and 
RNA production to maintain cellular proliferation and growth. This is achieved through 
the utilization of intermediates from glycolysis and the TCA cycle, and the upregulation 
of enzymes that catalyse the de novo pathway (351, 352). In comparison, the nucleotide 
salvage pathway in cancer is not well understood. Our findings suggest a possible down-
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regulation in the purine salvage pathway, which conflicts with some other reports. Other 
studies have found an upregulation of HPRT1 gene expression with disease progression 
in prostate cancer (353, 354). 
SDHA 
SDHA showed a significantly increased expression in the recurrent versus non-recurrent 
group (p<0.05). Similar to HPRT1, SDHA had originally been included on the array as 
a housekeeping gene. 
SDHA (succinate dehydrogenase complex flavoprotein subunit A) encodes one of the 
main catalytic subunits of succinate dehydrogenase (SDH: mitochondrial complex II), 
a mitochondrial enzyme involved in two essential processes of cellular energy 
production: the TCA cycle and oxidative phosphorylation (355). The TCA cycle is a final 
common pathway for the oxidation of glucose, glutamine and fatty acids, which is 
central to cellular energy production and provision of intermediates for macromolecule 
synthesis (356). Succinate dehydrogenase (SDH) couples the oxidation of succinate to 
fumarate in the TCA cycle, with the transfer of electrons to ubiquinone in the electron 
transfer chain (355). The electron transfer chain is the site of oxidative phosphorylation 
and the final stage of aerobic respiration, which is responsible for production of energy 
in the form of ATP.  
Increased SDHA expression could potentially reflect increased activity in both the TCA 
cycle and the electron transfer chain, and therefore elevated energy production through 
aerobic respiration. Initially, this finding appears contradictory to the Warburg effect, 
a feature of many cancers, which describes a shift towards aerobic glycolysis whereby 
pyruvate is converted to lactate rather than oxidised through the TCA cycle (180). In fact, 
SDHA mutations leading to a reduction or loss of the SDH catalytic subunit and defective 
SDH function are found in some cancers such as paragangliomas and gastrointestinal 
stromal tumours (357, 358). However, metabolic reprogramming exhibits high 
variability both between and within different cancers and it is now generally accepted 
that tumour cells rely on a combination of both aerobic glycolysis (Warburg effect) and 
oxidative metabolism to supply their energy and macromolecular needs (183).  
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As previously described, normal prostate cells have a distinctive metabolism due to 
a truncated TCA cycle which prevents citrate oxidation and ATP production, thereby 
limiting oxidative metabolism (359). In comparison to the energy inefficient normal 
prostate cells, malignant prostate cells switch to a highly energy efficient metabolism, 
with large quantities of citrate oxidised through the TCA cycle (360). The Warburg effect 
tends to become pronounced only at the most advanced stages of the disease (184). 
Our findings suggest increased TCA cycle activity in recurrent disease. Due to the role of 
SDH in coupling the TCA cycle with the electron transfer chain, this may reflect a point 
at which there is increased flux through the final stage of cellular respiration (oxidative 
phosphorylation) to keep up with the increasing energy demands of the cancerous cells 
as the disease progresses. However, in addition to energy production, the TCA cycle is 
important for channelling glycolytic intermediates into various anabolic pathways to 
support the proliferation and growth of cancerous cells (181). For instance, the TCA cycle 
provides precursors for anabolic pathways such as amino acid and fatty acid synthesis. 
Activity in these anabolic pathways and also in catabolic pathways that replenish the 
TCA cycle with metabolites are known to be increased with prostate cancer progression 
(353, 361).  
Other studies have identified TCA cycle activation in prostate cancer (353, 361, 362). 
A recent study by Shao et al. using a combined approach of metabolomics and 
transcriptomics found significant accumulations of TCA cycle metabolites in prostate 
cancer tissue in comparison to normal adjacent tissue (361). The levels of fumarate and 
malate were positively correlated with GS and tumour stage. Of particular interest is the 
fact that most genes involved in the TCA cycle showed significantly increased expression 
in the prostate cancer vs normal tissue. A number of these genes including SDHA were 
positively correlated with GS and tumour stage. These findings directly implicate an 
increased gene expression of SDHA with accumulation of fumarate levels and show 
a positive correlation of SDHA with prostate cancer progression, which concurs with our 
findings. Importantly, several studies that have identified an increased respiratory 
capacity in prostate cancer suggest a significant shift during oxidative phosphorylation 
from NADH (through mitochondrial complex I) towards succinate-supported oxidation 
(via SDH; mitochondrial complex II)(363, 364). It is also important to link the finding of 
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both increased SDHA expression and reduced PTEN expression in recurrent disease in 
this study. This concurs with other studies that found a significant association between 
loss of PTEN in prostate cancer and accumulation of intracellular succinate levels and 
higher succinate-supported oxidation via mitochondrial complex II, which may provide 
cancer cells with a growth and survival advantage (364). 
PLAU 
PLAU (plasminogen activator, urokinase), which encodes a serine protease, was found 
to show significantly increased expression in the recurrent group (p-value 0.020). Of 
interest, PLAU expression was also increased in the GS ≥7 group. The enzyme PLAU, 
upon binding its receptor PLAUR, catalyses the conversion of plasminogen to plasmin, 
promoting the degradation of the basement membrane and ECM by the activation of 
a cascade of proteolytic enzymes (200). This enzyme is one of an array of different 
proteolytic enzymes, which may be released from cancer cells (and transformed stromal 
cells) to facilitate cancer cell invasion and migration through remodelling of the tumour 
microenvironment (200). In agreement with our findings, several studies have found 
increased PLAU and PLAUR protein expression in prostate cancer tissue to be correlated 
with adverse clinicopathological parameters (198, 365). PLAU, either alone or in 
combination with plasminogen activator inhibitor 1 (SERPINE1) has been found to 
independently predict BCR after RP in some studies (198, 365). Increased serum/plasma 
levels of PLAU and PLAUR have also shown promise as independent predictors of poor 
outcome in prostate cancer (366, 367). Few studies have investigated mRNA expression 
of PLAU in prostate cancer. 
PTEN 
PTEN (phosphatase and tensin homolog) was significantly downregulated in the 
recurrent compared with the non-recurrent samples (p-value 0.038). PTEN is a tumour 
suppressor gene whose protein product is an important negative regulator of the 
PI3K/AKT pathway, which promotes cellular growth and survival (146). Genomic loss of 
PTEN is a frequent finding in prostate cancer (145). PTEN deletion is a well-characterised 
poor prognostic factor in prostate cancer, correlated with adverse clinicopathological 
parameters (368, 369) and independently predictive of poor outcome such as 
recurrence after RP (145, 370).  
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Immunohistochemistry (IHC) detection of PTEN protein expression offers a much 
cheaper and less time-consuming method for the detection of PTEN loss than the 
detection of PTEN deletion by Fluorescence In Situ Hybridization (FISH). Furthermore, 
levels of the PTEN protein can be affected by mechanisms other than gene deletion, 
including mutation and epigenetic regulation (371). This would not be identified by FISH 
analysis which may underestimate the extent of PTEN loss. A reduction in PTEN protein 
expression has been found to be a predictor of poor prognosis, including shorter 
recurrence-free survival after RP (372) and an increased risk of prostate cancer-specific 
mortality after surgery and other modalities (373, 374). The studies of PTEN/PTEN loss 
in prostate cancer have favoured in situ methods such as FISH and IHC due to the high 
degree of variability of PTEN between different regions of a tumour (375, 376). 
Therefore, the prognostic potential of PTEN loss at the transcriptional level has not been 
extensively explored. It is interesting to note that loss of PTEN has been found to 
decrease oxidative phosphorylation and promote glycolysis (the Warburg effect)(364). 
This may potentially link the findings in this study of a reduction in the expression of 
both PTEN and NDUFAF1. 
ABL1 
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) was significantly 
upregulated in the recurrent samples (p-value 0.045) and was the gene that showed the 
greatest upregulation in terms of the fold difference (fold difference of ~43). ABL1 
encodes one of the two members of the Abelson family of non-receptor protein tyrosine 
kinases, which have roles in a variety of biological processes including cell proliferation, 
survival and motility (377). ABL1 is commonly associated with chronic myelogenous 
leukaemia, which is driven by activation of the ABL1 gene through its translocation with 
the Breakpoint Cluster Region gene on chromosome 22 to form a fusion gene BCR-ABL1 
(378). 
It is now appreciated that ABL1 and/or ABL2 show increased expression and/or 
activation in many types of solid cancers by mechanisms that do not involve gene 
mutation or translocation. ABL1 protein expression has been found to be increased in 
several types of cancer and correlated with poor prognosis (379, 380). ABL1 activation 
has also been implicated in prostate cancer progression, with some studies identifying 
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a role for ABL1 in the proliferation, survival and motility of prostate cancer cells (381, 
382). A role for ABL1 in bone metastatic growth has been documented in prostate cancer 
(383) and an ABL tyrosine kinase inhibitor has been used experimentally for the 
treatment of bone metastases (384). Few studies have directly correlated ABL1 
expression with prognosis in prostate cancer. However, a recent study by Gupta et al. 
found an increase in copy number gains of ABL1 in circulating tumour cells (CTCs) from 
men with mCRPC (385). 
CDH1 
CDH1 (cadherin 1) showed significantly increased expression in the recurrent versus 
non-recurrent group (p-value 0.052). CDH1 was the only gene that showed a similar 
change in expression in the recurrence analysis of the pilot study. CDH1 encodes an 
important cell adhesion molecule of the cadherin family. The finding of increased CDH1 
expression in the recurrent samples was contradictory to the many studies that have 
documented widespread loss of CDH1 protein expression in epithelial cancer (386). Loss 
of CDH1 is considered a cardinal feature of EMT, whereby cancerous epithelial cells 
acquire a migratory phenotype through the loss of epithelial characteristics and the 
development of mesenchymal properties (387). 
In prostate cancer, most studies have found CDH1 protein expression to be significantly 
downregulated (206, 388). Reduced CDH1 expression has also been correlated with 
adverse clinicopathological parameters in prostate cancer (206, 389) and found to be 
a predictor of BCR and cancer-specific mortality after RP (201, 207). A possible 
explanation of our findings may be the fact that loss of CDH1 is only a transient change 
that occurs at certain stages of disease progression. Some studies have found CDH1 to 
be re-expressed in advanced prostate cancer, where its expression may aid the growth 
and establishment of metastases (390, 391). In fact, CDH1 was downregulated in the GS 
≥7 vs <7 group in our study, suggesting that CDH1 loss may be an earlier change in 
prostate cancer progression.  
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 Genes included less frequently in the top two- and three-gene 
models  
ATP10B 
ATP10B (ATPase phospholipid transporting 10B (putative)) expression was higher in the 
recurrent versus non-recurrent group, with a p-value of 0.054, which was slightly above 
the conventional significance level (p<0.05). ATP10B was found in two of the final two- 
and three-gene models. 
ATP10B encodes a protein with a putative role as the catalytic subunit of an enzyme that 
belongs to the family of P-type ATPases, which function as phospholipid flippases. These 
enzymes couple the hydrolysis of ATP with the translocation of phospholipids from the 
outer to the inner surface of membranes (392). The role of ATP10B in cancer is not 
currently known, although some studies have identified dysregulation of phospholipid 
flippases in cancer cell lines (393). 
PGC 
PGC (progastricsin) expression was lower in the recurrent versus non-recurrent samples 
(p-value 0.070). PGC encodes an aspartic protease produced mainly in the stomach, 
which is a precursor to the digestive enzyme pepsin. However, ectopic expression of 
PGC is found in other organs including the prostate (394). PGC expression has been 
found to be increased in cancerous tissue from some of these organs including prostate 
cancer (395, 396). Our findings concur with several studies which have found increased 
PGC protein expression to be associated with a more favourable prognosis in various 
cancers including prostate cancer (397-399). 
ANXA2 
ANXA2 (annexin A2) was upregulated in the recurrent compared with the non-recurrent 
group (p-value 0.072). ANXA2 encodes a calcium-dependent phospholipid-binding 
protein localized on the cell surface, which is involved in various biological processes 
including cytoskeletal organisation, endosome trafficking and fibrinolysis (400, 401). 
ANXA2 is also expressed by many types of tumour cells and increased ANXA2 expression 
has been documented in a variety of cancers (402). In these cancers, a central 
mechanism by which ANXA2 may promote cancer progression is through its role as a co-
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receptor for plasminogen, which accelerates the conversion of plasminogen to plasmin 
by tissue-type plasminogen activator (403). Plasmin is a serine protease which is 
centrally involved in angiogenesis and tumour cell migration through metalloproteinase 
activation and degradation of the ECM. In the fewer cancers where ANXA2 is 
downregulated its role in progression would likely be through plasminogen-
independent mechanisms (404). 
In prostate cancer ANXA2 expression has been found to be downregulated in well and 
moderately differentiated prostate cancer tissue in comparison to benign prostate 
tissue, but then ANXA2 expression re-emerges in poorly differentiated disease (405). 
A positive relationship between ANXA2 protein expression and disease progression in 
prostate cancer has been demonstrated in several studies (406, 407). For instance, 
increased ANXA2 expression has been found to be predictive of earlier BCR after RP or 
RT (407, 408). 
PVT1 
PVT1 (Pvt1 oncogene) was upregulated in the recurrent group (p-value 0.073), which is 
in agreement with an identified tumourigenic role for PVT1 in prostate cancer through 
its role in cellular proliferation and inhibition of apoptosis (409). The PVT1 gene encodes 
a long non-coding RNA. This gene is mapped to chromosome 8q24, an important risk 
locus for many cancers including prostate cancer, which also contains the well-
characterised oncogene MYC (410). PVT1 has been found to be upregulated in prostate 
cancer, with expression positively correlated with grade and tumour stage in some 
studies (409, 411). Furthermore, increased PVT1 expression has been found to be 
significantly associated with poor disease-specific and overall survival (409, 411). 
POP5 
POP5 (POP5 homolog, ribonuclease P/MRP subunit) showed increased expression in the 
recurrent group (p-value 0.088). The significance of this finding is unclear. The POP5 
protein is a subunit of the RNase MRP and RNase P complexes, which are 
endoribonucleases with a role in the processing of precursor ribosomal RNA (rRNA) and 
precursor transfer RNA (tRNA) respectively (412). This gene has not been previously 
associated with prostate cancer or any other cancers in the literature. 
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DPT 
DPT (dermatopontin) expression was increased in the recurrent versus non-recurrent 
group (p-value 0.098). DPT is a tyrosine-rich ECM protein, which has a role in cell-ECM 
adhesion and ECM assembly, and is centrally involved in wound healing (413). DPT has 
been found to be downregulated at both the mRNA and protein level in some cancers 
(414, 415). In these cancers it appears to act as a metastasis suppressor with lower 
expression correlated with poorer prognosis (414, 415). Its expression in prostate cancer 
has not been described with regard to prognosis. Although the studies in other cancers 
suggest a tumour suppressor role for DPT which is contrary to our findings, a recent 
study has found a pro-angiogenic role for DPT in cancer (416). 
CD109 
CD109 (CD109 molecule) was upregulated in the recurrent group in our study (p-value 
0.125). CD109 is a glycosylphosphatidylinositol-anchored surface antigen with 
a documented role as a negative regulator of TGF-beta-1 signalling (417). Upregulation 
of CD109 mRNA/protein expression has been found to be significantly correlated with 
poor prognosis in some cancers including lung cancer (418, 419). The expression of 
CD109 in prostate cancer has not been described in the literature. 
TRAFD1 
TRAFD1 (TRAF-type zinc finger domain containing 1) was upregulated in the recurrent 
group although the significance was low (p-value of 0.149). TRAFD1 was only found in 
a couple of the final two-gene models and one three-gene model and did not make a 
large contribution to any of these models. TRAFD1 is a negative feedback regulator that 
controls excessive innate immune response through an inhibitory action on TNF 
receptor-associated factor 6 (TRAF6), thereby suppressing nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and MAPK signalling, which are activated by 
TRAF6 (420, 421). The findings in this study of an upregulation of TRAFD1 with recurrent 
disease are contradictory to the studies of other malignancies in which TRAF6 has been 
found to be upregulated and a poor prognostic factor (422, 423). In prostate cancer 
TRAF6 and other members of the TRAF family (with which TRAFD1 also interacts) such 
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as TRAF2 and TRAF4 have been found to be upregulated with high expression associated 
with disease progression (424-426). 
GUCY1A1 
GUCY1A1 (guanylate cyclase 1 soluble subunit alpha 1) was downregulated in the 
recurrent group (p-value of 0.149). GUCY1A1 encodes a subunit of the enzyme soluble 
guanylate cyclase, which through its association with another subunit (GUCY1B1), 
mediates nitric oxide signalling by catalyzing the synthesis of cyclic guanosine 
monophosphate (cGMP). GUCY1A1 is an androgen regulated gene (427) and has been 
found to promote the proliferation and survival of prostate cancer cells independently 
of its enzyme activity, mediators of nitric oxide or androgens (428). Contrary to our 
findings, other studies have found GUCY1A1 expression to be significantly 
overexpressed in prostate cancer tissue (353, 427). GUCY1A1 expression has also shown 
a positive correlation with advanced stage and lethal disease in some prostate cancer 
studies (290, 353). 
EFNA5 
EFNA5 (ephrin A5) was found in the three-gene model with the highest χ2, despite 
a p-value of 0.151 in the independent samples t-test. EFNA5 expression was reduced in 
the recurrent group compared with the non-recurrent group. EFNA5 encodes the 
ephrin-A5 ligand, which is a member of the ephrin A subclass of ephrin ligands. 
Ephrins are membrane bound ligands, which activate tyrosine kinase Eph receptors and 
have regulatory roles in the building and maintenance of organized tissue structures 
during embryonic development (429). Eph-ephrin interactions may result in forward or 
reverse signalling, eliciting a wide array of different cellular effects including both cell 
repulsion and adhesion (430). Eph receptors and ephrins may be upregulated (431, 432) 
or downregulated (433, 434) in cancer, and have demonstrated roles in tumour cell 
proliferation, adhesion, migration and angiogenesis (430). 
Ephrin-A5 is a glycosylphosphatidylinositol-anchored protein with a role in axon 
guidance and migration during brain development (435). Our findings of downregulation 
of EFNA5 in the recurrent patients suggests a tumour suppressor role in prostate cancer. 
Downregulation of EFNA5 mRNA and protein have been demonstrated in other 
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malignancies including glioma, chondrosarcoma and colon cancer, with expression 
negatively associated with their progression (436-438). Downregulation of EFNA5 has 
been documented in malignant versus benign prostate cancer (439, 440), although 
a prognostic role for EFNA5 has not been previously described. However, some of the 
receptors with which ephrin-A5 may interact, have been found to be dysregulated in 
prostate cancer and correlated with disease progression; e.g. downregulation of EPHA5 
and EPHA7, and upregulation of EPHA2 and EPHA3 (441-444). A mechanism by which 
ephrin-A5 may exert a tumour suppressor role could be explained by its effect on cellular 
adhesion. Studies have found that activation of ephrin-A5 by EPHA5 induces signalling 
in the ephrin-A5 expressing cells, which enhances their adhesive properties (445). 
Therefore a reduction in ephrin-A5 may provide a potential mechanism by which tumour 
cells can lose their adhesive properties, allowing tumour cell migration. 
NDUFAF1 
NDUFAF1 (NADH:ubiquinone oxidoreductase complex assembly factor 1) presented as 
a variable in only one of the top two-gene models. A reduction in expression was found 
in the recurrent versus non-recurrent group (p-value of 0.154). The NDUFAF1 protein 
has a role in the assembly of mitochondrial complex I (NADH dehydrogenase)(446), the 
largest enzyme involved in oxidative phosphorylation, which catalyses the first step of 
the mitochondrial electron transport chain. As NDUFAF1 is essential for the proper 
functioning of mitochondrial complex I, the down-regulation of NDUFAF1 in our study 
with recurrent disease implies a possible dysregulation of NADH dehydrogenase in more 
aggressive disease (446). The findings of increased TCA cycle activation (increased SDHA 
expression) but potential dysfunction of a central component of the electron transfer 
chain (reduced NDUFAF1) in more aggressive disease may reflect the start of a shift away 
from complete oxidative metabolism towards aerobic glycolysis (so-called Warburg 
effect) to allow the immediate generation of macromolecules and rapid energy 
production. Alternatively, the two findings together may reflect increased TCA cycle 
activity and functional oxidative metabolism, but with the aforementioned shift from 
NADH to succinate-supported ATP production through mitochondrial complex II (363, 
364). 
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Some studies have found the expression of several key genes involved in oxidative 
phosphorylation to be negatively associated with high Gleason grade and poor outcome 
in prostate cancer (447, 448). These studies did not measure NDUFAF1 expression 
specifically. Downregulation of NDUFAF1 mRNA or protein expression has been 
demonstrated in other cancers and identified as a poor prognostic factor (449, 450). 
It is difficult to state definitively that reduced expression of NDUFAF1 contributes to 
a downregulation in oxidative phosphorylation, as the exact role of NDUFAF1 as one of 
many assembly proteins for mitochondrial complex I is uncertain. 
PCDH18 
PCDH18 (protocadherin 18) was downregulated in the recurrent group (p-value of 
0.197). PCDH18 encodes a member of the nonclustered protocadherins of the cadherin 
superfamily of adhesion molecules (451). PCDH18 is involved in cell-cell adhesion with 
important roles during development of the brain (452, 453). Several of the nonclustered 
protocadherins have now been established as tumour suppressor genes (454, 455). 
PCDH8, PCDH10 and PCDH17 are downregulated by promoter methylation in prostate 
cancer, with downregulation significantly associated with adverse clinicopathological 
parameters and poor outcome (456-458). PCDH18 has not been specifically identified as 
a tumour suppressor gene in prostate cancer. In other cancers PCDH18 has been found 
to be downregulated, with lower PCDH18 expression identified as a poor prognostic 
factor (459, 460). 
 Discussion regarding genes of interest 
In this study, it was evident that a large proportion of the genes found to be important 
predictors in the best performing models of recurrence were genes encoding key 
enzymes of metabolic pathways. These pathways included fatty acid oxidation (AMACR), 
the TCA cycle (SDHA), oxidative phosphorylation (NDUFAF1) and purine metabolism 
(HPRT1, GUCY1A1). 
Metabolic reprogramming is now considered a hallmark trait of cancer and is necessary 
to allow tumour cells to meet their metabolic requirements, which differ from normal 
cells (116). Tumour cells reprogram their anabolic and catabolic metabolism to acquire 
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sufficient energy and cellular building blocks for biomass synthesis, in order to maintain 
growth and support rapid proliferation (461). The study of metabolism in prostate 
cancer is an active area of research, and understanding prostate cancer through 
a metabolic perspective is of great interest (189). In fact, an emerging risk factor for 
prostate cancer is metabolic syndrome, which describes a collection of metabolic risk 
factors for cardiovascular disease including visceral obesity, insulin resistance and 
abnormal cholesterol levels (462). Metabolic syndrome is also associated with 
aggressive potential in prostate cancer as the chronic inflammation associated with this 
condition may promote tumour growth (463, 464).  
Various metabolic changes have previously been identified in prostate cancer and 
associated with its progression (465). Activated metabolic pathways, metabolomic 
signatures and alterations in key metabolic genes have been found to show prognostic 
potential in some recent studies (361, 466). 
The most highly prevalent gene in the best performing gene models of this study, whose 
prevalence far exceeded any other gene, was AMACR, a well-characterised gene in 
prostate cancer which encodes an enzyme involved in fatty acid oxidation (191). A large 
number of studies has described upregulation of AMACR expression (mRNA and protein) 
in prostate cancer and the diagnostic value of AMACR protein expression has been well-
described (191, 467). However, the prognostic role of AMACR has been less fully 
explored, with conflicting results (343, 345). In agreement with our results, some studies 
have found reduced AMACR mRNA/protein expression in more aggressive prostate 
cancer (339, 340). Upregulation of AMACR expression in prostate cancer is likely to 
reflect the reliance of early prostate cancers on fatty acid oxidation as a source of energy 
(468). The significance of reduced AMACR expression in recurrent disease is unclear but 
may relate to the shift towards de novo lipid synthesis, which is feature of advanced 
prostate cancer, or the changing availability of other energy sources at this stage (469).  
The study found a potential shift towards oxidative metabolism in recurrent disease, as 
shown by possible activation of the TCA cycle (increased SDHA expression). Reactivation 
of the TCA cycle is a well-documented characteristic in prostate cancer and has been 
associated with its progression (353, 361). This finding alongside decreased PTEN and 
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NDUFAF1 expression in recurrent disease may reflect a shift towards succinate-
supported oxidation in more aggressive prostate cancer, which has been described by 
others (363, 364). The identification of SDHA and HPRT1 (another metabolic gene) as 
important predictor variables was novel as these genes have rarely been investigated 
with regard to outcome in prostate cancer as they have long been regarded as reference 
genes (289, 470). 
This study identified several other genes as important predictor variables in the best 
performing models, some of which have previously been associated with outcome in 
prostate cancer (e.g. PLAU and PTEN)(366, 369). In particular, PTEN loss is one of the 
most commonly cited genomic events in prostate cancer, which has a strong association 
with disease progression (471). Other important genes of interest found in this study 
have not been previously described in relation to prostate cancer progression (e.g. 
ATP10B and EFNA5). 
It is important to remember that the study identified genes that were differentially 
expressed between the recurrent and non-recurrent group and had strong predictive 
value in combination. It is possible to postulate the effect that these gene changes may 
have on prostate cancer progression. However, it is difficult to directly link mRNA 
changes with a final protein and its activity due to the numerous regulatory mechanisms 
that may occur at the post-transcriptional and post-translational level (472, 473). 
Furthermore, many of these genes encode ‘components’ of proteins only and the exact 
role of these components may not be known (e.g. a subunit or assembly factor of an 
enzyme). Despite a lack of understanding of the precise effect of these transcriptomic 
changes, this does not reduce their predictive value. 
 General discussion and future studies  
A plethora of studies has identified gene expression profiles of disease progression in 
prostate cancer using technologies such as oliognucleotide or cDNA microarray 
technologies. Gene expression profiles have been identified in prostate cancer with the 
potential to predict various clinical endpoints such as BCR, systemic progression and 
prostate cancer-specific death (262, 354, 474). These technologies analyse vast numbers 
of genes, resulting in large amounts of data that are difficult to resolve further. 
182 
 
Generally, these studies have used more sensitive techniques such as real-time qPCR or 
IHC to validate genes of interest in larger numbers of archival samples (261, 290). As 
real-time qPCR is time-consuming, usually only small numbers of genes are validated 
using this technique. Despite the large numbers of potential gene biomarkers and panels 
that have been identified as being associated with outcome in prostate cancer, few have 
been thoroughly validated or brought into clinical practice. The candidate genes have 
also rarely overlapped between studies (334). 
The TaqMan array was chosen for this study as it allowed a significant number of genes 
to be analysed at once, whilst retaining the necessary sensitivity of real-time qPCR, 
which allowed the use of minimally-sized FFPE biopsy samples (277). Archival biopsy 
samples were both readily available and had the necessary clinical follow-up to allow 
correlation of the gene expression data with patient outcome. By testing a significant 
number of genes, it was more likely that useful predictive models could be identified as, 
due to the complexity of the genetic changes in prostate cancer, predictive models 
incorporating multiple genes would seem most feasible (475). 
TaqMan arrays have been used in a small number of other studies to analyse mRNA 
panels in prostate cancer using various selections of candidate genes, although they 
have been used more frequently with microRNA (miRNA) panels (476, 477). Importantly, 
the aforementioned commercially available prognostic gene expression panels called 
Prolaris® and Oncotype DX® use TaqMan array technology (268). 
Many reported gene expression panels in prostate cancer selected candidate genes 
from a limited set of genes or biological pathways that had been previously implicated 
in carcinogenesis. For example, the Prolaris test selected its final gene panel of 31 genes 
from only 126 cell cycle progression genes chosen from the Gene Expression Omnibus 
database (271).   
The genes on our TaqMan array had been selected from 12,600 genes in a published 
microarray dataset. A novel method of machine learning based on a single layer artificial 
neural network (ANN) was utilised to learn from and reduce this data to 44 genes that 
were strongly associated with prostate cancer (286). This method was chosen as it is 
ideally suited to handling complex datasets and reduces them to smaller datasets, which 
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are more likely to contain the most relevant genes of interest (478). Other genes were 
selected due to their repeated association with prostate cancer progression in the 
literature review or as a result of previous work in the department. To the best of my 
knowledge, this particular gene panel has not been described in other studies.  
A number of two- and three-gene logistic regression models were identified that could 
predict 5-year recurrence with relatively high accuracy in a set of prostate cancer 
patients treated with radical prostatectomy/radiotherapy. The particular gene 
combinations found to have powerful predictive value in this study have not been 
described in other studies. In particular, a number of key metabolic genes were well 
represented in the best performing gene models, which have not been extensively 
explored with regard to risk stratification in prostate cancer.  
As a discovery study, this study included various measures to limit the production of 
spurious models, including the avoidance of too many predictor variables for the sample 
size and the avoidance of high multi-collinearity. However, it is imperative to remember 
that these models have only been found to predict recurrence in this particular dataset. 
To understand if the final models would be generalizable to other prostate cancer 
patients, their performance would need to be independently validated in another 
dataset from a completely separate group of prostate cancer patients (external 
validation)(479). An external validation study could focus on the final 28 two-gene and 
9 three-gene models found in this training dataset. The expression of the 19 genes 
included in these models could be measured in biopsy samples from the new set of 
patients (treated with radical prostatectomy/radiotherapy as in the training set) using 
identical methods. It would be essential that the 5-year recurrence status for each of 
the new patients be known to allow each of the final models to be applied to the new 
dataset. The model performance could be assessed initially by calculating the predicted 
probability of 5-year recurrence for each new patient using the previously identified 
parameter estimates for each model in the LR equation. ROC curves could then be 
plotted using these probabilities to assess the discrimination accuracy of the model on 
the new dataset. The AUC value would be a measure of the accuracy of the model to 
discriminate patients into either the recurrent or non-recurrent group and this value 
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could be directly compared with the value obtained for the training set (480). A measure 
of calibration that measures the agreement between predicted and observed outcome 
(e.g. calibration plot) could also be used to assess the performance of each final model 
in the validation compared with the training dataset (481). 
As the collection of data from an entirely new set of prostate cancer patients would be 
difficult to achieve, an alternative method would be to run the final 28 two-gene and 
9 three-gene models on an in silico validation set such as The Cancer Genome 
Atlas/Memorial Sloan-Kettering Cancer Center (TCGA/MSKCC) or Stand Up to 
Cancer/Prostate Cancer Foundation (SU2C/PCF) dataset using a cohort of similarly 
treated prostate cancer patients to this study. 
It is important to consider a potential limitation of using biopsy samples for gene 
expression studies. The well-characterised problem of intratumour heterogeneity may 
also affect gene expression analysis. This may have affected both this study and the pilot 
study as both relied on the use of minimally-sized tissue punches from only one or two 
individual areas (482). However, the selection of the area of highest Gleason grade may 
have been more reliable in the pilot study as the entire prostate was available for 
examination by the pathologist. In comparison, due to sampling error, the biopsy sample 
may have either missed or over-represented the area of highest Gleason grade (103). 
Despite these concerns, several studies have suggested that molecular features may be 
widespread throughout a prostate tumour (483) and prognostic molecular signatures 
have been identified in biopsy samples that were not affected by sampling error (272, 
484). 
Another limitation of the study was the use of recurrence as an endpoint. Ideally, 
systemic progression or prostate cancer-specific death would have been more relevant 
clinical endpoints. Although patients who had suffered metastastic progression (clinical 
recurrence) were included in the recurrent group, many of the patients had suffered 
only BCR within the tested time frame. Therefore, some of the identified genes may 
have been relevant to BCR only, rather than systemic progression. Men who develop 
BCR may have no clinical sign of recurrent disease or may have locally recurrent disease 
or even the presence of metastatic disease, and the clinical course of these patients is 
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highly variable (354). Therefore, BCR is not a relevant predictor of systemic progression 
and a large proportion of these men do not progress to metastatic progression (81). As 
explained earlier, there were insufficient numbers of patients who suffered systemic 
progression or death from prostate cancer within the time frame, to allow these 
endpoints to be used in this study. Future studies using larger datasets, e.g. in silico, 
could potentially investigate whether the identified gene models have the potential to 
predict either systemic progression or prostate cancer-specific death. 
 
2.5 Conclusions 
This study used a TaqMan array to measure the expression of a set of putative 
progression-related genes in diagnostic biopsies of prostate cancer patients treated with 
radical prostatectomy and/or radiotherapy. Using binary logistic regression analysis, 
28 two-gene models and 9 three-gene models were identified, which demonstrated 
good overall performance for the prediction of 5-year recurrence (biochemical/clinical) 
in these patients. Many of the genes found to be important predictors in the models 
were key genes encoding components of metabolic pathways, underlining the 
importance of metabolic reprogramming in prostate cancer progression. 
The best performing three-gene models were: AMACR.EFNA5.SDHA (χ2(3) = 22.483, 
p<0.0001) and AMACR.HPRT1.SDHA (χ2(3) = 22.265, p<0.0001). In addition to their good 
overall performance (low p-value for the LRT statistic (χ2) describing the fit of the data 
under the model as a highly significant improvement over the null model), these models 
showed high discriminatory accuracy as demonstrated by AUC values of 0.812 and 0.829 
respectively. Using an optimal threshold for categorisation of patients into either the 
recurrent or non-recurrent group, AMACR.EFNA5.SDHA demonstrated a sensitivity and 
specificity of 81% and 73.9% respectively. AMACR.HPRT1.SDHA had a sensitivity and 
specificity of 81% and 87% respectively.  
The best performing two-gene models were AMACR.SDHA (χ2(2) = 16.722, p<0.0005) 
and HPRT1.PLAU (χ2(2) = 14.777, p<0.001). In addition to their good overall performance 
as shown by the high significance of χ2, AMACR.SDHA and HPRT1.PLAU had AUC values 
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of 0.784 and 0.808 respectively. AMACR.SDHA demonstrated a sensitivity and specificity 
of 71.4% and 78.3% respectively. HPRT1.PLAU had a sensitivity and specificity of 71.4% 
and 76.1% respectively.  
It is important to remember that the two-gene models, despite their poorer overall 
performance, may be more statistically valid than the three-gene models due to the 
smaller number of predictors, which would make overfitting of the data less likely, 
particularly in this relatively small dataset (11 EPV for the two-gene models in 
comparison to only 7 for the three-gene models). 
The study provided evidence that a panel of progression-related genes could be 
measured in archival prostate biopsies using TaqMan array and a selection of these 
genes could be useful in combination to inform treatment decisions in prostate cancer 
patients, e.g. for the selection of RP patients who would benefit from adjunctive 
treatments such as RT and/or ADT to increase their chance of progression-free survival. 
The predictive models identified in this study would require further validation. Only if 
found to improve upon the use of standard clinical and pathological tools would they be 
suitable for risk stratification at the time of clinical decision-making in prostate cancer. 
As the study followed on from and expanded a pilot study, a large component of this 
study was the method development (275). Several important changes were made to 
increase both the clinical applicability and potentially the validity of the study in 
comparison to the pilot study. As a result of these changes, there were few similarities 
in the results between the two studies regarding the genes of interest identified and the 
predictive models generated. The changes in the BB study included those to enhance 
the robustness of the analysis methods, such as the use of individual baseline and 
threshold settings for each gene to improve the accuracy of the Ct values.  
To increase the clinical applicability of the study, biopsy samples were used in 
preference to radical prostatectomy samples. Importantly, the outcome data for the 
patients was more complete than in the pilot study and the gene expression data were 
analysed with a longer follow-up time.  
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A greater number of models were tested in comparison to the pilot study, as the 
criterion for inclusion of predictors into the multivariate logistic regression analysis was 
relaxed. This was done to prevent the premature exclusion of variables, which could be 
important predictors, despite less than conventional significance (in t-tests). This 
presented a new challenge of ranking the large number of processed models, 
necessitating a new automated approach to analysis.  
A more valid parameter of overall model performance, the LRT statistic (χ2), was used 
for ranking the models rather than the overall percent accuracy that had been used in 
the pilot study, which has several limitations.  
This study detailed a method for whittling down the large number of ranked models to 
a final set of models, taking into consideration the need for the logistic regression 
models to exhibit both high calibration and discriminatory accuracy whilst retaining 
parsimony to prevent overfitting. 
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Appendix 1 Examples of potential biomarkers of prostate cancer progression   
Name of biomarker 
 
Role gene/ 
mRNA/ 
protein 
↑/↓ 
with 
progression 
Sample 
type 
Advantages Disadvantages 
Self-sufficiency in growth signals 
 
MKI67 
 
proliferation marker  
protein Ki-67 
 
cellular marker of 
proliferation 
 
 
 
protein 
 
 
 
 
↑ 
 
tissue 
 
Prognostic value has been demonstrated in RP and 
biopsy samples in prostate cancer (485, 486). 
 
In biopsy samples, expression positively correlated 
with adverse clinicopathological parameters (487); it 
is an independent predictor of various clinical 
endpoints including BCR and prostate cancer-specific 
mortality (PCSM) after RP/RT in some studies (485, 
488). 
 
 
Some biopsy studies failed to find any independent 
prognostic value (489, 490). 
 
As a biopsy-based marker, may suffer from difficulties 
related to molecular heterogeneity between different 
regions of the tumour and limited tumour sampling. 
 
Prognostic potential dependent on cut-off value and 
no standard value has been defined.   
 
EZH2/EZH2 
 
enhancer of zeste 2 
polycomb repressive 
complex 2 subunit 
 
 
 
 
methyltransfer-
ase involved in 
transcriptional 
repression 
 
 
mRNA 
 
 
 
protein 
 
↑ 
 
tissue 
 
 
 
 
EZH2 mRNA expression upregulated in metastatic vs 
localized prostate cancer tissue (491, 492). 
 
 
EZH2 protein expression in RP samples correlates 
with clinicopathological parameters of aggressive 
disease (493); EZH2 found to independently predict 
BCR after RP in a number of studies (494). 
 
 
Some studies found no independent predictive value 
for EZH2 mRNA or protein (495, 496). 
 
Few studies have investigated EZH2 as a biopsy-based 
marker. EZH2 expressed in <10% of prostate cancer 
cells so could be missed in biopsy samples (495, 497). 
 
 
 
MYC 
 
MYC proto-oncogene, 
bHLH transcription factor 
 
transcription 
factor 
 
 
DNA 
 
 
 
 
 
↑ 
 
tissue 
 
MYC amplification increases in frequency with 
prostate cancer progression (129); some studies 
have found MYC amplification to be an independent 
predictor of BCR after RP/RT (129, 130). 
 
MYC amplification may be infrequently found in low 
grade/early stage prostate cancers so its prognostic 
value may be relevant to advanced prostate cancers 
only (129). 
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Measurement of MYC amplification requires 
Fluorescence In Situ Hybridisation (FISH) which makes 
it difficult to implement routinely.  
 
Insensitivity to anti-growth signals 
 
PTEN/PTEN 
 
phosphatase and tensin 
homolog 
 
negative 
regulator of the 
PI3K/AKT 
pathway 
 
gene 
 
 
 
 
 
 
 
protein 
 
 
 
↓ 
 
 
 
 
 
 
 
↓ 
 
 
tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTEN genomic deletion increases in frequency with 
prostate cancer progression (145); some studies 
have found PTEN deletion to be significantly 
associated with early recurrence after RP (145, 369). 
 
 
 
 
Limited number of studies have investigated the 
potential of PTEN loss to predict PCSM (369, 498). 
 
FISH analysis is labour-intensive and may 
underestimate the frequency of PTEN protein loss as 
genomic deletion is not the only mechanism of PTEN 
loss. 
 
Variability in reported frequency of PTEN protein loss; 
studies investigating the prognostic value of PTEN 
protein loss have shown conflicting results with an 
independent prognostic value demonstrated in some 
studies (373, 499), but not others (145, 500). 
 
 
31-gene signature of cell 
cycle progression (CCP) 
genes 
   
mRNA 
 
↑ CCP score 
 
tissue 
 
 
 
 
 
 
 
 
 
Validated in several independent cohorts using 
biopsy samples and found to be an independent 
predictor of BCR after RP/RT (269, 501); and PCSM in 
conservatively managed patients (502). Prognostic 
ability found to exceed standard clinicopathological 
variables in some studies (503). 
 
Commercially available as the biopsy-based Prolaris 
test (Myriad Genetics), which may provide additional 
meaningful information to risk assessment of 
localized prostate cancer at the time of treatment 
selection (268). 
 
 
 
Prospective studies are required to monitor the 
outcome of changing treatments in response to 
Prolaris test results (particularly shifting patients from 
interventional to conservative treatment). 
 
Expensive. 
 
 
 
Evading apoptosis 
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BCL2 
 
apoptosis regulator Bcl-2 
inhibits the action 
of proapoptotic  
proteins at the 
cell membrane 
 
 
protein 
 
↑ 
 
tissue 
Has been found to independently predict BCR after 
RP/RT in a handful of studies (504, 505). 
 
Other studies have found no significant predictive 
value (201, 506). 
Limited number of studies. 
 
 
IGFBP3 
 
insulin-like growth factor- 
binding protein 3 
 
proapoptotic role 
by limiting the 
availability of free 
insulin-like 
growth factors 
 
protein 
 
↓ 
 
plasma/ 
serum 
 
Inversely correlated with clinicopathological 
parameters of aggressive disease and poor prognosis 
in some studies (152, 507). 
 
 
 
 
Limited number of studies with some failing to find any 
prognostic value for circulating IGFBP3 (508, 509). 
 
IGFBP3 is highly abundant in circulation and affected 
by a variety of factors. 
Sustained angiogenesis 
 
MVD 
 
microvessel density 
 
 
 
 
 
 
 
 
measured by IHC 
against 
endothelial cell 
markers 
 
 
 
 
 
 
protein 
 
↑ 
 
tissue 
 
Correlated with adverse clinicopathological 
parameters (510); studies have found MVD to be an 
independent predictor of BCR after RP (177, 511). It 
has also been found to be predictive of poor survival 
(512, 513). 
 
 
 
 
 
No independent predictive value found by others 
(514), likely due to differing methodologies including 
the endothelial marker chosen, the representative 
tumour area selected and the counting method (515). 
 
Problems with lack of specificity of markers/difficulties 
with staining newly formed vessels. 
 
Few studies have investigated predictive value of MVD 
in biopsy samples. 
 
 
PTGS2 
 
prostaglandin G/H 
synthase 2 
 
 
 
 
 
 
enzyme involved 
in the production 
of prostaglandins; 
a central 
mediator of 
angiogenesis 
 
protein 
 
 
 
 
 
 
 
 
 
 
 
↑ 
 
tissue 
 
 
 
 
 
 
 
 
 
Correlated with adverse clinicopathological 
parameters (172); an independent predictor of BCR 
and PCSM after RP in some studies (172, 516). 
 
 
 
 
 
Conflicting results by others who have either failed to 
find any predictive value for PTGS2 or found no 
independent predictive value (517, 518). 
 
Variation in the methods used for measuring staining 
intensity. 
 
PTGS2 expression may be restricted to infiltrating 
inflammatory cells including lymphocytes and 
macrophages (519). 
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Invasion and metastasis 
 
PLAU/PLAUR 
 
urokinase-type 
plasminogen 
activator/urokinase 
plasminogen activator 
surface receptor 
 
 
serine protease 
involved in 
degradation of 
the basement 
membrane and 
ECM 
 
protein 
 
↑ 
 
plasma/ 
serum 
 
PLAU and PLAUR positively correlated with clinical 
parameters of disease progression (520); 
preoperative PLAU found to be an independent 
predictor of progression after RP (520, 521). 
 
PLAUR alone or in combination with miR-375 
microRNA has been found to be highly predictive of 
disease-specific/overall survival (367, 522). 
  
 
Relatively few studies have investigated the prognostic 
potential of soluble PLAU/PLAUR. 
 
Cleaved forms of soluble PLAUR may be most 
significant prognostically (523, 524). 
 
 
CDH1 
 
cadherin-1 
 
epithelial cell 
adhesion 
molecule 
 
protein 
 
↓ 
 
tissue 
 
Reduced expression is correlated with adverse 
clinicopathological parameters (206); independent 
predictor of recurrence after RP and RT (201, 525); 
reduced expression associated with poor disease-
specific survival (207, 389). 
 
 
 
 
Other studies failed to find any independent predictive 
value for CDH1 (526, 527). 
 
A wide variety of different methods for scoring 
between studies. 
 
Loss of CDH1 may be a transient change at certain 
stages of progression only and CDH1 may be re-
expressed in mCRPC (205). 
 
 
Four-kallikrein panel 
 
 
 
algorithm using 
results from four 
prostate-specific 
kallikrein assays 
(total PSA (tPSA), 
free PSA (fPSA), 
intact PSA and 
kallikrein-2) and 
clinical 
information 
 
protein 
 
↑ 
 
plasma 
 
Has undergone extensive validation and 
commercially available as the 4Kscore® Test (OPKO 
Lab); improves the prediction of biopsy detectable, 
high grade (≥7) prostate cancer (528, 529). 
 
Improves the prediction of aggressive histopathology 
found at RP (pT3-pT4, extracapsular extension, 
tumour volume >0.5cm3 or any Gleason grade ≥4) 
when added to a clinical model containing age, 
stage, PSA and biopsy findings (530); another study 
found that the panel predicts 20-year risk of 
metastasis (531). 
 
 
High cost. 
 
Shows significant potential for limiting unnecessary 
biopsies (532) but prognostic potential is limited by the  
small number of studies that have investigated more 
specific endpoints such as recurrence after treatment 
and disease-specific mortality. 
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[-2]proPSA(p2PSA) and its 
derivatives;  
Beckman Coulter 
Prostate Health Index 
(PHI)  
[(p2PSA/fPSA)x √tPSA] 
 
p2PSA is an isoform of 
precursor PSA 
(component of fPSA) 
  
protein 
 
↑ 
 
serum 
 
PHI has been found to have greater ability to predict 
prostate cancer and GS ≥7 disease than tPSA 
or %fPSA (533). 
 
Predictive of unfavourable pathology and BCR in RP 
patients (534, 535); may be useful in preoperative 
setting. 
 
PHI improves prediction of biopsy reclassification 
during follow-up in active surveillance patients 
(Gleason ≥7, >2 positive cores, >50% of any core 
involved with cancer) (536). 
 
 
Further research needed to assess clinical utility. 
 
Limited number of studies which tended to use 
samples with tPSA values of <10ng/ml-may have 
exaggerated the predictive potential of PHI. 
 
 
 
Genomic instability 
 
TMPRSS:ERG 
 
transmembrane serine 
protease 2:ETS 
transcription factor ERG 
 
 
 
gene fusion 
measured using 
FISH/ 
RT-qPCR/ERG 
immunostaining 
 
DNA/ 
mRNA/ 
protein 
 
 
 
 
 
 
 
 
 
 
mRNA 
 
 
positive vs 
negative/↑ 
 
 
 
 
 
 
 
 
 
 
 
↑ 
 
tissue 
 
 
 
 
 
 
 
 
 
 
 
 
urine 
 
Correlated with adverse clinicopathological 
parameters (537); independent predictor of BCR and 
PCSM after RP in some studies (538, 539). 
 
Independent predictor of disease progression and 
PCSM in conservatively managed cohorts in some 
studies (540, 541).  
 
 
 
 
 
 
 
Useful for the detection of aggressive disease (542, 
543). 
  
 
Other studies have found a null or even an inverse  
association with poor clinical outcome (500, 544). 
 
Prognostic significance may be dependent on the type 
of rearrangement causing the fusion, e.g. 
rearrangement through deletion; therefore FISH may 
be the most appropriate method, which is labour-
intensive (545). 
 
ERG immunostaining offers a much easier assay but 
may also detect fusions between ERG and other genes. 
 
Only a proportion of prostate cancers carry this fusion 
gene, hence its prognostic ability may be dependent 
on its combination with other markers. 
 
Stromal interactions 
 
stromal HA/tumoural 
HYAL1 
 
glycosamino-
glycan 
 
protein 
 
↑ 
 
tissue 
 
HA correlated with some adverse clinicopathological 
parameters (237); HYAL1 alone or in combination 
 
No independent prognostic value for HA found in 
other studies (237, 547). 
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stromal 
hyaluronan/tumoural 
hyaluronidase-1 
 
component of the 
ECM/ 
hyaluronidase 
degrades 
hyaluronan 
 
with HA has been found to independently predict 
BCR after RP in some studies (241, 546). 
 
 
Limited number of studies. 
 
 
 
serum BAP/uNTX 
 
serum bone-specific 
alkaline phosphatase/ 
urinary N-telopeptide 
 
 
bone formation 
marker/bone 
resorption marker 
 
protein 
 
↑ 
 
serum/ 
urine 
 
Both predict poor overall survival in patients with 
metastatic disease (548, 549); may be useful to 
monitor response to treatment in metastatic disease 
. 
 
No prognostic value in non-metastatic disease.  
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Appendix 2 Genes on the BB and SL array 
Appendix 2a List of genes and assay numbers on the BB array. Genes in green were 
included on the BB array only. Assay numbers in red denote the use of a different assay 
number to the SL array.  
Gene name Alternative 
name(s) 
Full name ABI assay ID 
number 
Oncogenes 
APOBEC3G CEM15  
MDS019 
bK150C2.7 
dJ494G10.1 
apolipoprotein B mRNA  
editing enzyme catalytic  
subunit 3G 
Hs00222415_m1 
EEF1A1 EE1A1 
EEF1A 
EF1A 
LENG7 
eukaryotic translation  
elongation factor 1 alpha 1 
Hs00265885_g1 
ERG erg-3 
p55 
ERG, ETS transcription factor Hs00171666_m1 
EZH2 ENX-1 
EZH1 
KMT6 
KMT6A 
enhancer of zeste 2 polycomb 
repressive complex 2 subunit 
Hs00544830_m1 
NELL2 NRP2 neural EGFL like 2 Hs00196254_m1 
PVT1 LINC00079 
NCRNA00079 
Pvt1 oncogene Hs01069044_m1 
RHBDL1 RHBDL 
RRP 
rhomboid like 1 Hs00610210_g1 
Tumour suppressor genes 
BRCA2 BRCC2 
FACD 
FAD 
FAD1 
FANCD  
FANCD1 
BRCA2, DNA repair associated Hs01037414_m1 
PTEN BZS 
MHAM 
MMAC1 
PTEN1 
TEP1 
phosphatase and tensin  
homolog 
Hs00829813_s1 
RAP1GAP RAP1GA1 
RAP1GAP1 
RAP1GAPII 
RAP1 GTPase activating  
protein 
Hs00182299_m1 
SERPINB5 PI5 
maspin 
serpin family B member 5 Hs00985285_m1 
TGFB2  transforming growth factor 
beta 2 
Hs00234244_m1 
Apoptosis related 
ABL1 JTK7 
c-ABL  
p150 
ABL proto-oncogene 1,  
non-receptor tyrosine kinase 
 Hs00245443_m1 
EDNRA ET-A 
ETA-R 
endothelin receptor type A Hs00609865_m1 
HSPB1 CMT2F 
Hs.76067  
heat shock protein family B 
(small) member 1 
Hs00356629_g1 
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HSP27 
HSP28 
Hsp25 
Angiogenic 
ANXA2 ANX2 
ANX2L4 
CAL1H 
LIP2 
LPC2D 
annexin A2 Hs00743063_s1 
EFNA1 ECKLG 
EPLG1 
LERK1 
TNFAIP4 
ephrin A1 Hs00358886_m1 
EFNA2 ELF-1 
EPLG6 
LERK6 
ephrin A2 Hs00154858_m1 
EFNA3 EPLG3 
Ehk1-L 
LERK3 
ephrin A3 Hs00191913_m1 
EFNA4 EPLG4 
LERK4 
ephrin A4 Hs00193299_m1 
EFNA5 AF1 
EPLG7  
LERK7 
ephrin A5 Hs00157342_m1 
MMP2 CLG4 
CLG4A 
TBE-1 
matrix metallopeptidase 2 Hs00234422_m1 
VASH1 KIAA1036 vasohibin 1 Hs00208609_m1 
Invasion and metastasis related 
ALCAM CD166 
MEMD 
activated leukocyte cell  
adhesion molecule 
Hs00233455_m1 
ANPEP CD13 
gp150 
LAP1 
p150 
PEPN 
alanyl aminopeptidase,  
membrane 
Hs00174265_m1 
CD44 CSPG8  
HCELL  
IN 
MC56 
MDU2 
MDU3 
MIC4 
Pgp1 
CD44 molecule (Indian blood 
group) 
Hs00174139_m1 
CD9 MIC3 
MRP-1 
TSPAN29 
CD9 molecule Hs00233521_m1 
CDC42EP3 BORG2 
CEP3 
UB1 
CDC42 effector protein 3 Hs00377831_m1 
CDH1 CD324 
UVO 
cadherin 1 Hs01023894_m1 
DPT  dermatopontin Hs00355056_m1 
F11R CD321 
JAM-1 
JAMA 
JCAM 
PAM-1 
F11 receptor Hs00375889_m1 
GUCY1A1 GUCY1A3 
GC-SA3  
GUC1A3 
guanylate cyclase 1 soluble 
subunit alpha 1 
Hs00168325_m1 
ITGA2 CD49B integrin subunit alpha 2 Hs00158127_m1 
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ITGA3 CD49c 
GAP-B3 
MSK18 
VCA-2 
VLA3a 
integrin subunit alpha 3 Hs00233722_m1 
ITGA5 CD49e 
FNRA 
integrin subunit alpha 5 Hs00233743_m1 
ITGB4 CD104 integrin subunit beta 4 Hs00236216_m1 
ITGB6  integrin subunit beta 6 Hs00168458_m1 
MUC1 CD227 
MCKD1 
PEM 
PUM 
mucin 1, cell surface  
associated 
Hs00904314_g1 
PCDH18 PCDH68L protocadherin 18 Hs01556217_m1 
PLAU UPA 
URK 
plasminogen activator,  
urokinase 
Hs01547054_m1 
Metabolic 
ALPG ALPPL2 
GCAP 
alkaline phosphatase, germ 
cell 
Hs00741068_g1 
AMACR P504S 
RACE 
alpha-methylacyl-CoA  
racemase 
Hs02786742_s1 
CYP11A1 CYP11A  
P450SCC 
cytochrome P450 family 11 
subfamily A member 1 
Hs00167984_m1 
FABP5 E-FABP 
KFABP 
PA-FABP 
fatty acid binding protein 5 Hs02339439_g1 
FADS1 D5D 
FADS6 
FADSD5  
LLCDL1 
TU12 
fatty acid desaturase 1 Hs00203685_m1 
HPX  hemopexin Hs00167197_m1 
INMT  indolethylamine N-
methyltransferase 
Hs00198941_m1 
PNP NP 
PUNP 
purine nucleoside  
phosphorylase 
Hs01002926_m1 
TF PRO1557 
PRO2086 
transferrin Hs00169070_m1 
Differentiation and proliferation 
ASB2 ASB-2 ankyrin repeat and SOCS box 
containing 2 
Hs00387867_m1 
CDKN1C BWCR 
BWS 
KIP2 
P57 
p57Kip2 
cyclin dependent kinase  
inhibitor 1C 
Hs00175938_m1 
ERBB2 HER-2 
HER2 
NEU 
erb-b2 receptor tyrosine  
kinase 2 
Hs01001598_g1 
GPR12 GPCR21 G protein-coupled receptor 12 Hs00271037_s1 
HOXC6 HOX3 
HOX3C 
homeobox C6 Hs00171690_m1 
HPN TMPRSS1 hepsin Hs00170096_m1 
IRF7  interferon regulatory factor 7 Hs00242190_g1 
ITGB1 CD29 
FNRB 
GPIIA 
MDF2 
MSK12 
integrin subunit beta 1 Hs00559595_m1 
MKI67 KIA 
MIB-1 
marker of proliferation Ki-67 Hs01032443_m1 
NUP50 NPAP60L nucleoporin 50 Hs00538109_m1 
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PSCA  prostate stem cell antigen Hs00194665_m1 
PTGFR FP prostaglandin F receptor  Hs00168763_m1 
PRELID3A SLMO1 
C18orf43 
HFL-EDDG1 
PRELI domain containing 3A Hs00272505_s1 
TBRG4 Cpr2 
FASTKD4 
transforming growth factor 
beta regulator 4 
Hs00191057_m1 
TRAFD1 FLN29 TRAF-type zinc finger domain 
containing 1 
Hs00198630_m1 
Detox 
GSTM3 GST5 glutathione S-transferase mu 3 Hs00356079_m1 
GSTM5  glutathione S-transferase mu 5 Hs00757076_m1 
MT1X MT-1l 
MT1 
metallothionein 1X Hs00745167_sH 
Others 
ATP10B ATPVB 
KIAA0715 
ATPase phospholipid  
transporting 10B (putative) 
Hs00391638_m1 
ATP5MPL C14orf2 
MP68 
ATP synthase membrane 
subunit 6.8PL 
Hs00191690_m1 
C3 ARMD9 
CPAMD1 
complement C3 Hs01100917_g1 
CANX CNX 
IP90 
P90 
calnexin Hs00233492_m1 
CD109 CPAMD7 CD109 molecule Hs00370347_m1 
CD4 CD4mut CD4 molecule Hs00181217_m1 
CHM DXS540 
REP-1  
TCD 
CHM, Rab escort protein 1 Hs00166083_m1 
CRHR1 CRF-R 
CRF1 
CRHR 
corticotropin releasing  
hormone receptor 1 
Hs00366363_m1 
GPM6A GPM6 glycoprotein M6A Hs00245530_m1 
GPR19  G protein-coupled receptor 19 Hs00272049_s1 
KLHL5  kelch like family member 5 Hs00375006_m1 
MNX1 HB9 
HLXB9  
HOXHB9  
SCRA1 
motor neuron and pancreas 
homeobox 1 
Hs00232128_m1 
NDUFAF1 CGI-65 
CIA30 
NADH:ubiquinone  
oxidoreductase complex  
assembly factor 1 
Hs00211245_m1 
PGC  progastricsin Hs00160052_m1 
PLCL2 PLCE2 phospholipase C like 2 Hs00392897_m1 
PLLP PMLP 
TM4SF11 
plasmolipin Hs00762550_s1 
POP5  POP5 homolog, ribonuclease 
P/MRP subunit 
Hs00372215_m1 
PRIM2 PRIM2A DNA primase subunit 2 Hs00386277_m1 
PVALB D22S749 parvalbumin Hs00161045_m1 
SLC44A2 CTL2 solute carrier family 44  
member 2 
Hs00220814_m1 
TERT EST2 
TCS1 
TP2 
TRT 
hEST2 
telomerase reverse  
transcriptase 
Hs00162669_m1 
TRIP13 16E1BP thyroid hormone receptor  
interactor 13 
Hs00188500_m1 
Housekeeping genes 
18S rRNA  18S ribosomal RNA Hs99999901_s1 
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HMBS PBGD 
PORC 
UPS 
hydroxymethylbilane synthase Hs00609297_m1 
HPRT1 HGPRT 
HPRT 
hypoxanthine  
phosphoribosyltransferase 1 
Hs99999909_m1 
SDHA FP 
SDH2 
SDHF 
succinate dehydrogenase 
complex flavoprotein subunit 
A 
Hs00188166_m1 
TBP GTF2D1 
SCA17 
TFIID 
TATA-box binding protein Hs00427620_m1 
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Appendix 2b List of genes and assay numbers on the SL array. Genes in blue were 
included on the SL array only. Assay numbers in red denote the use of a different assay 
number to the BB array. 
Gene name Alternative 
name(s) 
Full name ABI assay ID 
number 
Oncogenes 
APOBEC3G CEM15  
MDS019 
bK150C2.7 
dJ494G10.1 
apolipoprotein B mRNA  
editing enzyme catalytic  
subunit 3G 
Hs00222415_m1 
EEF1A1 EE1A1 
EEF1A 
EF1A 
LENG7 
eukaryotic translation  
elongation factor 1 alpha 1 
Hs00265885_g1 
ERG erg-3 
p55 
ERG, ETS transcription factor Hs00171666_m1 
EZH2 ENX-1 
EZH1 
KMT6 
KMT6A 
enhancer of zeste 2 polycomb 
repressive complex 2 subunit 
Hs00172783_m1 
NELL2 NRP2 neural EGFL like 2 Hs00196254_m1 
PVT1 LINC00079 
NCRNA00079 
Pvt1 oncogene Hs00413039_m1 
RHBDL1 RHBDL 
RRP 
rhomboid like 1 Hs00610210_g1 
SFPQ PSF 
PPP1R140 
splicing factor proline and  
glutamine rich 
Hs00192574_m1 
Tumour suppressor genes 
BRCA2 BRCC2 
FACD 
FAD 
FAD1 
FANCD  
FANCD1 
BRCA2, DNA repair associated Hs00609060_m1 
RAP1GAP RAP1GA1 
RAP1GAP1 
RAP1GAPII 
RAP1 GTPase activating  
protein 
Hs00182299_m1 
SERPINB5 PI5 
Maspin 
serpin family B member 5 Hs00184728_m1 
TGFB2  transforming growth factor 
beta 2 
Hs00236092_m1 
Apoptosis related 
ABL1 JTK7 
c-ABL  
p150 
ABL proto-oncogene 1,  
non-receptor tyrosine kinase 
 Hs00245443_m1 
EDNRA ET-A 
ETA-R 
endothelin receptor type A Hs00609865_m1 
HSPA5 GRP78 
BiP 
heat shock protein family A 
(Hsp70) member 5 
Hs00607129_gH 
HSPB1 CMT2F 
Hs.76067  
HSP27 
HSP28 
Hsp25 
heat shock protein family B 
(small) member 1 
Hs00356629_g1 
MYC c-Myc 
MYCC 
MYC proto-oncogene, bHLH 
transcription factor 
Hs00153408_m1 
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HSP90B1 TRA1 
GRP94 
GP96 
heat shock protein 90 beta 
family member 1 
Hs00427665_g1 
Angiogenic 
ANXA2 ANX2 
ANX2L4 
CAL1H 
LIP2 
LPC2D 
annexin A2 Hs00743063_s1 
EFNA1 ECKLG 
EPLG1 
LERK1 
TNFAIP4 
ephrin A1 Hs00358886_m1 
EFNA2 ELF-1 
EPLG6 
LERK6 
ephrin A2 Hs00154858_m1 
EFNA3 EPLG3 
Ehk1-L 
LERK3 
ephrin A3 Hs00191913_m1 
EFNA4 EPLG4 
LERK4 
ephrin A4 Hs00193299_m1 
EFNA5 AF1 
EPLG7  
LERK7 
ephrin A5 Hs00157342_m1 
MMP2 CLG4 
CLG4A 
TBE-1 
matrix metallopeptidase 2 Hs00234422_m1 
MMP9 CLG4B matrix metallopeptidase 9 Hs00234579_m1 
VASH1 KIAA1036 vasohibin 1 Hs00208609_m1 
Invasion and metastasis related 
ALCAM CD166 
MEMD 
activated leukocyte cell  
adhesion molecule 
Hs00233455_m1 
ANPEP CD13 
gp150 
LAP1 
p150 
PEPN 
alanyl aminopeptidase,  
membrane 
Hs00174265_m1 
CD44 CSPG8  
HCELL  
IN 
MC56 
MDU2 
MDU3 
MIC4 
Pgp1 
CD44 molecule (Indian blood 
group) 
Hs00174139_m1 
CD9 MIC3 
MRP-1 
TSPAN29 
CD9 molecule Hs00233521_m1 
CDC42EP3 BORG2 
CEP3 
UB1 
CDC42 effector protein 3 Hs00377831_m1 
CDH1 CD324 
UVO 
cadherin 1 Hs00170423_m1 
CDH2 NCAD 
CDHN 
CD325 
cadherin 2 Hs00169953_m1 
CTNNA1 CAP102 catenin alpha 1 Hs00426996_m1 
DPT  dermatopontin Hs00170030_m1 
F11R CD321 
JAM-1 
JAMA 
JCAM 
F11 receptor Hs00375889_m1 
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PAM-1 
GUCY1A1 GUCY1A3 
GC-SA3  
GUC1A3 
guanylate cyclase 1 soluble 
subunit alpha 1 
Hs00168325_m1 
ITGA2 CD49B integrin subunit alpha 2 Hs00158127_m1 
ITGA3 CD49c 
GAP-B3 
MSK18 
VCA-2 
VLA3a 
integrin subunit alpha 3 Hs00233722_m1 
ITGA5 CD49e 
FNRA 
integrin subunit alpha 5 Hs00233743_m1 
ITGB4 CD104 integrin subunit beta 4 Hs00173995_m1 
ITGB6  integrin subunit beta 6 Hs00168458_m1 
PCDH18 PCDH68L protocadherin 18 Hs00251855_m1 
TGM2 TGC transglutaminase 2 Hs00190278_m1 
WIF1  WNT inhibitory factor 1 Hs00183662_m1 
Metabolic    
ALPG ALPPL2 
GCAP 
alkaline phosphatase, germ 
cell 
Hs00741068_g1 
AMACR P504S 
RACE 
alpha-methylacyl-CoA  
racemase 
Hs00204885_m1 
CYP11A1 CYP11A  
P450SCC 
cytochrome P450 family 11 
subfamily A member 1 
Hs00167984_m1 
FABP5 E-FABP 
KFABP 
PA-FABP 
fatty acid binding protein 5 Hs02339439_g1 
FADS1 D5D 
FADS6 
FADSD5  
LLCDL1 
TU12 
fatty acid desaturase 1 Hs00203685_m1 
INMT  indolethylamine N-
methyltransferase 
Hs00198941_m1 
PNP NP 
PUNP 
purine nucleoside  
phosphorylase 
Hs00165367_m1 
Differentiation and proliferation 
ASB2 ASB-2 ankyrin repeat and SOCS box 
containing 2 
Hs00387867_m1 
CDKN1C BWCR 
BWS 
KIP2 
P57 
p57Kip2 
cyclin dependent kinase  
inhibitor 1C 
Hs00175938_m1 
GPR12 GPCR21 G protein-coupled receptor 12 Hs00271037_s1 
HOXC6 HOX3 
HOX3C 
homeobox C6 Hs00171690_m1 
HPN TMPRSS1 hepsin Hs00170096_m1 
IRF7  interferon regulatory factor 7 Hs00242190_g1 
ITGB1 CD29 
FNRB 
GPIIA 
MDF2 
MSK12 
integrin subunit beta 1 Hs00559595_m1 
KCNN4 IK 
hSK4 
KCa3.1 
potassium calcium-activated 
channel subfamily N member 
4 
Hs00158470_m1 
NUP50 NPAP60L nucleoporin 50 Hs00855432_g1 
PSCA  prostate stem cell antigen Hs00194665_m1 
PTGFR FP prostaglandin F receptor  Hs00168763_m1 
PRELID3A SLMO1 
C18orf43 
PRELI domain containing 3A Hs00398895_m1 
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HFL-EDDG1 
TBRG4 Cpr2 
FASTKD4 
transforming growth factor 
beta regulator 4 
Hs00191057_m1 
TRAFD1 FLN29 TRAF-type zinc finger domain 
containing 1 
Hs00198630_m1 
Detox 
GSTM3 GST5 glutathione S-transferase mu 3 Hs00168307_m1 
GSTM5  glutathione S-transferase mu 5 Hs00757076_m1 
Others 
ATP10B ATPVB 
KIAA0715 
ATPase phospholipid  
transporting 10B (putative) 
Hs00391638_m1 
ATP5MPL C14orf2 
MP68 
ATP synthase membrane 
subunit 6.8PL 
Hs00191690_m1 
CANX CNX 
IP90 
P90 
calnexin Hs00233492_m1 
CD109 CPAMD7 CD109 molecule Hs00370347_m1 
CD4 CD4mut CD4 molecule Hs00181217_m1 
CHM DXS540 
REP-1  
TCD 
CHM, Rab escort protein 1 Hs00166083_m1 
CRHR1 CRF-R 
CRF1 
CRHR 
corticotropin releasing  
hormone receptor 1 
Hs00366363_m1 
GPM6A GPM6 glycoprotein M6A Hs00245530_m1 
GPR19  G protein-coupled receptor 19 Hs00272049_s1 
KLHL5  kelch like family member 5 Hs00375006_m1 
MNX1 HB9 
HLXB9  
HOXHB9  
SCRA1 
motor neuron and pancreas 
homeobox 1 
Hs00232128_m1 
NDUFAF1 CGI-65 
CIA30 
NADH:ubiquinone  
oxidoreductase complex  
assembly factor 1 
Hs00211245_m1 
PGC  progastricsin Hs00160052_m1 
PLCL2 PLCE2 phospholipase C like 2 Hs00392897_m1 
PLLP PMLP 
TM4SF11 
plasmolipin Hs00762550_s1 
POP5  POP5 homolog, ribonuclease 
P/MRP subunit 
Hs00372215_m1 
PRIM2 PRIM2A DNA primase subunit 2 Hs00386277_m1 
PVALB D22S749 parvalbumin Hs00193520_m1 
RBM12 SWAN 
KIAA0765 
RNA binding motif protein 12 Hs00246072_s1 
SLC44A2 CTL2 solute carrier family 44  
member 2 
Hs00220814_m1 
TERT EST2 
TCS1 
TP2 
TRT 
hEST2 
telomerase reverse  
transcriptase 
Hs00162669_m1 
TRIP13 16E1BP thyroid hormone receptor  
interactor 13 
Hs00188500_m1 
Housekeeping genes 
18S rRNA  18S ribosomal RNA Hs99999901_s1 
HMBS PBGD 
PORC 
UPS 
hydroxymethylbilane synthase Hs00609297_m1 
HPRT1 HGPRT 
HPRT 
hypoxanthine  
phosphoribosyltransferase 1 
Hs99999909_m1 
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SDHA FP 
SDH2 
SDHF 
succinate dehydrogenase 
complex flavoprotein subunit 
A 
Hs00188166_m1 
TBP GTF2D1 
SCA17 
TFIID 
TATA-box binding protein Hs00427620_m1 
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Appendix 3 Background information 
Taqman arrays 
The TaqMan array is a 384-well microfluidic card, which allows up to 384 real-time qPCR 
reactions to be run simultaneously. The card can be customised with 12 to 384 gene 
targets from Applied Biosystems inventoried collection of TaqMan® Gene Expression 
Assays that are preloaded into each well of the card. cDNA samples mixed with PCR 
master mix are loaded via the 8 sample loading ports which are each connected to 
48 (1µl) wells via a network of microchannels, allowing delivery of the sample to the 
wells via a centrifugal filling process.   
 
 
 Picture of a) TaqMan arrays b) TaqMan array loading ports 
 
TaqMan® Gene Expression Assays use TaqMan detection chemistry, which utilises the 
innate 5’ nuclease activity of Taq DNA polymerase to cleave a fluorescently labelled 
sequence-specific probe and produce a detectable signal (550). Each assay contains 
a forward and reverse primer, which are designed to be complementary to specific 
regions of the target sequence, and a TaqMan probe which is complementary to an 
internal region of the template between the two primer sites. The probe is labelled with 
two dyes of different fluorescence emission wavelengths: a reporter dye and a quencher 
dye situated on the 5’ and 3’ end respectively. When the probe is intact, an excited 
Sample loading 
Sample port 
Well 
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reporter dye does not fluoresce but transfers energy to the quencher dye by 
fluorescence resonance energy transfer (FRET) due to the proximity of the two dyes. If 
the target DNA sequence is present, annealing of the forward and reverse primers will 
be followed by binding of the probe to its complementary sequence. Then during the 
extension step of the PCR amplification reaction, as the enzyme reaches the bound 
probe, it utilises its 5’ exonuclease activity to displace the probe and cleave the reporter 
dye from it. The release of the reporter dye prevents FRET, allowing emission of the 
fluorescent signal from the reporter dye, which increases proportionally to the amount 
of accumulated PCR product. These assays show high specificity as the generation of 
a fluorescent signal is dependent on the binding of three different nucleotide sequences 
(forward and reverse primers and probe)(551).  
TaqMan® Gene Expression Assays use a TaqMan MGB probe. The TaqMan MGB probe 
contains a 6-FAM (fluorescein) reporter dye on its 5’ end and both a non-fluorescent 
quencher and a conjugated minor groove binder (MGB) on its 3’ end. 
The use of a non-fluorescent quencher over the more commonly used quencher dye 
TAMRA increases the sensitivity of the assay by keeping the background fluorescence 
low, hence increasing signal to noise ratio (552). The MGB serves to enhance the 
specificity of the assay by increasing the melting temperature of the probe (553). This 
allows shorter probes to be used, which may be designed for enhanced sequence 
discrimination. For instance, in multi-exon genes, probes can be designed which span an 
exon-exon boundary. This ensures that a fluorescent signal will only be generated from 
correctly spliced templates thereby preventing interference of gene quantification by 
genomic DNA (552). 
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Real-time qPCR 
In contrast to conventional PCR which relies on end-point analysis, real-time qPCR allows 
the measurement of accumulated products as the PCR reaction progresses by including 
a fluorescent molecule in the reaction mixture. As the template (cDNA) is simultaneously 
amplified and quantified in real-time qPCR, measurement can take place in the 
exponential phase of the reaction rather than in the plateau phase as in conventional 
PCR, offering a more accurate approach to nucleic acid quantification. During the 
exponential phase, the reaction is working at maximum efficiency as there are no 
limitations in terms of enzyme activity and/or substrate availability (e.g. NTPs)  and there 
is an approximate doubling of the PCR product with each cycle. Therefore during the 
exponential phase, the fluorescent signal is directly proportional to the amount of PCR 
product and can be used for quantification of the initial starting amount of the target. 
Other attributes of real-time qPCR, which make it the preferential technology for gene 
expression studies include its high sensitivity, wide dynamic range  and high 
reproducibility (554).  
The amplification plot is central to the analysis of real-time qPCR data, which shows the 
fluorescent signal (y-axis) against the cycle number (x-axis). 
 
 
Real-time qPCR amplification plot (555) 
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It is possible to determine the initial starting amount of a target gene through 
characterisation of the point in time (fractional number of PCR cycles) at which 
amplification of the target generates enough fluorescent signal to exceed a threshold 
value. This timepoint is called the Ct (cycle threshold) value and will be inversely 
proportional to the starting amount, if the threshold is set within the exponential phase 
(556). Therefore a larger amount of starting template will have a lower Ct value as fewer 
cycles are required for the fluorescent signal to cross the threshold, and a smaller 
amount will have a higher Ct value. 
The following equation describes amplification in qPCR: 
Xn = X0 (E+1)n  
n = number of cycles 
Xn = number of target amplicons at cycle n 
X0 = initial number of target molecules 
E = efficiency of the amplification of the target 
 
If Xn is the amount of amplicon produced at the threshold, n is the number of cycles 
required for the amplicon to reach this level (i.e. the Ct value for the sample). 
Xn = X0 (E+1)Ct 
Therefore the initial number of target molecules is: 
X0 = Xn/(E+1)Ct 
As the threshold is set during the exponential phase where efficiency is theoretically 1, 
this equation becomes: 
X0 = Xn/2Ct 
As both the target and reference gene amplification are compared at a constant 
threshold value, at which they have exactly the same amounts of amplicon (Xn), Xn can 
be given the value of 1 in the exponential amplification equation: 
X0 = 1/2Ct  
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Therefore, the initial number of target molecules is: 
X0 = 2-Ct 
Relative quantification 
Relative quantification is the most commonly used method for quantification using real-
time qPCR data, which normalises the target gene expression to the expression of 
a reference gene. The simplest method of relative quantification is the 2-∆Ct method 
which uses the following equation: 
Ratio (target/reference) =  
2−𝐶𝑡(𝑡𝑎𝑟𝑔𝑒𝑡)
2−𝐶𝑡(𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒)
 = 2-[Ct(target)-Ct(reference)]  
The reference gene is also used as an endogenous control that controls for sample to 
sample variations of input quantity and quality (such as the degree of RNA degradation) 
and reverse transcription efficiency.  
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Appendix 4 Selection of reference gene 
The housekeeping genes HMBS, HPRT1, SDHA and TBP were investigated as candidate 
reference genes. The housekeeping gene 18S was not included due to its well- 
documented drawbacks and the fact that it was the only gene that did not undergo 
a preamplification procedure (557). The stability of the four housekeeping genes was 
initially tested using a ΔCt approach that compared the relative expression of each pair 
of housekeeping genes. Firstly, the relative expression of each pair of genes was 
calculated for each sample (ΔCt) followed by calculation of the mean ΔCt and standard 
deviation for each gene pair between the samples. The mean standard deviation for 
each housekeeping gene was then calculated. 
Comparison of housekeeping genes using ΔCt method 
Genes Mean ΔCt Std dev Mean Std dev 
    
HMBS vs HPRT1 2.832 2.201  
HMBS vs SDHA -1.433 0.754  
HMBS vs TBP 1.003 1.001 1.319 
    
HPRT1 vs HMBS -2.832 2.201  
HPRT1 vs SDHA -4.265 2.137  
HPRT1 vs TBP -1.829 2.009 2.116 
    
SDHA vs HMBS 1.433 0.754  
SDHA vs HPRT1 4.265 2.137  
SDHA vs TBP 2.436 0.873 1.255 
    
TBP vs HMBS -1.003 1.001  
TBP vs HPRT1 1.829 2.009  
TBP vs SDHA -2.436 0.873 1.294 
 
The housekeeping genes HMBS, SDHA and TBP showed relatively stable expression 
between the samples, as demonstrated by relatively low values for the mean standard 
deviations of 1.319, 1.255, and 1.294 respectively.  
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The variation in the Ct values of each housekeeping gene between the samples is shown 
below. These values are given for the recurrent and non-recurrent group, as well as the 
GS ≥7 and <7 group. 
Mean Ct value of each housekeeping gene with standard deviation and percentage 
coefficient of variation 
Gene  Mean Ct Std dev %CV 
     
HMBS Total  26.304 1.855 7.054 
 Recurrent 26.964 2.257 8.372 
 Non-recurrent 26.002 1.577 6.066 
 GS ≥7 26.399 1.689 6.397 
 GS <7 26.163 2.104 8.041 
     
HPRT1 Total 29.135 3.712 12.742 
 Recurrent 30.614 4.429 14.467 
 Non-recurrent 28.460 3.164 11.117 
 GS ≥7 29.157 3.660 12.554 
 GS <7 29.103 3.858 13.258 
     
SDHA Total 24.871 1.994 8.017 
 Recurrent 25.215 2.326 9.223 
 Non-recurrent 24.713 1.829 7.402 
 GS ≥7 24.895 1.996 8.019 
 GS <7 24.834 2.028 8.165 
     
TBP Total 27.307 2.122 7.772 
 Recurrent 27.905 2.389 8.561 
 Non-recurrent 27.034 1.956 7.236 
 GS ≥7 27.280 1.975 7.240 
 GS <7 27.346 2.362 8.638 
 
HMBS is the housekeeping gene which shows the lowest overall variation in Ct value 
between the samples (%CV of 7.054). For all four of the housekeeping genes, there is 
little difference between the mean Ct value of the GS ≥7 and <7 group. The difference 
between the mean Ct value of the recurrent and non-recurrent group is low for HMBS, 
SDHA and TBP but much higher for HPRT1. 
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Box plots are also included to show the distribution of the Ct values for each 
housekeeping gene. Box plots are shown for the recurrent/non-recurrent and GS ≥7/<7 
groups. 
 
 
 
Box plot representation of raw Ct values of the four housekeeping genes in the 
recurrent and non-recurrent groups are shown as medians (lines), 25th percentile to 
75th percentile (boxes) and ranges (whiskers) 
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Box plot representation of raw Ct values of the four housekeeping genes in the GS ≥7 
and <7 groups are shown as medians (lines), 25th percentile to 75th percentile (boxes) 
and ranges (whiskers) 
 
The short boxes and whiskers for HMBS demonstrate its low variability between the 
samples. Additionally, the median values are at similar levels between the recurrent and 
non-recurrent group and between the GS ≥7 and <7 group. In comparison, HPRT1 
showed much higher variability and had median values at different levels, particularly 
between the recurrent and non-recurrent group. 
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Appendix 5 Binary logistic regression/Receiver 
Operating Characteristic (ROC) curves 
Binary logistic regression 
Binary logistic regression is a statistical method used for the prediction of dichotomous 
category membership. This method exploits the association between the dependent 
and independent variables to predict the category membership of the dependent 
variable with the highest possible accuracy. In this study, the independent (predictor) 
variables were relative expression of the chosen genes and the dependent variable 
(binary outcome) was 5-year disease recurrence (0=non-recurrent, 1=recurrent). 
Logistic regression estimates a theoretical probability curve from the data, which shows 
the predicted probability of an individual being in the “1” binary category (recurrent 
group) as a function of the predictor variables (gene expression). This probability curve 
is called the logistic regression function and would be a nonlinear function of the 
predictor variables. Hence based on the level of expression of a particular gene, the 
logistic regression probability curve could show the probability of the patient being in 
the recurrent group. Further predictor variables (expression of other genes) could then 
be added to improve the predictive accuracy of the model. 
To understand how logistic regression works, it is important to understand two 
important measures of likelihood: odds and probability. The odds of an event are the 
number of ways that an event could occur divided by the number of ways it could fail to 
occur. The probability is the number of ways that an event could occur divided by the 
total number of outcomes possible. Probability is related to the odds as follows: 
Probability (p) = 
𝑜𝑑𝑑𝑠
1+𝑜𝑑𝑑𝑠
 
In logistic regression, the probability of the outcome is expressed as a function of the 
logit, which is the ln of the odds: 
Logit = ln(odds) 
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p = 𝑒
𝑙𝑜𝑔𝑖𝑡
1+𝑒𝑙𝑜𝑔𝑖𝑡
 
The logit is assumed to show a linear relationship with the predictor variables X1, X2...Xp 
where b0 is the regression constant and b1, b2...bp are the regression coefficients of the 
predictor variables. This is shown by the logit equation:   
Ln(odds) = b0 + b1x1 + b2x2 + ........+ bpxp 
The probability can therefore be described by the logistic regression equation: 
p = 
𝑒𝑏0+𝑏1𝑋1+𝑏2𝑋2+⋯+𝑏𝑝𝑋𝑝
1+𝑒𝑏0+𝑏1𝑋1+𝑏2𝑋2+⋯+𝑏𝑝𝑋𝑝
 
In this study, the logit could be described as the ln(odds) of the patient being in the 
recurrent group.  
Logistic regression estimates the values of the parameters (regression coefficients) in 
the logit equation using Maximum Likelihood Estimation (MLE), whereby parameters 
are selected which maximize the probability of the observed data (likelihood). MLE is 
performed in SPSS by a series of iterations using highly intensive computing algorithms. 
The parameter estimation in SPSS aims to achieve the greatest likelihood of the 
observed outcome, i.e. the smallest deviance between the predicted and the observed 
data. In logistic regression, the ln likelihood rather than the likelihood is used and this 
value is multiplied by -2 to make calculation easier. Therefore, SPSS aims to achieve the 
lowest value possible for the -2*ln likelihood (-2LL), which demonstrates a better fit to 
the data.  
It then uses the Likelihood Ratio Test (LRT) to compare the “goodness of fit” of the final 
model with the null model (constant only model without predictor variables). It 
separately fits the null model and the final model to the data and calculates a -2LL value 
for each. Then it calculates a value for the LRT statistic (ΔG2) as follows: 
ΔG2 = -2*ln   
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑓𝑜𝑟 𝑛𝑢𝑙𝑙 𝑚𝑜𝑑𝑒𝑙
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑓𝑜𝑟 𝑓𝑖𝑛𝑎𝑙 𝑚𝑜𝑑𝑒𝑙
 
= (-2LL null model) - (-2LL final model) 
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A higher value for ΔG2 is preferable, as it represents a greater improvement in the fit of 
the final model (in comparison to the null model).  
SPSS also calculates a p-value for ΔG2, which was essential to identify whether the 
improvement in fit obtained by adding the gene(s) to the null model was statistically 
significant. The ΔG2 follows a chi-squared distribution, with the degrees of freedom 
equal to the number of predictor variables added to form the final model. A larger value 
for ΔG2 results in a smaller p-value, which provides evidence for selecting the final model 
over the null model. 
The important parameters of the SPSS logistic regression output are described below, 
using the gene model AMACR.EFNA5.SDHA as an example. 
The beginning of the SPSS output showed the -2LL value for the null model. This was 
followed by the classification table for the null model. 
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The predictions of the null model were based on the most frequently predicted category 
in the dataset which was non-recurrent (46 patients out of 67). SPSS categorised all 
patients as non-recurrent, resulting in an overall accuracy of the null model of 68.7%. 
The next table was the Omnibus Tests of Model Coefficients, which gave the results of 
the LRT, which tested the fit of the final model in comparison to the null model. This 
included the value for ΔG2 (χ2) and its significance.  
 
Here, the low p-value indicated that the model including predictor variables (genes) was 
an improvement over the null model for the prediction of recurrence. 
The model summary contained the value of the -2LL for the final model (used in the 
Omnibus Tests of Model Coefficients) and the pseudo R2 values for the final model. 
 
The Nagelkerke R2 is a pseudo R2 statistic, as logistic regression does not have an 
equivalent to the R2 found in Ordinary Least Squares regression. Although the 
Nagelkerke R2 has limitations and should not be considered a measure of the goodness-
of-fit, it does offer a relative measure of the proportion of variation in outcome that is 
explained by a model. Here, this value showed that the gene model 
AMACR.EFNA5.SDHA explained approximately 40% of the variation in recurrence. 
The next table showed the results of the Hosmer and Lemeshow Test, another 
goodness-of-fit test. The p-value for this test should be >0.05 as demonstrated here to 
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indicate good fit to the data. However, the Hosmer and Lemeshow test was not 
considered useful in this study as it is unreliable with small sample sizes. 
 
SPSS calculated the predicted probability of each patient being in the recurrent group 
using the logistic regression equation and the expression of the genes included in the 
models (predictor variables). It then classified patients into either the recurrent or non-
recurrent group based on their predicted probability (classified as recurrent if 
probability was ≥0.5 and non-recurrent if <0.5). The classification table compared the 
predicted categories with the observed categories. 
 
The example shows that the gene model AMACR.EFNA5.SDHA correctly categorised 
80.6% of the patients in this dataset (overall percent accuracy of 80.6%). 
In more detail, the table showed that 13 patients with recurrent disease were correctly 
classified as recurrent (true positives) and 41 patients with non-recurrent disease were 
correctly classified as non-recurrent (true negatives). In comparison, 5 patients with 
non-recurrent disease were incorrectly classified as recurrent (false positives) and 
8 patients with recurrent disease were incorrectly classified as non-recurrent (false 
negatives).  
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From these values, the true positive rate (sensitivity) was calculated as 61.9% [true 
positives/(true positives+false negatives)](61.9%). The true negative rate (specificity) 
was calculated as 89.1% [true negatives/(true negatives+false positives)].  
The overall percent accuracy was calculated as: 
 (true positives+true negatives)/total * 100 
The final table was very important as it showed the variables in the logistic regression 
equation. 
 
 
The parameters for the logistic regression equation were shown in the left hand column 
B. In this example, the regression constant (b0) was 0.694. The regression coefficient (b1) 
for the gene AMACR was -0.699, (b2) for the gene EFNA5 was -0.606 and (b3) for the 
gene SDHA was 2.279. These values showed the increase or decrease in the logit 
(ln(odds)) of the patient being in the recurrent group for a one-unit increase in gene 
expression, whilst keeping all other predictors constant. Here, the negative sign of the 
coefficient for AMACR and EFNA5 showed how much the ln(odds) of the patient being 
in the recurrent group decreased for a one-unit increase in AMACR and EFNA5 
expression respectively. Conversely, the positive sign of the coefficient for SDHA showed 
how much the ln(odds) of the patient being in the recurrent group increased for a one-
unit increase in SDHA expression. 
The righthand column of the table Exp(B) gave a value for the antilog of the regression 
coefficient or (eB). This value is called the odds ratio and is much easier to interpret than 
the regression coefficient. The odds ratio was the number by which the odds in favour 
of the patient being in the recurrent group was multiplied for a one-unit increase in 
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expression of the gene. Here the odds ratio for AMACR was 0.497, meaning that the raw 
odds of the patient being in the recurrent group were approximately halved for a one- 
unit increase in AMACR expression. In comparison, the odds ratio for SDHA was 9.772, 
meaning that the odds in favour of the patient being in the recurrent group were 
multiplied by nearly 10 for a one unit increase in SDHA expression. Therefore, SDHA 
expression had the greatest effect out of the three predictors on the raw odds of the 
patient being in the recurrent group.  
This table also contained the results of the Wald test which was used to test the 
significance of each independent variable in the model by testing the null hypothesis 
that the regression coefficient for the variable was 0. The significance of the Wald test 
for the independent variables AMACR, EFNA5 and SDHA was 0.002, 0.039 and 0.004 
respectively. Therefore, the null hypothesis that the regression coefficient was 0 could 
be rejected with a 95% confidence level for each gene. In other words, each of the three 
genes made a significant contribution to the logistic regression model for the prediction 
of recurrence.  
SPSS calculated the predicted probability of each patient being in the recurrent group 
by inserting the parameters of the logit equation and the expression of the predictor 
variables into the logistic regression equation.  
Predicted probability  = 
𝑒𝑙𝑜𝑔𝑖𝑡
1+𝑒𝑙𝑜𝑔𝑖𝑡
 
=   
𝑒0.694−0.699𝐴𝑀𝐴𝐶𝑅−0.606𝐸𝐹𝑁𝐴5+2.279𝑆𝐷𝐻𝐴
1+𝑒0.694−0.699𝐴𝑀𝐴𝐶𝑅−0.606𝐸𝐹𝑁𝐴5+2.279𝑆𝐷𝐻𝐴
 
ROC curves 
Goodness-of-fit tests measure the agreement between the observed and predicted 
probabilities, which provides an important measure of calibration of a logistic regression 
model. In addition to good calibration, a predictive model should exhibit high 
discriminatory accuracy. The discriminatory accuracy in this study described the ability 
of the predictive model to distinguish between the recurrent and non-recurrent group. 
This was tested using ROC curves. 
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An ROC curve is a plot showing the true positive rate (sensitivity) vs false positive rate 
(1-specificity) at all possible threshold values (cut-off points). The cut-off points in this 
study were the calculated probabilities of being in the recurrent group. As the ROC curve 
is a plot of sensitivity against 1-specificity, a good test shows a high sensitivity and low 
1-specificity on the ROC plot, hence will show a curved line that covers much of the top 
left hand corner of the plot. Ideally, the AUC (area under the curve) should be as near to 
1 as possible to reflect the greatest discriminatory ability of a model over all cut-off 
points.  
The output in SPSS showed the ROC plot and the value for the AUC. Importantly, it 
provided a list of coordinates of the curve showing the sensitivity and 1-specificity at 
various cut-off points (c-values), which allowed determination of an optimal cut-off 
point (c*). At c*, the model had optimal differentiating ability with equal weight 
attributed to sensitivity and specificity. 
Patients could then be assigned to the recurrent group if they had a value for the 
predicted probability above this optimal cut-off point (c*), and to the non-recurrent 
group if the predicted probability was below this point. 
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Appendix 6 Arrays for method development 
and testing the control cDNA 
The array used in the method development differed from the array used for testing the 
control cDNA by only one gene (ERBB2 rather than LEMD as shown). 
Gene name Alternative 
name(s) 
Full name ABI assay ID number 
ABCA2 ABC2 ATP binding cassette subfamily A 
member 2 
Hs01096987_g1 
MTHFR  methylenetetrahydrofolate 
reductase 
Hs01114482_m1 
TYMP ECGF1 
MNGIE 
thymidine phosphorylase Hs01034314_g1 
UGT1A6 GNT1 
HLUGP 
UGT1F 
UDP glucuronosyltransferase family 1 
member A6 
Hs00153559_m1 
UGT2B7 UGT2B9 UDP glucuronosyltransferase family 2 
member B7 
Hs02556232_s1 
SLC28A2 CNT2 
HCNT2 
HsT17153 
SPNT1 
solute carrier family 28 member 2 Hs00188407_m1 
CADPS2 CAPS2 calcium dependent secretion 
activator 2 
Hs01095965_m1 
SCUBE2 Cegb1 
Cegf1 
signal peptide, CUB domain and EGF 
like domain containing 2 
Hs00221277_m1 
CYP19A1 ARO 
ARO1 
CPV1 
CYAR 
P-450AROM 
cytochrome P450 family 19 subfamily 
A member 1 
Hs00903411_m1 
SLC28A1 CNT1 solute carrier family 28 member 1 Hs00984391_m1 
18S rRNA  18S ribosomal RNA Hs99999901_s1 
SLC28A3 CNT3 solute carrier family 28 member 3 Hs00910437_m1 
DCK  deoxycytidine kinase Hs00176127_m1 
CASP1 ICE 
IL1BC 
caspase 1 Hs01554467_m1 
BAG1  BCL2 associated athanogene 1 Hs00185390_m1 
DAPK3 ZIP 
ZIPK 
death associated protein kinase 3 Hs00154676_m1 
BCL2L11 BIM 
BOD 
BCL2 like 11 Hs00375807_m1 
BNIP3 Nip3 BCL2 interacting protein 3 Hs00969293_mH 
GADD45B GADD45BETA 
MYD118 
growth arrest and DNA damage 
inducible beta 
Hs01548007_g1 
RAD23B HHR23B 
HR23B 
P58 
RAD23 homolog B, nucleotide 
excision repair protein 
Hs01011338_g1 
POLD1 CDC2 
POLD 
DNA polymerase delta 1, catalytic 
subunit 
Hs01100833_g1 
POLE POLE1 DNA polymerase epsilon, catalytic 
subunit 
Hs00173030_m1 
POLG POLG1 
POLGA 
DNA polymerase gamma, catalytic 
subunit 
Hs01018681_m1 
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POLH RAD30A 
XP-V 
DNA polymerase eta Hs00197814_m1 
RPA1 HSSB 
REPA1 
RF-A 
RP-A 
RPA70 
replication protein A1 Hs01556867_m1 
WRN RECQ3 
RECQL2 
Werner syndrome RecQ like helicase Hs01087898_m1 
ERCC4 FANCQ 
RAD1 
ERCC excision repair 4, endonuclease 
catalytic subunit 
Hs01063530_m1 
ATM ATA 
ATC 
ATD 
ATDC 
TEL1 
TELO1 
ATM serine/threonine kinase Hs01112306_g1 
MYC c-Myc 
MYCC 
MYC proto-oncogene, bHLH 
transcription factor 
Hs01562521_m1 
TGFA  transforming growth factor alpha Hs00608187_m1 
ESR1 ESR 
Era 
NR3A1 
estrogen receptor 1 Hs00174860_m1 
ESR2 ER-beta 
Erb 
NR3A2 
estrogen receptor 2 Hs00230957_m1 
PGRMC1 HPR6.6 progesterone receptor membrane 
component 1 
Hs00198499_m1 
CDKN1B KIP1 
P27KIP1 
cyclin dependent kinase inhibitor 1B Hs00153277_m1 
TUBA1A B-ALPHA-1 
TUBA3 
tubulin alpha 1a Hs00362387_m1 
CCNB1 CCNB cyclin B1 Hs01030101_g1 
S100P  S100 calcium binding protein P Hs00195584_m1 
AURKA AIK 
ARK1 
AurA 
BTAK 
PPP1R47 
STK15 
STK6 
STK7 
aurora kinase A Hs00269212_m1 
MYB c-myb 
 
MYB proto-oncogene, transcription 
factor 
Hs00920554_m1 
GRB7  growth factor receptor bound 
protein 7 
Hs00180450_m1 
LEMD2 
(control 
cDNA test) 
ERBB2 
(method 
development) 
NET25 
dJ482C21.1 
 
 
HER-2 
HER2 
NEU 
LEM domain containing 2 
 
 
 
erb-b2 receptor tyrosine kinase 2 
Hs00397754_m1 
 
 
 
Hs01001598_g1 
ALOX5 5-LOX arachidonate 5-lipoxygenase Hs00167536_m1 
PTGS2 COX2 prostaglandin-endoperoxide  
synthase 2 
Hs00153133_m1 
IGFBP3 BP-53 
IBP3 
insulin like growth factor binding 
protein 3 
Hs00181211_m1 
MAPT DDPAC 
MAPTL 
MSTD 
MTBT1 
microtubule associated protein tau Hs00213487_m1 
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MTBT2 
PPND 
TAU 
IPC   IPC 
XenoRNA   XenoRNA 
HMBS PBGD 
PORC 
UPS 
hydroxymethylbilane synthase Hs00609297_m1 
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Appendix 7 Patient demographics 
The following table shows detailed information about the final 67 patients including 
clinicopathological parameters, treatments and follow-up data. 
Abbreviations 
AA antiandrogen 
BCR biochemical recurrence 
DOB date of birth 
GS Gleason score 
LHRH luteinizing hormone-releasing hormone agonist 
mets metastatic disease 
PCa prostate cancer 
RT radiotherapy 
RP radical prostatectomy 
TURP transurethral resection of the prostate 
Tx treatment 
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1 14/02/31   1998 
1998 and AA 2010-13, 
abiraterone 2016   1 BCR mets alive   27   6 biopsy 
2 26/11/24 C 03/05/05  
LHRH 2005, AA and LHRH 
2009, LHRH 2010/11  1 
BCR and 
mets  dead 30/10/2014 PCa 0.5  6 8 biopsy 
3 28/09/32   2002 and 11/07 
LHRH 2002, salvage AA 2005, 
LHRH, stilboestrol 10/07 
zoledronic acid 2008-10, 
chemotherapy 10/08 1 
BCR and 
mets  dead 20/10/2010 PCa 11.1 T2 7  biopsy 
4 12/01/42  03/08/03 
salvage RT 5 to 
7/2005 AA 2/05, LHRH 3/05  1 BCR  alive   40  8(TURP) 9 TURP 
5 04/07/42  08/09/03    0 0 0 alive   8.9   4 biopsy 
6 28/07/34  02/12/03 
salvage RT 7/07 
to 8/07   1 BCR  alive   7.6 T3 5 6 biopsy 
7 07/09/36  05/01/04  
LHRH and AA 3/05 after 
mets, LHRH 3/2014, LHRH 
and AA 2/2015  1 
BCR and 
mets  alive   7.6 T3a 8 5 biopsy 
8 28/03/46  13/04/04    0 0 0 alive   4.5 pT2  6 RP 
10 20/06/37 C 03/08/04  
AA 2005, salvage LHRH 8/10, 
salvage AA 6/13  0  BCR alive   7.6  6 7 biopsy 
11 19/11/47 C 24/05/04  ?2014  1 
BCR and 
mets  alive      6 RP 
12 04/12/37  25/05/04    0 0 0 alive   10.3 T1c  6 RP 
13 10/02/36  12/10/04    0 0 0 alive   13.2   5 biopsy 
14 04/08/29  27/07/04    1 BCR  alive   10.8   5 RP 
15 30/07/47  23/11/04  3/05   0 0 0 alive   8.6  6 7 biopsy 
16 07/11/40  22/11/04    0 0  dead 23/08/2012 
other 
causes 2.4 pT2  5 biopsy 
17 26/02/43  20/12/04 salvage RT 9/06   1 BCR  alive   5.5   7 biopsy 
19 28/09/48  09/11/04  
salvage AA 7/06, LHRH 12/09 
to 2014 after mets, LHRH 
2015  1 
BCR and 
mets  alive   2.9 T3b  7 RP 
20 31/01/50 C 12/09/05    0 0 0 alive   4.9 tert 4 6 5 biopsy 
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22 14/11/43 C 31/01/05    0 0 0 alive   5.5   7 RP 
23 17/05/35   12/07 LHRH 2007  0 0  dead 7/01/2013 
other 
causes 6.8   7 biopsy 
25 24/03/46  08/02/05 ?5/06 ?AA 11/05  1 BCR  ?   17   7 RP 
26 09/10/46  28/02/05    0 0 0 alive   7 pT2c  5 RP 
27 16/04/59  03/05/05    0 0  dead 30/03/2013 
other 
causes 10   7 RP 
28 24/04/46  17/05/05 9/05 to 10/05   0 0  ?   8.7 T4  7 RP 
30 29/12/33 C  finished 8/06 LHRH finished early 2007  0 0 0 alive   8  8  biopsy 
31 02/10/35 C  started 8/06 started 3/06, LHRH 2014/5  1 BCR  alive   20.3  8  biopsy 
35 11/08/54  22/05/06    0 0 0 alive   4.6 T2b 6 7 biopsy 
37 26/09/32   3/08 to 4/08 8/07  0 0 BCR alive   24   6 biopsy 
38 08/11/31   2/08 to 3/08 LHRH 7/07 to 8/08   0 0  alive   18  7  biopsy 
39 05/11/35   11/07 to 11/07 LHRH, AA 9/07  0 0  dead 29/12/2014 
other 
causes 19.3  6  biopsy 
40 06/08/41 C  summer 2010   0 0  alive   25.3  6  biopsy 
42 15/05/40 C 02/01/07    0 0 0 dead 3/04/2017 
other 
causes 6.2 pT3 6  biopsy 
43 23/08/35 C  4/07 to 5/07 AA, LHRH 10/06 to 8/07  0 0  dead 22/09/2013 
other 
causes 8.9  7  biopsy 
44 23/06/40 C  6/07 AA, LHRH 12/06  0 0 0 alive   2.3  7  biopsy 
46 08/11/40 C  3/07 to 5/07 LHRH 10/06 to 10/07  0 0 0 alive   10.2  6  biopsy 
50 07/09/48 C  finished 6/07 1/07 to 1/08  0 0 0 alive   3.6  6  biopsy 
51 25/12/39 C  2008   0 0  alive   40.6  7  biopsy 
52 24/06/36   2008   1 BCR  alive   11.2  7  biopsy 
53 13/07/39   6/08 
LHRH 2/13, AA and LHRH 
2014    1 BCR  alive   19.3  6  biopsy 
54 16/07/34 C  7/07 to 9/07   0 0 0 alive   7.9  
            
8(TURP)  TURP 
55 23/05/48 C 25/06/07 10/07 to 11/07 
 AA 2007/AA since 2011, 
enzalutamide for bony mets  1 BCR mets alive 27/02/2017 ? 2.6 pT4  9 biopsy 
56 03/10/37 C  2/11 LHRH 1/07 and 2011  0 0  alive   20.4  
            
7(TURP)  TURP 
57 26/12/39 C  finished 5/08 9/07  0 0  alive   13.3  6  biopsy 
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58 18/09/45 C 12/06/07 9/07 to 11/07   0 0 0 alive   12.8 pT2c  5 biopsy 
60 23/05/41 C 11/06/07 11/07 to 1/08 LHRH started 08/07  0 0  alive   0.4   9 biopsy 
61 10/01/45  17/07/07    1 BCR  alive   11 T2c  6 biopsy 
62 11/11/46  06/08/07 1/08 to 2/08 LHRH 2008  0 0 0 alive   13.7   8 biopsy 
65 12/11/44  8/07    0 0 0 alive   7.3  6  biopsy 
67 07/04/31   finished 10/07 LHRH finished 5/08  0 0  alive   39 T2 6  biopsy 
68 07/11/41   2008 LHRH 2008  0 0  alive   18  7  biopsy 
69 10/10/34   finished 2/08 LHRH 2007 and 11/11  1 BCR  alive   24  7  biopsy 
72 12/02/35   4/08 to 5/08   0 0 BCR alive   10  7  biopsy 
75 19/05/48   11/07 to 1/08 7/07  0 0 BCR alive   88  7  biopsy 
76 24/10/40  16/10/07 12/11   1 BCR  alive   6.6   7 biopsy 
77 01/05/37   early 2008 restarted LHRH 2016  0 0 BCR alive   6  7  biopsy 
78 11/09/29   1/08 to 2/08 2/08  0 0 BCR alive   12  8  biopsy 
80 20/09/47   1/08 to 3/08 LHRH 10/07  0 0  ?   7.5  7  biopsy 
85 19/03/38  10/09/07 2008 LHRH 2008 and 2/16  1 BCR mets alive   8.1 T2c 8 8 RP 
88 21/10/37   10/08   0 0  alive   7.6  6  biopsy 
89 12/03/30   3/08 LHRH 11/07  0 0  dead 3/02/2017 
other 
causes 10.1 T1 8  biopsy 
91 07/12/33   3/08 LHRH 2007  0 0  alive   18.9  9  biopsy 
92 07/01/37   11/07 LHRH 11/07  0 0  dead 13/12/2014 
other 
causes 9.6  7  biopsy 
93 04/02/42   finished 4/08 
LHRH 07 and 2012 LHRH 
4/14  chemotherapy 2015 1  mets BCR dead 6/11/2015 PCa 6  7  biopsy 
94 24/04/34   2008 LHRH 2008  0 0  alive   9.5  8  biopsy 
97 14/04/37   finished 4/08 
AA and LHRH 2012, then  
intermittent LHRH  1 BCR  alive   7.2  7  biopsy 
99 22/10/42  27/11/07    0 0  ?   7.4   6 RP 
101 27/12/36  11/01/05    0 0 0 ?   4.8   6 biopsy 
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Appendix 8 Electronic appendix 
• Documents for gaining new ethical permissions 
• Parameters from standard curves and replicate plates for all genes  
• Full logistic regression dataset for BB study including correlation analysis 
• Comparison of Ct values between non-preamplified and preamplified samples 
• Logistic regression models of recurrence (SL study) 
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Appendix 9 Form UPR16 
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